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Chapter 1
Introduction
"These yellow bodies of the ovary have been
puzzling to scientists ever since they were first
described by Regner de Graaf
Corner, 1943
1.1 Overview
The corpus luteum is an endocrine gland of the ovary. It is formed from the
dominant follicle after the oocyte has been ovulated and has all but disappeared at
the time of menstruation. During its short life-span, it has a huge capacity for
hormone synthesis and secretion. Indeed, weight for weight, it is the most active
endocrine gland in the body (Zeleznik and Fairchild Benyo, 1994). The principle
hormone secreted by the corpus luteum is progesterone, a C21 steroid.
Progesterone alters the morphology and function of the endometrium. This results
in its stabilisation and prepares the uterine environment for implantation of the
blastocyst (Bell, 1983). The integrity of the corpus luteum is thus fundamental to
the establishment of pregnancy.
The human corpus luteum has a functional life-span of approximately 14 days
(Lenton and Woodward, 1988). This is known as the luteal phase of the ovarian
cycle, during which the synthetic capacity of the corpus luteum changes.
Progesterone production increases in the early-luteal phase to reach a maximum in
the mid-luteal phase. However, in the late-luteal phase, the functional integrity of
the corpus luteum is lost and progesterone production falls (Behrman et al., 1993).
Progesterone withdrawal destabilises the endometrium and stimulates
inflammatory cascades which result in endometrial shedding (Salamonsen and
Woolley, 1996). Thus, failure of luteal progesterone production is the cause of
menstruation in a non-conception cycle.
The structure of the corpus luteum also changes during the luteal phase. After
ovulation, the cystic follicle, with its avascular granulosa cells, is transformed into
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the solid, highly vascular, corpus luteum. The mid-luteal corpus luteum measures
up to two centimetres in diameter and can be clearly identified on the surface of
the ovary (Zeleznik and Fairchild Benyo, 1994). It has an orangy-red colouration
which reflects its high vascularity and lipid content. However, in the late-luteal
phase, as progesterone production falls, the corpus luteum regresses structurally
(Behrman et al., 1993). At the time ofmenstruation, the corpus luteum can still be
identified in the ovary, but it has become a small, relatively avascular, fibrous
remnant (Corner, 1956). This loss of the corpus luteum from the ovary is known
as luteolysis. During luteolysis, the corpus luteum, therefore, loses both its
functional and structural integrity.
The functional and structural integrity of the corpus luteum are maintained in the
presence of an implanting blastocyst. Human chorionic gonadotrophin (hCG) is
synthesised in logarithmically increasing amounts by the trophoblast of a
developing pregnancy (Lenton and Woodward, 1988). Luteolysis is prevented by
exposure of the corpus luteum to hCG from the conceptus. This means that
progesterone continues to be produced and the structure of the corpus luteum is
maintained. The continued presence of progesterone maintains the uterine
environment and prevents menstruation, allowing implantation and early
embryonic development (Stouffer, 1988). Therefore, in a conception cycle, the
corpus luteum is 'rescued' from luteolysis and this is fundamental for the maternal
recognition of pregnancy.
The corpus luteum is therefore one of the lynchpins of human reproduction. It is
the primary interface between menstruation and maternal recognition of
pregnancy. An understanding of the physiological processes central to the corpus
luteum would have wide implications for both fertility promotion and prevention.
However, the molecular events surrounding functional and structural luteolysis,
and how they are prevented by hCG during maternal recognition of pregnancy, are
still not clear in women. The corpus luteum remains one of the great enigmas of
modem reproductive biology.
This chapter reviews the current understanding of the control of the primate
corpus luteum. It begins by discussing the ovarian cycle and gonadotrophin
control of follicular growth. The molecular mechanisms of ovulation, luteinisation
and formation of the corpus luteum are then discussed. This is followed by a
review of our understanding of the functional properties of the corpus luteum. The
next aspect to be covered is our current understanding of luteolysis, luteal
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involution and the factors implicated in its control. Maternal recognition of
pregnancy and luteal 'rescue' are then discussed. This highlights the adequacies
and the deficiencies in our current understanding and the need to develop novel
model systems to study the human corpus luteum. This chapter serves as an
introduction to the following experimental chapters which report studies of the
human corpus luteum during maternal recognition of pregnancy.
1.2 Folliculogenesis
Any discussion of the corpus luteum must begin with a discussion of general
ovarian physiology, in particular follicular growth and development. This is
because the structure, function and control of the corpus luteum all have their
origin in the preovulatory follicle. In addition, it is increasingly clear that there are
a great many parallels in the control of the follicle and that of the corpus luteum
(Zeleznik and Fairchild Benyo, 1994; Fortune, 1994; Gougeon, 1996). Normal
folliculogenesis is necessary for the development of a normal corpus luteum.
1.2.1 The Ovarian Cycle
The ovary is the endocrine gland responsible for the release of the female gamete,
the oocyte. As well as growth, development and release of the oocyte, the ovary
secretes the steroid hormones which are responsible for female secondary sexual
characteristics and set the hormonal milieu for the establishment of pregnancy.
During the follicular phase of the ovarian cycle, cystic follicles, containing
oocytes, grow, mature and secrete increasing amounts of oestrogen (Adashi,
1994). Eventually one follicle is selected to become the dominant follicle and the
other follicles die by the process of atresia (Gougeon, 1996). The high
concentration of oestrogen secreted by the mature dominant follicle triggers a
positive feedback response in the hypothalamo-pituitary axis resulting in a
gonadotrophin surge (Zeleznik and Fairchild Benyo, 1994). This luteinising
hormone (LH) surge results in ovulation, with follicular rupture, release of the
oocyte and transformation of the follicular remnants into the corpus luteum
(Behrman et al., 1993). The corpus luteum secretes large amounts of progesterone
during the luteal phase of the ovarian cycle (Fig. 1.1). After luteolysis,
progesterone secretion fails and the ovary enters the follicular phase of the ovarian
cycle once again (Adashi, 1994).








Hormone profile of the human menstrual cycle
Diagrammatic representation of the changes in serum concentrations of the main
sex steroids, 17p-oestradiol (E) and progesterone (P), and the gonadotrophins,
luteinising hormone (LH) and follicle stimulating hormone (FSH), throughout the
menstrual cycle. The days of the cycle, and the timing of menstruation and
ovulation, are indicated. The menstrual cycle incorporates the follicular and luteal
phases of the ovarian cycle.
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1.2.2 Anatomy of the Ovarian Follicle
Mammalian ovaries have a pool of primordial follicles consisting of an oocyte,
arrested in prophase of meiosis I, and a single layer of flattened epithelial-like
granulosa cells (Zeleznik and Fairchild Benyo, 1994). During reproductive life, a
cohort of these follicles begin to grow and mature. The factors responsible for the
initiation of follicular development are still not clear (Fortune, 1994). However,
once follicular growth begins, the follicle has one of two fates: ovulation or
atresia. Only a tiny proportion of follicles ovulate (Fig. 1.2).
The primordial follicle may remain dormant in the ovary for more than forty years.
The first stage in its transition to a primary follicle is characterised by enlargement
and proliferation of the granulosa cells, and an increase in the size of the oocyte
(Gougeon, 1996). When the follicle has acquired three to six layers of granulosa
cells, some stromal cells near the basal lamina become aligned parallel to each
other around the primary follicle. These fibroblast-like cells change into
epithelioid-like cells, capable of steroidogenesis, and stratify into the theca cell
layers. At this stage the follicles develop an independent blood supply (Gougeon,
1996). This is the preantral stage of follicular development.
The appearance of the antral cavity starts with the development of small fluid-
filled spaces, within the granulosa cell layer, that coalesce to form the antrum.
From this point onwards there is a specific group of granulosa cells which
surround the oocyte. These granulosa cells form the cumulus cells which have
cytoplasmic connections to the oocyte. There appears to be a stratification of the
rest of the granulosa cells, as those nearest the basement membrane become more
columnar in shape (Gougeon, 1996). At this stage, in the human, the follicles
measure 180 to 250 pm in diameter. Through the accumulation of fluid, in the
antral cavity, and the proliferation of granulosa and thecal cell layers, the follicles
continue to grow until they measure between two and five millimetres in diameter.
This process takes about 85 days and these small antral follicles can be found at
all stages of the ovarian cycle (Zeleznik and Fairchild Benyo, 1994). It is not clear
what factors are involved in controlling this stage of follicular growth. However,
the next stages of follicular growth are gonadotrophin-dependent (Fig. 1.2).
The size of the follicle destined for ovulation increases greatly during the
follicular phase of the ovarian cycle by cellular multiplication and accumulation of
follicular fluid. This process requires trophic stimulation by follicle stimulating













Figure 1.2 0 5 15 25 35 45 55 65 75 85 days
Follicular growth and development
A cartoon of the important stages of follicular growth and development. The
gonadotrophin-independent preantral stage of follicular development takes 85
days. The antral stage of follicular development is gonadotrophin-dependent and
is associated with rapid growth of the follicle. This stage is completed within 15
days. The growth of large follicles becomes less dependent on FSH and the
granulosa cells ofmature follicles develop the ability to respond to LH.
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hormone (FSH). The diameter of the preovulatory follicle increases from 6.9 ±0.5
mm in the early follicular phase to 18.8 ±0.5 mm in the late follicular phase
(Pache et al., 1990). During this period, the mean number of granulosa cells
increases from approximately 2-5 million in the early follicular phase to 50-100
million at the time of ovulation (Gougeon, 1979). This growth occurs during the
follicular phase of the ovarian cycle and is completed within 15 days (Fig. 1.2).
There is a direct correlation between the size of the follicle and its blood supply
(Balakier and Stronell, 1994). The preovulatory follicle becomes a highly vascular
structure because of active endothelial cell proliferation in the theca cell layers
(McClure et al., 1994). The granulosa cells are separated from the theca cells by a
basement membrane and remain avascular. The granulosa cells obtain their
nutrients by diffusion, and the thickness of the granulosa cell layer in the dominant
follicle is therefore limited to a maximum of seven cells (Espey and Lipner, 1994).
At this stage of development, the granulosa cells of the follicle have matured to
acquire the capacity to respond to the ovulatory LH surge (Richards and Midgley,
1976).
1.2.3 Ovarian Steroid Secretion
The granulosa cells and the theca cells of the antral follicle, and the luteal cells of
the corpus luteum, are steroidogenic in nature. Analysis of ovarian venous blood
shows that the ovary secretes oestrogens (17p-oestradiol & oestrone),
progestagens (progesterone, pregnenolone & 17a-hydroxyprogesterone) and
androgens (androstenedione, dehydroepiandrosterone & testosterone) (Adashi,
1994). In order to identify the cell types involved in the production of these
hormones, steroid hormones have been identified and quantified in conditioned
media from ovarian preparations, follicular preparations, luteal preparations and
ovarian cell suspensions. These studies have identified oestrogens as the major
products of the follicular granulosa cells. Androgens were found to be the major
products of the thecal cells of the follicle. In contrast, luteal cells in vitro were
able to secrete both progestagens and oestrogens (Fowler et al., 1978) (Fig. 1.1).
Studies using labelled C2j and C19 precursors revealed that isolated granulosa
cells were capable of producing oestrogens only when precursor hormones were
present. They could not synthesise the androgens that are the immediate
precursors of oestrogens in the steroidogenic pathway. In contrast, isolated theca
cells produced progestagens and androgens (McNatty et al., 1979). Localisation of
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steroidogenic enzymes within the follicle (Conley et al., 1995) have demonstrated
that theca cells express 17a-hydroxylase, C17,20 lysase (17a-hydroxylase), the
enzyme responsible for androgen synthesis. They do not express cytochrome P450
aromatase (P450arom), the enzyme responsible for aromatisation of androgens to
oestrogens. In contrast, granulosa cells express P450arom but do not have 17a-
hydroxylase activity. Follicular oestrogen biosynthesis therefore requires the co¬
operation between granulosa cells and their thecal neighbours (Hillier, 1985).
1.2.4 Gonadotrophic Control of Ovarian Steroid Secretion
Granulosa and theca cell types are responsive to two gonadotrophins, LH and FSH
(Hillier, 1994). Classic studies on hypophysectomised rats demonstrated that both
LH and FSH are required for follicular oestrogen biosynthesis (Zeleznik and
Fairchild Benyo, 1994). FSH receptors are located on granulosa cells and LH
receptors are located on thecal cells throughout the antral stage of follicular
development (Hillier, 1991). A model for gonadotrophic action within the follicle
is set out in the two-cell, two-gonadotrophin hypothesis of ovarian steroid
synthesis (Armstrong and Dorrington, 1979) (Fig. 1.3).
1.2.5 Maturation of Granulosa Cells
Growth of the follicle in the antral stage is dependent on gonadotrophin action.
FSH binds to its cell surface receptor on the granulosa cell and activates adenylyl
cyclase (Richards et al., 1987). As well as stimulating cell growth, FSH induces
proteins involved in steroidogenesis, such as P450arom. This is one of the factors
responsible for the marked increase in steroidogenic capacity as the follicle
matures (Gougeon, 1996). As described previously, both LH and FSH are
generally required for follicular steroidogenesis. However, during the late-
follicular maturation of the granulosa cells, FSH induces the expression of LH
receptors that are also coupled to adenylyl cyclase (Richards and Midgley, 1976).
Consequently, in the preovulatory follicle, LH can regulate both androgen
synthesis (in thecal cells) and aromatisation of androgen (in granulosa cells). This
increases the responsiveness of the follicle in the face of FSH levels which are
declining (Hillier, 1991). The decline in FSH is secondary to negative feedback
actions of ovarian oestrogens and inhibins (Hillier, 1991; Groome et al., 1996).





























The two-cell, two-gonadotrophin hypothesis
A cartoon of the currently accepted model for follicular oestrogen synthesis. LH
acts on the theca cells to stimulate androgen synthesis. These androgens diffuse to
the neighbouring granulosa cells. The granulosa cells are stimulated by FSH to
aromatise these androgens to oestrogens. Therefore it is thought that normal
follicular oestrogen synthesis requires two cell types and two gonadotrophins.
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positive feedback control of pituitary LH release (Yen, 1986). The follicle can
now respond to the oestrogen-induced ovulatory LH surge (Fig 1.1).
Developmental events occurring during the follicular phase, under the control of
FSH, are essential for the appropriate functioning of the corpus luteum. The
preovulatory granulosa cells become the principle steroidogenic cells of the corpus
luteum. Granulosa cells isolated from immature follicles are steroidogenically
quiescent and require the trophic support of FSH to become steroidogenically
active (Gougeon, 1996). In contrast, those collected from preovulatory follicles
secreted both oestrogen and progesterone in culture conditions (Hillier et al.,
1981). This FSH-dependent maturation of granulosa cells during follicular
development is associated with increases of messenger ribonucleic acids (RNA)
(mRNAs) for the LH receptor and steroidogenic enzymes (Richards et al., 1995).
These are all required for the secretion of steroid hormones by the corpus luteum.
Indeed, a disturbance in the normal pattern of FSH secretion during the primate
follicular phase results in an abnormal luteal phase characterised by reduced
progesterone production from the corpus luteum (Stouffer and Hodgen, 1980). It
is likely that normal function of the corpus luteum requires a normal follicular
phase.
1.2.6 Paracrine Control of Follicular Growth and Function
Although FSH and LH are the primary regulators of ovarian cellular function, it
has become increasingly clear that the ovarian cellular responses to
gonadotrophins can be modified by factors that are produced, and have actions,
within the follicle (Hillier, 1991; Adashi, 1995; Gougeon, 1996). Many of the
disparate actions of gonadotrophins on the follicle are transduced by multiple
regulatory factors in a local paracrine fashion (Hillier, 1991). The local regulators
which have generated the most interest are steroids, the insulin-like growth factors
(IGFs) (Jones and Clemmons, 1995) and the inhibin/activin family of proteins
(Aloi et al., 1995).
Oestrogens are present in large concentrations within the follicular fluid. As it has
been shown that oestrogens can augment FSH action in rat granulosa cells
(Richards et al., 1987), a role for local oestrogen in follicular development has
been postulated (Hillier et al., 1980). However, this effect cannot be seen in
human granulosa cells in vitro or in vivo (Hillier, 1991). Androgens have been
reported to augment granulosa cell aromatase activity (Hillier and deZwart, 1981)
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and may promote follicular atresia (Tsafriri and Braw, 1984). The physiological
importance of these actions remains unclear (Adashi, 1994). However, oestrogen,
progesterone and androgen receptors have been detected on the steroidogenic cells
of the primate follicle (Hild-Petito et al., 1988; Suzuki et al., 1994). It is therefore
possible that steroids have significant intracrine or paracrine actions during
follicular growth and development in the primate. At present, however, there is
little information available about their role (Adashi, 1994).
There is good evidence that IGFs are involved in the augmentation of FSH effects
on granulosa cell growth and differentiation (Hillier, 1991). IGFs are single chain
peptides which share considerable structural and functional homologies with
proinsulin (Jones and Clemmons, 1995). IGF-I and IGF-II interact with the insulin
receptor, but each has a specific high-affinity receptor linked to a tyrosine kinase
intracellular signalling cascade (Jones and Clemmons, 1995). The biological
availability of IGFs appears to be modulated by an increasing family of specific
binding proteins, the insulin-like growth factor binding proteins (IGFBPs) (Jones
and Clemmons, 1995). IGFs, IGF receptors and IGFBPs can all be detected within
the ovarian follicle.
Granulosa cells express IGF-I receptors and these increase after FSH treatment in
vitro (Adashi et al., 1989). IGF-I synergises with FSH to induce aromatase activity
in granulosa cells, and with LH in the production of androgens (Hillier, 1991).
There is evidence that ovarian cells can synthesise IGFs, and both IGF-I and IGF-
II can be measured in follicular fluid (Zeleznik and Fairchild Benyo, 1994).
Granulosa cells also synthesise IGFBPs and at least five different ones have been
detected in follicular fluid (San Roman and Magoffin, 1992). The main IGFBP in
follicular fluid was IGFBP-3. In vitro, FSH and LH reduced the expression of
IGFBP-3 in granulosa and thecal cells respectively (San Roman and Magoffin,
1992). This complex regulatory system has not been fully dissected, but most
investigators agree that the IGF system is likely to have important paracrine
actions during follicular growth and development.
The inhibins and activins are proteins composed of two of three peptide subunits:
an a subunit, a PA subunit and a PB subunit. An a subunit with a P subunit results
in the formation of inhibin A or inhibin B. Two P subunits together form activin
A, activin B or activin AB. Inhibins and activins were first identified on the basis
of their action on pituitary FSH secretion: inhibins inhibit whereas activins
stimulate (Burger and Igarashi, 1988). Activins act through specific receptors
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which have now been characterised at a molecular level (Shinozaki et al., 1992;
Cameron et al., 1994). An intensive search for specific inhibin receptors has, to
date, proved unsuccessful. A specific binding protein, known as follistatin, has
been described which will bind inhibin and affect its biological bioavailability
(Ying, 1988). The proportions of activins and inhibins synthesised, are likely to
have major effects on their net biological action (Findlay, 1993).
Changing expression of inhibin/activin subunits during follicular growth suggests
that they may have a paracrine role during folliculogenesis (Fraser et al., 1993;
Roberts et al., 1993; Fraser and Lunn, 1993; Findlay, 1993; Fraser et al., 1995a).
Inhibins and activins share structural homology with a family of growth factors,
which includes transforming growth factor (TGF) (3, that are involved in
embryogenesis, tissue repair and remodelling (Roberts et al., 1988). Early antral
follicles primarily express the PB subunit and preovulatory follicles express the PA
and a subunits. This is likely to explain the changing expression of inhibin A and
inhibin B during the menstrual cycle (Groome et al., 1996). This also suggests that
activins may be involved in the early stages of antral follicular development and
that inhibins may be involved in the final stages of preovulatory development
(Zeleznik and Fairchild Benyo, 1994).
Secretion of inhibin/activin is regulated by gonadotrophins and sex steroids in
vitro (Hillier, 1991). FSH induces inhibin production from granulosa cells and this
is augmented by the presence of androgen (Hillier, 1991). Inhibin itself induces
potent and selective stimulation of human thecal androgen synthesis in vitro
(Hillier et al., 1991a). In contrast, activin antagonises the stimulatory effect of LH
on thecal androgen production (Hillier et al., 1991a). Inhibin and activin may also
have effects on cellular proliferation within the follicle. Inhibin has some
inhibitory effects on ovarian cellular proliferation (Matzuk et al., 1992), whereas
activin can stimulate cellular proliferation in vitro (Rabinovici et al., 1990; Li et
al., 1995). It is likely that the differential effects of activins and inhibins on the
follicle (Miro and Hillier, 1992), and their different temporal expression, are
important during folliculogenesis. At present, however, more work is required into
the roles of these proteins in ovarian function.
Other molecules have been implicated as having potential roles as paracrine
regulators of follicular development. These include growth factors such as
epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), TGFa and
TGFp. EGF, bFGF and TGFa have been shown to promote proliferation in vitro,
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and all these molecules can both positively and negatively affect steroid synthesis
(Gougeon, 1996). In addition, various cytokines, that are primarily white cell
products, have been shown to affect steroidogenesis (Adashi, 1990). Tumour
necrosis factor (TNF) a , interleukins (IL) 1,2 and 6 and interferons (IFN) a, (3 and
y have all been shown to inhibit gonadotrophin-induced steroidogenesis in vitro.
(Gougeon, 1996). However, these molecules tend to increase prior to ovulation
and their primary role may be as regulators of ovulation (Espey, 1994), rather than
steroidogenesis. Although all the above molecules can be detected in the ovary,
the physiological implications of their actions is not yet clear.
To recap, the dominant follicle has two distinct steroidogenic cell layers.
Steroidogenesis is dependant on pituitary gonadotrophins and relies on an
interaction between the steroidogenic cell layers. Cellular proliferation and
steroidogenesis can be modified by a range of local paracrine regulators. Although
the exact role of these regulators is not clear, they include steroids, growth factors,
cytokines and other peptides. As follicles grow and mature, oestrogen secretion
increases and a dominant follicle is selected. When the dominant follicle is fully
mature, the secreted oestrogen has prepared the endometrium for pregnancy. The
oocyte is now ready for release and, therefore, the next process to be considered is
ovulation.
1.3 Ovulation
The next stage of the ovarian cycle to be considered is ovulation. Ovulation is
induced by LH from the pituitary gland in response to increasing ovarian steroid
synthesis from the dominant follicle. This gonadotrophin surge induces a series of
changes in various follicular compartments cumulating in the release of a
fertilisable ovum and the transformation of the follicle into the corpus luteum
(Espey and Lipner, 1994). The ovulatory response can be divided into three main
components: reactivation of oocyte maturation, follicular rupture, and altered




Ovulation is induced by LH acting on specific LH receptors. These LH receptors
are localised to the steroidogenic cells of the dominant follicle. Therefore
steroidogenic cell factors must be involved in the initiation of each element of the
ovulatory response. As inhibitors of RNA and protein synthesis have been shown
to block ovulation (Tsafriri and Dekel, 1994), it is clear that the ovulatory process
involves the stimulation of new transcription and translation. The oocyte does not
express LH receptors, so its reactivation in response to the LH surge must depend
on signals released from the LH responsive cells.
Oocytes mature spontaneously when removed from granulosa cell contact (Espey
and Lipner, 1994). This maturation can be prevented by addition of cyclic
adenosine monophosphate (cAMP) or adenylyl cyclase to the oocyte. As the
oocyte contains little natural adenylyl cyclase activity (Tsafriri and Dekel, 1994),
the source of the cAMP required to delay maturation is likely to be the granulosa
cells, through their direct cytoplasmic connections (Weiss et al., 1976). The high
granulosa cell cAMP, stimulated during the LH surge, breaks down intracellular
connections between granulosa cells, and between granulosa cells and the oocyte
(Albertini and Anderson, 1974). The oocytes exposure to cAMP therefore falls.
This results in altered protein phosphorylation within the oocyte and it reenters the
cell cycle (Tsafriri and Dekel, 1994).
1.3.2 Follicular Rupture
The LH surge, by acting on the steroidogenic cells of the follicle, also results in
follicular rupture. Morphological studies demonstrate a reaction in the follicle wall
which is akin to an acute inflammatory response (Espey, 1994). The exact
mechanisms of follicular rupture are not fully understood, but cellular changes
occur in cell layers which do not express LH receptors. This suggests that the
steroidogenic cells must respond to the LH surge by influencing factors which act
on the outer layers of the follicle (Espey and Lipner, 1994). It is not clear what
these factors are, but eicosanoids and steroids have been implicated (LeMaire and
Marsh, 1975; Priddy and Killick, 1993). The net result of these factors is to
stimulate and augment the early stages of an inflammatory reaction (Espey, 1980)
in the follicle wall.
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The inflammatory reaction stimulates cascades leading to serine protease activity.
Collagenases are synthesised and then activated by these proteases (Reich et al.,
1985; Reich, 1991), which soften the follicular wall at the stigma. As the wall
becomes softer, fibroblasts become more motile and active, and migrate away
from the stigma (Espey and Lipner, 1994). The follicle wall becomes thinner and
more avascular, the internal pressure of the follicular fluid causes ballooning of
this portion of the wall, the epithelial cells slough off, and the follicle ruptures
(Espey and Lipner, 1994). The cumulus-oocyte complex is released over many
minutes in a wave of follicular fluid. Ovulation is also associated with a change in
the synthetic capacity of the granulosa cells (Tsafriri and Dekel, 1994). The
collapsing follicle, with its luteinised granulosa cells, becomes the corpus luteum.
1.3.3 Luteinisation
Luteinisation is the process where the granulosa cells of the preovulatory follicle
acquire the machinery to produce progesterone, in preparation for their role in the
corpus luteum. Until the LH surge, the steroidogenic role of granulosa cells is
largely limited to the aromatisation of the androgen products from the thecal cells
(Hillier, 1994). FSH-induced maturation of the granulosa cells, with the LH surge,
induces the expression of the steroidogenic enzymes, P450 cholesterol side-chain
cleavage (P450scc) and 3p-hydroxysteroid dehydrogenase (3P-HSD), that catalyse
the synthesis of progesterone from cholesterol (vide infra) (Miller, 1988). The
granulosa cells change their appearance during this process. They become larger
(increasing in size by 250%), develop intracellular granules, and become rich in
smooth and rough endoplasmic reticulum, and mitochondria with tubular cristae
(Zeleznik and Fairchild Benyo, 1994).
This process can be mimicked by the introduction of cAMP into the granulosa
cells, and is not affected by inhibitors of prostaglandins and other mediators of
acute inflammation (Tsafriri and Dekel, 1994). Granulosa cells will spontaneously
luteinise and produce progesterone in culture (Hillier et al., 1981). This means that
the follicular environment has an inhibitory effect on luteinisation, which is
removed by the LH surge. Luteinisation induced by removing the granulosa cells
from the follicular environment, does not involve large increases in intracellular
cAMP, nor can it be prevented by incubating the cells in granulosa cell
conditioned media, or follicular fluid (Espey and Lipner, 1994). Although the
molecular events causing luteinisation are not clear, it may be that the breakdown
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of granulosa cell communications with each other, induced hormonally by the LH
surge and mechanically during removal from the follicle, is involved.
The follicle has now grown, matured and ruptured, releasing a fertilisable oocyte.
The collapsing follicle still contains an avascular layer of granulosa cells
surrounded by highly vascular thecal cells. These granulosa cells, however, have
luteinised and are able to synthesise and secrete progesterone, as well synthesising
oestrogens by aromatisation of thecal androgens. They have lost their FSH
receptors and now are controlled by the major gonadotrophin involved in the
luteal phase of the ovarian cycle: LH. These follicular remnants are transformed
into the corpus luteum.
1.4 The Corpus Luteum
We have now reached the luteal phase of the ovarian cycle. This phase is
dominated by the corpus luteum. This dynamic gland is formed from the follicular
remnants, secretes large amounts of progesterone, and then regresses in the
absence of pregnancy. The function of the corpus luteum and the mechanisms
responsible for its regression and 'rescue' during pregnancy will be discussed in
detail. However, the first aspects of the corpus luteum to be covered are its
formation, structure and cellular composition.
1.4.1 Formation of the Corpus Luteum
The transformation of the dominant follicle into the corpus luteum is still not
understood at a molecular level. The early work of Corner (1956) was
instrumental in defining the structural and morphological characteristics of the
human corpus luteum throughout the luteal phase. These elegant descriptions give
snap-shots of the human corpus luteum at different time points in its life-cycle.
The dynamic nature of the formation of the corpus luteum, however, required
comprehensive studies of carefully controlled rat models. Although the control of
the rat corpus luteum differs from that of the primate (Niswender and Nett, 1994),
there is no reason to suggest that the cellular events surrounding luteinisation and
the formation of the rat corpus luteum differ from those in the human (Behrman el
al., 1993).
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Following the LH surge, the basement membrane between the theca interna and
the granulosa cells begins to break down. The theca engorges with blood during
this process, becomes oedematous, and begins to form invaginations into the
avascular granulosa cells (Pederson, 1951). There is extravasation of red blood
cells into the antral cavity, and this fills with blood. Blood vessels from the theca
invade the follicular antral space and, under the influence of angiogenic factors,
new, and more extensive, vascular structures develop (Reynolds et al., 1992;
McClure et at., 1994; Redmer and Reynolds, 1996). Both the theca and granulosa
cell layers undergo hypertrophy at this time. Theca cells invaginate into the
granulosa cell layer, but unlike other species (Niswender et at., 1994), remain
separate from the granulosa-lutein cells. Fibroblasts also invade into the
granulosa-lutein cell layer to give structural support.
The human corpus luteum has a central core of fibrin clot (Fig. 1.4). Surrounding
this is the thickened granulosa-lutein cell layer with numerous infoldings. This
cell layer is highly vascular and each granulosa-lutein cell is thought to abut a
vascular endothelial cell (Dharmarajan et at., 1985). The theca derived cells are
easily distinguishable from the granulosa derived cells in the human corpus
luteum (Sasano et at., 1989; Rodger et at., 1995). They form small clumps at the
periphery of the granulosa-lutein cells (Fig. 1.4). The theca-lutein cells invaginate
the granulosa-lutein cell layer along vascular fibrous infoldings which gives the
gland a spoke and wheel appearance (Corner, 1956). The steroidogenic cells are
surrounded by a dense fibrous stroma containing blood vessels, fibroblasts,
immune cells and extracellular matrix (ECM) (Behrman et at., 1993) (Fig. 1.4).
1.4.2 Composition of the Corpus Luteum
It is clear that the corpus luteum contains several different types of cell. These are
all likely to be involved in luteal function. Firstly, the corpus luteum contains cells
whose primary function is that of steroidogenesis. These cells will contain the
steroidogenic enzymes necessary to synthesise not only progesterone but other
steroid hormones such as oestrogen (Miller, 1988), and peptide hormones such as
inhibin A (Illingworth et at., 1991; Groome et at., 1996) and relaxin (Sherwood,
1994). The corpus luteum is the most vascular tissue in the body, with a blood
supply per unit mass, eight times that of the kidney (Bruce and Moor, 1976; Ford
et at., 1982). Endothelial cells, lining blood vessels and capillaries, are therefore
likely to form a large component of the gland. It has been estimated that over fifty
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Figure 1.4
Histological structure of the corpus luteum
Haematoxylin and eosin stained section of a human corpus luteum from the mid-
luteal stage of the luteal phase. The central portion of the corpus luteum contains
extravasated red blood cells and fibrin clot (C). Surrounding this are the
granulosa-lutein cells (G). On the periphery of the gland, in separate clumps, are
the smaller theca-lutein cells (T). The fibrous connective tissue (F) invaginates the
gland in a spoke and wheel appearance. The corpus luteum is contained in a
stromal capsule (S) containing blood vessels, fibroblasts and extracellular matrix
(BY). Scale Bar =200 pm.
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percent of cells in the corpus luteum are endothelial cells (Reynolds et al., 1992;
Zheng et al., 1994) and that each steroidogenic cell is surrounded by a network of
capillaries (Dharmarajan et al., 1985).
Another group of cells in the corpus luteum are those whose primary function is
likely to be structural. These will include fibroblasts and pericytes in the gland
capsule and around blood vessels (Lei et al., 1991). Lastly, there are the migratory
cells such as macrophages, monocytes and leukocytes. Their presence has been
clearly described in corpora lutea (Brannstrom et al., 1994a) and they have been
implicated in the regulation of luteal integrity (Brannstrom and Norman, 1993).
All these cells are contained within the ECM. This serves as the glue holding the
corpus luteum together. However as well as having a major structural role, the
ECM probably contributes essential elements to the functional activity of the
gland (Salamonsen, 1996; Hulboy et al., 1997).
1.4.3 Steroidogenic Cells
There are two types of steroidogenic cells in the corpus luteum. Those classified
as small (theca-lutein), with a thecal origin, and those classified as large
(granulosa-lutein), with a granulosal origin. They can be distinguished on the basis
of their size, morphology and functional characteristics. Granulosa-lutein cells
continue to express P450arom and theca-lutein cells continue to express 17a-
hydroxylase (Sasano et al., 1989). Although these two cell types can be found in
most mammalian species, they are usually found intermixed together (Niswender
and Nett, 1994). In the human however, they remain in discrete clumps separated
from each other. In the human, there are about twice as many large as small luteal
cells (Lei et al., 1991). This pattern does not appear to change throughout the
luteal phase (Lei et al., 1991).
Although theca cell hyperplasia occurs at the time of the LH surge, luteinisation is
associated with terminal cellular differentiation. Studies in rats have convincingly
demonstrated that steroidogenic cells in corpora lutea do not incorporate [3H]
thymidine into nuclei, a measure ofDNA synthesis, whereas such incorporation is
readily apparent in follicular granulosa cells (Hirschfield, 1984). In addition, the
mitotic index of granulosa cells decreases markedly after the LH surge and mitotic
figures in human corpora lutea are rare (Corner, 1956; Gougeon, 1996). Recent
studies using immunohistochemical assessment of nuclear proliferation markers
have elegantly shown that cellular proliferation in the primate corpus luteum is
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largely limited to endothelial cells (Christenson and Stouffer 1996a; Rodger et al.,
1997). In addition luteal 'rescue' is not associated with an increase in cellular
proliferation. (Rodger et al., 1997). The steroidogenic cells of the corpus luteum
have one fate: death when their function is served.
The granulosa-lutein and theca-lutein cells express LH receptors, but not FSH
receptors. They both express the steroidogenic enzymes responsible for the
synthesis of progesterone (Miller, 1988). There is little evidence, in the human, to
show functional differences in the steroidogenic nature of the theca-lutein and
granulosa-lutein cells. In the ruminant, however, it is thought that progesterone
production from the small cells is LH responsive, and that from the large cells in
largely autonomous (Niswender et al., 1985). As the primate corpus luteum is
absolutely dependant on the trophic support of LH (Hutchison and Zeleznik,
1984), this is unlikely to be the case in the primate. As luteal oestrogen production
parallels that of progesterone (Lenton and Woodward, 1988), and requires the
steroidogenic capacity of both cell types (Sasano et al., 1989; Sanders and
Stouffer, 1997), it is likely that both cell types are equally active within the
primate corpus luteum. However, detailed studies of these cells in the primate are
not yet available.
1.4.4 Vascular Endothelial Cells
The granulosa cell layer of the dominant follicle contains no blood vessels. These
cells are nourished by diffusion of nutrients from the blood vessels in the theca
cell layer (Gougeon, 1996). The corpus luteum has one of the highest blood flow
rates in the body (Bruce and Moor, 1976; Ford et al., 1992). In the rat, over 60%
of the luteal cell surface abuts a capillary and the remainder faces the interstitial
space which extends to the surface of capillaries (Dharmarajan et al., 1985). In
both ruminants (Lei et al., 1991) and primates (Reynolds et al., 1992), over half of
the cells in the mature corpus luteum are endothelial cells. The steroidogenic cells
of the corpus luteum of granulosa cell origin are found within a luxurious network
of blood vessels. Luteinisation is therefore associated with intense angiogenic
activity.
Blood vessels invade the granulosa from the theca during dissolution of the
membrana granulosa. New vessel growth involves several distinct phases
(Folkman, 1985; Reynolds et al., 1992). The first step is the dissolution of the
endothelial cell basement membrane. This is likely to involve the action of
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proteolytic enzymes. Although both matrix metalloproteinases (MMPs) (Tsang el
al., 1995) and serine proteases (Liu et al., 1996) have been detected in the corpus
luteum, their role in luteal angiogenesis has not yet been established. The next
stage of angiogenesis is the proliferation and migration of endothelial cells
(Reynolds et al., 1992). It is clear that in ruminants (Zheng et al., 1994), non-
human primates (Christenson and Stouffer, 1996a), and women (Rodger et al.,
1997), there is marked endothelial cell proliferation in the early-luteal phase.
Several factors have been identified as inducing trophic and proliferative
responses on endothelial cells, to stimulate angiogenesis.
There is no single angiogenic factor which is thought to be wholly responsible for
angiogenesis in the developing corpus luteum. Many growth factors and cytokines,
that can be detected in the corpus luteum, have been shown to have angiogenic
activity (Klagsbrun and D'Amore, 1991; Gordon et al., 1996). EGF (Huang et al.,
1995; Tamura et al., 1995), platelet derived growth factor (PDGF) (Bagavandoss
and Wilks, 1991), IGF-1 (Jones and Clemmons, 1995), TGFa and TGFp
(Behrman et al., 1993; Tamura et al., 1995), TNFa, IL-1 and IL-6 (Bagavandoss
and Wilks, 1991) are all thought to influence luteal angiogenesis. However,
experimental and observational studies in vitro suggest that bFGF and vascular
endothelial growth factor (VEGF) are the principle luteal endothelial cell mitogens
(Reynolds et al., 1992; Redmer and Reynolds, 1996; Redmer et al., 1996). Indeed,
although there appears to be redundancy in many of these angiogenic factors, it
has recently been shown that VEGF is essential for corpus luteum angiogenesis
(Ferrara et al., 1998).
1.4.5 Extracellular Matrix
The ECM constitutes a large part of the shape and volume of the corpus luteum. It
serves as the glue which holds the cellular components of the corpus luteum
together and forms the pathways for migration of transient cells. It consists of
collagen, proteoglycans, laminin, fibronectin and other components. As well as a
structural role, it is now clear that the ECM also has dynamic functions. It
influences cell proliferation, cell death and cell differentiation and forms a
repository for biologically active growth factors (Hulboy et al., 1997). The ECM
clearly has to be in a dynamic state during the tissue remodelling (Woessner,
1991) that occurs during the growth, development and atrophy of all tissues,
including the corpus luteum (Hulboy et al., 1997).
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It is therefore clear that agents that modify the ECM, have the potential to affect a
wide range of physiological and pathological processes (Matrisian, 1990).
Remodelling of connective tissue requires both breakdown and resynthesis of
ECM components. The degradation of ECM proteins can be effected by a variety
of proteolytic enzymes. The MMPs are the key enzymes involved in ECM
remodelling (Matrisian, 1990; Woessner 1991; Birkedal-Hansen, 1995;. Hulboy et
al., 1997). They are the only secreted enzymes capable of denaturing fibrillar
collagens, they are tightly controlled, but active under physiological conditions,
and are localised to areas of active tissue remodelling (Hulboy et al., 1997).
MMPs can be detected in the corpus luteum (Endo et al., 1993a; Tsang et al.,
1995).
1.4.6 Immune Cells
Other notable cells of the corpus luteum are the immune cells. Macrophages are
prominent cells in the corpora lutea of several species (Wang LJ et al., 1992;
Brannstrom et al., 1994b; Hehnke et al., 1994; Naftalin et al., 1997). Macrophages
appear to increase in number throughout the luteal phase (Best et al., 1996) and
are particularly present in the regressing corpus luteum at the time ofmenstruation
(Wang LJ et al., 1992; Brannstrom et al., 1994a). Much less is known about other
immune cells in the human corpus luteum. It is likely that there are T-
lymphocytes, neutrophil polymorphonuclear leukocytes, eosinophils and
monocytes (Brannstrom et al., 1994a; Best et al., 1996) in corpora lutea. It is
likely that these immune cells serve important roles in the regulation of luteal
function. They are fundamental sources of cytokines, that are increasingly
recognised as potential local regulators of luteal function (Brannstrom and
Norman, 1993).
1.5 Steroidogenesis
The main function of the corpus luteum is steroidogenesis, and the principle
secreted steroid hormone is progesterone. Indeed, the progesterone the corpus
luteum secretes is fundamental to its function. In the absence of any ovarian
activity, oestrogen followed by progesterone supplementation adequately prepares
the endometrium for implantation (Hodgen, 1983). In anovulatory cycles,
exogenous progesterone replacement and withdrawal will mimic the normal
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uterine environment and menstrual response (Li et al., 1991a). In the absence of a
corpus luteum, in donor oocyte pregnancies, progesterone supplementation alone
will maintain an early pregnancy (Lutjen et al., 1984). Luteectomy in the first few
weeks of pregnancy, will cause miscarriage (Csapo et al., 1973). Supplementation
with exogenous progesterone after luteectomy will maintain the pregnancy (Csapo
et al., 1973). It is clear that progesterone secretion is the primary function of the
corpus luteum.
1.5.1 Progesterone Synthesis
The human corpus luteum secretes huge amounts of progesterone. At its peak of
activity, it produces up to 25 mg of progesterone each day (Strauss et al., 1981).
The building block for progesterone and other steroid hormones is cholesterol.
Although the corpus luteum can synthesise cholesterol de novo, the available
evidence suggests luteal cholesterol is derived directly from the plasma, and the
mobilisation of intracellular stores (Strauss et al., 1981; Behrman et al., 1993).
Cholesterol is transported in the plasma as lipoprotein complexes (Goldstein and
Brown, 1977). Although cholesterol is present in both low-density lipoproteins
(LDL) and high-density lipoproteins (HDL), in the human ovary it seems that the
main source of cholesterol is LDL (Soto et al., 1984).
LDL receptors on the membranes of luteal cells bind LDL. The bound receptors
then aggregate into coated pits on the cell surface and are internalised (Strauss et
al., 1981). The internalised complexes associate with lysozymes, and cholesterol
is liberated (Stocco and Clark, 1996). This cholesterol is either used immediately,
for steroidogenesis, or esterified and stored in lipid droplets within the cell
(Strauss et al., 1981). Steroidogenic cells in the corpus luteum can clearly be seen
to contain lipid droplets at the ultrastructural level (Gillim et al., 1969). It is the
stored lipid which is partly thought to be responsible for the characteristic colour
and texture of the corpus luteum. Expression of LDL receptors has been shown to
be stimulated by gonadotrophins (Talavera and Menon, 1989). This means that
one of the luteotrophic effects of gonadotrophin is stimulation of the availability
of cholesterol substrate. However, it is generally accepted that the rate limiting
stages of progesterone production involve the enzymatic processing, rather than
the supply, of cholesterol (Stocco and Clark, 1996).
The sex steroid synthetic pathway is well defined (Figure 1.5). Cholesterol is
modified by specific steroidogenic enzymes acting in series. The first step is the
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Figure 1.5
The synthetic pathway for sex steroid hormones
A cartoon of the synthetic pathway, and the enzymes involved, in the production
of sex steroids. Most reactions occur in the cell cytosol and endoplasmic
reticulum, but the conversion of cholesterol to pregnenolone is catalysed by an
enzyme complex located on the inner mitochondrial membrane. This involves the
action of a specific cholesterol transport protein.
Chapter 1 Introduction
conversion of cholesterol to pregnenolone. This is carried out by a P450scc
(Simpson and Boyd, 1967). However, the P450scc enzyme complex is located on
the inner mitochondrial membrane (Stocco and Clark, 1996), and the cholesterol
is located within the cell cytosol. In order to gain access to the inner mitochondrial
space, the hydrophobic cholesterol has to cross the fluid space between the
mitochondrial membranes. It is clear that this hydrophilic space is a barrier to the
hydrophobic cholesterol and that carrier molecules are necessary to transport the
cholesterol to the P450scc complex. De novo protein synthesis is necessary for this
step (Garren et al., 1965), implying that specific carrier proteins are involved in
cholesterol transport.
Several different carriers have been implicated in this process, including sterol
carrier protein-2 (SCP-2) and other molecules (Hall, 1985; Stocco and Clark,
1996). However, it now seems likely that the best candidate molecule for the
cholesterol transport protein, is the recently characterised steroidogenic acute
regulatory protein (StAR) (Clark et al., 1994; Stocco and Clark, 1996). StAR has
been shown to be absolutely required for regulated steroidogenesis (King et al.,
1995; Lin et al., 1995; Waterman, 1995) and it has been detected in ovine (Juengel
et al., 1995), bovine (Hartung et al., 1995), and primate corpora lutea (Kiriakidou
et al., 1996). Other carrier molecules must also be physiologically relevant, as
StAR is not involved in placental progesterone production (Lin et al., 1995).
However, it seems likely that StAR expression is of fundamental importance in
luteal steroidogenesis (Stocco and Clark, 1996)
The conversion of cholesterol to pregnenolone is the rate limiting step in
steroidogenesis (Hall, 1985). The rate of this step is dependent on StAR (King et
al., 1995). It is therefore likely that StAR expression and activity is the rate
limiting step of acutely regulated steroidogenesis. In the cytosol, in association
with mitochondria, pregnenolone is converted into progesterone by the action of
3P-HSD. Progesterone itself can be converted into oestradiol via an androgen
intermediate. The enzyme 17a-hydroxylase converts progesterone into
androstenedione, which in turn is converted to 17(3-oestradiol by P450arom
(Strauss and Miller, 1991).
1.5.2 Other Steroid Products of the Corpus Luteum
As well as secreting progesterone, the primate corpus luteum also secretes
oestrogen (Lenton and Woodward, 1988; Zeleznik and Fairchild Benyo, 1994).
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Oestrogen synthesis in the corpus luteum appears to involve the same ontogeny as
oestrogen biosynthesis in the follicle (Sanders and Stouffer, 1997). Both
granulosa-lutein cells and theca-lutein cells are involved in its synthesis. Like the
follicle, the theca-lutein cells are responsible for the synthesis of androgen
substrates and the granulosa-lutein cells are responsible for their aromatisation to
oestrogens. In the corpus luteum, however, it is probable that the progesterone
required for androgen biosynthesis is obtained from both the theca-lutein and the
granulosa-lutein cells. It is also likely that the LH receptors, now present on both
these cell types, are wholly responsible for the oestrogen synthesis. The role for
FSH is not clear, there are no FSH receptors in the corpus luteum, and oestrogen
biosynthesis occurs when only LH is replaced in the luteal phase (Hutchison and
Zeleznik, 1984).
1.5.3 Non-Steroid Products of the Corpus Luteum
In addition to steroid hormones, the primate corpus luteum also synthesises and
releases a variety of protein hormones including relaxin (Sherwood, 1994),
oxytocin (Khan-Dawood et al., 1984), inhibin and activin (Fraser and Lunn,
1993). Relaxin is a protein hormone with structural similarities to insulin and
IGFs (Sherwood, 1994). Relaxin protein and mRNA can be detected in the
steroidogenic cells of the corpus luteum (MacLennan et al., 1991; Stoelk et al.,
1991; Sherwood, 1994). Indeed, the development of sensitive relaxin
immunoassays has demonstrated that it is secreted into the peripheral circulation
during the luteal phase of the cycle (Sherwood, 1994; Duffy et al., 1995). Relaxin
has been shown to have effects on ligaments, the cervix, uterus and vagina
(Sherwood, 1994), and it has a clear role during gestation. However, to date, the
biological endocrine or paracrine role of luteal relaxin during the menstrual cycle
has not been determined.
Oxytocin and its carrier protein have been localised to the steroidogenic cells of
the primate corpus luteum (Khan-Dawood and Dawood, 1983). Ovarian venous
oxytocin concentrations in the luteal phase are higher than in the peripheral
circulation (Dawood and Khan-Dawood, 1986), and are reduced after luteectomy
(Khan-Dawood et al., 1988). In addition, the oxytocin gene has also been shown
to be expressed in primate corpora lutea (Ivell et al., 1990; Khan-Dawood et al.,
1995). However, the pituitary gland is the major source of oxytocin in the
circulation, and there is no evidence for any endocrine effects of luteal oxytocin.
Chapter 1 Introduction
Indeed, there is no evidence for an endocrine effect of physiological levels of
oxytocin on the corpus luteum (Auletta and Flint, 1988). However, there are
oxytocin receptors within the corpus luteum (Khan-Dawood et al., 1993) and
some authors have postulated a paracrine action of oxytocin in the primate corpus
luteum (Khan-Dawood, 1997).
In the primate, inhibin production is a characteristic function of the corpus luteum
(Illingworth et al., 1991). Indeed, the corpus luteum produces substantially more
inhibin than does the follicle, and concordant changes in circulating inhibin and
progesterone are evident throughout the menstrual cycle (McLachlan et al., 1987).
Recently, it has been clearly shown that the human corpus luteum secretes large
amounts of inhibin A and pro-a-C subunit (Groome et al., 1995; Groome et al.,
1996). Indeed, mRNAs for inhibin subunits are highly expressed in the primate
corpus luteum (Fraser et al., 1993; Roberts et al., 1993). One role of luteal inhibin
secretion may be to augment the inhibition of FSH secretion, and inhibit antral
follicular growth, during the luteal phase of the ovarian cycle (Fraser and Lunn,
1993; Baird and Smith, 1993). The decrease of inhibin secretion at luteal
regression (Illingworth et al., 1991), may cause the elevation of serum FSH levels
that begins at menses and is responsible for subsequent follicular development.
1.5.4 Systemic Regulators of Steroidogenesis
The corpus luteum is not an autonomous gland. In the absence of systemic
gonadotrophic support, its function rapidly ceases (Hutchison and Zeleznik, 1984).
LH from the pituitary is the principal regulator that controls luteal function.
Removal of the pituitary surgically, or the gonadotrophins pharmacologically,
results in rapid loss of luteal function (Asch et al., 1982; Fraser et al., 1986).
Replacement of LH or hCG alone maintains normal luteal function (Thau et al.,
1983; Hutchison and Zeleznik, 1984). In addition, LH can directly increase
progesterone output from isolated luteal cells and luteal tissue (Stouffer et al.,
1977; Dennefors et al., 1982). The steroidogenic cells of the corpus luteum
express specific receptors to LH (Ravindranath et al., 1992a).
LH binds to specific high affinity receptors on luteal cells (Cole et al., 1973;
Bramley et al., 1987). The LH receptor has been cloned and it belongs to the
family of transmembrane GTP binding protein (G-protein)-coupled receptors
(Minegishi et al., 1990). LH receptors have seven transmembrane domains, a large
glycosylated extracellular N-terminal domain and a smaller C-terminal
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intracellular domain (Segaloff and Ascoli, 1993) (Fig. 1.6). Binding of LH
activates G-proteins and stimulates the enzyme adenylyl cyclase to produce cAMP
(Niswender and Nett, 1994). Other molecules and enzymes, including calcium
ions, phospholipase C, diacylglycerol (DAG), inositol triphosphate (ITP) and
protein kinase C (PKC), have also been implicated in the second messenger
pathways activated by the LH receptor (Cooke et al., 1989; Lopez Bemal et al.,
1995). However, it appears that cAMP is the primary second messenger molecule
and that responsible for the stimulation of steroidogenesis (Marsh, 1976;
Dennefors et al., 1982; Rojas et al., 1989)
Although LH is absolutely required to maintain luteal function, circulating LH
levels are low throughout the luteal phase and do not parallel the output of
progesterone (Ellinwood el al., 1984). Although there are changes in the LH
receptor (Ravindranath et al., 1992a; Nishimori et al., 1995) and adenylyl cyclase
(Eyster et al., 1985; Rojas et al., 1989) throughout the luteal phase, these do not
always parallel progesterone secretion. It is therefore likely that the action of LH
on steroidogenic luteal cells is modulated in a paracrine fashion by local regulators
of steroidogenesis.
1.5.5 Local Regulators of Steroidogenesis
Just as local paracrine regulators of steroidogenesis have been described in the
ovarian follicle (Gougeon, 1996), they have been described in the corpus luteum.
IGFs, inhibins and activins, steroids, eicosanoids, cytokines, growth factors and
other molecules (Tsafiri and Adashi, 1994) have been reported as potential local
regulators of luteal function. It is clear from studies of infraprimate species, and
studies of primate luteal cells, or luteinised granulosa cells, in vitro, that many
molecules have the potential to affect steroid secretion. Clearly, the molecules
with stimulatory or inhibitory effects in vitro which can be localised to the corpus
luteum are all potential local regulators of steroidogenesis. However, the
physiological role of these molecules remains unclear.
The IGFs have a probable role in folliculogenesis and it is likely that they have a
local role in the corpus luteum. Work in the primate corpus luteum is limited, but
IGFs, IGF receptors and IGFBPs can be localised to the corpus luteum of
infraprimate species (Amselgruber et al., 1994; Perks and Wathes, 1996; Juengel
et al., 1997). Indeed, there is increasing data that these molecules, in particular
IGF-1 and IGFBP-3 can also be localised in the primate corpus luteum
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Figure 1.6
The structure of the LH receptor
Cartoon of the LH receptor showing the large extracellular N-terminal domain,
with glycosylation points, the smaller intracellular C-terminal domain and the
seven transmembrane loops.
(Segaloff and Ascoli, 1993)
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(Hernandez et al., 1992; Johnson et al., 1996; Vandessel et al., 1996). IGF-1
stimulates progesterone production from isolated luteal cells (Devoto et al., 1995)
and this effect seems to be mediated by specific IGF-1 receptors. IGF-1 receptors
have been identified in human corpora lutea from spontaneous and clomiphene
induced cycles (Hernandez et al., 1992; Obasiolu et al., 1992; Johnson et al.,
1996). IGFBP-3 localises to endothelial cells and may be involved in the local
availability and actions of IGFs (Fraser et al., 1997). Clearly the study of the role
of IGFs in the' primate corpus luteum is nascent.
Inhibins and activins may have a local paracrine effect in the corpus luteum. As
discussed above, these molecules have been shown to have direct effects on
steroidogenesis (Hillier et al., 1991a). It is not clear, however, whether inhibin can
affect luteal steroidogenesis in vivo or whether its anti-proliferative action
(Matzuk et al., 1992) is important in the corpus luteum. There is more evidence
that activin inhibits luteal cell steroidogenesis (Hillier et al., 1991a; Miro and
Hillier, 1992; Brannian et al., 1992). Activin binding sites, presumably activin
receptors, can be detected within the corpus luteum (Woodruff et al., 1993) and
the subunits responsible for its production are clearly present (Fraser et al., 1993;
Roberts et al., 1993). It is not known how important the inhibitory effect of activin
is in the corpus luteum, but, in view of the recent data suggesting increased activin
concentrations during luteolysis (Muttukrishna et al., 1996), its role may be
significant, and more work is clearly required.
Several authors have postulated a role for progesterone in controlling its own
synthesis (Duffy et al., 1994; Rothchild, 1996). Recent studies have shown that
the human (Iwai et al., 1990; Suzuki et al., 1994) and non-human primate corpus
luteum contains specific nuclear hormone receptors for progesterone (Hild-Petito
et al., 1988; Hild-Petito and Fazleabas, 1997). Progesterone receptor protein can
be detected in the corpus luteum by immunohistochemistry (Hild-Petito et al.,
1988), western blotting (Duffy et al., 1997), ligand binding (Slayden et al., 1994)
and mRNA can be detected by reverse transcriptase (RT) polymerase chain
reaction (PCR) (Chandrasekher et al., 1994). Co-localisation immuno-
histochemical studies have suggested that the steroidogenic cells responsible for
progesterone synthesis express genomic receptors for the progesterone they
produce (Hild-Petito et al., 1988; Suzuki et al., 1994). In addition, some novel
data using ovine and porcine corpora lutea have suggested that the corpus luteum
has novel membrane associated progesterone binding proteins and these may be
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non-genomic progesterone receptors (Bramley and Menzies, 1988; Menzies and
Bramley, 1994; Bramley and Menzies, 1994).
Although the hypothesis of progesterone controlling its own production is
attractive (Rothchild, 1981; Duffy et al., 1994; Rothchild, 1996), its paracrine role
in the corpus luteum is not clear. The progesterone receptor antagonist
mifepristone (RU486) can induce luteolysis when administered in the luteal phase.
However, RU486 affects luteotrophic gonadotrophin secretion (Schaison et al.,
1985; Batista et al., 1994), and when gonadotrophins are given in combination
with RU486 there is no effect (Croxatto et al., 1989). Elegant studies investigating
the effect of trilostane, an inhibitor of 3P-HSD, on luteal lifespan are now
producing interesting results (Duffy et al., 1994; Duffy and Stouffer, 1995; Duffy
et al., 1996). Although these studies have postulated several roles for progesterone
in the local control of luteal function (Duffy et al., 1994; Duffy and Stouffer,
1995), specific physiological roles for local progesterone have not yet been clearly
identified.
Androgen receptors have been identified in primate corpora lutea (Suzuki et al.,
1994). They appear to be maximal just after ovulation (Horie et al., 1992).
Although androgens have been implicated in some forms of follicular atresia, their
local role in the corpus luteum is not known. A direct action of androgens in the
corpus luteum has not been demonstrated, but androgens inhibit progesterone
synthesis and LH receptor expression on luteinised granulosa cells (Polan et al.,
1986). In addition, they can act with LH to stimulate inhibin production from
luteinised granulosa cells (Hillier et al., 1991b). Androgens have some anabolic
effects. They stimulate cellular growth and may be involved in ECM deposition
(Behrman et al., 1993). However, at present their role in the corpus luteum is not
clear.
Other molecules that can be detected in corpora lutea have been shown to affect
steroidogenesis in vitro (Nappi et al., 1994). Prostaglandin (PG) F2ct has been
shown to have negative effects on steroidogenesis under a variety of conditions
(Jordan, 1981; Dennefors et al., 1982; Auletta and Flint, 1988; Abayasekara et al.,
1993). Other prostaglandins, notably PGE2, have been shown to have pro-
steroidogenic effects in some experiments (Dennefors et al., 1982; Hahlin et al.,
1988; Zelinski-Wooten and Stouffer, 1990). This has lead several authors to
postulate a role for the ratio of different prostaglandins in determining luteal
function (Mitchell et al., 1991; Olofsson and Leung, 1994). In addition,
Chapter 1 Introduction
arachidonic acid itself, and leukotrienes, have also been shown to have negative
effects on steroidogenesis (Yoshimura et al., 1992; Ciereszko et al., 1995).
Receptors for prostaglandins are present in primate corpora lutea (Powell et al.,
1974; Rao et al., 1977a), and it is likely that they have a significant role in luteal
function. The precise nature of that role, however, remains obscure (Olofsson and
Leung, 1994).
Cytokines have clear effects on luteal function in vitro (Brannstrom and Norman,
1993; Nappi et al., 1994). IFN-y has been shown to inhibit basal, as well as hCG-
stimulated, progesterone synthesis in human luteal cells (Wang HZ et al., 1992).
Various reports have suggested that IL-1, IL-2 and IL-6 have both pro- and anti-
steroidogenic effects (Wang et al., 1991; Sjogren et al., 1991; Fukouka et al.,
1992; Brannstrom and Norman, 1993). One of the best studied cytokines in luteal
function is TNFa. TNFa can be detected in corpora lutea (Roby and Terranova,
1989), particularly during luteal regression (Bagavandoss et al., 1990). It has clear
anti-steroidogenic effects in culture conditions (Wang HZ et al., 1992; Fairchild
Benyo and Pate, 1992). It is likely that cytokines are important in luteal function,
but it remains to be shown whether their effects on steroidogenesis occur at
physiological, rather than pharmacological, levels.
In summary, luteal steroidogenesis is absolutely dependent on LH from the
pituitary gland. LH binds to LH receptors to activate intracellular messenger
cascades, notably cAMP. Cyclic AMP stimulates the synthesis of StAR, the
transport of cholesterol to the inner mitochondrial membrane, and the activity of
the steroidogenic enzymes. This results in progesterone synthesis and secretion.
Progesterone synthesis can be modified by various molecules acting in autocrine
and paracrine pathways. These molecules include proteins, growth factors,
cytokines, eicosanoids and steroids. These molecules are likely to exert a major
influence on the control of luteal steroidogenesis. However, the exact role of these
factors in luteal steroidogenesis in vivo is not yet clear.
1.6 Luteolysis
In the absence of conception, the corpus luteum will lose its functional and
structural integrity. Historically, corpus luteum regression, or luteolysis, has been
divided into two distinct stages: functional and structural luteolysis. Functional
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luteolysis refers to the increasing failure of progesterone synthesis and secretion
(Zeleznik and Fairchild Benyo, 1994), whereas structural luteolysis refers to the
processes involved in the dissolution and resorption of the gland (Behrman et al.,
1993), that are classically thought to follow functional luteolysis (Luck and Zhao,
1995). These definitions were based on studies of the rat corpus luteum (Malven,
1969), where these processes are clearly separate events, under separate endocrine
control (Niswender and Nett, 1994). In the human, there appears to be no clear
temporal and endocrinological distinction between these stages of luteolysis
(Behrman et al., 1993). However, for the purpose of this discussion, the cessation
of progesterone production can be viewed as one end-point of luteolysis and luteal
involution as another.
1.6.1 The Cessation of Luteal Steroidogenesis
Progesterone synthesis and secretion by the corpus luteum is dependant on the
action of the trophic hormone, LH, from the pituitary gland. One could postulate
that changes in LH secretion during the luteal phase could be responsible for the
initiation of luteal regression. Withdrawal of LH using gonadotrophin releasing
hormone (GnRH) antagonists (GnRHant) during the luteal phase, results in a rapid
loss of both the functional and structural integrity of the primate corpus luteum
(Hutchison and Zeleznik, 1984, Fraser et al., 1986). In fact, pituitary LH secretion
does change as the luteal phase progresses. There is a progesterone-mediated
reduction of the frequency of LH pulses from approximately one pulse per hour,
during the early to mid-luteal phase, to one pulse every four to six hours, from the
mid-luteal to the late-luteal phase (Ellinwood et al., 1984). Some widely-read
undergraduate textbooks state that luteolysis is secondary to the reduction of LH
secretion, secondary to progesterone feedback on the hypothalamic-pituitary axis
(O'Riordan et al., 1982).
Luteolysis is not caused by alterations in pituitary LH pulse frequency.
Maintenance of menstrual cycles in anovulatory rhesus monkeys and humans by
unvarying GnRH pulse frequencies, typical of the follicular and early luteal
phases, does not prolong the life span of the corpus luteum (Crowley and
McArthur, 1980). Moreover, using a pulse frequency of one pulse per eight hours,
typical of the late-luteal phase, throughout the luteal phase does not alter its
duration (Hutchison et al., 1986). When plasma concentrations of LH are reduced
by 50% to 75%, by limiting the amount of GnRH delivered per pulse,
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progesterone secretion is maintained (Zeleznik and Little-Ihrig, 1990). These
findings suggest that during the early and mid-luteal phases there is a surfeit of
LH. During the mid- to late-luteal phases the corpus luteum appears to become
much less sensitive to the ambient concentrations of LH.
Although luteolysis cannot be attributed to hypothalamic pituitary regulation, it is
possible that it results from the inability of LH to bind to the corpus luteum. In
ruminants, there is a decline in both LH receptors and progesterone as luteolysis
approaches (Guy et al., 1995; Smith et al., 1996a). However, it appears that the
fall in progesterone production precedes the loss of LH receptors. A similar
conclusion has been reached in non-human primates (Cameron and Stouffer,
1982). In addition, the binding affinity of the luteal LH receptor does not appear to
consistently change throughout the luteal phase (Rao et al., 1977b; Cameron and
Stouffcr, 1982; Ottobrc et al., 1984; Yeko et al., 1989). It appears that falling
progesterone production in spontaneous luteolysis is not preceded by a change in
the number or affinity of the luteal LH receptors.
The presence of LH receptors per se is not the only dictate of receptor function in
the corpus luteum. Coupling of these receptors to adenylyl cyclase and the
generation of cAMP is vital for mediation of the action of LH (Segoloff and
Ascoli, 1993). There is some evidence that LH receptors can uncouple from
adenylyl cyclase, and that adenylyl cyclase itself may be regulated independently
from the LH receptor (Eyster et al., 1985; Rojas et al., 1989). However, most data
on LH receptors are from rodents or rodent cell lines (Segaloff and Ascoli, 1993).
There is some indication that LH receptors behave differently in the corpus luteum
of rodents and humans. Ligand causes LH receptor down regulation in rat corpora
lutea (Peegel et al., 1994), but does not appear to in the primate corpus luteum
(Ottobre and Stouffer, 1986). Clearly, further work on the human luteal LH
receptor is required.
It is not known whether failure of progesterone production is secondary to
alterations in the levels of the steroidogenic enzymes. Steroidogenic enzymes are
not expressed in the non-functioning corpus luteum at the time of menstruation
(Doody et al., 1990; Bassett et al., 1991). Various studies have suggested a
reduction of mRNA, and possibly protein, of the steroidogenic enzymes P450scc
and 3(3-HSD during the primate luteal phase (Bassett et al., 1991; Suzuki et al.,
1993; Sanders and Stouffer, 1997). However, it is not clear whether this effect
occurs before or after the fall in progesterone begins. Although StAR can be
Chapter 1 Introduction
detected in the human corpus luteum (Kiriakidou et al., 1996), and it is the best
candidate for the rate-limiting step of luteal steroidogenesis (Stocco and Clark,
1996), it is not clear how the expression of StAR changes throughout the
functional luteal phase, or whether it is regulated independently from the other
steroidogenic enzymes. The role of an alteration in steroidogenic enzyme
expression during the functional lifespan of the corpus luteum is not clear.
1.6.2 The Involution of the Corpus Luteum
During the mid-luteal phase, at the peak of its functional activity, in a non-
conception cycle, the corpus luteum is clearly visible on the surface of the ovary.
During the early follicular phase of the next cycle, it is difficult to identify that
corpus luteum on the ovary macroscopically (Zeleznik and Fairchild Benyo,
1994). Microscopically, it has become a small, relatively avascular, fibrous
remnant (Corner, 1956). During this marked luteal involution, there has been a
loss of luteal cells and a clear change in its size and structure. This involves
marked remodelling of the ECM and the influx of fibroblasts (Adams and Hertig,
1969).
1.6.3 Apoptosis
There is good evidence that the loss of cells from the corpus luteum during
luteolysis is by a form of physiological cell death known as apoptosis (Wyllie et
al., 1980; Arends and Wyllie, 1991). Indeed, apoptosis was first described in
hormonally responsive tissues after loss of trophic support (Kerr et al., 1972).
Apoptosis is an active process involving the activation and expression of several
different genes (Arends and Wyllie, 1991). The biochemical and morphological
characteristics of apoptosis are now well established.
Cells undergoing apoptosis shrink and become denser with pyknotic nuclei. Their
chromatin is cleaved, and the nucleus and cytoplasm break up into small
membrane-bound packages called apoptotic bodies, that are phagocytosed by
macrophages and neighbouring cells. These morphological changes of apoptosis
can be seen in tissues by conventional light microscopy (Wyllie, 1994). However,
apoptosis occurs rapidly, and apoptotic bodies are only visible for short periods of
time in tissues. When they are easily seen, there tends to be high rates of apoptotic
cell death within the tissue (Arends and Wyllie, 1991).
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Biochemically, apoptosis is associated with a characteristic pattern of
deoxyribonucleic acid (DNA) degradation. The DNA is cleaved between histones
resulting in fragments which are multiples of 180-200 base pairs (bp). This gives
rise to a typical laddering pattern when the DNA is separated by gel
electrophoresis (Wyllie, 1994). In addition, techniques have now been developed
to allow the in situ detection of DNA fragments. These in situ end-labelling
techniques are claimed to detect apoptotic cells in tissue sections (Shikone et al.,
1996; Young et al., 1997).
The early morphological studies of the corpus luteum described features which are
now recognised as characteristic of apoptotic cell death (Corner, 1956). More
recent studies, looking specifically at apoptosis, have shown morphological
evidence of apoptosis in the corpora lutea of domestic animals and primates
(Zheng et al., 1994; Fraser et al., 1995b). Apoptosis can also be detected by DNA
laddering and in situ 3' end-labelling of oligonucleosomes in primate and ruminant
corpora lutea (Juengel et al., 1993; Rueda et al., 1995a; Shikone et al., 1996;
Young et al., 1997). There seems to be no doubt that apoptosis occurs in the
corpus luteum.
If apoptosis is involved in the involution of the corpus luteum, the rates of
apoptosis should increase during luteolysis and reduce during luteal 'rescue1. This
appears to be what happens. Induction of luteolysis in the primate and ruminant
clearly induces apoptosis (Juengel et al., 1993; Fraser et al., 1995b; Rueda et al.,
1995a; Young et al., 1997). In women, regressing corpora lutea have the
biochemical features of apoptosis, and these are not evident in the mid-luteal
corpus luteum (Shikone et al., 1996; Yuan and Giudice, 1997). Rates of apoptosis
have been reported to be reduced in the corpus luteum of early pregnancy
(Shikone et al., 1996). In addition, studies in vitro have suggested a role for hCG
in promoting luteal cell survival (Dharmarajan et al., 1994). The loss of the corpus
luteum from the ovary is likely to involve apoptotic cell death and luteal 'rescue'
appears to inhibit apoptotic cell death.
Apoptosis is regulated by a variety of proteins, genes and proto-oncogenes (Hale
et al., 1996). Apoptosis and proto-oncogenes, particularly bax and bcl-2 have clear
roles in follicular atresia (Hsueh et al., 1994; Tilly, 1996). These proteins can be
detected in human corpora lutea (Rodger et al., 1995; Rodger et al., 1998), but
they do not seem to change during the luteal phase or after luteal 'rescue' with
hCG. Another proto-oncogene, c-myc, can also be detected in primate corpora
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lutea (Fraser et al., 1995b), and may be involved in induced luteolysis. However,
at present, there is little convincing data about the role of proto-oncogenes in the
apoptosis associated with luteolysis, and further work needs to be done.
1.6.4 Remodelling of the Extracellular Matrix
Remodelling is a term used to describe changes in size, shape and cellular
composition during growth, development and atrophy of tissues. The corpus
luteum undergoes extensive tissue remodelling throughout its functional lifespan.
The elegant observational studies of Corner systematically documented the
marked tissue changes in the corpus luteum throughout the luteal phase (Comer,
1956). As well as changes in the appearance and composition of the cellular
component, he documented marked alterations in the supporting connective tissue.
Connective tissue forms a large proportion of each tissue and it is primarily
responsible for the shape and volume of different organs. It is composed of
stromal elements, such as cellular basement membranes, vessels, carrying blood
and lymph, and cells such as fibroblasts and macrophages. All these elements are
found within a supporting ECM. One of the major features of tissue remodelling is
the continued synthesis and breakdown of the ECM (Luck and Zhao, 1995). The
degradation and synthesis of ECM is orchestrated by a variety of hormones,
cytokines and local growth factors (Hulboy et al., 1997). The enzymes responsible
for this remodelling, however, are tightly controlled at a cellular level.
1.6.5 The Matrix Metalloproteinases
The MMPs are the key enzymes involved in the degradation of ECM proteins
during tissue remodelling (Birkendal-Hansen, 1995; Hulboy et al., 1997). They
are the only secreted enzymes capable of denaturing fibrillar collagens, and are
localised to areas of active tissue remodelling (Hulboy et al., 1997). The MMPs
are a group of structurally related, zinc-dependant, proteolytic enzymes which are
tightly controlled, but active under physiological conditions (Birkendal-Hansen,
1995). At present, 17 different MMPs have been described (Hulboy et al., 1997).
Although most are secreted into the ECM (Matrisian, 1990), the most recently
described MMPs are transmembrane enzymes expressed on cellular membranes
(Hulboy et al., 1997). Of the 17 MMPs, the ones that have been studied most are
interstitial collagenase (MMP-1), gelatinase A (MMP-2) and gelatinase B (MMP-
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9) (Woessner, 1991). These are the enzymes which are capable of degrading the
major structural collagens, gelatines and elastins.
As the MMPs are highly active proteolytic enzymes, their activity is tightly
controlled at several levels. The first level of control is the transcriptional
activation of mRNA synthesis (Birkendal-Hansen, 1994). The second level of
control is their synthesis as pro-enzymes which require proteolytic cleavage to be
fully active (Woessner, 1991; Hulboy et al., 1997). The third level of control is the
presence of specific tissue inhibitors. Tissue inhibitors of metalloproteinases
(TIMPs) bind to, and inhibit, MMP enzymes with a one-to-one stoichiometry
(Matrisian, 1990). At present there are four members of the TIMP family. TIMP-1
and TIMP-2 are secreted proteins which are widely expressed (Hulboy et al.,
1997). TIMP-3 is found is association with the basement membrane, but is less
well characterised, and TIMP-4 has recently been reported, but has not yet been
fully investigated (Hulboy et al., 1997). TIMPs are frequently regulated in co¬
ordination with MMPs (Salamonsen, 1996; Hulboy et al., 1997).
Alterations in MMP activity have been shown to be important in several
physiological and pathological processes. MMPs have been implicated in the
spread of neoplastic tissues (Naylor et al., 1994), as well as in remodelling of
reproductive tissues, such as the endometrium at menstruation (Hulboy et al.,
1997), and the follicle wall at ovulation (Curry et al., 1992). It is likely that MMPs
are involved in luteinisation and luteolysis but, although they can be detected in
infraprimate corpora lutea (Endo et al., 1993a; Tsang et al., 1995; Nothnick et al.,
1996), little is known about their expression and activity in the corpus luteum. A
great deal more is known about the expression of TIMPs in the corpus luteum.
The corpus luteum expresses large amounts of TIMPs, indeed TIMP-1 has been
shown to be one of the major secretory products of the ovine corpus luteum
(Smith et al., 1993). Although first described in the sheep corpus luteum, it is now
clear that TIMP-1 is produced in large amounts by the corpus luteum of many
species, including the rat (Nothnick et al., 1995), sheep (Smith GW et al., 1994),
cow (Juengel et al., 1994) and pig (Smith MF et al., 1994). It is not just TIMP-1
that is expressed in the corpus luteum, TIMP-2 is also produced by corpora lutea
of rats (Nothnick et al., 1995), sheep (Smith et al., 1995a) and cows (Smith et al.,
1996b), and that TIMP-3 can also be detected in rat ovaries (Nothnick et al.,
1995). It is likely that TIMPs have significant roles in the control of luteal
structure and function.
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The expression of TIMP-1 has been shown to change during PGF2a-induced
luteolysis (Juengel et al., 1994). In addition, exposure to gonadotrophins, during
the LH surge, up-regulates TIMP-1 expression in preovulatory granulosa cells
(Smith GW et al., 1994). These observations support a hypothesis that the
remodelling associated with luteolysis is modulated by a reduction in TIMP-1
expression and luteal 'rescue' by hCG is associated with an up-regulation in the
expression of TIMP-1, or other TIMPs. This hypothesis implies a role for MMP
activity during the functional lifespan of the corpus luteum. However, at present
little is known about MMP expression during the lifespan of the corpus luteum,
and nothing is known about their expression in the primate corpus luteum. In
addition, it is not clear how MMPs can function in an environment which
contains, by all accounts, a large excess of specific inhibitors.
To recap, in a non-conception cycle, the corpus luteum undergoes luteolysis.
There is a reduction of LH-stimulated progesterone production. The molecular
mechanisms for this decrease are not clear but are likely to involve an increasing
block to steroidogenesis somewhere in the progesterone production pathway. In
addition, the corpus luteum regresses structurally. This regression is likely to
involve apoptotic cell death and tissue remodelling involving the MMPs.
However, the molecular mechanisms, and controls, of these processes, particularly
in the primate, are still unknown.
1.7 The Search for a Luteolysin
What makes the corpus luteum undergo luteolysis? The answer to that question is
unknown, undoubtedly complex, and continues to baffle. Several molecules have
been studied as potential luteolysins. Most of these molecules have been shown to
have roles in infraprimate species. It is unlikely, however, that a single luteolysin
exists in the primate. Clearly though, transducer molecules, other than LH, must
be involved in the control of both functional and structural luteolysis in women.
Identification of these molecules has proven difficult. However, the molecules
implicated in luteolysis in other species may well have roles in the primate, to a
greater or lesser extent (Auletta and Flint, 1988). These molecules are now
discussed in detail and their relevance to primate physiology reviewed.
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1.7.1 Oestrogen
The primate corpus luteum synthesises and secretes oestrogen (Lenton and
Woodward, 1988; Sanders and Stouffer, 1997). Oestrogen is clearly luteolytic in
some infraprimate species such as rabbits (Niswender and Nett, 1994). It has been
suggested that locally produced oestrogens may facilitate the corpus luteum to
self-destruct and lead to regression (Knobil, 1973). Direct injection of oestrogen
into the ovary containing the corpus luteum results in premature menstruation
(Gore et al., 1973; Karsch and Sutton, 1976). This seems to be a local effect, as
systemic oestrogen, or injection into the contralateral ovary did not shorten the
menstrual cycle (Karsch et al., 1973), and it, at that time, appeared that plasma LH
concentrations were not significantly reduced (Karsch and Sutton, 1976). It has
also been reported that the concentrations of oestrogens in the macaque corpus
luteum increase during the late-luteal phase as the progesterone concentrations
decline (Butler et al., 1975). Therefore, under experimental situations oestrogens
can indeed be luteolytic.
The physiological relevance of oestrogen-induced luteal regression however is not
clear. Recent studies have failed to detect oestrogen receptors, by
immunohistochemistry and RT-PCR analysis, in primate corpora lutea
(Chandrasekher et al., 1994). However, in the rabbit corpus luteum, where
oestrogen is thought to be of physiological relevance, oestrogen receptors have
been clearly identified (Lee et al., 1971). The negative effects of oestrogen on the
primate corpus luteum are now thought likely to be due to a suppressive effect on
LH secretion (Schoonmaker et al., 1982). Oestrogen does not induce regression
when LH is added back (Hutchison et al., 1987). It is likely that oestrogen-induced
luteal regression is due to the suppression of LH secretion, and there is no
evidence of a physiological role in vivo.
1.7.2 Prostaglandins
In non-primate mammals, luteolysis has been attributed to the uterine synthesis
and secretion of PGF2a (Niswender and Nett, 1994), and its subsequent transport
to the ovary via a local countercurrent mechanism (Auletta and Flint, 1988). This
is clearly not the case in primates, as hysterectomy does not affect the ovarian
cycle, or the luteal life-span (Neill et al., 1969a). Although non-primate mammals
and primates have evolved alternative mechanisms of luteolysis, it is possible that
they share some common effector molecules. There is good evidence to suggest
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that PGF2a is also luteolytic in non-human primates and women (Auletta et al.,
1984a; Auletta et al., 1990).
Systemic PGF2a is luteolytic when administered to smaller primates, such as the
marmoset monkey, in pharmacological doses (Fraser et al., 1995b). It is also
luteolytic when administered to rhesus monkeys in the early stages of pregnancy
(Wilks, 1980). Although pharmacological doses of PGF2a do not alter cycle
length in most primates (Wilks, 1980; Auletta and Flint, 1988), transient
reductions in circulating progesterone have been reported after systemic, intra-
luteal, and intra-arterial administration of PGF2a, in rhesus monkeys (Auletta et
al., 1973; Auletta and Flint, 1988) and women (Wentz and Jones, 1973; Auletta
and Flint, 1988). There is a rapid metabolism of prostaglandins during their
passage through the pulmonary circulation, that seriously interferes with their
bioavailability (Samuelsson et al., 1971). When PGF2a is infused, at physiological
rates, through a local mechanism, directly into the rhesus monkey corpus luteum,
it has been shown to be luteolytic (Auletta et al., 1984a).
If PGF2a is a physiological luteolysin in non-human primates and women, it
would need to be generated within the ovary or the corpus luteum itself (Auletta
and Flint, 1988). Evidence for the local production of PGF2a is however still
contradictory. Some groups report higher concentrations of PGF2cc in human luteal
tissue during luteolysis (Shutt et al., 1976; Patwardhan and Lanthier, 1980), but
other groups have failed to confirm this (Challis et al., 1976; Swanston et al.,
1977). Measurement of 13,14-dihydro-15-keto-PGF2a (DHKF2a), the major
circulating metabolite of PGF2a, in peripheral plasma, failed to show any change
at the time of luteolysis (Auletta et al., 1984b). However, the primate corpus
luteum has the capacity to synthesise PGF2a (Challis et al., 1976; Balmaceda et
al., 1979), and DHKF2a levels are higher in ovarian venous blood from the ovary
containing the corpus luteum, when compared to the other ovary, during the late-
luteal phase in the rhesus monkey (Auletta et al., 1984b). In addition, like non-
primate mammals (Niswender and Nett, 1994), the corpus luteum of non-human
primates and women express PGF2oc receptors (Powell et al., 1974; Rao et al.,
1977a).
PGF2oc is not the only prostaglandin which has been shown to affect luteal
function. In vitro, whereas PGF2cc inhibits luteal function (Auletta and Flint,
1988), PGE2, PGD2 and PGI2 generally stimulate luteal function (Zelinski-
Wooten and Stouffer, 1990; Zeleznik and Fairchild Benyo, 1994). Injections of
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indomethacin, a cyclooxygenase (COX) inhibitor, into rhesus monkeys, at doses
that prevented the initiation of labour, failed to affect the life-span of the corpus
luteum (Manaugh and Novy, 1976). However, infusion of the prostaglandin
synthase inhibitor, meclofenamate, into the corpus luteum of the rhesus monkey,
during the mid-luteal phase, actually caused premature luteolysis (Sargent et al.,
1988). This suggests that prostaglandin synthesis may be required for normal
luteal function at this time. Indeed, it has been demonstrated that direct infusion of
PGE2 into the corpus luteum inhibits PGF2ot-induced luteal regression in monkeys
(Zelinski-Wooten and Stouffer, 1990). However exogenous PGE2 infusion, during
the time of luteal regression, did not extend the life-span of the corpus luteum. If
prostaglandins are involved in luteal function, their net effect is likely to depend
on the relative abundance of luteotrophic and luteolytic forms (Olofsson and
Leung, 1994).
1.7.3 Oxytocin
Exogenous oxytocin has been shown to induce luteal regression or insufficiency in
ruminants (Auletta and Flint, 1988; Niswender and Nett, 1994). Although these
effects were initially considered pharmacological, several lines of evidence
suggest that oxytocin may have a physiological role during luteolysis in ruminants.
It has become clear that the mechanism of action of oxytocin is to stimulate
uterine secretion of the luteolytic agent PGF2a (Auletta and Flint, 1988).
Immunisation against endogenous oxytocin was found to delay luteolysis
(Sheldrick et al., 1980). It has also become clear that oxytocin is synthesised,
stored and released from the steroidogenic cells of the ruminant corpus luteum
(Wathes and Swarm, 1982). At the time of luteolysis, there is an increase in the
sensitivity of the uterus to oxytocin, and PGF2a secretion increases (Roberts et al.,
1976; Sheldrick and Flint, 1985). It is therefore likely that luteal oxytocin is
involved in luteolysis at a systemic, rather than a local, level.
Some in vitro data suggests, however, that oxytocin may have direct effects on
luteal steroidogenesis. Oxytocin has an inhibitory effect on hCG-stimulated
progesterone synthesis in dispersed bovine luteal cells (Tan et al., 1982a; Tan et
al., 1982b), although this finding is not universal (Rodgers et al., 1985). Oxytocin
receptors can, however, be detected on luteal cells (Niswender et al., 1985),
although whether these are steroidogenic or endothelial is not clear (Auletta and
Flint, 1988). Indeed, it is possible that oxytocin has direct effects on luteal blood
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flow, as it has been shown that oxytocin alters the blood flow in many organs
(Aulettaand Flint, 1988).
The role of oxytocin in the primate is less clear. As the ovarian cycle and
luteolysis continues in the absence of a uterus (Neill et al., 1969a), oxytocin
cannot have the same role. However, oxytocin receptors are present in the primate
corpus luteum (Khan-Dawood et al., 1993) and oxytocin is synthesised in the
primate corpus luteum (Einspanier et al., 1994; Dawood and Khan-Dawood,
1986). Although some authors have reported some inhibitory effects of oxytocin
on stimulated progesterone production by isolated human luteal cells (Tan et al.,
1982a; Bennegard et al., 1987), this has not been found by others (Richardson and
Masson, 1985). However, oxytocin in pharmacological, rather than physiological,
doses does seem to have some luteolytic effects in monkeys (Auletta et al.,
1984c). The role of oxytocin in primate luteal steroidogenesis and local blood
flow remains to be clarified.
1.7.4 Prolactin
In the rat, prolactin serves an essential role in the formation and maintenance of
the corpus luteum (Niswender and Nett, 1994). While PGF2a induces functional
luteolysis, it does not directly cause cellular degeneration in rat or bovine luteal
cells (Jordan, 1981). In the rat, prolactin is the agent that induces structural
involution of the corpus luteum (Endo et al., 1993a). Paradoxically, prolactin is
luteotrophic in the rat during luteinisation (Niswender and Nett, 1994).
Differentiation of functional corpora lutea is induced by prolactin secretion in
response to vaginal and cervical stimulation during mating (Spies and Niswender,
1971). Prolactin appears to work by inducing the expression of LH receptors in the
corpus luteum following their down-regulation at ovulation (Richards and
Williams, 1976). However, after functional luteolysis has occurred, prolactin
induces structural luteolysis. The mechanisms of action of prolactin in the rat
corpus luteum are not clear. As prior exposure to indomethacin will block the
luteolytic effect of prolactin (Sanchez-Criado et al., 1987), it appears that prior
exposure to prostaglandins is necessary. PGF2a may sensitise the luteal cells to the
luteolytic effects of prolactin.
It is unlikely that prolactin has similar luteotrophic and luteolytic actions in the
primate. However, prolactin receptors have been described in the human ovary
and corpus luteum (McNeilly et al., 1980; Bramley et al., 1987). It has been
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reported that inhibition of prolactin secretion using bromocriptine, a dopaminergic
agent, will slightly shorten the luteal phase, and reduce the peak progesterone
levels, when given to women with normal menstrual cycles (Schulz et al., 1978).
On the other hand, short luteal phases have also been reported associated with
hyperprolactinaemia (Doody and Carr, 1991). It is clear, however, that prolactin
can interfere with pituitary gonadotrophin production (Bohnet and McNeilly,
1979), and this may explain its effects on luteal function. Indeed, although one
study has shown a direct effect of prolactin on luteal cell steroidogenesis in vitro
(Hunter, 1984), most studies find that exogenous prolactin does not appear to
influence progesterone production from dispersed luteal cells (Stouffer et al.,
1980; Tan and Biggs, 1983). At present, there does not appear to be a distinct role
for prolactin in the control of the primate corpus luteum.
1.7.5 Immune Cells and Cytokines
Immune cells and their cytokine products appear to be normal constituents of the
ovary and corpus luteum (Brannstrom and Norman, 1993). It is possible that they
have essential roles in the regulation of ovarian function. There are several pieces
of evidence which point to local interactions between the immune and
reproductive systems. White blood cells have clearly been shown to be involved in
the ovulatory process (Brannstrom and Norman, 1993). Interfering with the
immune system in mice can cause failure of proper ovarian development
(Nishizuka and Sakakura, 1969). Glucocorticoids, which block leukocyte influx
and impair immune cell cytokine production, prevent luteal regression in the rat
(Wang et al., 1993). In addition, the induction of lymphopaenia has been shown to
cause luteal dysfunction in the cow (Alila and Hansel, 1984). Indeed, luteolysis is
associated with a leukocyte infiltration which has been documented in rodents
(Brannstrom et al., 1994b), rabbits (Naftalin et al., 1997), ruminants (Murdoch,
1987; Lei et al., 1991) and women (Wang LJ et al., 1992; Brannstrom et al.,
1994a).
Immune cells have the potential to directly affect steroidogenesis. The presence of
macrophages increases progesterone synthesis in cultures of murine and human
luteinised granulosa cells (Kirsch et al., 1981; Halme et al., 1985). The addition of
leukocytes, or leukocyte conditioned medium, has the same effect (Emi et al.,
1991). Although, these reports suggest a role for immune cells in the promotion of
steroidogenesis, it is increasingly clear that there is an influx of these cells during
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luteolysis (Brannstrom and Norman, 1993). It is therefore likely that products of
these cells, that have a negative effect on steroidogenesis, are important during
luteolysis.
Several immune cell products have been shown to be negative regulators of
steroidogenesis. Leukocytes are prominent generators of prostaglandins (vide
supra) and reactive oxygen species (vide infra). The best studied cytokine, TNFa,
is a product of macrophages that is released in luteal tissues in response to
macrophage activation (Bagavandoss et al., 1990). It can be detected in the
bovine, human and rat corpus luteum (Roby and Terranova, 1989; Brannstrom and
Norman, 1993). TNFa appears to exert some anti-steroidogenic effects on
cultured human granulosa cells (Fukuoka et al., 1992). It acts with other cytokines
to augment their inhibition (Wang HZ et al., 1992) of progesterone production. In
addition, TNFa is anti-steroidogenic to bovine and pig luteal cells (Veldhuis et
al., 1991; Fairchild Benyo and Pate, 1992), where it also stimulates the synthesis
of PGF2a (Fairchild Benyo and Pate, 1992). Indeed, a TNFa-like factor has been
shown to increase during luteolysis in the ewe (Ji et al., 1991) and cause luteolysis
when infused into pig corpus luteum (Wuttke et al., 1993). Specific TNFa
receptors have also been described in pig corpora lutea (Richards and Almond,
1994). Therefore immune cell TNFa is a good candidate for one of the tissue
mediators of luteolysis.
1.7.6 Reactive Oxygen Species
Reactive oxygen species are generated in a variety of biological conditions and are
known to inhibit cellular synthetic and metabolic pathways. The cytochrome P450
enzymes, involved in steroidogenesis, appear to be particularly sensitive to
inhibition by free oxygen radicals (Behrman and Preston, 1989; Endo et al.,
1993b). Therefore, these highly reactive molecules, such as the superoxide anion
(02*-), hydrogen peroxide (H202) and the hydroxyl radical (OH*), are clear
candidates for effector molecules during luteolysis (Behrman et al., 1993). There
is now increasing evidence that reactive oxygen species mediate some of the early
events during luteolysis in the rat, and possibly the primate, corpus luteum.
Reactive oxygen species are generated in the rat corpus luteum in response to
exogenous PGF2oc and during natural luteal regression (Riley and Behrman, 1991).
Exposure of luteal cells to H202 results in marked inhibition of steroidogenesis
(Behrman and Preston, 1989). Although the cells remain viable, they display a
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rapid inhibition of LH-dependent cAMP and progesterone production (Margolin et
al., 1990). Generation of superoxide radicals in luteal cells in response to PGF2ct
precedes the decline in progesterone production (Sawada and Carlson, 1991). It is
therefore likely that part of the mechanism of action of PGF2a on luteal cells is
through the generation of reactive oxygen species.
Reactive oxygen species have multiple sites of action on the steroidogenic
pathway. They rapidly inhibit LH-induced cAMP synthesis (Behrman and Preston,
1989). This effect appears to be independent of the numbers and affinity of LH
receptors, or the activity of adenylyl cyclase (Behrman and Preston, 1989). It has
been suggested that there is a functional uncoupling of LH receptors from adenylyl
cyclase (Segaloff and Ascoli, 1993). This is rapid, and appears to be related to a
decrease in membrane fluidity, secondary to membrane lipid peroxidation (Riley
and Carlson, 1987). In addition, H202 blocks cAMP-dependent steroidogenesis.
This effect does not seem to be related to intracellular mobilisation of cholesterol
or inhibition of P450scc activity (Behrman and Aten, 1991). It appears to be at the
level of protein synthesis (Musicki et al., 1993), inhibiting the translocation of
cholesterol to the inner mitochondrial membrane (Behrman and Aten, 1991). It
seems that inhibition of StAR synthesis is one of the anti-steroidogenic effects of
reactive oxygen species.
It is still uncertain if reactive oxygen species are involved in luteolysis in the
primate, where the physiological relevance of PGF2a as a luteolysin is unclear. In
vitro, H202 has luteolytic-like effects on granulosa-lutein cells (Endo et al.,
1993b). The effects on the steroidogenic pathway appear to be similar to those
observed in rat luteal cells (Musicki et al., 1993). In addition, there appears to be a
direct inhibition of the activity of the steroidogenic enzymes P450scc, 3P-HSD and
P450arom (Behrman and Preston, 1989; Endo et al., 1993b). Although it is not
known if H202 is generated in the human corpus luteum in vivo, there is some
evidence of its production in vitro (Michael et al., 1994). It remains possible that
reactive oxygen species serve a functional role in mediating luteal regression in
women.
1.8.7 Regulation of Blood Supply
Early observational studies of the ovine corpus luteum during luteolysis reported
marked early blanching, and decrease in luteal blood flow (Niswender et al.,
1976). As the blood supply is important in bringing nutrients and substrates to
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luteal cells, regulation of the local vasculature may have a role in the luteolytic
process. Prostaglandins themselves have marked effects on blood flow (Nett et al.,
1976), and they are clearly involved in regulation of blood vessel tone during
menstruation (Abel, 1985). In addition, the corpus luteum contains various
vasoactive substances including nitric oxide (NO) (Shiels et al., 1996),
endothelins (Flores et al., 1995), and vasoactive cytokines (Brannstrom and
Norman, 1993). Effects on the vasculature, including apoptosis of endothelial
cells, have been reported during induced and natural luteolysis, in the primate and
bovine corpus luteum (Fraser et al., 1995c; Modlich et al., 1996).
In sheep, serum progesterone is closely correlated to the rate of blood flow to the
ovary containing the corpus luteum (Niswender et al., 1976). Indeed, in this
species, decreased luteal flow is associated with an inadequate luteal phase
(Niswender and Nett, 1994). This correlation is not only seen in sheep, it exists to
a degree in women. Blood flow to the corpus luteum has been examined by colour
doppler ultrasound studies. Maximum blood flow was seen in the mid-luteal
phase, a time of maximal progesterone production (Tinkanen, 1994; Bourne et al.,
1996). There was a positive correlation between the systolic blood flow velocity,
luteal volume and serum progesterone in women. Low luteal blood flow rates
have been shown to have an association with inadequate progesterone production,
and miscarriage (Salim et al., 1994; Glock and Brumsted, 1995; Kupesic and
Kurjak, 1997).
The role of luteal blood flow in the corpus luteum in relation to its function is not
clear. It is not known whether the decline in luteal flow is a cause or effect of
declining progesterone secretion, or indeed, if both are secondary to a another
unknown process. Steroid hormones have vasoactive properties, and hCG itself
may have effects of blood vessel tone (Toth et al., 1994). It is not clear if changes
in luteal blood flow are involved in the luteolytic process, but the early evidence
suggests they may be associated with it. However, the regulation of luteal blood
flow and local factors involved in its control are not known. Clearly, this is an area
requiring further study.
In summary, the effector molecules involved in stimulating the processes involved
in luteolysis are not clear in the human. There is evidence that PGF2a, cytokines,
especially TNFa, reactive oxygen species and vasoactive molecules may be
involved. However, their role, and control at a molecular level, remain to be
determined. The factors responsible for their production during luteolysis, and
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how this is prevented by hCG during luteal 'rescue', are still not clear. However,
the next topic to be considered is the process of luteal 'rescue' during maternal
recognition ofpregnancy.
1.8 Maternal Recognition of Pregnancy
In the absence of a successful pregnancy, the corpus luteum has a finite life span.
Luteal progesterone production starts declining from the mid-luteal phase onwards
and will cease after an average of 14 days (Lenton and Woodward, 1988).
However, if conception occurs, progesterone production from the corpus luteum is
maintained (Stouffer, 1988), and is increasing at the time when luteolysis
normally would have occurred (Figure 1.7) (Lenton and Woodward, 1988;
Tovanabutra et al., 1993). These findings led to the conclusion that the corpus
luteum is "rescued" during early pregnancy (Neill et al., 1969b).
Mechanisms of maternal recognition of pregnancy differ between species. Clearly,
that of the primate is of fundamental importance for the purpose of this thesis.
However, it is wise to review the disparate mechanisms involved in maternal
recognition of pregnancy in infraprimate species. Often an understanding of these
mechanisms will put the situation in the primate into context, and give pointers to
potential additional effector molecules in the primate.
1.8.1 Infraprimate Species
Progesterone must be secreted throughout pregnancy in most mammalian species.
This provides a stable uterine environment to nurture the fetus throughout
gestation. In some species, such as carnivores and marsupials, gestation lasts no
longer than a functional luteal phase (Niswender and Nett, 1994). In these species,
there is no need for the conceptus to alter luteal function to support its gestation.
Most species, however, have evolved mechanisms to shorten the luteal phase to
allow earlier return to fertility in the event of a non-conception cycle. The luteal
phase is lengthened in a conception cycle. This is achieved by the conceptus-
uterine unit being involved in the inhibition of luteolysis throughout gestation, or
until the feto-placental unit can produce enough progesterone of its own to
maintain pregnancy.
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(Lenton and Woodward, 1988)
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1.8.2 Rodents
The corpus luteum of the rat is very transient indeed (Smith et al., 1975).
However, the act of cervical stimulation during mating, or experimentally,
prolongs the lifespan of the corpus luteum for up to 12 days (Spies and
Niswender, 1971). A cervical neuroendocrine feedback reflex causes prolactin
concentrations to rise. This prolactin acts on the corpus luteum to maintain and
enhance progesterone output. Indeed, daily injections of prolactin will maintain
luteal function in an unstimulated female (von Berswoldt-Wallabre et al., 1964),
and an inhibitor of prolactin terminates pseudopregnancy (Gibori et al., 1974).
The gestation of a rat is 22 days however, and ovarian progesterone is required
throughout most of this period (Niswender and Nett, 1994). Further prolongation
of the lifespan of the corpus luteum during actual pregnancy is therefore required.
Maintenance of the corpus luteum during the second half of gestation in rats
depends on the secretion of placental luteotrophins (Niswender and Nett, 1994).
These appear to be a mixture of placental lactogen, a prolactin-like molecule, and
a type of chorionic gonadotrophin, an LH-like molecule (Gibori et al., 1974;
Jayatilak et al., 1984). These have direct stimulatory effects on luteal progesterone
secretion and reduce the sensitivity of the corpus luteum to the luteolytic effects of
the uterine PGF2a (Niswender and Nett, 1994), that continues to be secreted
throughout gestation.
1.8.3 Rabbits
Rabbits are stimulated to ovulate by mating (Niswender and Nett, 1994) and their
corpus luteum secretes progesterone for 16 to 17 days. The trophic hormone for
luteal function is oestradiol produced by LH action on ovarian follicles (Bill and
Keyes, 1983). In the absence of pregnancy, the corpus luteum undergoes
luteolysis, probably as a result of uterine PGF2a secretion. Indeed, it may be the
increasing concentrations of oestradiol which stimulate its secretion (Browning et
al., 1980). During pregnancy, the corpus luteum is maintained for the 31 days of
gestation. A placental product is responsible for this prolongation, but this factor
does not have gonadotrophin-like properties (Niswender and Nett, 1994). It is
likely that the presence of the conceptus prevents the secretion of luteolytic PGF2cc
in response to increasing oestradiol. Although not fully characterised, it may be
that the placental luteotrophic factor is PGE2, which is secreted in high
concentrations by the rabbit conceptus (Lytton and Poyser, 1982).
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1.8.4 Guinea Pigs
In the guinea pig, uterine PGF2cc is responsible for luteolysis after 11 to 13 days
(Niswender and Nett, 1994). Placental progesterone production maintains
pregnancy, but the contribution of the corpus luteum is required throughout the
first 30 days of gestation. The function of the corpus luteum must therefore be
prolonged by the feto-placental unit in pregnancy. The exact mechanisms whereby
this is achieved are not fully clear, but it is likely to be a combination of a
reduction in uterine PGF2a secretion, and the secretion of a placental chorionic
gonadotrophin with LH-like properties (Babra et al., 1984).
1.8.5 Ruminants
In sheep and cows, luteolysis is attributed to the uterine synthesis and secretion of
PGF2oc, and its subsequent transport to the ovary via a local countercurrent
mechanism (Auletta and Flint, 1988). In the ewe, the corpus luteum must be
present through the first 50, and in the cow the first 200, days of gestation
(Niswender and Nett, 1994). The conceptus must prevent normal luteal regression.
This is achieved probably by a combination of inhibiting uterine PGF2a
production and reducing the sensitivity of the corpus luteum to PGF2a.
(Niswender and Nett, 1994). It is now generally accepted that the conceptus in
sheep and cattle secrete a trophoblastic protein (TP) (ovine TP (oTP-1) and bovine
TP (bTP-1)) which inhibits pulsatile secretion of PGF2(X from the pregnant uterus.
There is considerable homology between the structures of oTP-1 and IFN-a
(Imakawa et al., 1989), and both molecules have antiviral activity (Poniter et al.,
1988). Secretion of uterine PGF2oc, and its metabolites, around the time of
luteolysis is inhibited during pregnancy. However, basal PGF2a levels are higher
in the pregnant state than the non-pregnant state (Niswender et al., 1994). This
implies a reduced sensitivity of the corpus luteum to PGF2a.
The luteotrophic effect of the embryo is exerted locally. Anastomosis of the
uterine vein draining the gravid hom to the opposite uterine vein results in
maintenance of the corpus luteum on the opposite ovary (Niswender and Nett,
1994). Intrafollicular or arterial injections of PGF2oc are less efficient in inducing
luteal regression in pregnancy (Auletta and Flint, 1988), confirming that the
corpus luteum is made more resistant to the luteolytic effects of PGF2a. This
effect is likely to be mediated by a conceptal product as, in the presence of two
embryos, the corpus luteum is more res and Nett, 1994). This
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antiluteolytic signal may be PGE2. Conceptuses secrete PGE2, and infusion of
PGE2 into the uterine lumen prolongs luteal lifespan for the duration of the
infusion (Shemesh et al., 1979; Reynolds et al., 1983). It is possible that other
embryonic proteins are involved but these remain to be characterised.
1.8.6 Pigs
The corpus luteum must continue to secrete progesterone throughout gestation in
the pig (Niswender and Nett, 1994). In pigs, luteolysis is associated with an
increased uterine secretion of PGF2oc. Porcine conceptuses secrete oestrogen and
PGE2. Infusion of oestrogen maintains the corpus luteum (Frank et al., 1977). It is
not fully characterised but it is likely that local oestrogens and PGE2 are involved
in maternal recognition ofpregnancy in the sow.
1.8.7 Horses
Maternal recognition of pregnancy in the horse is not well understood. It is likely
that uterine PGF2oc is responsible for luteal regression and that the conceptus
prevents its action (Niswender and Nett, 1994). There is a clear reduction in
uterine PGF2oc secretion during early pregnancy (Douglas and Ginther, 1976).
There is a need for interaction with the endometrium and the conceptus interacts
with as much lining endometrium as possible (Leith and Ginther, 1984). The
substance involved in reducing PGF2a secretion may be oestrogen. The conceptus
synthesises oestrogen in vitro, and exogenous oestrogen has these effects in vivo
(Niswender and Nett, 1994). This delays luteolysis until about day 35 when the
conceptus produces large amounts of equine chorionic gonadotrophin (eCG).
Follicles present on the ovaries at this time ovulate and produce secondary corpora
lutea (Niswender and Nett, 1994). The primary and secondary corpora lutea are
stimulated to produce progesterone until the feto-placental unit takes over, at
about 150 days of gestation. At this time the eCG disappears from the circulation.
Progestational support for the remainder of the pregnancy is provided by the feto¬
placental unit.
1.8.8 Primates
It is clear from infraprimate species that, commonly, luteotrophic substances are
secreted by the uterine-conceptus unit. These substances prolong the luteal
lifespan. The same is true of the primate. In 1927 some elegant experiments
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demonstrated that urine from pregnant women stimulated luteinisation in rats
(Zeleznik and Fairchild Benyo, 1994). This was the first demonstration of a
specific luteotrophic factor of pregnancy. It became clear that this substance was
separate from the gonadotrophins found in menopausal women's urine, as it did
not possess the ability to stimulate follicular growth. This gonadotrophin was not
of pituitary origin, as media from cultured trophoblast contained this luteotrophic
factor in large amounts (Gey et al., 1938). Further experiments showed that
injections of this chorionic gonadotrophin into rhesus monkeys, during the luteal
phase, prolonged the functional lifespan of the corpus luteum (Zeleznik and
Fairchild Benyo, 1994). The conceptus is therefore the source of the luteotrophic
signal which 'rescues' the corpus luteum. That luteotrophic signal is hCG.
The structure and functional characteristics of hCG have now been well
documented (lies and Chard, 1993). It is a glycoprotein hormone with structural
similarities to LH, FSH and thyroid stimulating hormone (TSH). Like these other
hormones it consists of two subunits: a common a-subunit linked to a specific (3-
subunit. The P-subunit of hCG is similar to that of LH, but with differences in size
and glycosylation pattern (lies and Chard, 1993). The hCG p-subunit shares the
amino acid sequence with LH p-subunit, but has an additional 30 amino-acids at
the carboxy-terminal (Pierce and Parsons, 1981). Gene analysis suggests that the
gene for hCG P-subunit is derived from that of the LH P-subunit, but the stop
codon has been altered to lengthen the molecule (lies and Chard, 1993). The
additional amino acids, and thus the different glycosylation pattern, make hCG
and LH have different properties in the circulation. The plasma half-life of hCG is
substantially longer than that of LH (36 hours vs. approximately 20 minutes)
(Rizkallah et al., 1969; Morell et al., 1971).
The lifespan of the corpus luteum is extended in early pregnancy by hCG secreted
by the developing syncytiotrophoblast. In women, hCG can first be detected in the
circulation nine to ten days after the LH surge (Lenton and Woodward, 1988).
This rises logarithmically to peak levels at eight to twelve weeks of gestation, and
then declines to lower, but detectable, levels throughout the remainder of
pregnancy (Zeleznik and Fairchild Benyo, 1994). The role, if any, of hCG after the
luteo-placental shift is not known. Although hCG can first be detected in the
peripheral circulation ten days after the LH surge, there is evidence for production
of hCG by the preimplantation blastocyst (Fishel et al., 1984), and hCG can be
detected in concentrated urine extracts before its appearance in the plasma (Baird
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et al., 1991). It is likely that hCG begins to exert its effect before it can be detected
in the peripheral plasma by conventional methods.
It has clearly been shown in both the non-human primate (Stouffer et al., 1987)
and women (Illingworth et al., 1990) that exogenous logarithmically increasing
hCG can 'rescue' the corpus luteum, and mimic the hormonal changes of early
pregnancy. Clearly at this stage of luteal 'rescue', hCG alone is enough to maintain
normal luteal function. However, maintenance of the corpus luteum with
exogenous hCG for more than 10 days has not been possible in the primate model
(Stouffer et al., 1987). At this stage, luteal function is still required for the
maintenance of pregnancy (Csapo et al., 1973). Although it is possible that
additional factors from the conceptus or uterus are necessary for prolonged luteal
function, it is likely that the doses of hCG in these experiments were inadequate,
or the exposure in vivo was not physiological. It seems highly likely that hCG is
the sole molecule required for luteal 'rescue'.
Some investigators claim that other products from the conceptus or the uterine-
conceptus unit, in addition to hCG, may be important during luteal 'rescue'
(Johnson et al., 1993; Lower et al., 1993). The basis of their argument is that
progesterone levels are lower in ectopic gestations, at a stage when hCG
concentrations are the same as intrauterine gestations. However, trophoblast
function in ectopic pregnancy is impaired (Ledger et al., 1994) and the corpus
luteum has a dynamic response to hCG, in that increasing hCG concentrations are
required to produce the same levels of progesterone, as the corpus luteum ages
(Knobil, 1973; Lenton and Woodward, 1988; Tovanabutra et al., 1993). It is likely
that the explanation for their observations (Johnson et al., 1993; Lower et al.,
1993) is the dynamic response of the corpus luteum to a suboptimal rate of rise in
hCG concentrations. To date, no other endocrine factors have been shown to have
a role in luteal 'rescue'.
How does hCG achieve luteal 'rescue'? It is clear that hCG acts through the LH
receptor (Cole et al., 1973; Segaloff and Ascoli, 1993). Stimulation of this
receptor on the steroidogenic cells maintains steroidogenesis. Both exogenous LH
and hCG can stimulate luteal cell progesterone synthesis in vivo and prolong the
luteal phase (Hanson et al., 1971). However, logarithmically increasing
concentrations of hCG are required to maintain progesterone synthesis (Stouffer et
al., 1987; Stouffer, 1988, Lenton and Woodward, 1988). This implies that the
steroidogenic cells are becoming increasingly insensitive to the trophic effects of
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hCG. However, the molecular mechanisms of this effect are obscure. In addition,
hCG must prevent apoptosis (Dharmarajan et al., 1994) and tissue remodelling.
As LH receptors are found on steroidogenic cells (Nishimori et al., 1995), cell
products from these cells must influence the rest of the gland during 'rescue'. The
molecular nature of how structural luteolysis is prevented by hCG, like functional
luteolysis, remains unknown. Clearly, further studies are required.
The continued function of the corpus luteum in early pregnancy is essential until
its endocrine activities, notably progesterone production, are assumed by the
placenta (Stouffer et al., 1987). Oophorectomy or luteectomy prior to the
development of sufficient placental steroidogenesis causes abortion (Csapo et al.,
1973). However, luteectomy after six or seven weeks of gestation does not result
in abortion (Csapo et al., 1973). At this stage, the placenta is secreting enough
progesterone to maintain pregnancy, and the corpus luteum is essentially
functionally redundant. This transition is known as the luteo-placental shift after
which serum hCG begins to decline (Hearn, 1986; Tovanabutra et al., 1993).
1.8.9 The Corpus Luteum during Pregnancy
To recap, there is great variation within mammalian species of the role of the
corpus luteum throughout gestation. In some species, the corpus luteum is present
throughout gestation, and its presence is absolutely required for the maintenance
of pregnancy (Niswender and Nett, 1994). In other species, the corpus luteum is
required for varying percentages of the length of gestation (Niswender and Nett,
1994; Zeleznik and Fairchild Benyo, 1994). In the human, the corpus luteum is
only required for maintenance of pregnancy during the first trimester of gestation.
Thereafter, the progesterone required to maintain pregnancy is derived from the
trophoblast cells of the maturing placenta. The stage of pregnancy when the
placenta produces enough steroids to maintain pregnancy and the corpus luteum
becomes functionally redundant, as described above, is known as the luteo-
placental shift (Zeleznik and Fairchild Benyo, 1994).
Endocrinological studies have been designed to track the relative contributions of
the corpus luteum and the placenta to circulating progesterone concentrations
throughout gestation. This is possible because the corpus luteum contains the
steroidogenic enzyme 17a-hydroxylase, that is not found in the placenta
(Tulchinsky and Hobel, 1973). The corpus luteum therefore secretes some 17a-
hydroxyprogesterone as well as progesterone, and these hormones have a similar
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pattern of secretion (Adashi, 1994). Although the adrenal gland produces some
17a-hydroxyprogesterone, the vast majority in the blood throughout gestation is of
luteal origin (Adashi, 1994).
Plasma 17a-hydroxyprogesterone concentrations peak on the fourth to fifth week
of gestation. Thereafter there is a marked decline (Tulchinski and Hobel, 1973).
Progesterone concentrations, however, continue to rise after the fifth week of
gestation and therefore, from this stage onwards, the placenta is the major source
of circulating progesterone (Knobil, 1973). Ovariectomy of rhesus monkeys at this
stage does not result in a significant fall in serum progesterone concentrations
(Knobil, 1973). Indeed, towards the end of the first trimester circulating hCG
concentrations also decline (Hearn, 1986). It is likely that this occurs after the
luteo-placental shift but the molecular basis of this decline is not fully understood.
After five weeks of completed gestation, the placenta is the primary source of
progesterone in the primate.
Although successful pregnancies occur if the ovaries are removed after the luteo-
placental shift, the human corpus luteum does not become non-functional during
the rest of gestation. The corpus luteum can sometimes be clearly identified on the
ovary at the time of caesarean section at term (Emmi et al., 1991). In addition,
although the steroid output wanes, it does not disappear completely. At term,
venous blood draining the ovary bearing the corpus luteum has greater
concentrations of progesterone than the contralateral side (Emmi et al., 1991).
Indeed, human ovarian luteal relaxin secretion has been reported throughout
gestation (Sherwood, 1994). The physiological significance of the primate corpus
luteum throughout gestation, after the luteo-placental shift, is not known.
In summary, hCG rescues the corpus luteum and maintains its progesterone
secretion for a further four weeks. Until this stage, the progesterone produced by
the corpus luteum is absolutely required to support an early pregnancy. After this
stage, the placenta provides enough progesterone to maintain the pregnancy and
the corpus luteum becomes functionally redundant. The molecular mechanisms of
how hCG prevents luteolysis are not known. However it is known that hCG acts
through the LH receptor which is found on the cell membranes of luteal cells. The
molecular control of luteolysis and luteal 'rescue' in the primate remain an enigma.
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1.9 The Continuing Enigma of the Corpus Luteum
This chapter has served to review our current understanding of ovarian and luteal
structure and function. It is clear that there are large deficiencies in our current
knowledge of the corpus luteum. Our understanding of the molecular mechanisms
of luteolysis and how they are prevented by hCG during maternal recognition of
pregnancy in women is limited. One of the factors which has limited our
knowledge of the human is the fact that infraprimate species control their corpus
luteum in different ways.
1.9.1 Model systems
Although some parallels of luteal function can be seen between primates and
infraprimate species, there are marked differences. This means that infraprimate
species have only limited use as models for the human corpus luteum. It also
means that data collected on infraprimate cannot be applied to the human corpus
luteum without independent testing. It is easy to study laboratory and farmyard
animals, under careful experimental conditions. It is much harder to study non-
human primates and women. This has, therefore, limited the opportunities to
investigate the human corpus luteum. It is clear that, to increase our knowledge of
human luteal function, a primate model is required. The best primate model is, of
course women. However, few groups throughout the world have access to human
corpora lutea. When human corpora lutea are available, these tend to be archival
samples or samples collected on an ad-hoc basis. This means that exact dating of
the corpora lutea in relation to the LH surge is difficult.
1.9.2 Early Pregnancy
One of the problems in studying the human corpus luteum, and the transition
between luteolysis and luteal 'rescue', is the lack of availability of suitable luteal
tissue from early pregnancy. It is unethical to collect such tissue, as luteectomy in
early pregnancy causes miscarriage. Some groups have obtained early pregnancy
corpora lutea from ectopic pregnancies. However, these often present around the
time of the luteo-placental shift, and when the corpus luteum is failing. Although
these corpora lutea have proven useful, they are clearly less than ideal. It is
possible to obtain corpora lutea from naturally pregnant monkeys, and this limited
approach has been used. A more user-friendly technique, where monkey corpora
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lutea are collected after luteolysis has been prevented by treatment with exogenous
hCG, has also been utilised. However, no studies on early 'rescued' human corpora
lutea have been possible. This has clearly been a bar to our understanding.
1.9.3 Luteolysis
There is no doubt that, in the primate, when compared to infraprimate species,
luteolysis is more gradual. This is probably because primates do not utilise a
systemic luteolysin. Although carefully timed primate corpora lutea, collected
throughout the cycle,can give insights into natural luteolysis, the more gradual
luteolytic process has the potential to mask some important changes. Therefore
some investigators have used models of induced luteolysis in the primate to
investigate specific changes. These approaches have not been used in women.
1.9.4 The Scope of this Thesis
This thesis reports work on the human corpus luteum. A model system has been
developed to allow the collection of carefully dated corpora lutea from women
throughout the functional luteal phase. Analysis of these corpora lutea has the
potential to map the functional and structural changes during the normal luteal
phase and during natural luteolysis. This model system has the potential to
overcome a lot of the problems involved in studying the human corpus luteum.
In addition, the model system also allows for the collection of 'rescued' corpora
lutea from simulated early pregnancy. Maternal recognition of pregnancy can be
simulated using exogenous hCG to mimic the hormonal changes of early
pregnancy. This means that, for the first time, the 'rescued' human corpus luteum
can be studied and compared to corpora lutea from throughout the luteal phase,
including those at the time of natural luteolysis.
In addition, an induced luteolysis model has also been developed. Unfortunately
the drugs required to induce luteolysis have yet to be formally licensed for the
treatment of women. This means that a non-human primate model has to be used.
This has the benefits of being a primate model, involving co-ordinated luteolysis,
and, because the ovaries are much smaller, allowing the examination of extra-
luteal ovarian tissue. Together, these models have the potential to allow detailed
investigation of the molecular mechanisms involved in controlling the luteolysis-
luteal 'rescue' transition in the primate.
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The experimental chapters of the thesis are laid out in two sections. Each section
begins with a brief introduction to set the scene for the following chapters. The
first section covers the functional aspects of the corpus luteum during luteolysis
and simulated maternal recognition of pregnancy. The second section deals with
the structural aspects of luteolysis and maternal recognition of pregnancy. At the
end of the thesis, these sections are combined in a final discussion which tries to
expand our understanding of the human corpus luteum, on the basis of the
experimental Work reported here. Firstly however, the materials and methods used
in these studies are described in detail.
Chapter 2
Subjects and Tissue Collection
2.1 Experimental Models
There are three distinct stages during the normal functional life-span of the human
corpus luteum: the early-luteal phase when the corpus luteum is forming and
increasing its production of progesterone; the mid-luteal phase when the corpus
luteum is fully formed and its progesterone production is maximal; the late-luteal
phase when the progesterone production falls and the gland begins to regress. The
fall in progesterone production by the corpus luteum in the late-luteal phase is
prevented by exposure to logarithmically increasing concentrations of hCG from
the trophoblast during maternal recognition of pregnancy. This 'rescued' corpus
luteum can be considered a fourth stage of the luteal life-span.
In order to investigate the effects of luteal 'rescue' at a structural and functional
level, a model has been designed to allow the collection of corpora lutea from all
four of these luteal stages. Human corpora lutea were collected at the time of
hysterectomy during carefully monitored menstrual cycles. They were dated on
the basis of the urinary LH surge, in conjunction with the date of the last
menstrual period (LMP), and the assessment of endometrial morphology. In
addition, a protocol using injections of hCG was used to mimic the hormonal
changes of early pregnancy, before some corpora lutea were collected. This
regime 'rescues' the corpus luteum and allows the study of the molecular effects of
maternal recognition of pregnancy.
The process of luteolysis is a gradual one in the primate, occurring over several
days. The molecular changes of luteolysis may therefore be diluted over the
course of the late-luteal phase. An additional model was therefore utilised to
produce a rapid co-ordinated luteolysis. In the primate, luteolysis can be induced
by acute LH withdrawal in the mid-luteal phase. This is achieved by systemic
treatment with GnRHant. As this experimental treatment has not yet been licensed
for use in women, a non-human primate model, using the marmoset monkey, was
utilised. One benefit of this model is that luteolysis can also be induced by
systemic treatment with PGF2a. It is therefore possible to compare and contrast
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luteolysis induced indirectly, through withdrawal of trophic support, or directly by
a known luteolysin.
These models allow the investigation of the structural and functional
characteristics of the primate corpus luteum during the normal luteal phase, at the
time of luteal 'rescue', during maternal recognition of pregnancy, and during co¬
ordinated luteolysis. Together they are unique and powerful tools for the
investigation of the primate corpus luteum during the functional luteal phase.
2.2 Human Tissue
2.2.1 Recruitment of Patients
This study was approved by the Reproductive Medicine Sub-Committee of the
South East Scotland Medical Ethics Committee. Informed consent was obtained
from all women involved and their consultant gynaecologists. The case records of
all women on the waiting list for hysterectomy, at the Royal Infirmary of
Edinburgh, under the age of 45 years, were obtained and scrutinised at regular
intervals. Healthy women, with regular menstrual cycles, who had not received
any form of hormonal therapy in the last three months, who did not have a history
of infertility, and who were having an open abdominal hysterectomy for benign
conditions, were identified.
A letter (Fig. 2.1) was sent to these women approximately two months before the
planned date of surgery. This letter briefly introduced the nature of the research
and invited the women to contact a telephone extension with a 24-hour answering
service if they were interested in participating. All the respondents were contacted
by telephone. During this conversation the clinical details were confirmed, the
study protocol was explained in detail, and any questions were answered.
If the woman was still interested in participating in the research, a detailed
menstrual history was taken to determine how long after her expected menses the
operation would take place. Each woman was classified on this basis as either
'unsuitable', 'routine' or 'suitable for rescue'. 'Unsuitable' women were those who
did not fulfil the inclusion criteria after detailed discussion, or those whose
operation would occur in the follicular phase of the cycle. 'Routine' women were
those whose operation would fall in the luteal phase of the cycle. If the operation
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I gather that you have a date to come into the Royal Infirmary for surgery and I am therefore
writing to you to seek your help with some important research while you are in hospital. This
research will investigate the establishment of early pregnancy in women. This is a very important
area as problems such as infertility and early miscarriage are unfortunately very common. We are
therefore trying to improve our knowledge of the vital process of pregnancy recognition in women
so that we can better help such problems.
The research would basically involve having a small biopsy taken from one of your ovaries while
you are asleep at the time of your operation. This will not add anything to the discomfort normally
experienced at your operation and in addition there will be not effect on your future hormone
production. We propose to use such tissue to study in great detail the processes by which the ovary
recognises a pregnancy and thus produces sufficient hormone to maintain the pregnancy.
If you would like to know more about this research or think you may be willing to take part please
eiephone our office (031-229 2902 — 24 hour answering service) leaving your name and telephone
number. I will then contact you to give you more information about the study and arrange a
convenient time to discuss the project with you further. This does not commit you to taking part
and you will be entirely free to withdraw at any time.
It is also, very important to emphasise that participation in this research is entirely voluntary and
therefore if you are not interested in taking part please disregard this letter. Participation or
otherwise in the research project will have no effect whatsoever on the treatment that you receive
at the Royal Infirmary.





Letter sent to suitable women
This letter was sent to all women identified on the elective waiting list for
abdominal hysterectomy who fulfilled the inclusion criteria of the study. During
the period 1993 to 1995 it was sent to 395 women, 45% of whom responded.
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was expected to occur in the interval of two days before expected menses to two
days after expected menses, these women were classified as 'suitable for rescue'.
No further action was taken if the woman was classified as 'unsuitable'. Those
classified as 'routine' or 'suitable for rescue' entered the pre-operative stage of the
protocol.
2.2.2 Pre-operative Protocol
Specimen bottles and patient information sheets (Fig. 2.2) were given to all
women classified as 'routine'. These women were instructed to collect an early
morning specimen of urine each day, from 7 days after their LMP until hospital
admission, and store these in their home freezer. On admission to hospital, these
urines were collected and stored at -20 °C until analysis. On the day of surgery, a
plasma sample was collected and this was stored at -20 °C until analysis. Plasma
progesterone concentration was measured using an in-house progesterone
radioimmunoassay (RIA) (Djahanbakhch et al. 1981a). This assay typically had a
intra-assay coefficient of variation (CV) of <4%, a inter-assay CV of <11%, and a
detection limit of 0.1 nmol/1.
Women classified as 'suitable for rescue' were visited at home and given a patient
information sheet (Fig. 2.3). Those who did not consent to hCG administration
were offered the opportunity to be treated as 'routine'. Those who agreed to
participate were instructed to collect daily urine samples from day 7 of the
menstrual cycle, and store these frozen at home. These samples were collected on
day 18 or 19 of their menstrual cycle and assayed for LH concentration using an
in-house assay (Djahanbackhch et al. 1981b). At 29 IU/1 this assay typically has
an intra-assay CV of 4% and an inter-assay CV of 10%. The date of ovulation was
defined as the date of any clear single urinary LH peak after adjustment for
urinary creatinine concentration. This date was classified as LH+0. Ovulation
occurs within 36 hours of the start of the serum LH surge (Djahanbackhch et al.
1981b). It is generally accepted, however that ovulation occurs within 24 hours of
the urinary LH surge (LH+1).
Daily intramuscular injections of hCG (Profasi; Serono, Welwyn Garden City,
Herts, UK) were given from LH+7 until operation (5 to 8 days, mean 7.5 days).
Dosage commenced at 125 IU (LH+7) and doubled daily, 250 IU (LH+8), 500 IU
(LH+9), 1000 IU (LH+10), 2000 (LH+11), 4000 (LH+12), 8000 (LH+13) and 16
000 (LH+14). Plasma samples were taken on LH+7, LH+9, LH+11 and LH+13
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THE MECHANISM OF PREGNANCY RECOGNITION IN WOMEN
PATIENT INFORMATION SHEET
CONTROL GROUP
Research into the establishment of early pregnancy in women.
What is the research about?
The establishment of early pregnancy is a very important process in women and problems such
as infertility and early miscarriage are unfortunately very common. It is known that a woman's
body will recognise pregnancy as a result of a hormone called hCG which is produced by the
early embryo. This hormone hCG stimulates the ovary leading to all the other changes of
pregnancy. However, we do still not understand the criucal processes by which the ovary
recognises this hCG and thus acts to maintain the pregnancy. This research is therefore
intended to improve our understanding of early pregnancy.
What will be involved?
Each month at the hme of a period, the ovary forms new cells which produce hormones and
then release an egg at the time of ovulation. If pregnancy does not occur, these cells continue to
produce hormone for 14 days before they die at the time of the next period. In this research we
propose to remove these cells (which will die anyway) from the ovary at the time of your
operation. This will extend the operation by approximately five minutes but will not add
anything to the discomfort normally experienced at such an operation. In addition there will be
no effect on your future hormone production.
In addition you will be asked to collect urine samples during the days leading up to your
operation in order that we can measure your normal hormone production.
Your participation or otherwise in this research will not in anyway affect the treatment you will
receive at the Royal Infirmary and you will be free to withdraw at any time.
Further information is available from Dr Colin Duncan, Clinical Research Fellow, MRC
Reproductive Biology Unit, 37 Chalmers Street, Edinburgh. Telephone 031 229 2575.
Figure 2.2
Patient information sheet for routine collection
It the patients were suitable for recruitment, they were given this information
sheet and instructed to collect daily urine samples. Of all the women who
collected urines, 65% had a suitable corpus luteum collected at surgery.
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THE MECHANISM OF PREGNANCY RECOGNITION IN WOMEN
PATIENT INFORMATION SHEET
HCG TREATMENT GROUP
Research into the establishment of early pregnancy in women.
What is the research about?
The establishment of early pregnancy is a very important process in women and problems such as infertility and
early miscarriage are unfortunately very common. It is known that a woman's body will recognise pregnancy as
a result of a hormone called hCG which is produced by the early embryo. This hormone hCG stimulates the
ovary leading to all the other changes of pregnancy. However, we do still not understand the critical processes by
which the ovary recognises this hCG and thus acts to maintain the pregnancy. This research is therefore intended
to improve our understanding of early pregnancy.
What will be involved?
Each month at the time of a period, the ovary forms new cells which produce hormones and then release an egg
at the time of ovulation. If pregnancy does not occur, these cells continue to produce hormone for 14 days before
they die at the time of the next period. In this research we propose to remove these cells (which will die anyway)
from the ovary at the time of your operation. This will extend the operation by approximately five minutes but
will not add anything to the discomfort normally experienced at such an operation. In addition there will be no
effect on your future hormone production.
In order to investigate how the ovary responds to hCG, you will be given small amounts of hCG by daily
injection for up to eight days. This is a naturally occurring female hormone which is in regular use in infertility
treatment at much larger doses with no significant side-effects. In particular there will be no pregnancy
symptoms at this very low dosage and no long term effects on your body.
Finally, blood samples will be required on alternate days in the days leading up to your operation and you will
be asked to collect daily urine samples in order that we can measure your normal hormone production. Your
participation or otherwise in this research is entirely voluntary and will not in anyway affect the treatment you
will receive at the Royal Infirmary and you will be free to withdraw at any time. We will not be able to make
any payments to volunteers for helping us with this research but we will meet the cost of any expenses incurred
by volunteers.
Further information is available from Dr Colin Duncan, Clinical Research Fellow, MRC Reproductive Biology
Unit, 37 Chalmers Street, Edinburgh. Telephone 031 229 2575.
Figure 2.3
Patient information sheet for luteal 'rescue'
This information sheet was given to all women suitable for treatment with
exogenous hCG to 'rescue' the corpus luteum prior to surgery. During the three
years of the study satisfactorily 'rescued' corpora lutea were obtained from 12
women.
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and stored at -20 °C until analysis. Concentrations of intact hCG were measured
in these samples using an immunometric assay (hCG Serono MAIAclone;
Intersep Ltd., Wokingham, Berks, UK). This method was calibrated against the
First International Reference Preparation 75/537 and the inter-assay CV was
typically 8%. Plasma hCG concentrations increased exponentially in these
patients (Illingworth et al. 1990; Illingworth et al., 1996). This regimen has
previously been shown to mimic the hormonal changes of early pregnancy
(Illingworth et al. 1990).
2.2.3 Collection of Tissue
Whole corpora lutea were enucleated from the ovary, at the time of hysterectomy,
by blunt dissection, and the ovary was oversewn. Corpora lutea were collected at
the beginning of the operative procedure before interruption of uterine or ovarian
blood flow. The tissue was immediately divided into radial blocks in order to
ensure that the whole thickness of the gland was represented in any piece. Two
pieces of tissue were rapidly snap frozen in liquid nitrogen and stored at -70 °C
for subsequent RNA and protein extraction. One piece was frozen in embedding
medium (Tissue-Tek OCT compound; Miles Inc., Elkhart, IN, USA) and stored at
-70 °C until frozen sections were cut. Another piece was fixed in 4%
paraformaldehyde for 24 hours and embedded in paraffin wax for subsequent
histological, and immunohistochemical examination. In addition, an endometrial
biopsy was obtained from the uterus immediately after removal. This was also
fixed in 4% paraformaldehyde for 24 hours and embedded in paraffin wax.
During the course of the study, human placental tissue was required. This was
obtained from the Simpson Memorial Maternity Pavilion which is connected to
the research building. Placental tissue was either used fresh, or snap frozen and
stored at -70 °C until required.
2.2.4 Dating of Corpora Lutea
LH concentrations were measured in each of the serial urine samples as described
above. The LH surge was defined as the date of the peak urinary LH
concentration, after standardisation for urinary creatinine concentration. If no LH
peak, or more than one disparate peak, was detected in the serial urine samples,
the associated corpus luteum was not classified, or used in any definitive studies.
Corpora lutea were classified as early-luteal, if collected one to five days after the
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urinary LH peak (LH+1 to LH+5). Likewise, they were classified as mid-luteal
from LH+6 to LH+10, and late-luteal from LH+11 to LH+14. Those corpora lutea
collected after hCG administration were classified as 'rescued'. In all cases,
morphological dating of the luteal phase endometrium using the method of Li et
al. (1988) was used to confirm the luteal phase classification. Only patients whose
urinary LH dating, LMP, and endometrial dating were in agreement were used in
subsequent definitive studies. Marked decidualisation of the endometrium was
seen after seven days treatment with exogenous hCG.
2.2.5 Distribution of Corpora Lutea
During the three-year period (1993-1995), 598 sets of case records were
scrutinised. Letters were sent out to the 395 (66%) women identified as suitable.
Of these, 177 women replied, a response rate of 45%. Urine samples were
collected by 90 (51%) of these women who were classified as 'routine' or 'suitable
for rescue' prior to operation. A corpus luteum was obtained from 59 (65%) of
these women. Of these corpora lutea, strictly accurate dating, by the above
criteria, was not possible for 14. Therefore, 45 (76%) accurately dated corpora
lutea were available for definitive study during this period. Of these, 10 (22%)
were classified as early-luteal, 11 (24%) as mid-luteal, 12 (27%) as late-luteal and
12 (27%) as 'rescued'. Plasma progesterone concentrations were 30.6 ±8.4 nmol/1
in the early-luteal phase, 38.6 ±7.2 nmol/1 in the mid-luteal phase, 18.7 ±6.5
nmol/1 in the late luteal phase and, after luteal 'rescue', progesterone
concentrations increased from a mean of 37.8 ±5.6 nmol/1 at the time of initiation
of hCG treatment, to 52.5 ±0.9 nmol/1 at the time of collection (Figure 2.4). One
corpus luteum was obtained on average for every 13 sets of case notes analysed
(7.5%).
2.2.6 Patient Characteristics
The mean age of the donors was 40 (range 29 to 42). The commonest indication
for hysterectomy was menorrhagia (50%), followed by fibroids (25%) and pelvic
pain, including endometriosis, (18%). At least one ovary was conserved at the
time of operation in 82% of cases.
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Figure 2.4
Progesterone concentrations during the luteal phase
Mean progesterone concentrations ± the standard error of the mean (S.E.M.) in
female plasma at different stages of the luteal phase, and after luteal 'rescue' with
logarithmically increasing exogenous hCG from LH+7. The stages of the luteal
phase are also shown. Early = LH+1 to LH+5; Mid = LH+6 to LH+10; Late =
LH+11 to LH+14. Resc = daily doubling hCG from LH+7 for 5 to 8 days.
Progesterone concentrations increase in the early-luteal phase to a maximum in
the mid-luteal phase and then decline in the late-luteal phase. After luteal 'rescue'
progesterone concentrations are maintained and increase from LH+11 to LH+14.
(Groome et al., 1996; Illingworth et al., 1996)
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2.3 Marmoset Tissue
2.3.1 Marmoset Colony
All experiments involving non-human primates were carried out in accordance
with the Animals (Scientific Procedures) Act 1986. Captive-bred common
marmoset monkeys (Callithrix jacchus jacchus) were maintained in a colony
which has been closed since 1973. Animals were housed in rooms that were
maintained at temperatures between 20 °C and 25 °C and artificially lit between
07.00 h and 19.00 h. Animals were fed on 'Mazuri' New World Diet (Scientific
Diet Services Ltd., Stepfield, Essex), fresh fruit, vegetables and seeds daily with
water available ad libitum. Blood samples (300 pi) were collected on alternate
days by femoral venepuncture without anaesthesia while the animals were held in
a restraining device (Hcarn et al., 1978). These samples were assayed for
progesterone to determine the date of ovulation and the luteal phase duration
(Smith et al., 1990). The marmoset monkey normally ovulates 2-3 follicles and
has a functional luteal phase of approximately 18-21 days.
2.3.2 Treatment Protocols
Luteolysis was induced in the mid-luteal phase using either a PGF2oc analogue or
GnRHant. Ovaries were collected on day 10 of the luteal phase from control
animals or animals treated with either a 1 pg intramuscular (i.m.) injection of the
PGF2cx analogue, cloprostenol (Planate; Coopers Animal Health Ltd., Crewe,
Cheshire, UK), or a 500 pg/kg subcutaneous (s.c.) injection of the GnRHant,
antarelix ([N-Ac-D-Nal1, D-pCl-Phe2, D-Pal3, D-(Hic)6, Lys(iPr)8, D-Ala10]
GnRH; Europeptides (GEIE), Argenteuil, Val-D'Oise, France) (Deghenghi et al.
1993), 12 hours or 24 hours previously.
2.3.3 Collection of Tissue
The animals were sedated using 100 pi i.m. ketamine hydrochloride (Parke-Davis
Veterinary, Pontypool, Gwent, UK) and killed with an intravenous (i.v.) injection
of 400 pi sodium pentobarbitone (Euthetal; Rhone Merieux, Harlow, Essex, UK).
Whole ovaries were removed immediately, fixed in 4% paraformaldehyde for 24
hours and embedded in paraffin wax. In addition, some marmoset ovaries were
frozen in embedding medium (Tissue-Tek OCT compound) after removal. Frozen
sections were prepared from these ovaries and stored at -70 °C until use.
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A bank of normal marmoset tissues, including follicular phase ovaries, collected
from this and other experiments, was also utilised. These tissues were removed
immediately post-mortem. A piece of each tissue was snap frozen in liquid
nitrogen and stored at -70 °C for subsequent RNA extraction. Another piece was
frozen in embedding medium, and stored at -70 °C until frozen sections were
prepared.
2.3.4 Distribution ofOvaries
Ovaries were collected from control animals, estimated to be day 10 of the luteal
phase of the ovarian cycle. Some control animals had their ovaries frozen in
embedding medium (n=4) and some had their ovaries fixed in paraformaldehyde
and processed into paraffin wax (n=4). Ovaries frozen in embedding medium
were also available from animals in the follicular phase of the cycle (n=4).
Ovaries were also collected after systemic treatment to induce luteolysis. Ovaries
were collected 12 hours after PGF2a treatment and fixed in paraformaldehyde
(n=3). Ovaries collected 24 hours after PGF2cc treatment were either fixed (n=3)
or frozen (n=4). Ovaries collected 12 hours after GnRHant treatment were fixed in
some animals (n=3) and frozen in others (n=2). Similarly, ovaries collected 24
hours after GnRHant treatment were either fixed (n=3) or frozen (n=4).
Chapter 3
General Materials and Methods
3.1 Source ofReagents
3.1.1 Source of Chemicals and Solutions
All reagents used were obtained from Sigma Chemical (Poole, Dorset, UK) unless
otherwise indicated. Restriction enzymes and RNA polymerases were purchased
from Promega (Southampton, Hants, UK). Iodinated LH (Chelsea Reagent) was
obtained commercially from Department of Chemical Pathology, Hammersmith
Hospital, London, UK. The specific activity of the iodinated LH is 100 pCi/pg
and 10 000 counts per minute (c.p.m.) is equivalent to 45 pg. The reverse
zymography kit was obtained commercially from University Technologies
International Inc. (Calgary, Alberta, Canada). Ovine luteal cell conditioned
medium, for use as a positive control for TIMP-1, was kindly provided by Prof
M.F. Smith (University of Missouri, Columbia, USA).
3.1.2 Source of Antibodies
Prof M.R. Waterman of Vanderbilt University, Nashville, TN, USA provided the
polyclonal rabbit antibody to human 17a-hydroxylase. The mouse monoclonal
antibodies to human CD 68 (PG-M1) and von Willebrand factor were obtained
commercially (Dako Ltd., High Wycombe, Bucks, UK). The polyclonal rabbit
antibody to human placental type I 3P-HSD was kindly provided by Prof Van
Luu-The (CHUL Research Centre, Quebec, Canada). A mouse monoclonal
antibody to human progesterone receptors was obtained commercially
(Novocastra PGR antibody; Novocastra laboratories, Newcastle, Tyne, UK). In
addition, mouse monoclonal antibodies which recognised both A' and 'B'
isoforms of the progesterone receptor, or solely the 'B' isoform of the receptor,
were kindly supplied by Dr C.L. Clarke, University of Sydney, Sydney, Australia.
Monoclonal mouse anti-human TIMP-1 antibody was obtained commercially
(TIMP-1 (Ab-1); Cambridge Bioscience, Cambridge, Cambs, UK).
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3.1.3 Source of Nucleic Acid Probes
A 1.5 kilobase (kb) complementary DNA (cDNA) construct, corresponding to
nucleotide 542 to the last nucleotide of the open reading frame (2124), of the
human LH receptor (Minegishi et al., 1990) in pBluescript (Stratagene,
Cambridge, Cambs, UK), was kindly supplied by Dr M. Atger of the Faculte de
Medecine de Bicetre, Universite Paris-Sud, Le Kremlin-Bicetre, France. A 1.2 kb
cDNA construct of human 3P-HSD in pIBI25 was kindly supplied by Prof J.I.
Mason, Dept of Clinical Biochemistry, University of Edinburgh, Edinburgh, UK.
A 600 bp cDNA fragment of bovine P450scc was obtained from Prof A.S.
McNeilly, MRC Reproductive Biology Unit, Edinburgh, UK.
The following nucleic acid probes were also used: a 0.7 kb fragment of human
MMP-1 in pBluescript; a 1.6 kb fragment (6-1576 bp) of human MMP-2 in
pGEM 4Z; a 1.3 kb fragment (759-2105 bp) of human MMP-9 in pGEM 4Z; full-
length human TIMP-1 in pGEM 4Z; full-length human TIMP-2 in pGEM 4Z; a
0.2 kb fragment (400-600 bp) of human TIMP-3 in pBluescript. The probes to
MMP-2, MMP-9, TIMP-1 and TIMP-2 were kindly provided by British Biotech
Pharmaceuticals Ltd., Oxford, Oxon, UK. Probes for TIMP-3, and MMP-1 were
purchased from University Technologies International Inc. A cDNA probe to
human (3-actin was obtained by PCR using commercial primers and template
(Clontech, Palo Alto, CA, USA). The oligonucleotide fragment used to detect 18S
RNA was obtained from Dr J. Brooks (MRC Reproductive Biology Unit,
Edinburgh, UK).
3.2 Immunohistochemistry
3.2.1 Preparation of Slides
Glass slides (BDH Laboratory Supplies, Poole, Dorset, UK) were cleaned in hot
soapy water. They were then washed in 0.1 M HC1, rinsed in ribonuclease
(RNAse)-free water and washed in ethanol. When RNAse-free slides were
prepared these were then placed in metal slide racks and baked for 2 h. The slides
were then coated with poly-L-lysine (50 pg/1), wrapped in a sterile paper towel,
dried at 55 °C, and stored in RNAse-free sterile boxes until use.
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3.2.2 Preparation of Fixed Tissue Sections
Five micron sections of paraffin wax-embedded tissues were cut onto poly-L-
lysine-coated slides and dried overnight at 50 °C. Slides were dewaxed in xylene
for 10 min and, rehydrated through graded alcohols into distilled water. If
preliminary experiments indicated that antigen retrieval techniques were required
to optimise specific primary antibody binding, these were performed at this stage.
3.2.3 Preparation of Frozen Sections
In the case of frozen tissue, six micron sections were cut from the frozen block
(2.1.3) onto poly-L-lysine-coated slides. The sections were dried briefly at 37 °C
and stored at -70 °C until use. Prior to immunohistochemistry, they were fixed at
4 °C in 15% (v/v) aqueous picric acid, containing 2% (w/v) paraformaldehyde,
pH 7.4, for 10 min and washed in 0.1 M phosphate buffered saline (pH 7.4) for 20
min at 4 °C. From this point onwards the frozen sections followed the same
immunohistochemical procedure as the fixed sections.
3.2.4 Antigen Retrieval
Treatment of the tissue sections to expose masked antigens involved either
proteolytic digestion or microwave antigen retrieval. Where proteolytic digestion
was required, the slides were incubated in 0.1% (w/v) trypsin with 0.1% (w/v)
calcium chloride, buffered to pH 7.4 with 0.25 M Tris HC1, for 30 min at 37 °C.
The sections were then washed in 0.05 M Tris buffered saline pH 8.0 (TBS)
before the next stage of the immunohistochemical procedure. Where microwave
antigen retrieval was required, the technique of Shi et al. (1993) was used.
Sections were microwaved at full power (1000 W) in 0.01 M citrate buffer (pH 6)
for 10 min and left to stand for 20 min. The sections were then washed in TBS
before the next stage of the immunohistochemical procedure.
3.2.5 Blocking Endogenous Peroxidase
Where a horseradish peroxidase (HRP) detection system was used, endogenous
peroxidase activity was blocked at this stage. Endogenous peroxidase activity was
blocked with 2% (v/v) H202 in 60% (v/v) methanol for 30 min at room
temperature. The slides were then rinsed in TBS before the next stage of the
immunohistochemical procedure.
Chapter 3 General Materials and Methods
3.2.6 Immunohistochemical Procedure
Tissue was permeabilised with 0.1% Triton-XlOO in TBS for 10 min. After
washing in TBS, the area of the slide around the tissue section was dried and the
slides were transferred to a humid chamber. Non-specific binding was blocked by
incubating the sections with serum diluted 1:5 in TBS containing either 4% or 5%
(w/v) bovine serum albumin (BSA) for 20 min at room temperature. Normal goat
serum (NGS) (SAPU, Carluke, Lanarkshire, UK) was used if the primary
antibody was raised in a rabbit and non-immune rabbit serum (NRS) (Dako Ltd.)
was used if the primary antibody had been raised in a mouse. Excess blocking
buffer was then removed and the primary antibody diluted in TBS, or diluted in
20% normal serum in TBS, was added to the section. The optimal dilution and
conditions of the primary antibody had been determined in previous experiments.
The sections were incubated with the primary antibody for 18 h at 4 °C in a humid
chamber.
The slides were washed twice in TBS for 5 min and then incubated with the
secondary antibody (diluted either 1:100 or 1:500 in TBS) for 30 min at room
temperature. Biotinylated goat antibodies to rabbit immunoglobulins (Dako Ltd.)
were used if the primary antibody was raised in a rabbit and biotinylated rabbit
antibodies to mouse immunoglobulins (Dako Ltd.) were used if a mouse was the
source of the primary antibody. The slides were washed again in TBS for 5 min
and the avidin-biotin (AB) enzyme complex was added to the section for 30 min
at room temperature. The detection enzyme linked to this complex was either
HRP (AB-HRP Kit; Dako Ltd.) or alkaline phosphatase (AP) (AB-AP Kit; Dako
Ltd.).
3.2.7 Colouration of Sections
Excess AB enzyme complex was washed off in TBS for 5 min twice. The sections
were then coloured. Where HRP was used as the detection enzyme, antibody
binding was visualised using diamino-benzidine (DAB) as a substrate, which
gives a stable brown end product (Vector Laboratories, Peterborough, Cambs,
UK). Where AP was used, the substrate was either a kit to give a red end product
(Alkaline Phosphatase Substrate Kit I; Vector Laboratories), or nitroblue
tetrazolium chloride (NBT) which gives a blue end product. When the colouration
reaction was complete, the slides were washed in water and counterstained with
haematoxylin. If NBT was used as the substrate, the sections were not
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counterstained with the purple haematoxylin dye. The slides were then dehydrated
through increasing concentrations of alcohol, cleared in xylene and mounted with
non-aqueous mounting medium (Pertex; Cellpath, Hemel Hempstead, Herts, UK).
3.2.8 Staining of Tissue Sections
Sections were counterstained with haematoxylin for 20 s to 3 min, and washed
with tap water. They were then looked at by light microscopy. If the staining was
inadequate, they were stained with haematoxylin for a further minute and
rechecked. If the staining was too intense the slides were cleared for 20 s in 1%
acid alcohol and restained with haematoxylin. When the haematoxylin staining
was adequate, the slides were dehydrated through graded alcohols, cleared in
xylene and mounting with Pertex mounting medium.
Sections for morphological study were stained for haematoxylin and eosin. In this
case the slides were cleared in xylene for 10 min then dehydrated through graded
alcohols, 100% ethanol (2 min), 95% ethanol (2 min), 70% ethanol (2 min), into
water. The slides were stained with haematoxylin as above, washed in tap water
and stained with eosin for 10 s. After thorough washing, the slides were
dehydrated through graded alcohols, cleared in xylene and mounted.
3.2.9 Negative Controls
Where the primary antibody was a polyclonal rabbit antibody, polyclonal rabbit
immunoglobulin G (IgG) (Dako Ltd.) at the same antibody concentration, or
rabbit serum with an equivalent immunoglobulin concentration (Dako Ltd.), was
used in place of the primary antibody, in serial sections, as a negative control.
Where the primary antibody was a monoclonal mouse antibody, the primary
antibody was replaced by mouse IgG (Vector Laboratories; Dako Ltd.), at the
same concentration (typically 5 pg/ml) in serial sections as negative controls. In
each case, further serial sections, where the primary antibody was omitted were
used as additional negative controls.
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3.3 Western Blotting
3.3.1 Preparation of Blot
In order to extract proteins from snap-frozen tissue, the tissue was cut into small
pieces and homogenised in 0.1% sodium dodecyl sulphate (SDS) on ice. After
sonication, the protein content was estimated by the method of Bradford (1976).
Two hundred-micrograms of protein was denatured by boiling in sample buffer
[4% (w/v) SDS, 40% (v/v) glycerol, 10% (v/v) (3-mercaptoethanol, 0.04% (w/v)
Bromophenol blue, 10 mM EDTA, 125 mM Tris, pH 7.0] and separated by
electrophoresis in fresh running buffer [0.1% (w/v) SDS, 50 mM Tris HC1, 0.4 M
glycine] on an 11% polyacrylamide gel at 180 V, for 4 h at 10 °C. Proteins were
electrophoretically transferred onto nitro-cellulose membrane (Amersham
International, Aylesbury, Bucks, UK) in transfer buffer [25 mM Tris HC1, 0.2 M
glycine, 20% (v/v) methanol] at 50 V, overnight at 4 °C. The following morning,
the voltage was increased to 100 V for 90 min. After transfer, the blot was washed
briefly in TBS containing 0.05% (v/v) Tween (TBST) and incubated in 10% (w/v)
dried skimmed milk powder (Marvel; Premier Beverages, Stafford, Staffordshire,
UK) in TBST.
3.3.2 Visualisation of Proteins
The blots were incubated with the primary antibody, at a concentration of 2
pg/ml, in TBST for 1 h at room temperature. After washing in TBST, the
membranes were incubated with biotinylated rabbit anti-mouse immunoglobulins,
at a dilution of 1:3000 in TBST, for 1 h at room temperature. After further
washing in TBST, the membranes were incubated with streptavidin AP solution
(Dako Ltd.) for 1 h. Antibody binding was visualised, after washing in TBST,
using a red chromogen (Alkaline Phosphatase Substrate Kit I; Vector
Laboratories). After the bands were visible, the reaction was stopped in water for
10 min. The blots were dried on filter paper and photographed. Molecular weight
markers (Biorad Laboratories, Hemel Hempstead, Bucks, UK) were run in an
adjacent lane to calculate the weight of the detected proteins.
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3.4 In situ Ligand Binding
3.4.1 Ligand Binding Reaction
In situ ligand binding was performed using a modification of the method
described by Molenaar et al. (1993). Frozen sections of 5 pm were cut onto poly-
L-lysine-coated slides (3.2.1) and stored at -70 °C until use. They were quickly
thawed and incubated in binding buffer (50 mM HEPES, 5 mM MgC^, 0.3%
(w/v) BSA, pH 7.4) at room temperature for 20 min. The area of the slide around
the tissue section was dried, to remove excess buffer, and the slides were
transferred to a humid chamber. One hundred microlitres of binding buffer,
containing 10 000 c.p.m. of iodinated LH (Chelsea Reagent) (3.1.1), was added
for 2 h at room temperature. As negative controls serial sections were incubated
with binding buffer containing 10 000 c.p.m. iodinated LH with excess (20 IU)
cold hCG (Profasi).
3.4.2 Visualisation of Ligand Binding
The slides were briefly washed four times in 0.05 M Tris pH 7.4 at 4 °C, dipped
in distilled water, and allowed to dry for 3 h at 4 °C. The slides were warmed to
37 °C on a slide warmer and dipped in photographic emulsion (Kodak NTB-2; IBI
Ltd, Cambridge, Cambs, UK), heated to 37 °C, using a glass dipping chamber.
They were then allowed to dry in the vertical position in a darkened moist box for
2 h at room temperature. The sections were then transferred to an air-tight slide
box containing silica desiccant and stored at 4 °C for 3 days in the dark. The
slides were developed at 15 °C in the dark in freshly filtered developer (Kodak D-
19; IBI Ltd) for 4 min, washed and fixed for 15 min (Kodak Unifix; IBI Ltd)
(3.7.6). The slides were then washed for 20 min in running tap water,
counterstained in haematoxylin, dehydrated through graded alcohols and mounted
in Pertex mounting medium (3.2.8),
3.5 Nucleic Acid Probe Preparation
3.5.1 Transfection and Amplification
The plasmids were transfected into competent E. coli (HB101; Clontech) using
the heat shock technique (at 42 °C), according to the manufacturer's instructions.
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The bacteria were then added to SOC medium [2% tryptone, 0.5% yeast extract,
10 mM NaCl, 2.5 mM KC1, 10 mM MgCl2, 10 mM MgS04, 20 mM glucose]
(Biol01 Inc., La Jolla, CA, USA) and incubated on a shaking platform at 37°C for
1 h. Fifty microlitres of these cultures were spread on sterile plates containing LB
agar (BiolOl Inc.) and ampicillin (50 pg/ml) and incubated overnight at 37 °C.
The following day individual colonies were identified and subcloned on
ampicillin-agar plates. One clonal colony was added to LB broth (BiolOl Inc.)
containing 50 pg/ml ampicillin. This culture was incubated overnight on a
shaking platform at 37 °C. The bacterial solution was only used if the control
tube, containing only LB broth and ampicillin, was clear when examined the
following morning. Plasmids were extracted from these bacterial cultures.
In some situations, PCR fragments were inserted into plasmid vectors. Here, fresh
PCR products were ligated into a cloning vector (PCR II Vector; Invitrogen, San
Diego, CA, USA), using a DNA ligase reaction at 14 °C, using a commercial
cloning kit (TA Cloning Kit; Invitrogen). The plasmid was transfected into
competent cells (as supplied) by heating to 42 °C for 2 min, in the presence of (3-
mercaptoethanol, and immediately placing on ice. Cells, containing the plasmid,
were selected on ampicillin (50 pg/ml)-containing X-galactose-coated agar plates.
Disruption of the lacZa gene fragment in the vector gives white colonies and
implies successful ligation of the PCR fragment. White colonies were subcloned,
and one subcloned colony was added to lysis buffer [20 mM Tris-HCl, pH 8.4, 2
mM EDTA, pH 8.0, 1% (v/v) Triton-X 100] and heated to 95 °C for 5 min. This
released the DNA to allow the detection of the plasmid insert in that clone by
direct lysis PCR (3.5.4).
3.5.2 Purification and Stock Preparation
Plasmids were extracted using the Wizard 373 DNA Purification System
(Promega). Briefly, the bacterial cultures obtained above were centrifuged at 3000
revolutions per minute (r.p.m.) for 20 min at room temperature and the
supernatant discarded. Cells were resuspended in buffer [50 mM Tris-HCl, pH
7.5, 10 mM EDTA, 100 pg/ml RNAse A], lysed with 0.2 M NaOH and 1% SDS
and neutralised with 1.32 M potassium acetate, pH 4.8, prior to centrifugation at
13 000 r.p.m at 4°C. The supernatant was mixed with DNA purification resin (as
supplied) and the DNA was trapped in the minicolumn supplied with the kit. The
DNA was washed with buffer [200 mM NaCl, 5 mM EDTA, 20 mM Tris-HCl,
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pH 7.5] and eluted from the minicolumn by adding water at 72°C for 1 min, then
pulse centrifuged at room temperature for 1 min. The elutant was reapplied to the
column, and collected by pulse centrifugation again, prior to visualisation.
The plasmids were visualised by ethidium bromide staining on an 0.8% agarose
gel run at 100 V. Purity and concentration were assessed by comparison with a
commercial plasmid DNA standard (pBR322; Pharmacia, Uppsala, Sweden) of
known concentration. In some cases, the plasmid DNA was further concentrated
by precipitation with 3 M sodium acetate, pH 5.5 and ethanol at -20°C for 2 h.
After precipitation, the DNA was collected by centrifugation at 13 000 r.p.m. for
20 min at 4 °C. The DNA pellet was washed with 70% ethanol, air-dried and
reconstituted in sterile water.
In each case, prior to plasmid purification, further bacterial stocks were prepared.
An aliquot of each culture was added to cold 50% (v/v) glycerol and mixed
thoroughly. These stocks were stored at -70 °C. When required these stocks were
thawed and an aliquot applied to agar plates, or broth, containing 50 pl/ml
ampicillin. This allowed the further propagation of these plasmid-containing
bacterial cells.
3.5.3 Restriction Digestion
The plasmids were cut with the required restriction enzymes. Reaction mixtures
containing the plasmid DNA, the restriction enzyme (20-40 U) and commercial
reaction buffer (One-Phor-All Buffer PLUS; Pharmacia) were incubated at 37 °C
for 1 h. A further 20-40 U of the restriction enzyme was added to each mixture,
and they were incubated again at 37 °C for 1 h. The samples were then incubated
with proteinase K for 30 min at 37 °C. The reaction mixture was incubated with
an equivalent volume of phenokchloroform and the layers separated by pulse
centrifugation at 13 000 for 3 min. The aqueous layer was removed to another
tube, mixed with an equivalent volume of chloroform and separated by pulse
centrifugation. The aqueous layer was mixed with 6 M ammonium acetate and ice
cold ethanol, and precipitated overnight at -20 °C.
The following day, the DNA was collected by centrifugation at 13 000 r.p.m. for
15 min at 4 °C. The pellets were washed by pulse centrifugation in 70 % ethanol
and air-dried for 2 h at room temperature. After reconstitution, an aliquot of the
cut plasmid DNA was visualised by ethidium bromide staining, after
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electrophoretic separation on a 1.2% agarose gel. Uncut plasmid was run on a
neighbouring lane to confirm the cutting reaction had been successful.
3.5.4 Polymerase Chain Reaction
PCR was used for the production of cDNA fragments from plasmids, and the
identification of fragments in plasmids by direct lysis PCR. Here, the
oligonucleotides used were based on the SP6 and T7 sequences sandwiching each
insert. A reaction mix containing the reaction buffer [100 mM Tris HC1, 500 mM
KC1, 15 mM MgCH, pH 8.3], the plasmid DNA, 10 mM of each
deoxynucleotides, the SP6 primer (5AGCTATTTAGGTGACACTATAGA-3', at
a concentration of 708 ng/pl), the T7 primer (5'-GTAATACGACTCACTAT-
AGGGC-3', at a concentration of 670 ng/pl) (Cruachem, Glasgow, Strathclyde,
UK) and Taq polymerase (Perkin Elmer, Branchburg, NJ, USA), made up to 50 pi
with sterile water.
In a thermal reactor (Hybaid Ltd., Teddington, Middlesex, UK), the DNA was
denatured at 94°C for 3 min, followed by 30 cycles of 94°C for 30 s, 45°C for 1
min and 72°C for 1 min, and finally 72°C for 10 min. The PCR products obtained
were run on a 1.2% agarose gel with ethidium bromide staining and photographed
under ultraviolet (u.v.) illumination. A pGEM marker (Promega) was run in an
adjacent lane to allow calculation of the size of the DNA fragments detected.
3.5.5 Labelling of cDNA Probes
The cDNA probes for Northern blotting were denatured at 95 °C for 5 min and
placed on ice for 1 min. They were then radiolabelled with 32P-dCTP (Amersham
International) using a commercial random priming kit (Multiprime DNA
Labelling System; Amersham International) for 1 h at 37 °C. The labelling
reaction was stopped by adding 5 M NaOH, and the sample was buffered and
neutralised 3 min later by the addition of 1 M Tris, pH 8.0 and 1 M HC1 according
to the manufacturers instructions. This mixture was added to the hybridisation
buffer during Northern blotting (3.6.2) experiments.
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3.6 Northern Blotting
3.6.1 Preparation ofBlot
Total RNA was isolated by the method of Chomczynski and Sacchi (1987) using
a commercial kit (RNAzol B; Biogenesis, Bournemouth, UK or Tri Reagent;
Sigma Chemical), and its concentration was determined by absorption at 260 nm.
Total RNA (20-30 pg depending on the experiment) was quickly thawed, added to
sample buffer [20 mM MOPS, 1 mM EDTA, 5 mM sodium acetate, 70% (v/v)
deionised formamide, 6% (v/v) formaldehyde] and heated to 65 °C for 5 min.
After incubating on ice, dye solution [7.5% (v/v) Ficoll 400, 0.1% (w/v)
Bromophenol blue] and lpl of ethidium bromide solution (1 mg/ml), were added
to the samples. The samples were electrophoresed in a 1.5% formaldehyde-
agarose gel in running buffer [20 mM MOPS, 1 mM EDTA, 5 mM sodium
acetate, pH 7.0] at 32 V for 16 h.
After photographing the gel under u.v. illumination, the separated RNA was
transferred to a nylon membrane (Amersham International), by capillary action in
20x SSC (lx SSC is 150 mM NaCl, 15 mM sodium citrate, pH 7), overnight at
room temperature. The following day the filter was air-dried and wrapped in cling
film. The RNA was then fixed onto membranes by u.v. cross-linkage (Spectronics
Corporation, New York, NY, USA). Membranes were stored at 4 °C until use.
The molecular size of the transcripts was determined by running commercial
RNA markers (Promega) in an adjacent lane.
3.6.2 Hybridisation
Membranes were prehybridised for 2-5 h in 15 ml hybridisation buffer [0.5 M
sodium phosphate, 1 mM EDTA, 1% (w/v) BSA, 7% (w/v) SDS, 6.7% (v/v)
deionised formamide], in rotating glass tubes (Hybaid Ltd.) at 65 °C. The cDNA
probe (3.1.3, 3.5.4) was labelled with 50 pCi 32P dCTP (Amersham International)
by the random priming method using a commercial kit (3.5.5) (Amersham
International) and added to the hybridisation buffer. Hybridisation was performed
for 20 h at 65 °C in the rotating glass tube in a Hybaid oven (Hybaid Ltd.).
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3.6.3 Detection ofHybridisation Signal
The membranes were washed twice at 65 °C with 2x SSC for 15 min and once
more with 2x SSC/0.1% SDS at 65 °C for 15 min in a rotating glass tube in the
Hybaid oven. The blots were then wrapped in cling film and laid down to a
phosphor screen for 24-72 h and visualised using a phosphorimager computer
(Molecular Dynamics, Maidstone, Kent, UK).
3.6.4 Reuse of Northern Blots
To confirm accurate loading ofRNA, the blots were stripped in stripping buffer (5
mM Tris HC1, 0.3 mM EDTA, O.lx Denhardt's reagent) for 2 h at 65 °C. The
blots were then re-probed for 18S RNA (3.1.3) with a 32P end-labelled
oligonucleotide which hybridises to 18S RNA as described previously (Brooks et
al. 1992). In some experiments, the blots were reprobed for (3-actin (3.1.3) with a
labelled p-actin PCR fragment..
3.7 In situ Hybridisation
Isotopic in situ hybridisation was performed on RNAse-free (3.2.1) fixed or
frozen sections (2.2.3) using 35S-labelled riboprobes.
3.7.1 Preparation of Plasmid
Plasmids containing the cDNA sequence linked to RNA polymerase initiation
sites were amplified (3.5.1) and purified (3.5.2) as described previously.
Antisense riboprobes were used to detect specific mRNAs in tissue sections.
Sense riboprobes were used as negative controls to detect non-specific binding.
Plasmids were linearised by restriction digestion as described previously (3.5.3).
Antisense and sense riboprobes were generated using T3, T7 or SP6 RNA
polymerases depending on the plasmid map and cDNA orientation. The restriction
enzyme/RNA polymerase combination used in each instance is reported in each
experimental chapter.
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3.7.2 Synthesis ofRiboprobe
Riboprobes, incorporating 35S-labelled UTP (Amersham International), were
synthesised using a commercial kit (Promega). The cut plasmids were used as a
template in the following labelling reaction: 5 pi of 5x Transcription buffer (Tsc
buffer; Promega), 2 pi of DNA template, 1 pi of 10 mM rATP, 1 pi of 10 mM
rCTP, 1 pi of 10 mM rGTP, 1 pi of 0.2 mM rUTP, 1 pi of 100 mM DTT, 5 pi of
35S-UTP (50 pCi), 1 pi of RNAse inhibitor (28 U/pl), 1 pi of RNA polymerase
(SP6, T3 or T7), made up to 25 pi with sterile water. This mixture was incubated
at 37 °C for 45 min, a further 1 pi ofRNA polymerase was added and the mixture
was incubated at 37 °C for a further 45 min.
Following this incubation, 2 pi of transfer RNA (tRNA) (11 mg/ml) and 1 pi of
RNAse-free deoxyribonuclease (DNAse) (1000 U/ml) were added, and the
mixture was incubated at 37 °C for 10 min. After adding sterile water to a final
volume of lOOpl, an equal volume of phenol/chloroform/isoamyl alcohol
(50:49:1) was added, and the solution was vortexed and centrifuged at 13 000
r.p.m for 15 s, at room temperature. The solvent was discarded and the extraction
procedure was repeated with chloroform/isoamyl alcohol (49:1). The riboprobe
was precipitated with 10 pi of 3 M sodium acetate, pH 5.2 and 250 pi ethanol
overnight at -70 °C. After recovery by centrifugation (3.5.3), the probe was
reconstituted in sterile water. After reconstitution, 1 pi of the labelled probe was
counted in 3 ml of scintillation fluid (Eco Scint; National Diagnostics, Atlanta,
Georgia, USA) using a scintillation counter.
3.7.3 Preparation of Sections
Fixed sections (5 pm) on poly-L-lysine-coated slides (3.2.1) were dewaxed in
fresh xylene, and rehydrated through graded alcohols (3.2.2). The slides were then
incubated with proteinase K (5 pg/ml) in buffer [100 mM Tris, 50 mM EDTA, pH
8] for 30 min at 37 °C. Where frozen sections were used, 5 pm sections on poly-
L-lysine-coated slides (3.2.1) were quickly thawed, fixed in 4% (w/v)
paraformaldehyde in 0.1 M sodium phosphate, pH 7.4, for 5 min at room
temperature. The frozen sections were then washed twice in 0.1 M sodium
phosphate for 5 min. Both types of slides were then treated identically.
The slides were rinsed first in water and then in 0.1 M triethanolamine (TEA) pH
8 for 5 min at room temperature. After rinsing, the slides were acetylated in
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0.25% (v/v) acetic anhydride (BDH Laboratory Supplies) in TEA for 10 min. The
slides were then washed in 2x SSC for 2 min twice. They were then dehydrated
through fresh graded alcohol solutions, 50% ethanol for 3 min, 70% ethanol for 3
min, 95% ethanol for 3 min and 100% ethanol for 5 min. After a further 5 min
wash in 100% ethanol, the slides were then dried under vacuum in a desiccator for
1 h at room temperature. The sections were then transferred to small moist plastic
dishes (BDH Laboratory Supplies) for hybridisation.
3.7.4 Hybridisation
One hundred microlitres of hybridisation buffer [50% deionised formamide, 10%
dextran sulphate, lx Denhardt's solution, 0.5 mg/ml yeast tRNA, 10 mM
dithiothreitol (DTT), 0.3 M NaCl, 10 mM Tris, 1 mM EDTA pH 8] containing 1
x 106 c.p.m. 35S-radiolabelled antisense probe was added to each section. The
35S-labelled sense riboprobe (1 x 106 c.p.m) was added to serial sections as a
negative control. The slides were covered with a hydrophobic coverslip (Gel
Bond; ICN Biomedical Ltd, High Wycombe, Bucks, UK) and incubated overnight
at 55 °C in a moist chamber.
3.7.5 Washing of Sections
The following day the coverslips were washed off in 4x SSC. After four 6 min
rinses in 4x SSC, the slides were treated with RNAse A (20 pg/ml) in RNAse
buffer [10 mM Tris, 1 mM EDTA, 0.5 M NaCl, pH 8] for 30 min at 37 °C. The
sections were de-salted by rinsing in 2x SSC/1 mM DTT for 6 min twice,
followed by lx SSC/1 mM DTT for 12 min and 0.5x SSC/1 mM DTT for 10 min
twice at room temperature. The slides were then washed for 30 min in O.lx SSC/1
mM DTT at 70 °C in a shaking water bath. After rinsing in O.lx SSC/1 mM DTT
at room temperature for 5 min, the sections were dehydrated through graded
alcohols (50%, 70% and 95% ethanol), containing 1 mM DTT and 0.08x SSC, for
3 min each. The sections were then washed in pure ethanol for 3 min, three times
and allowed to dry.
3.7.6 Detection ofHybridisation Signal
The slides were air-dried and gently heated to 37 °C on a hot-plate in the dark.
They were then dipped in photographic emulsion (Kodak NTB-2) at 37 °C in a
glass dipping chamber. The slides were allowed to dry vertically for 2 h in a light-
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tight moist container. They were then transferred to a slide rack and stored at 4 °C
for 18-21 days in light-tight boxes containing silica gel. The slides were then
developed. They were incubated with freshly filtered developer (Kodak D-19) for
4 min at 15 °C in the dark. The slides were rinsed in water containing 0.1% (v/v)
glacial acetic acid and fixed for 15 min (Kodak Unifix) at 15 °C. The slides were
washed in water and rinsed in running tap water for 1 h, counterstained in
haematoxylin (3.2.8), dehydrated through graded alcohols, cleared in xylene and
mounted in ' Pertex mounting medium. The sections were viewed and
photographed under dark-field illumination. The localisation of the grains was
determined by reference to the section viewed under bright-field.
Chapter 4
Experimental Section I: Functional Effects
4.1 General Introduction
This first section explores the functional capacity of the corpus luteum at different
stages of its lifespan. To recap, the main synthetic function of the corpus luteum is
the production of progesterone (Behrman et al., 1993). Progesterone secretion
increases during the early-luteal phase and reaches a peak in the mid-luteal phase
(Fig. 4.1). In the absence of hCG from the implanting blastocyst, progesterone
production declines during the late-luteal phase (Fig. 4.1). At the time of
menstruation, luteal progesterone production has virtually ceased (Lenton and
Woodward, 1988). In a conception cycle, hCG is secreted by the trophoblastic
tissue of the conceptus in a logarithmically increasing manner (Lenton and
Woodward, 1988; Tovanabutra et al., 1993). This hCG acts directly on the corpus
luteum to maintain, and increase, the progesterone output of the corpus luteum in
the short term (Stouffer, 1988). Therefore, after luteal 'rescue' with hCG,
progesterone synthesis increases during the late-luteal phase (Fig. 4.1) and
menstruation is prevented.
The reason that the progesterone output of the corpus luteum changes over the
luteal phase is not clear. The time when progesterone production is at its greatest
flux is in the late-luteal phase (Fig. 4.1). At this time, there are fundamental
differences in progesterone synthesis in the absence or presence of hCG (Lenton
and Woodward, 1988). Progesterone synthesis from the corpus luteum is
absolutely dependent on gonadotrophic stimulation (Hutchison and Zeleznik,
1984; Fraser et al., 1986). During the normal luteal phase, LH from the pituitary
gland is responsible for progesterone synthesis (Hutchison and Zeleznik, 1984).
LH binds to and activates a specific glycoprotein receptor (Segaloff and Ascoli,
1993) on the surface of the steroidogenic cells (Bramley et al., 1987). The LH
receptor is a classic G-protein coupled receptor linked to adenylyl cyclase
(Segaloff and Ascoli, 1993; Rojas and Ciridon, 1996). Ligand binding stimulates
the activation of intracellular second messenger cascades (Segaloff and Ascoli,
1993; Lopez Bernal et al., 1995), and the synthesis of cAMP (Eyster et al., 1985)
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Figure 4.1
Progesterone output of the corpus luteum
A schematic cartoon indicating progesterone synthesis by the human corpus
luteum throughout its functional lifespan. Progesterone output increases in the
early-luteal phase (LH+1 to LH+5), is maximal in the mid-luteal phase (LH+6 to
LH+10) and declines in the late-luteal phase (LH+11 to LH+14). After luteal
'rescue' with hCG, progesterone production in the late-luteal phase is increased.
Progesterone is produced in luteal cells by the actions of the steroidogenic
enzymes after LH stimulation.
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(Fig. 4.2). Cyclic AMP stimulates the action of the steroidogenic enzymes to
convert cholesterol into progesterone (Marsh, 1976) (Fig. 4.2).
The first stage in the conversion of cholesterol to progesterone is the transport of
cholesterol from the cell cytosol to the inner mitochondrial membrane, where the
first enzyme of the steroidogenic pathway is located (Adashi, 1994; Stocco and
Clark, 1996). The transport of cholesterol across the mitochondrial membrane is
thought to be under the control of the StAR protein (Clark et al., 1994; Stocco and
Clark, 1996). This is likely to be the rate-limiting stage of the steroidogenic
pathway (Stocco and Clark, 1996) (Fig. 4.2). The enzyme complex P450scc is
located on the inner mitochondrial membrane. It catalyses the conversion of
cholesterol into pregnenolone (Simpson and Boyd, 1967). Pregnenolone is
converted to progesterone by the action of 3P-HSD (Strauss and Miller, 1991). De
novo synthesised progesterone is secreted by the steroidogenic cells of the corpus
luteum into the local and then systemic circulation (Fig. 4.2). Progesterone acts on
its target tissues by binding to a specific nuclear receptor which is responsible for
the genomic effects of progesterone (Graham and Clarke, 1997).
For progesterone synthesis to fall during the late-luteal phase, there much be an
increasing block to its synthesis somewhere in this pathway. We know that LFl
withdrawal using GnRH inhibition (Hutchison and Zeleznik, 1984; Fraser et al.,
1986) causes progesterone synthesis to cease and induces luteolysis (Fraser et al.,
1995b). During the normal luteal phase, the exposure of the corpus luteum to
pituitary LH decreases due to a reduced LH pulse frequency (Ellinwood et al.,
1984). However this alone is not the cause of functional luteolysis as progesterone
synthesis still declines in the presence of artificially maintained LH levels
(Hutchison et al., 1986). It is therefore the action of LH which seems to be
blocked during the late-luteal phase, when progesterone synthesis is declining.
This decline in progesterone synthesis in the late-luteal phase is prevented by
exposure to hCG from the implanting blastocyst (Stouffer, 1988). The molecular
mechanisms of how hCG 'rescues' the corpus luteum are not clear. However hCG
shares a great homology with LH (lies and Chard, 1993), albeit with a different
glycosylation pattern (Wilson et al., 1990), and exerts its biological actions by
activating the LH receptor (Cole et al., 1973). HCG has a longer bioavailability
than LH (Wilson et al., 1990) and is present in logarithmically increasing
concentrations (Lenton and Woodward, 1988) in early pregnancy. HCG clearly
maintains progesterone production by its actions on the LH receptor. However,
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(2)
Steroidogenic luteal cell, illustrating enzymes and processes involved in synthe¬
sis of progesterone. Dc novo cholesterol synthesis (1) proceeds from acetate through action
of, primarily, 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMG-CoA reductase).
Cholesterol and cholesterol esters are also taken up (2) from low-density lipoprotein (LDL)
via receptor-mediated endocytosis or (3) from high-density lipoprotein (HDL) through a
nonendocytic process. Cholesterol is esterified (4) by acyl coenzyme A:cholesterol
acyltransferase (ACAT) for storage in lipid droplets. Cholesterol esterase (CE) effects dees-
terification (5), and the resultant cholesterol is transported (6) to the inner mitochondrial
membrane where cytochrome P450scc cleaves the side chain of cholesterol to produce preg¬
nenolone. Pregnenolone proceeds (7) to the smooth endoplasmic reticulum (SER), where it is
converted to progesterone by 3p-hydroxysteroid dehydrogenase/A5-A4 isomerase (3fi-HSD).
Figure 4.2
Progesterone synthesis by luteal cells
Cartoon illustrating the synthetic pathways involved in the synthesis of
progesterone by luteal cells.
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how this happens is not immediately clear. Exposure to its ligand has been shown
to down-regulate the LH receptor in vitro and in vivo (Segaloff and Ascoli, 1993;
Peegel et al., 1994) and negate its biological action. The effects of hCG on the LH
receptor and the other elements of the steroidogenic pathway at a molecular level
are not clear.
4.2 Scope of the Section
The following four chapters aim to systematically address the steroidogenic
pathway in the primate corpus luteum throughout its functional lifespan with
particular emphasis on luteal 'rescue' during maternal recognition of pregnancy.
Each chapter is deliberately written in the form of a scientific paper. This allows
each chapter to be read in isolation, in parallel or in series. This format, however,
does not facilitate the development of a coherent thesis in this section. At the end
of the thesis, therefore, the conclusions of all the experimental chapters will be
drawn together in order to develop a paradigm of the corpus luteum during its
functional lifespan.
The first part of the steroidogenic pathway to be investigated was the LH receptor
itself. The LH receptor was studied during the normal luteal phase, during
luteolysis and during simulated maternal recognition of pregnancy. Chapter 5
addresses the expression and localisation of the LH receptor in the human corpus
luteum throughout the functional luteal phase and after luteal 'rescue' with
exogenous hCG to simulate early pregnancy. Chapter 6 addresses the expression
of luteal and follicular LH receptors in the primate ovary in response to
withdrawal of its ligand and treatment with PGF2a. Both of these treatment
modalities inhibit progesterone synthesis and initiate luteolysis.
The second part of the steroidogenic pathway to be investigated was the
steroidogenic enzymes, and factors downstream from the LH receptor. Chapter 7
addresses the expression of StAR, P450scc and 3P-HSD in human corpora lutea
throughout the functional luteal phase and after luteal 'rescue' with exogenous
hCG. Chapter 7 also addresses the detailed localisation of the 3p-HSD enzyme
and its mRNA. Chapter 6 also addresses the effect of induced luteolysis on the
expression and localisation of 3P-HSD in the primate ovary.
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The third element of the steroidogenic pathway to be investigated was
progesterone itself. There is increasing evidence that progesterone may directly
effect its synthesis. Chapter 8 addresses the autocrine role of progesterone in the
corpus luteum by investigating the amount, localisation and nature of
progesterone receptors in the corpus luteum. Luteal progesterone receptors were
studied throughout the luteal phase and after luteal 'rescue' with exogenous hCG.
Their expression in the corpus luteum was compared and contrasted with that seen
in a classic progesterone-target tissue, the endometrium.
Chapter 5
LH receptor in the human corpus luteum: lack of
down-regulation during maternal recognition of
pregnancy
5.1 Abstract
Luteal progesterone production is dependent on LH from the pituitary gland.
Despite continuing LH secretion, the human corpus luteum undergoes functional
luteolysis unless it is 'rescued' by hCG, produced by the implanting blastocyst. As
LH and hCG act through a common receptor, this study sought to determine the
expression of the LH/hCG receptor in the corpus luteum during maternal
recognition of pregnancy. Corpora lutea were collected at hysterectomy from
women in the normal luteal phase and after luteal 'rescue' with exogenous hCG. In
each case the corpus luteum was classified according to the date of the LH surge
measured in daily urine samples. The expression of the LH receptor was
investigated by northern blotting, in situ hybridisation and in situ ligand binding.
LH receptor mRNA and ligand binding activity were detected in corpora lutea
from all stages of the luteal phase. LH receptor expression and binding were
maintained during maternal recognition of pregnancy, in the presence of
exponentially increasing hCG. These data show that the LH receptor is maintained
throughout the functional life-span of the human corpus luteum and is not down-
regulated during maternal recognition of pregnancy.
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5.2 Introduction
Progesterone production by the primate corpus luteum is dependent on circulating
LH from the pituitary gland (Hutchison and Zeleznik, 1984; Fraser et al., 1986).
Withdrawal of circulating LH results in both structural and functional luteolysis.
However, despite the continued secretion of LH, functional luteolysis occurs after
14 days unless hCG is secreted by the implanting blastocyst (Hutchison et al.,
1986). Both LH and hCG exert their luteotrophic actions through a common
receptor (Cole et al., 1973). The human LH/hCG receptor cDNA has now been
cloned and sequenced (Minegishi et al., 1990). It is part of a family of G-protein-
coupled receptors, with seven transmembrane regions and a large glycosylated
extracellular domain (Segaloff and Ascoli, 1993).
In the presence of increasing hCG, during maternal recognition of pregnancy in
women, luteal progesterone production increases, and circulating progesterone
concentrations rise (Lenton and Woodward, 1988; Tovanabutra et al., 1993).
However, in other species the LH receptor has been shown to undergo
desensitisation and down-regulation after exposure to its ligand (Niswender et al.,
1985; Segaloff and Ascoli 1993; Peegel et al., 1994). In addition, previous studies
investigating the LH receptor in the human corpus luteum have reported low
levels of receptor in the corpus luteum of ectopic pregnancy (Rao et al., 1977b;
Bramley et al., 1987; Yamoto et al., 1988). It is therefore not clear how the human
corpus luteum is able to augment progesterone production during maternal
recognition of pregnancy.
This study aimed to investigate the luteal LH/hCG receptor during the process of
maternal recognition of pregnancy at the time of menstrual delay. We studied
LH/hCG receptor mRNA expression and ligand binding in carefully dated human
corpora lutea from throughout the normal luteal phase and after luteal 'rescue' with
logarithmically increasing doses of exogenous hCG.
5.3 Specific Materials and Methods
5.3.1 Tissues Studied
Corpora lutea were enucleated at the time of hysterectomy in women undergoing
surgery for benign conditions (2.2). Four corpora lutea were classified as early-
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luteal, four as mid-luteal, four as late-luteal and four were classified as luteal
'rescue' (2.2.4). At operation, a piece of tissue was rapidly snap frozen in liquid
nitrogen and stored at -70 °C for subsequent RNA extraction (2.2.3). Another
piece of the corpus luteum was frozen in embedding medium and stored at -70 °C
until frozen sections were cut (2.2.3). Frozen sections were stored at -70 °C until
required. In each case, an endometrial biopsy was also fixed in 4%
paraformaldehyde and processed into paraffin wax for luteal phase-dating by
tissue morphometry (3.2.8).
5.3.2 Northern Blotting
Total RNA was extracted from each tissue sample as described previously (3.6.1).
Twenty-five micrograms of RNA was separated by electrophoresis in a 1.5%
formaldehyde-agarose gel, transferred to a nylon membrane and fixed by u.v.
cross-linkage (3.6.1). Membranes were then pre-hybridised for 3 hours at 65 °C
(3.6.2). A human LH receptor probe (3.1.3) was labelled with 50 pCi 32P dCTP
by the random priming method (3.5.5). The membranes were then hybridised
overnight at 65 °C (3.6.2), After washing (3.6.3), the membranes were laid onto a
phosphor screen for 36 hours and visualised using a phosphorimager computer
(3.6.3). To correct for minor differences in RNA loading the blots were stripped
(3.6.4) and re-probed for 18S RNA using an oligonucleotide probe (3.1.3). The
molecular size of the detected transcripts was determined by running RNA
markers in an adjacent lane (3.6.1).
5.3.3 In situ Hybridisation
Isotopic in situ hybridisation was performed on frozen sections using 35S-labelled
riboprobes. The antisense probe was generated from the plasmid vector (3.1.3)
linearised by Hindlll (3.7.1) using T3 RNA polymerase (3.7.2). The sense probe
was used as a negative control. This was generated from the plasmid vector
linearised by EcoRl (3.7.1) using T7 RNA polymerase (3.7.2),
Frozen sections (2.2.3) on poly-L-lysine-coated, RNAse free, slides (3.2.1) were
thawed, fixed and prepared as described previously (3.7.3). One hundred
microlitres of hybridisation buffer (3.7.4) containing 1 x 106 c.p.m. radiolabeled
probe was added to each section. The slides were covered with a hydrophobic
coverslip and incubated overnight at 55 °C in a moist chamber. The following day
the coverslips were washed off, the slides were rinsed and treated with RNAse A
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(3.7.5). The slides were then washed under increasingly stringent conditions,
dehydrated and allowed to dry (3.7.5). The slides were then dipped in
photographic emulsion and incubated in the dark for 21 days (3.7.6). They were
developed and fixed at 15 °C in the dark (3.7.6). After rinsing in running tap
water, the sections were counter-stained with haematoxylin and mounted (3.2.8).
5.3.4 In situ Ligand Binding
In situ ligand binding was performed on frozen sections (3.4). Five micron
sections on poly-L-lysine coated slides (3.2.1) were quickly thawed and incubated
in binding buffer (3.4.1) at room temperature for 20 min. Excess buffer was
removed and iodinated LH (3.1.1) or iodinated LH with excess cold hCG (3.1.1)
was added to each slide for 2 hours at room temperature (3.4.1), The slides were
washed, dried and dipped in photographic emulsion (3.4.2). After incubation at 4
°C for 3 days in the dark, the sections were developed (3.7.6), washed,
counterstained and mounted (3.2.8).
5.3.5 Analysis of Results
The distribution and number of silver grains was analysed by dark-field
microscopy after image capture, using computer-based image analysis systems. To
quantify the results of the in situ hybridisation, the area proportion of silver grains
over the steroidogenic cells was measured in five random fields for each section
using an image analysis program (NIH Image 1.55; NIH, MD, USA). Acellular
areas, or areas without the steroidogenic cells, were ignored. Only sections from
the same run, performed under carefully controlled conditions, were analysed. The
results of the in situ ligand binding were analysed in a similar fashion except that
the grain distribution in this case allowed measurement of absolute numbers of
grains. Grains were counted using the Cue-2 image analysis system (Olympus
Optical Co. UK Ltd, London, UK). In each case the grain density was compared at
each stage of the luteal phase using analysis of variance (ANOVA) with a 5%
level of significance.
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5.4 Results
5.4.1 Plasma Progesterone Concentrations
The classification of the corpora lutea by serial urinary LH measurement agreed
with the luteal-phase dating of endometrial biopsies using the method of Li et al.
(1988). The plasma progesterone concentrations were 36.4 ±9.3 nmol/1 in the
early luteal samples, 40.4 ±9.9 nmol/1 in the mid-luteal samples and 18.8 ±12.8
nmol/1 in the late luteal samples. After luteal 'rescue' by exogenous hCG the
plasma progesterone concentrations had increased to 52.8 ±1.1 nmol/1.
5.4.2 Detection of LH/hCG Receptor mRNA
A major 4.5 kb band and minor 6.8 to 7.2 kb bands were detected by northern
blotting in the human corpus luteum (Fig. 5.1). These are consistent with the size
of the major LH receptor transcripts previously reported in the corpus luteum of
primates (Ravindranath et al., 1992a; Nishimori et al., 1995). LH/hCG receptor
mRNA could be detected in corpora lutea from all stages of the luteal phase and
after luteal 'rescue' with hCG. The LH/hCG receptor mRNA was localised to the
steroidogenic cells of the corpus luteum by in situ hybridisation (Fig. 5.2a). No
specific localisation was seen in any of the control sections incubated with the
sense probe (Fig. 5.2b). Messenger RNA for the LH/hCG receptor could be
detected, by in situ hybridisation, at all stages of the functional luteal phase and
after luteal 'rescue' with exogenous hCG (Fig. 5.2c,d). No significant differences
in the level of LH/hCG receptor expression, as measured by grain density, were
found between different stages of the luteal phase (Fig. 5.3). Expression of
LH/hCG receptor mRNA during luteal 'rescue' was similar to that seen in the mid-
luteal phase corpus luteum.
5.4.3 Detection of LH Binding Sites
Specific binding sites for LH were detected in the steroidogenic cells of the
normal corpus luteum (Fig. 5.4a,b). These binding sites were detected in all
corpora lutea from each stage of the luteal phase. In addition, they could also be
found after exposure to logarithmically increasing doses of hCG in vivo, to
simulate maternal recognition of pregnancy (Fig. 5.4c). No specific binding of LH
was observed in the negative control sections (Fig. 5Ad). When the binding sites
were quantified, using grain counting, no significant differences were observed at
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Figure 5.1
Northern blotting for LH receptors in human corpora lutea
Northern blotting for LH receptor in human corpora lutea. The position of the 28S
and 18S ribosomal RNA bands are indicated on the right. Expression of 18S RNA
is shown to control for differences in RNA loading. LH receptor mRNA could be
detected in corpora lutea from all stages of the luteal phase [Early (LH+1 to
LH+5), Mid (LH+6 to LH+10), Late (LH+11 to LH+14)] and after luteal 'rescue'
with exogenous hCG (Resc).
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Figure 5.2
In situ hybridisation for LH receptor mRNA in human corpora lutea
In situ hybridisation for LH receptor mRNA in the human corpus luteum: a) dark-
field of corpus luteum from the early luteal phase, many more grains are seen over
the steroidogenic cells (C) than the surrounding stroma (S); b) negative control
dark-field serial section of (a) after in situ hybridisation with the sense riboprobe,
showing no difference in background hybridisation between the steroidogenic
cells (C) and the surrounding stroma (S); c) dark-field late-luteal corpus luteum
showing LH receptor mRNA in the steroidogenic cells (C) and not in the stroma
(S); d) dark-field of LH receptor mRNA in a corpus luteum after 'rescue' with
exogenous hCG, expression is maintained in the steroidogenic cells (C) and is
absent from the surrounding stroma (S). (Scale bar = 200 pm).
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Figure 5.3
LH receptor expression in human corpora lutea
LH receptor mRNA in the human corpus luteum as measured by grain density
after in situ hybridisation. No differences were seen in the expression of LH
receptor message in the early-, mid- and late-luteal phases or after luteal 'rescue'
with exogenous hCG. Values are means ± S.E.M.
Chapter 5 LHreceptors in luteal 'rescue' 100
Figure 5.4
In situ LH binding in human corpora lutea
Demonstration of the LH receptor in the human corpus luteum by in situ ligand
binding: a) dark-field of corpus luteum from the mid-luteal phase, many more
grains are seen over the steroidogenic cells (C) than the surrounding stroma (S); b)
light-field of section (a) showing the localisation of the steroidogenic cells (C) and
the surrounding stroma (S); c) dark-field of LH binding in the corpus luteum after
'rescue' with exogenous hCG, showing continued binding to the steroidogenic
cells (C) but not the stroma (S); d) dark-field of negative control serial section of
(c) showing no specific binding to the steroidogenic cells (C) or the surrounding
stroma (S). (Scale bar =100 pm).
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any stage of the luteal phase or after luteal 'rescue' with hCG (Fig. 5.5). The
LH/hCG receptor protein, as measured by specific binding, was maintained during
maternal recognition ofpregnancy at similar levels to the mid-luteal phase.
5.5 Discussion
This paper describes the expression of the LH/hCG receptor in human corpora
lutea throughout the functional luteal phase and after luteal 'rescue' with
exogenous hCG. Messenger RNA for the LH/hCG receptor has previously been
demonstrated in the primate corpus luteum at different stages of the luteal phase
(Ravindranath et al., 1992a; Nishimori el al., 1995). Ravindranath et al. (1992a)
studied the expression of the LH receptor in corpora lutea of cynomolgus
monkeys. They reported that LI I receptor mRNA increased in the early-luteal
phase and was continually expressed, in the corpus luteum, throughout the luteal
phase. Our data confirm that the LH/hCG receptor is expressed throughout the
functional life-span of the primate corpus luteum.
These observations differ slightly from those of Nishimori et al. (1995) who
reported a significant reduction in expression of LH receptor mRNA in the late-
luteal phase. Although levels ofLH receptor mRNA tended to be lower in the late-
luteal corpus luteum, this did not reach statistical significance in our study. This is
unlikely to be explained by the number of corpora lutea examined as the same
number were investigated in each study. We studied the expression of the LH
receptor by quantifying the grain density over steroidogenic cells after in situ
hybridisation. Nishimori et al. (1995) used northern blotting of whole gland
mRNA to quantify LH receptor expression, and the difference may reflect these
different techniques. However, as the LH receptor is not expressed in the corpus
luteum after menstruation (Ravindranath et al., 1992a; Nishimori et al., 1995), it
is clear that its expression is switched off at the completion of functional
luteolysis. As the definition of the late-luteal phase differs in each study, it is
possible that the late-luteal glands studied by Nishimori et al. (1995) were closer
to the completion of functional luteolysis than in our study.
It has been suggested that the stability of transcribed LH receptor mRNA may be
decreased to prevent translation into the receptor protein (Lu et al., 1993). We
used in situ ligand binding to identify the LH receptor protein in the human corpus
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Figure 5.5
LH receptor ligand binding in human corpora lutea
LH receptors in the human corpus luteum as measured by grain counting after in
situ ligand binding. No differences were seen in the number of LH binding sites in
the early-, mid- and late-luteal phases or after luteal 'rescue' with exogenous hCG.
Values are means ±S.E.M.
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luteum. Numerous studies have demonstrated the presence of LH/hCG receptors
in the human corpus luteum using ligand binding assays (Rao et ah, 1977b;
McNeilly et al., 1980; Shima et al., 1987). Although these studies reported that
LH receptor binding was reduced in the late-luteal phase, it has subsequently
become clear that when receptor occupancy was taken into account, levels of total
receptor are similar throughout the luteal phase (Bramley et al., 1987; Yeko et al.,
1989). We have confirmed that the LH receptor protein, in addition to mRNA, is
maintained in the corpus luteum throughout its functional life-span.
The cause of functional luteolysis in the primate is not clear (Behrman et al.,
1993). The decline in progesterone secretion in the late-luteal phase is not
associated with falling serum LH concentrations (Hutchison et al., 1986). This
suggests that the corpus luteum is becoming increasingly insensitive to LH.
Expression of the LH/hCG receptor is regulated both transcriptionally and post-
transcriptionally (Segaloff and Ascoli 1993). However, the continued presence of
both the receptor mRNA and protein, as measured by ligand binding, suggest that
the luteal LH/hCG receptor is maintained while progesterone production is falling.
This is consistent with the findings of Cameron and Stouffer (1982) who
compared cell-membrane LH-binding with progesterone production in the
macaque corpus luteum. These data suggest that functional luteolysis may be
associated with an increasing block to steroidogenesis down-stream from LH/hCG
receptor binding.
We found that LH receptor mRNA and protein were maintained during maternal
recognition of pregnancy with exogenous hCG. Previous studies have investigated
the luteal LH/hCG receptor by binding assay in early human pregnancy (Rao et
al., 1977b; McNeilly et al., 1980; Bramley et al., 1987; Dawood and Khan-
Dawood, 1994). Concentrations of LH receptors were variable but were much
lower than the mid-luteal corpus luteum. In addition, LH/hCG receptor mRNA
has now been identified in the corpus luteum of pregnancy (Nishimori et al.,
1995). Like receptor binding, levels ofmRNA expression were much lower than
in the mid-cycle corpus luteum. However, in each case material from the corpus
luteum of ectopic pregnancies was investigated. In established pregnancies,
maternal recognition of pregnancy has taken place, and although luteal
progesterone production is continuing, it is beginning to decline (Tovanabutra et
al., 1993). In addition, ectopic pregnancies have sub-optimal serum hCG and
progesterone concentrations (Barnea et al., 1986; Ledger et al., 1994) and are
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usually associated with vaginal bleeding (Li et al., 1991b). It appears that luteal
LH/hCG receptor expression is maintained to a greater degree during maternal
recognition of uterine pregnancy than in established ectopic pregnancy.
These data are in agreement with that of Ottobre and Stouffer (1986) who studied
LH binding to homogenates of rhesus monkey corpora lutea after exogenous hCG
administration. They found that, although the number of available receptors
dropped, the total number of receptors remained the same. However, it was not
clear if these receptors were membrane bound or if recycling of receptors was
occurring. Using in situ hybridisation in association with in situ ligand binding,
we have confirmed the continued presence of the LH/hCG receptor and
demonstrated the continued transcription of receptor mRNA. These data give
strong evidence that the LH receptor is not down-regulated during maternal
recognition of pregnancy in the primate.
In contrast, there is considerable evidence for ligand-induced down-regulation of
the LH receptor in other cellular systems. In cell lines expressing the LH receptor,
exposure to ligand causes a down-regulation of LH receptor binding (Segaloff and
Ascoli, 1993). This loss of ligand binding activity is associated with a loss of the
LH receptor mRNA (Hoffman et al., 1991). In the rat corpus luteum, LH receptor
mRNA could not be detected 24 hours after ligand-induced down-regulation
(Peegel et al., 1994). The LH receptor mRNA expression in the same corpora
lutea recovered, but not until 72 hours after a single exposure to ligand. In
addition, in the adult rat testis, exposure to hCG resulted in a prolonged down-
regulation of the LH receptor message (Pakarinen et al., 1990). In ruminants,
administration of hCG was also associated with a marked down-regulation of
luteal LH receptors (Niswender et al., 1985). Although the LH receptor can be up-
regulated in the growing follicle of the rat (LaPolt et al., 1990), this has not been
described in the corpus luteum. In the corpus luteum of non-primate species, it is
clear that LH receptors are down-regulated both in vitro and in vivo by exposure to
hCG.
It thus seems likely the effect of hCG on the LH receptor is species specific.
Caldwell et al. (1980) treated luteal phase rats and women with equivalent doses
of hCG. In the rat, both progesterone production and LH receptor content fell
significantly, whereas in women, luteal progesterone production increased. The
mechanisms of luteolysis and maternal recognition of pregnancy differ in primates
and non-primate species (Auletta and Flint, 1988). It appears that, by using an LH-
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like chorionic gonadotrophin to maintain progesterone production from the corpus
luteum, primates have adapted to overcome down-regulation of the LH/hCG
receptor during maternal recognition ofpregnancy.
The LH receptor is regulated by other mechanisms in addition to transcription and
translation. Desensitisation of the receptor to its ligand, with uncoupling from
second messenger systems, has been reported in vitro and in vivo (Segaloff and
Ascoli, 1993): Such desensitisation may explain why increasing doses of hCG are
required to maintain progesterone production during pregnancy. In addition, there
are multiple transcripts of the LH receptor regulated by alternative splicing
(Themmen el al., 1994). Bacich et al. (1994), using an ovine model, showed that
full length receptor mRNA was a minority of the LH receptor mRNA species
detected in the corpus luteum. Most mRNA species coded for truncated or non¬
functioning receptors. This alternative splicing of the LH receptor has also been
reported in other species (Aatsinki et al., 1992; VuHai-LuuThi et al., 1992).
However, the functional significance of these transcripts is not yet clear and it is
not known whether they are expressed in corpora lutea of primates.
In summary, this study shows that both LH receptor mRNA and protein are
maintained in the human corpus luteum during maternal recognition of pregnancy.
The lack of down-regulation is further evidence that primates and non-primates
exhibit different mechanisms to control function of the corpus luteum.
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Chapter 6
Induced luteolysis in the primate: rapid loss of LH
receptors
6.1 Abstract
The molecular mechanisms involved in luteolysis are still unclear in the primate.
This study aimed to investigate the effect of induced luteolysis on the ovarian LH
receptor and the steroidogenic enzyme, 3P-HSD, in the marmoset monkey.
Luteolysis was induced in the mid-luteal phase either directly by systemic PGF2oc,
or indirectly by LH withdrawal, using systemic GnRHant treatment. The LH
receptor was studied by isotopic mRNA in situ hybridisation and in situ ligand
binding, and 3(3-HSD expression was studied using isotopic mRNA in situ
hybridisation and immunohistochemistry. Induced luteolysis was associated with
a reduction in the expression of LH receptor (pO.OOOl) and 3P-HSD mRNA,
closely followed with a reduction in the LH receptor (p<0.05) and 3P-HSD
protein levels, within 24 hours. There were no differences in the findings whether
luteolysis was induced with PGF2a or GnRHant. This study shows that disparate
mechanisms to induce luteolysis in the primate result in an identical rapid loss of
the LH receptor and 3P-HSD. In conclusion, induced luteolysis leads to a rapid
loss of the steroidogenic pathway in luteal cells.
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6.2 Introduction
The molecular mechanisms of luteolysis in the primate, and how the functional
and structural integrity of the corpus luteum are lost, are still unclear (Auletta and
Flint 1988; Auletta et al., 1990; Behrman et al., 1993). It has recently been shown
that cell death by apoptosis (Juengel et al., 1993; Fraser et al., 1995b; Young et
al., 1997) and remodelling of the ECM by MMPs (Endo et al., 1993a; Tsang et
al., 1995) are likely to contribute to the loss of the structural integrity of the
corpus luteum during luteolysis. The molecular mechanisms responsible for the
loss of its functional integrity, and its falling progesterone output, however, are
still not fully understood.
The primate corpus luteum is dependent on the trophic support of LH from the
pituitary gland. LH binds specifically to the LH receptor, a seven transmembrane
region, G-protein-coupled receptor (Segaloff and Ascoli, 1993), on the surface of
luteal cells, to stimulate steroidogenic enzymes to produce progesterone.
Withdrawal of LH results in luteolysis (Hutchison and Zeleznik, 1984; Fraser et
al., 1986), whereas hCG, from the implanting blastocyst, acts through the LH
receptor to maintain steroidogenesis and 'rescue' the corpus luteum (Stouffer,
1988). In Chapter 5 we have shown that during luteal 'rescue' the LH receptor is
maintained and not down-regulated by its ligand (Duncan et al., 1996a).
There is a significant reduction in luteal LH receptors preceded by reduced
receptor mRNA levels after PGF2a-induced luteolysis in ruminants (Guy et al.,
1995; Smith et al., 1996a). This is thought to contribute to the functional decline
of the ruminant corpus luteum. However, in the monkey, LH receptor mRNA
increased during the late-luteal phase (Ravindranath et al., 1992a), when
progesterone output declined. Similarly, in the human, LH receptor mRNA and
binding activity can be detected in the late-luteal corpus luteum (Nishimori et al.,
1995; Duncan et al., 1996a), but not in the corpus luteum after menstruation
(Ravindranath et al., 1992a; Nishimori et al., 1995). In the primate, functional
luteolysis is thought to occur initially in the presence of normal concentrations of
LH receptors.
The primate corpus luteum is capable of recovering from a transient withdrawal
of gonadotrophic support (Hutchinson and Zeleznik, 1985) but not from natural
functional luteolysis (Stouffer et al., 1977). This study investigated the effect of
co-ordinated induced luteolysis on LH receptor and 3(3-HSD expression in the
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primate. The marmoset monkey was used, as luteolysis can be induced by
systemic PGF2cc, although uterine PGF2a is not the natural luteolysin in this
species. In addition, luteolysis can be induced by LH withdrawal using GnRHant.
We aimed to discover whether PGF2a had the same effect on luteal LH receptors
in the primate as the ruminant, and whether induced luteolysis by withdrawal of
gonadotrophic support had the same effect.
6.3 Specific Materials and Methods
6.3.1 Tissues Studied
Ovaries from captive-bred common marmoset monkeys (Callithrix jacchus
jacchus) were studied (2.3.1). The stage of the normal ovulatory cycle was
determined by serial plasma progesterone estimation (2.3.1). Ovaries were
collected on day 10 of the luteal phase, from untreated control animals (n=4) and
animals treated with PGF2a analogue 24 hours (n=4) previously, or GnRHant 12
hours (n=2) or 24 hours (n=4) previously (2.3.2). Whole ovaries were snap-frozen
in embedding medium until frozen sections (5 pm) were prepared (2.3.3). In
addition, ovaries were also available from control (n=4) and treated animals (n=6)
(2.3.2) which had been fixed in 4% paraformaldehyde for 24 hours and embedded
in paraffin wax (2.3.3). Sections (5 pm) were cut onto poly-L-lysine-coated slides
(3.2.1) for immunohistochemical analysis (3.2.2).
6.3.2 In situ Hybridisation
Isotopic in situ hybridisation was performed on frozen sections using 35S-labelled
riboprobes (3.7). Antisense and sense LH receptor riboprobes (3.1.3)
incorporating 35S-labelled UTP were prepared using a commercial kit. The
antisense probe was generated from the plasmid vector linearised by Hindlll
(3.7.1) using T3 RNA polymerase (3.7.2), The sense probe was used as a negative
control. It was generated from the plasmid vector linearised by EcoRl (3.7.1)
using T7 RNA polymerase (3.7.2). The antisense riboprobe for 3P-HSD mRNA
(3.1.3) was generated by T7 RNA polymerase (3.7.2) after plasmid linearisation
by SstI (3.7.1).
Frozen sections on poly-L-lysine-coated slides were quickly thawed, fixed,
washed, acetylated and dehydrated as described previously (3.7.3). The slides
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were then dried under vacuum (3.7.3) and 100 pi of hybridisation buffer
containing 1 x 106 c.p.m. radiolabeled probe was added to each section (3.7.4).
The slides were covered with a hydrophobic coverslip and incubated overnight at
55 °C in a moist chamber (3.7.4). The following day the coverslips were washed
off, the slides were rinsed and treated with RNAse A (3.7.5). The sections were
then washed under increasingly stringent conditions with a final wash for 30
minutes in O.lx SSC at 70 °C (3.7.5). The sections were dehydrated (3.7.5) and
allowed to dry. They were then dipped in photographic emulsion (3.7.6) and
stored at 4 °C for 18 days in the dark. After developing and fixing (3.7.6) the
slides were washed in water, counterstained with haematoxylin, dehydrated
through graded alcohols and mounted (3.2.8).
6.3.3 In situ Ligand Binding
In situ ligand binding was performed as described previously (3.4). Frozen
sections (2.3.3) were quickly thawed and incubated in binding buffer (3.4.1).
Excess buffer was removed and 10 000 c.p.m. of iodinated LH (3.1.1) or 10 000
c.p.m. iodinated LH with excess cold hCG (3.1.1) was added to each slide (3.4.1).
The slides were washed and allowed to dry for 3 hours at 4 °C (3.4.2). They were
then dipped in photographic emulsion (3.4.2) and stored at 4 °C for 3 days in the
dark. After developing and fixing (3.7.6), the slides were washed, counterstained
with haematoxylin, dehydrated through graded alcohols and mounted (3.2.8).
6.3.4 Immunohistochemistry
Fixed sections were prepared as described previously (3.2.2). Non-specific
binding was blocked with 20% NGS made up in TBS containing 5% BSA (3.2.6).
The sections were incubated overnight at 4 °C with the polyclonal rabbit anti-
human 3|3-HSD antisera (3.1.1) diluted 1:1000 in 20% NGS in TBS (3.2.6). The
following day, the sections were washed and incubated with biotinylated goat
anti-rabbit immunoglobulins (3.2.6) diluted 1:500 in TBS, for 30 minutes at room
temperature. Specific antibody binding was visualised using an AB-AP complex
(3.2.6) with a chromagen which gave a stable red end product (3.2.7). Sections
were counterstained with haematoxylin, dehydrated through graded alcohols and
mounted (3.2.8). Polyclonal rabbit IgG at the same antibody concentration was
used in place of the primary antibody, in serial sections, as a negative control
(3.2.9).
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6.3.5 Analysis of Results
The distribution and number of silver grains was analysed by dark-field
microscopy after image capture, using computer-based image analysis systems. To
quantify the results of the in situ hybridisation, the area proportion of silver grains
over the steroidogenic cells was measured in five random fields for each section
using an image analysis program (NIH Image 1.55). Acellular area's or areas
without the steroidogenic cells were ignored. Only sections from the same run,
performed under carefully controlled conditions, were analysed. The results of the
in situ ligand binding were analysed in a similar fashion except that the grain
distribution in this case allowed measurement of absolute numbers of grains. In
each case the grain density was compared in each treatment group using ANOVA
with a 5% level of significance using a commercial statistics computer program
(StatView 4.0; Abacus Concepts Inc, Berkeley, CA, USA).
6.4 Results
6.4.1 Plasma Progesterone Concentrations
Progesterone concentrations in the control animals were 330 ±69 nmol/1 (mean
±S.E.M.). Functional luteal regression was observed in all animals treated with
either the GnRHant or the PGF2a analogue (Fraser et al., 1995b). PGF2a treatment
resulted in a decline in progesterone concentrations to 22 ±6 nmol/1 after 24
hours, and treatment with GnRHant resulted in progesterone concentrations of 13
nmol/1 after 12 hours and 23 ±11 nmol/1 after 24 hours. All progesterone
concentrations after induced luteolysis were within the normal range of follicular
phase levels in the marmoset (Smith et al., 1990).
6.4.2 LH Receptor after Induced Luteolysis
Messenger RNA for the LH receptor was detected by in situ hybridisation in
corpora lutea of marmoset ovaries from the mid-luteal phase (Fig. 6Aa,d). No
specific signal was present in the negative control sections incubated with the
sense riboprobe (Fig. 6.1c). LH receptors were localised to individual
steroidogenic cells within corpora lutea. No hybridisation signal could be seen in
cells without the morphological appearance of steroidogenic cells which
expressed 3(3-HSD, including endothelial cells (Fig. 6.1 d). The localisation of LH
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Figure 6.1
LH receptors in the marmoset corpus iuteum
LH receptor in the mid-luteal marmoset corpus luteum: a) dark-field in situ
hybridisation of LH receptor mRNA in the control mid-luteal corpus luteum (CL),
no signal is seen in the stroma and tiny follicles (F); b) light-field serial section of
(a) showing the position of the corpus luteum (CL), stroma and tiny follicles (F);
c) dark-field serial negative control section of (a) using the sense probe for LH
receptor mRNA, no signal can be seen in the corpus luteum (CL) or the tiny
follicles (F); d) light-field higher power (scale bar = 25 pm) section of corpus
luteum showing silver grains in steroidogenic cells (S) but not in endothelial-like
cells (E); e) dark-field serial section of (a) after LH binding studies showing
binding over the corpus luteum (CL) and not over the stroma and tiny follicles
(F). Scale bar = 200 pm.
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receptor binding corresponded to the localisation of LH receptor mRNA (Fig
6.1e). No specific binding was seen in negative control sections where excess cold
hCG was added.
Messenger RNA for the LH receptor was also expressed in the theca cell layer of
antral follicles in ovarian tissue from the mid-luteal phase (Fig. 6.2a,b). After
induced luteolysis, by PGF2a or GnRHant administration, LH receptor mRNA
disappeared from corpora lutea but was maintained in the theca cell layer of antral
follicles (Fig. 62c,d). Luteal LH receptor mRNA concentrations fell after
treatment to very low levels 12 and 24 hours (p<0.0001) after induced luteolysis
(Fig. 6.3). Luteal LH receptor binding was similar to controls 12 hours after
induced luteolysis but was significantly reduced by 24 hours (p<0.05) (Fig. 6.3).
Although the small numbers at 12 hours precluded statistical analysis, the loss of
LH binding appeared to lag behind the loss of LH receptor mRNA (Fig. 6.3; Fig
6Aa-f). There were no differences in luteal LH receptor mRNA or binding where
luteolysis was induced with PGF2a or GnRHant.
6.4.3 3P-HSD after Induced Luteolysis
Both mRNA (Fig. 6.5a) and protein (Fig. 6.5b) for 3P-HSD could be detected in
corpora lutea of mid-luteal phase ovaries. Twenty-four hours after induced
luteolysis, with either PGF2a or GnRHant, no mRNA for 3P-HSD could be
detected in corpora lutea (Fig. 6.5c), although it could still be detected in the theca
cell layer of developing follicles. After 24 hours after induced luteolysis, 3p-HSD
protein could still be detected by immunohistochemistry (Fig. 6.5c/): however, the
immunostaining was more patchy and less intense (Fig. 6.5d) in each ovary
studied.
6.5 Discussion
This study reports the expression of the LH receptor and the steroidogenic
enzyme, 3P-HSD, after induced luteolysis in the primate. We have previously
reported the expression and localisation of the LH receptor in the human corpus
luteum throughout the functional luteal phase and during simulated early
pregnancy (Duncan et al., 1996a). In that study, it was not clear that LH receptor
mRNA fell during the late-luteal phase. Other studies have suggested either an
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Figure 6.2
Expression of LH receptors in the marmoset ovary after induced luteolysis
LH receptor mRNA in the marmoset ovary after induced luteolysis: a) light-field
section of a mid-luteal marmoset ovary showing the corpus luteum (CL) and the
theca (T) and granulosa cells of an antral follicle; b) dark-field section of (a) after
in situ hybridisation for LH receptor mRNA showing specific signal in the corpus
luteum (CL) and theca (T) cells of the follicle, but not the granulosa cells (G) of
the follicle; c) light-field section of a marmoset ovary 24 hours after induced
luteolysis with GnRHant showing the corpus luteum (CL) and the theca (T) and
granulosa (G) cells of an antral follicle; d) dark-field section of (c) after in situ
hybridisation for LH receptor mRNA showing no signal in the corpus luteum
(CL) and granulosa cells (G) but maintenance of the signal in the theca cells (T)
of the antral follicle. Scale bar = 200 pm. Insert shows higher power view of the
follicle wall showing the grains to be localised to the thecal (T) rather than
granulosa (G) cells.
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LH Receptor mRNA expression after induced luteolysis
LH receptor in marmoset corpora lutea after induced luteolysis. Grain density of
LH receptor mRNA and grain counts of LH receptor binding in marmoset corpora
lutea in the mid-luteal phase (control) (n=4), 12 hours after induced luteolysis
with GnRHant (GnRH 12h) (n=2), 24 hours after induced luteolysis with GnRHant
(GnRH 24h) (n=4) and 24 hours after induced luteolysis with PGF2(X (PG 24).
Values are means ±S.E.M.; (*=p<0.05, **=p<0.0001 (ANOVA)).
Chapter 6 LH receptors after induced luteolysis 115
0 ■W >>• & 'A. . :V
. ->y. <S • •
o
S - CL ' *
.r ~ *'• L * * : s §§ACLs|)|* i w- • +: ,**•}. ■ •. • i 'w
-Si / . V • • Vrj •• t *" ■ . -v.■ > ..■
-
•




V'-.■*:*' *!, ' ' "r--..2c V.
•
.





. • T> ,fi'- * j •
• AV'- • ' '
• • - . • • " * 4 .
i r >
Figure 6.4
Loss of LH receptors after induced luteolysis
LH receptor in the marmoset corpus luteum 12 and 24 hours after induced
luteolysis: a) dark-field section of a mid-luteal marmoset ovary after in situ
hybridisation for LH receptor mRNA showing signal in the corpus luteum (CL)
but not in the surrounding stroma (S); b) dark-field section of a marmoset ovary
12 hours and c) 24 hours after luteolysis was induced with GnRHant after in situ
hybridisation for LH receptor mRNA showing no signal in the corpus luteum
(CL) or stroma (S); d) dark-field serial section of (a) showing LH binding in the
corpus luteum (CL) but not the surrounding stroma (S); e) dark-field serial section
of (b) showing persistence of LH binding in the corpus luteum (CL) and its
absence from the surrounding stroma (S); f) dark-field serial section of (c)
showing reduced specific LH binding in the corpus luteum (CL) and stroma (S).
Scale bar = 100 pm.
Chapter 6 LH receptors after induced luteolysis 116
Figure 6.5
3P-HSD in the marmoset corpus Iuteum after induced luteolysis
3P-HSD in the marmoset corpus luteum after induced luteolysis: a) dark-field
section of a mid-luteal marmoset ovary after in situ hybridisation for 3P-HSD
mRNA showing signal in the corpus luteum (CL) but not the surrounding stroma
(S); b) section of a mid-luteal marmoset ovary after immunohistochemistry for
3P-HSD showing staining of the corpus luteum (CL) but not the surrounding
stroma (S); c) dark-field section of a marmoset ovary 24 hours after luteolysis was
induced with PGF2oc after in situ hybridisation for 3P-HSD mRNA showing no
signal in the corpus luteum (CL) and stroma (S); d) section of a marmoset ovary
24 hours after luteolysis was induced with PGF2ct after immunohistochemistry for
3P-HSD showing patchy staining of the corpus luteum (CL) but not the
surrounding stroma (S). Scale bar =100 pm.
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increase (Ravindranath et al., 1992a) or a fall (Nishimori et al., 1995; Minegishi
et al., 1997) in luteal LH receptor mRNA during the late-luteal phase in the
primate. We therefore used a well established model (Fraser et al., 1996a; Fraser
et al., 1996b) of induced luteolysis in the primate in this follow-up study, to
investigate the effect of luteolysis on LH receptor expression. It is now clear that
induced luteolysis in the primate is associated with a rapid loss of LH receptors
from the corpus luteum.
Induced luteolysis, has been shown to result in a fall in LH receptor expression in
rodents (Bjurulf and Selstam, 1996) and ruminants (Guy et al., 1995; Smith et al.,
1996a). In these animals, PGF2oc is an important physiological luteolysin. In rats,
luteal prostaglandin increases during the last days of the luteal phase (Olofsson et
al., 1990), and inhibition of prostaglandin synthesis by indomethacin prolongs the
natural life-span of the corpus lutcum (Bjurulf et al., 1994). In sheep and cows,
natural luteolysis is clearly attributed to the uterine synthesis and secretion of
PGF2a (Niswender et al., 1985; Auletta and Flint, 1988). In these species, it is
thought that PGF2a has a direct effect on luteal LH receptor mRNA expression
(Bjurulf and Selstam, 1996; Smith et al., 1996a). Although it is not clear in this
study whether the reduced LH receptor mRNA is due to decreased transcription or
decreased stability (Segaloff and Ascoli, 1993), it is clear that, despite different
mechanisms of luteolysis in primates, (Auletta and Flint, 1988; Auletta et al.,
1990), the effect ofPGF2a ofLH receptor mRNA levels appears to be the same.
There is evidence that locally produced PGF2a may have a role in primate
luteolysis (Auletta et al., 1984b; Auletta and Flint, 1988; Behrman et al., 1993).
Prostaglandins are produced by the human corpus luteum and PGF2a receptors
can be detected in the human corpus luteum (Powell et al., 1974; Challis et al.,
1976; Rao et al., 1977a). Pharmacological doses of prostaglandins can reduce
progesterone secretion from the primate corpus luteum (Wentz and Jones, 1973;
Auletta et al., 1984a). In addition, some studies have reported increased intra-
luteal PGF2cc during the end of the functional human luteal phase (Shutt et al.,
1976; Patwardhan and Lanthier, 1980). As LH receptors cannot be detected in
follicular phase primate corpora lutea (Ravindranath et al., 1992a; Nishimori et
al., 1995; Takao et al., 1997), it is clear that they disappear with functional
luteolysis. Local PGF2oc may be involved in the inhibition of LH receptor
expression at the end of the primate luteal phase.
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The steroidogenic pathway can also be affected at other sites by PGF2a. In vitro,
PGF2a inhibits LH-stimulated progesterone production, and this is thought to be a
post cAMP-mediated effect (Auletta and Flint, 1988; Abayasekara et al., 1993;
Michael et al., 1994). PGF2a is known to activate PKC (Niswender et al., 1994).
PKC has several effects on the steroidogenic pathway. It inhibits cholesterol
transport to P450scc (Wiltbank et al., 1993), which suggests an inhibitory effect
on SCP-2 (McLean et al., 1995) or StAR (Stocco and Clark, 1996). In addition, it
has been shown that expression of 3P-HSD can also be inhibited in vitro
(Hawkens et al., 1993). We have shown that 3P-HSD mRNA and protein
expression are inhibited during PGF2a induced luteolysis in the primate. This
confirms the multiple sites of inhibition of steroidogenesis during PGF2a-induced
luteolysis are also seen in the primate.
Induced luteolysis using LH withdrawal had the same effects on luteal LH
receptor and 3P-HSD expression. It has previously been shown that removal of
LH support in monkeys caused a dramatic down regulation of mRNA for both
P450scc and 3P-HSD (Ravindranath et al., 1992b). Indeed, levels of 3P-HSD have
been shown to decline during natural luteal regression in the primate (Doody et
al., 1990). We have confirmed the fall in 3P-HSD message, and shown that this is
associated with a fall in LH receptor mRNA. The similarity of the effects of the
disparate ways to induce luteolysis in the marmoset suggests common final
pathways of action. It is not known whether LH withdrawal induces local PGF2a
formation. However, it has been shown that hCG, acting through the LH receptor
(Cole et al., 1973), has an inhibitory effect on luteolysis induced by PGF2oc
(Auletta and Kelm, 1994). It is therefore likely that LH withdrawal, and PGF2oc,
activate a common final pathway to induce luteolysis.
That common pathway might be progesterone withdrawal. It is clear that acute
administration of PGF2a can inhibit progesterone synthesis in the absence of
changes in the expression of steroidogenic enzymes (Michael et al., 1994). Its
effects on cAMP stimulation and progesterone output precede the observed
decrease in mRNA levels (Khan and Rosberg, 1979; Bjurulf and Selstam, 1996).
Likewise, withdrawal of LH results in rapid cessation of progesterone output
(Fraser et al., 1986). It is possible that progesterone itself has an autocrine role in
the corpus luteum. The primate corpus luteum possesses receptors to the
progesterone it produces (Chandrasekher et al., 1994; Suzuki et al., 1994). Recent
work using trilostane to inhibit progesterone synthesis suggests that progesterone
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may indeed have a major role in the function of the corpus luteum (Duffy et al.,
1994; Slayden et al., 1994; Duffy and Stouffer, 1995). However, It is not yet clear
if progesterone maintains the enzymes responsible for its production. Evidence
from the rat, where PGF2a only induces a transient decline in LH receptor and 3(3-
HSD mRNAs, suggests that their recovery occurs in the presence of follicular
phase levels of progesterone (McLean et al., 1995; Bjurulf and Selstam, 1996).
The fact that we did not see this recovery, and that the rat does not appear to
express luteal progesterone receptors (Parke-Sarge et al., 1995) suggests that this
may be a species effect. Progesterone therefore remains a potential candidate in
the control of luteal function during luteolysis.
The effect of induced luteolysis on mRNA was evident before the effect on
protein levels. We could detect little LH receptor and 3(3-HSD mRNAs 12 hours
after induced luteolysis. In sheep, Smith et al. (1996a) reported that this reduction
was evident within six hours of induced luteolysis. We found continued LH
receptor binding 12 hours after induced luteolysis and could detect some 3|3-HSD
protein 24 hours after induced luteolysis in the absence of mRNA. The patchy
appearance of 3P-HSD we observed after induced luteolysis is similar to that seen
during natural luteolysis in the monkey (Sanders and Stouffer, 1997). This time
difference of effects on mRNA and protein levels was also seen in ovine corpora
lutea after induced luteolysis with PGF2a (Smith et al., 1996a). This is consistent
with protein having a longer turnover time than mRNA. However, as progesterone
levels were at follicular levels, 12 hours after induced luteolysis, it appears that
this protein is not stimulated enough to be functional at this stage. It therefore
needs to be stressed that at the first time point studied (12 hours), the progesterone
concentrations were already at follicular levels. It is not clear whether the decline
in progesterone precedes the inhibition of LH and 3P-HSD expression, is
secondary to it, or related through another common factor. It would be interesting
to dissect the pathway at time points earlier than 12 hours.
Induced luteolysis in the marmoset monkey is associated with cell death and
disruption of the cellular architecture (Fraser et al., 1995b). Indeed it has been
suggested that PGF2ct can directly cause apoptotic cell death (Sawyer et al.,
1990). It is possible that the fall in mRNA and protein for the LH receptor and 3p-
HSD reflects a general loss of cell viability within the corpus luteum rather than
being specific to functional luteolysis. This is unlikely as the loss of mRNA
clearly precedes the loss of protein for both the LH receptor and 3P-HSD, and
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other mRNA species are still present in the corpus luteum 12 hours after induced
luteolysis (see Chapter 11; Duncan et al., 1996b). In addition, some proteins
have been shown to increase in the corpus luteum after induced luteolysis in the
marmoset (Woad et al., 1996). This suggests that the steroidogenic pathway is
specifically and rapidly switched off during induced luteolysis.
The rapid loss of LH receptor mRNA in the corpus luteum was not seen in the
thecal layers of antral follicles after induced luteolysis. This LH receptor will be
equally starved of its ligand after GnRHant-induced luteolysis. The inhibitory
effects on LH receptor and 3P-HSD mRNAs were clearly not seen in the thecal
cells. This suggests that the common luteolytic pathway is not found in follicular
thecal cells. It is not known whether these cells express PGF2cc receptors. In the
sheep corpus luteum, PGF2a receptors are located on the large luteal cells, and not
the small luteal cells, that are thought to be of thecal origin (Fitz et al., 1982).
This may be one of the differences. Thecal cells of the follicle, however, may
express progesterone receptors (Suzuki et al., 1994). Clearly studying the
differences between follicular thecal cells and luteal cells may aid understanding
of the luteolytic process.
In conclusion, the rapid reduction of LH receptors and the steroidogenic enzyme,
3P-HSD, during induced luteolysis in the primate suggests an inhibition to
synthesis of the components of the steroidogenic pathway as well as their function
during luteolysis. It is still not clear if this is a cause or effect of low progesterone
levels but it is likely to contribute to the continued inhibition of progesterone
synthesis during luteolysis. The similarity of effect of PGF2a treatment and LH
withdrawal suggests a common inhibitory pathway. Dissection of this pathway
may give more information about the continuing enigma of primate luteolysis.
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Chapter 7
Steroidogenic enzyme expression in human
corpora lutea in the absence and presence of
exogenous hCG
7.1 Abstract
In a conception cycle, the expected decline in progesterone production by the
human corpus luteum, during the late-luteal phase, is prevented by hCG secreted
by the implanting blastocyst. This study investigated the expression of
components of the synthetic pathway for progesterone in human corpora lutea in
the presence and absence of hCG in vivo. Corpora lutea were obtained from
normally cycling women at the time of hysterectomy and classified, on the basis
of the urinary LH surge, as early- (n=3), mid- (n=3), or late-luteal (n=3). In
addition, corpora lutea were also obtained from women who had received daily
doubling doses of hCG (n=3) to 'rescue' the corpus luteum. Expression of StAR,
P450scc and 3P-HSD were investigated by northern blotting. In addition, 3|3-HSD
expression was also analysed by isotopic in situ hybridisation and
immunohistochemistry. Luteal 'rescue' with hCG was associated with the
continued expression of these components of the steroidogenic pathway. In the
absence of hCG, they continued to be expressed in the late-luteal phase, although
their expression was more variable. The expression of 3P-HSD mRNA, however,
fell during the late luteal phase (p<0.01). In conclusion, during luteal 'rescue',
hCG acts to maintain the steroidogenic pathway. In the absence of hCG, the
decline in luteal progesterone production begins in the presence of the main
components of the steroidogenic pathway. It is therefore unlikely that changing
expression of these components initiates this decline. However changing
expression, particularly of 3P-HSD, may contribute to the continued reduction in
progesterone production.
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7.2 Introduction
In non-conception cycles, the human corpus luteum will undergo luteolysis, with
loss of functional and structural integrity after 14 days. In the presence of hCG
from the implanting blastocyst, the corpus luteum is 'rescued' and its function and
structure are maintained (Behrman et al., 1993). The molecular mechanisms of
luteolysis and how they are prevented by exposure to hCG are still not clear in the
primate.
Progesterone production by the primate corpus luteum is dependent on LH from
the anterior pituitary gland (Hutchison and Zeleznik, 1984; Fraser et al., 1986).
LH binds to, and activates, a specific glycoprotein LH/hCG receptor present on
the membranes of steroidogenic luteal cells (McNeilly et al., 1980; Bramley et al.,
1987; Segaloff and Ascoli, 1993). The LH receptor is a G-protein-coupled
receptor with a large glycosylated extracellular domain, seven transmembrane
loops, and a smaller intracellular C-terminal domain (Segaloff and Ascoli, 1993).
Specific ligand binding activates second messenger systems, notably cAMP
(Segaloff and Ascoli, 1993). This stimulates the uptake of cholesterol into
mitochondria by the action of StAR (Stocco and Clark, 1996), its conversion into
pregnenolone by the enzyme P450scc (Simpson and Boyd, 1967) and the further
conversion of pregnenolone into progesterone by 3(3-HSD (Strauss and Miller,
1991).
Luteolysis can be induced by the withdrawal of LH, by inhibition of GnRH
(Hutchison and Zeleznik, 1984; Fraser et al., 1986). However, LH withdrawal is
not the cause of luteolysis in natural cycles, as luteolysis still occurs in the
presence of continued exposure to LH in the late-luteal phase (Hutchison et al.,
1986). This suggests that functional luteolysis is associated with an increasing
block to LH action within the corpus luteum. We have therefore investigated the
expression of LH/hCG receptors in human (Chapter 5) and monkey (Chapter 6)
corpora lutea (Duncan et al., 1996a; Duncan et al., 1998a). We, and others, have
shown that the primate corpus luteum continues to express LH receptors at a time
when progesterone synthesis is declining (Ravindranath et al., 1992a; Nishimori
et al., 1995; Duncan et al., 1996a). Recent reports have suggested that the rate-
limiting step in steroidogenesis may be the transport of cholesterol to the inner
mitochondrial membrane under the action of StAR (Clark et al., 1994; Stocco and
Clark, 1996). In this study we therefore aimed to investigate the expression of
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components of the steroidogenic pathway beyond the LH/hCG receptor, notably
StAR, P450scc and 3P-HSD, in the human corpus luteum throughout the luteal
phase and after luteal 'rescue' with hCG in vivo to simulate early pregnancy.
7.3 Specific Materials and Methods
7.3.1 Tissues Studied
Corpora lutea were enucleated at the time of hysterectomy in 12 women
undergoing surgery for benign conditions (2.2) and dated on the basis of serial
urinary LH measurements (2.2.4), Three corpora lutea were classified as early-
luteal, three as mid-luteal and three as late-luteal (2.2.4). Three corpora lutea were
collected from women after luteal 'rescue' with exogenous hCG (2.2.2). One piece
of each corpus luteum was fixed in 4% paraformaldehyde and embedded in
paraffin wax (2.2.3) for subsequent immunohistochemistry, another piece was
frozen in embedding medium for the preparation of frozen sections (2.2.3) and a
third piece was stored at -70 °C for subsequent RNA extraction (2.2.3). An
endometrial biopsy was also fixed in paraformaldehyde and processed into
paraffin wax for luteal phase dating by tissue morphometry (3.2.8).
7.3.2 Cloning of StAR from the Human Corpus Luteum
Total cellular RNA was extracted from a mid-luteal human corpus luteum by the
method of Chomczynski and Sacchi (1987) and reverse transcribed into cDNA
using a commercial kit (Promega). Specific oligonucleotide primers for StAR
were synthesised by Oswell DNA Services (Southampton, Hants, UK). The
primer sequences, 5'-AACCAGGAAGGCTGGAA-3' and 5'-CCATGCAGGTG-
GGGCCGTGTTCAGC-3' (Clark et al., 1994) were used to amplify the expected
400 bp fragment of StAR cDNA using the PCR conditions as described
previously (Clark et al., 1994). This was cloned into a plasmid PCR II vector
using a commercial kit (TA Cloning Kit; Invitrogen, NV Leek, Netherlands) and
sequenced using a Taq di-deoxy termination cycle sequencing kit (Applied
Biosystems, Warrington, Cheshire, UK) using an automatic sequencer (373A;
Applied Biosystems). Data were analysed using a commercial computer program
(GeneJockey II; Biosoft, Cambridge, Cambs, UK).
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7.3.3 Northern Blotting
Twenty micrograms of total cellular RNA was denatured, electrophoresed in a
1.5% formaldehyde-agarose gel, transferred to a nylon membrane and fixed by
u.v. cross-linkage (3.6.1). The membranes were then pre-hybridised for 5 h in
hybridisation buffer (3.6.2). The cDNA probes (3.1.3) were labelled with 50 pCi
32P dCTP by the random priming method (3.5.5) and added to the hybridisation
buffer for 20 h at 65 °C (3.6.2). The membranes were washed (3.6.3), laid down
to a phosphor screen for 48 h and visualised using a phosphorimager computer
(3.6.3). The blots were then stripped and then re-probed for 18S RNA (3.6.4). The
molecular size of the detected transcripts was determined by running RNA
markers in an adjacent lane (3.6.1).
7.3.4 In situ Hybridisation
Isotopic in situ hybridisation was performed on frozen sections using 35S-labelled
riboprobes (3.7). The antisense 3P-HSD riboprobe (3.1.3) was generated by T7
RNA polymerase (3.7.2). Frozen sections were quickly thawed and fixed in 4%
paraformaldehyde (3.7.3). The slides were then washed, acetylated, dehydrated
and dried under vacuum (3.7.3). One hundred microlitres of hybridisation buffer
containing 1 x 106 c.p.m. radiolabeled probe was added to each section (3.7.4),
The slides were covered with a hydrophobic coverslip and incubated overnight at
55 °C in a moist chamber (3.7.4). The coverslips were then washed off and the
slides were treated with RNAse A (3.7.5). The sections were then washed in
increasingly stringent conditions, dehydrated and allowed to dry (3.7.5). They
were dipped in photographic emulsion (3.7.6) and stored at 4 °C for 18 days in the
dark. After developing and fixing (3.7.6), the slides were washed in water,
counterstained with haematoxylin and mounted (3.2.8). The sections were viewed
and photographed under dark-field illumination. The localisation of the grains was
determined by reference to the section viewed under bright-field.
7.3.5 Immunohistochemistry
Paraffin wax sections on poly-L-lysine-coated slides (3.2.1) were de-waxed and
rehydrated (3.2.2). After the endogenous peroxidase activity was blocked (3.2.5),
non-specific antibody binding was blocked with 20% NGS in TBS with 4% BSA
(3.2.6). Sections were incubated overnight at 4 °C with the polyclonal rabbit anti-
human 3P-HSD antisera (3.1.2) diluted 1:1000 in 20% NGS in TBS (3.2.6).
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Specific antibody binding was detected with biotinylated goat anti-rabbit
immunoglobulins diluted 1:500 in TBS (3.2.6), and visualised with AB-HRP
using DAB to give a stable brown end product (3.2.7). The sections were
counterstained with haematoxylin, dehydrated and mounted (3.2.8). Polyclonal
rabbit IgG at the same antibody concentration was used in place of the primary
antibody, in serial sections, as a negative control (3.2.9).
7.3.6 Analysis of Results
Northern blot band intensity was measured using the phosphorimager computer.
To correct for minor differences in loading, the ratio of the relative band intensity
to the 18S band intensity was used for data analysis. One-way ANOVA was used
to investigate differences in expression throughout the luteal phase. The early-
luteal corpora lutea were compared to the mid and late-luteal corpora lutea using
an unpaired t-test. A commercial software package was used for statistical
analysis (StatView 4.0). Immunohistochemical staining for 3p-HSD was assessed
in sections from the same run performed under carefully controlled conditions by
an observer blinded to tissue identity. This was repeated two weeks later to
confirm consistency of scoring. The staining intensity in the granulosa-lutein cell
layer was graded as absent (-), faint (+), moderate (++), intense (+++) or very
intense (++++) for each section. Where the sections differed between each scoring
session an intermediate value was given.
7.4 Results
7.4.1 Plasma Progesterone Concentrations
The classification of the corpora lutea by serial urinary LH measurement agreed
with the luteal-phase dating of endometrial biopsies using the method of Li et al.
(1988). The plasma progesterone concentrations were 35.3 ±9.8 nmol/1 in the
early-luteal samples, 41.0 ±9.9 nmol/1 in the mid-luteal samples and 19.2 ±12.9
nmol/1 in the late-luteal samples. After luteal 'rescue' by exogenous hCG the
plasma progesterone concentrations had increased to 52.6 ±1.5 nmol/1.
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7.4.2 Cloning of Human StAR
The specific oligonucleotide primers for StAR amplified the expected 400 bp
fragment (Clark et al., 1994) from cDNA obtained from a mid-luteal human
corpus luteum. When this fragment was sequenced, the sequence was 97%
identical to the sequence for human StAR in the gene sequence databases. This
StAR cDNA sequence was used to study the expression of StAR mRNA in the
human corpus luteum.
7.4.3 Expression of Steroidogenic Enzymes in Human Corpora Lutea
Specific mRNA transcripts for StAR, P450scc and 3[3-HSD could be detected in
corpora lutea from different stages of the luteal phase and after luteal 'rescue' with
exogenous hCG (Fig. 7.1). Two major StAR mRNA transcripts of 1.7 kb and 4.8
kb were detected. These are consistent with the size of human StAR transcripts
already published (Kiriakidou et al., 1996). Major transcripts of 2.0 kb and 1.7 kb
were detected in corpora lutea after northern blotting for P450scc and 3(3-HSD
respectively (Fig. 7.1) These are consistent with the expected size of the mRNAs
for these steroidogenic enzymes in the primate (Doody et al., 1990; Bassett et al.,
1991).
7.4.4 Changes in Steroidogenic Enzyme Expression in the Luteal Phase
As can be seen in Fig. 7.1, expression of the steroidogenic enzymes did not appear
to be constant throughout the luteal phase. In the late-luteal phase band intensity
was more variable than during other stages of the luteal phase. Band intensity was
measured and corrected for 18S RNA expression for each steroidogenic enzyme
(Fig. 7.2). It can be seen that expression of enzymes tended to be lower in the late-
luteal phase. However, this trend did not reach statistical significance for any of
the enzymes. However, when the mid- and late-luteal phases were combined, the
expression of 3p-HSD was markedly lower (p<0.01) than in the early-luteal phase
or after luteal 'rescue' with hCG. The most marked change in steroidogenic
enzyme expression throughout the luteal phase was that of 3|3-HSD.
7.4.5 Localisation and Expression of 3P-HSD in Human Corpora Lutea
As northern blotting revealed that 3P-HSD changed most during the luteal phase,
its expression and localisation were further investigated by isotopic in situ
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Figure 7.1
Expression of the steroidogenic pathway in corpora lutea
Composite picture of northern blots for StAR, P450scc and 3|3-HSD mRNA in
human corpora lutea at different stages of the luteal phase. Specific hybridisation
bands are shown in the early- (LH+1 to LH+5), mid- (LH+6 to LH+10) and late-
luteal (LH+11 to LH+14) phases and after luteal 'rescue' with exogenous hCG
(hCGx5 to hCGx7). The intensity of the 18S RNA band is shown, after specific
oligonucleotide hybridisation, to confirm equal mRNA loading between lanes.
Unfortunately, there has been some under-loading of one of the mid-luteal
samples in these blots.
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Figure 7.2
Quantification of steroidogenic enzyme expression in human corpora lutea
Expression of mRNA for steroidogenic factors as measured by corrected
hybridisation band intensity after northern blotting in human corpora lutea at
different stages of the luteal phase. The mean band intensities for the 1.7 kb
StAR, the 2.0 kb P450scc and the 1.7 kb 3|3-HSD mRNA transcripts are shown
±S.E.M., in the early- (LH+1 to LH+5), mid- (LH+6 to LH+10) and late-luteal
(LH+11 to LH+14) phases and after luteal 'rescue' with exogenous hCG (hCGx5
to hCGx7) (n=3 per group). There were no significant differences across the luteal
phase (ANOVA). When the early-luteal samples were compared with the mid-
and late-luteal samples, the expression of 3P-HSD was found to decrease from the
early-luteal phase (p<0.01; t-test).
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hybridisation and immunohistochemistry. Messenger RNA could be detected by
in situ hybridisation in corpora lutea at all stages of the luteal phase. However,
during the late-luteal phase, detection of 3P-HSD mRNA was variable. The
hybridisation signal at the beginning of the late-luteal phase (Fig. 7.3a) was
similar to that seen in the mid-luteal phase. However, towards the end of the late-
luteal phase much less 3P-HSD mRNA could be detected by in situ hybridisation
(Fig. 7.3c). In contrast, 3P-HSD protein, as detected by immunohistochemistry,
could be detected throughout the late-luteal phase (Fig. 7.3b,d). When 3P-HSD
immunostaining was analysed, the intensity did not vary across the luteal phase or
after luteal 'rescue' with exogenous hCG (Fig. 7.4).
7.5 Discussion
We have previously reported the expression of LH/hCG receptors in human
corpora lutea throughout the luteal phase and after luteal 'rescue' with hCG
(Duncan et al., 1996a). We found that LH/hCG receptor mRNA and binding
activity were retained in corpora lutea during the late-luteal phase when
progesterone production is falling. There is a decline in LH secretion during the
luteal phase (Ellinwood et al., 1984), but this is not wholly responsible for the
falling luteal progesterone production (Hutchison et al., 1986). The reasons for
reduced progesterone synthesis in the late-luteal phase in the presence of LH and
LH receptors are therefore not yet clear. The stage of steroidogenesis which is
generally thought to be rate-limiting is the conversion of cholesterol to
pregnenolone (Strauss and Miller, 1991; Stocco and Clark, 1996). This stage
involves the actions of both StAR (Stocco and Clark, 1996) and P450scc
(Simpson and Boyd, 1967). As the tools are now available to investigate StAR
expression at a molecular level, in this follow-up study, we looked at its
expression during the luteal phase and compared its expression with that of the
steroidogenic enzymes involved in progesterone synthesis, P450ssc and 3p-HSD.
We have cloned StAR from the human corpus luteum and shown it to be
expressed throughout the luteal phase and after luteal 'rescue' with exogenous
hCG. Since it was first characterised at a molecular level in 1994 (Clark et al.,
1994), it has become increasingly clear that StAR has a fundamental role in the
control of steroidogenesis (Lin et al., 1995; King et al., 1995). It has been shown
to be involved in steroidogenesis in ovine (Juengel et al., 1995) and bovine
Chapter 7 Steroidogenic enzyme expression 130
Figure 7.3
3P-HSD mRNA and protein in late-luteal corpora lutea
Expression and immunolocalisation of 3P-HSD in the late-luteal human corpus
luteum: a) dark-field view of a corpus luteum from LH+11 after isotopic in situ
hybridisation for 3P-HSD mRNA showing expression in the corpus luteum (CL)
but not in the surrounding stroma (S); b) the same corpus luteum as (a) after
immunohistochemistry for 3P-HSD protein showing specific staining in the
corpus luteum (CL) and not in the surrounding stroma (S); c) dark-field view of a
corpus luteum from LH+14 after isotopic in situ hybridisation for 3P-HSD mRNA
showing no expression in the stroma (S) and little expression in the corpus luteum
(CL); d) the same corpus luteum as (c) after immunohistochemistry for 3P-HSD
protein showing continued specific immunostaining in the corpus luteum (CL)
with no staining in the surrounding stroma (S). Scale bar =100 pm.
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Figure 7.4
3P-HSD immunostaining in human corpora lutea
Intensity of immunostaining for 3P-HSD in the human corpus luteum at different
stages of the luteal phase. Staining intensity was graded as absent (-), faint (+),
moderate (++), intense (+++) or very intense (++++) by an observer blinded to
tissue identity. There is little variation in staining intensity in the early- (LH+1 to
LH+5), mid- (LH+6 to LH+10) and late-luteal (LH+11 to LH+14) phases or after
luteal 'rescue' with exogenous hCG (hCGx5 to hCGx7).
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(Hartung et al., 1995) corpora lutea. Recently, Kiriakidou et al. (1996) reported
the expression of StAR in the human ovary. We have confirmed that StAR is
expressed by the human corpus luteum during the functional luteal phase after
luteal 'rescue' in simulated early pregnancy. This suggests that expression of StAR
may be a major factor in the control of luteal steroidogenesis.
StAR is a good candidate molecule to explain how progesterone production falls
in the late-luteal phase and is increased by hCG during luteal 'rescue'. Expression
of StAR has been shown to be regulated by LH and cAMP in granulosa-luteal
cells (Sugawara et al., 1995; Kiriakidou et al., 1996), and it is the expression of
StAR that is now thought to be the major rate limiting step in the steroidogenic
pathway (Stocco and Clark, 1996). However, we have found that StAR expression
continues across the luteal phase in a similar fashion to P450scc and the LH
receptor (Duncan et al., 1996a). Clearly, the elements of the steroidogenic
pathway must decline in the late-luteal phase, as LH receptor and steroidogenic
enzyme expression is absent from corpora lutea collected during menstruation
(Doody et al., 1990; Bassett et al., 1991; Ravindranath et al., 1992a; Nishimori et
al., 1995). In our study, there was more heterogeneity of expression in the late-
luteal phase but this did not reach statistical significance. It appears that the fall in
progesterone production occurs in the continued expression of the main elements
of the steroidogenic pathway including StAR. It is unlikely that differential
regulation of StAR expression initiates functional luteolysis.
While expression of StAR seems to vary in a similar fashion to P450scc and LH
receptors (Duncan et al., 1996a), the changes in expression of 3(3-HSD were more
marked. Of the components of the steroidogenic pathway studied, we found the
expression of 3P-HSD mRNA to vary most throughout the luteal phase. Previous
studies of steroidogenic enzyme expression in primate corpora lutea have shown
similar results. Doody et al. (1990) reported expression of P450scc and 3P-HSD in
a mid-luteal and a late-luteal human corpus luteum. Whereas P450scc was easily
detected in the late-luteal phase, this was not true of 3P-HSD. In a larger study of
the primate corpus luteum, Bassett et al. (1991) found no change in the expression
of P450scc mRNA but a marked reduction in 3P-HSD mRNA during the
functional luteal phase. Although 3P-HSD is not classically thought to be rate-
limiting in steroidogenesis (Strauss and Miller, 1991), its expression appears to be
more tightly regulated than other steroidogenic components in the primate corpus
luteum.
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We found the steroidogenic components to be expressed in high levels in the
early-luteal corpus luteum when progesterone production is increasing. This
agrees with previous studies on the primate corpus luteum (Doody et al., 1990;
Bassett et al., 1991). It is possible that the increase in progesterone production in
the early-luteal phase is due to the increasing translation of this mRNA into
functional enzymes. However, we could immunolocalise 3P-HSD at this stage,
and other groups have reported no differences in immunodetectable steroidogenic
enzymes in the early-luteal phase (Suzuki et al., 1993; Conley et al., 1995;
Sanders and Stouffer, 1997). The likely explanation for the apparent difference in
steroidogenic capacity in the early-luteal phase and the circulating progesterone
levels is substrate availability (Carr et al., 1982; Bassett et al., 1991).
It is uncertain whether the changes in 3fyHSD expression are involved in the
initiation of functional luteolysis. We, and others (Bassett et al., 1991), have
provided evidence that the fall in 3P-HSD mRNA expression begins in the mid-
luteal phase at a time of maximal progesterone output. In vivo, maximal
stimulation of progesterone production from luteal cells occurs in the early-luteal
phase and declines throughout the rest of the luteal phase (Fisch et al., 1990).
Although there may be changes in the distribution of 3P-HSD immunostaining in
the late-luteal stage (Sanders and Stouffer, 1997), we and others have shown that
3P-HSD protein continues to be present, and presumably functional, throughout
the luteal phase (Suzuki et al., 1993; Hild-Petito and Fazleabas, 1997). Inhibition
of 3P-HSD, using trilostane, inhibits progesterone function but the non-
steroidogenic functions of the corpus luteum, such as relaxin production continue
normally (Duffy et al., 1994; Duffy et al., 1995). Other factors must be involved
in controlling the lifespan of the corpus luteum. A fall in 3P-HSD activity does
not appear to be able to initiate normal luteolysis by itself.
The mechanism for the apparent differential control of 3P-HSD and P450scc
expression is not known. It remains possible that it is a function of mRNA
stability and different half-lives of mRNA species. There is some preliminary
evidence for differential control of expression of these enzymes. In rats (Oonk et
al., 1989), and humans (Voultilainen et al., 1986) it appears that after the LH
surge, expression of P450scc is constitutive and not augmented by gonadotrophin
stimulation. In contrast, gonadotrophins have been shown to have a slight
stimulatory effect of 3fyHSD expression in vitro (Chedrese et al., 1990).
However, in the primate corpus luteum, Ravindranath et al. (1992b) reported
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similarities in the control of P450scc and 3P-HSD expression by showing LH is
mandatory for the continued expression of both. Further work is required to study
the control of 3P-HSD expression in the corpus luteum.
All elements of the steroidogenic pathway were maintained in the 'rescued' corpus
luteum of simulated early pregnancy. In granulosa cells, the LH surge initiates the
expression of P450scc and 3P-HSD (Strauss and Miller, 1991). Recently, it has
been shown that granulosa cell StAR expression is also initiated by LH at the time
of the LH surge (Kiriakidou et al., 1996). Administration of GnRHant in the mid-
luteal phase clearly shows that LH is required for the continued expression of
these enzymes in the corpus luteum (Ravindranath et al., 1992b). During luteal
'rescue', hCG acts through the LH receptor (Cole et al., 1973) to prevent luteolysis
and maintain progesterone production. It appears that LH/hCG has a stimulatory
effect on the expression of the key elements of the steroidogenic pathway. One of
the effects of hCG in early pregnancy appears to be the facilitation of the
expression of the enzymes responsible for progesterone synthesis.
The causes of the fall in the expression of luteal steroidogenic enzymes towards
menstruation is not clear. Expression is variable in the late-luteal phase and absent
from the corpus luteum after menstruation (Bassett et al., 1991; Suzuki et al.,
1993; Sanders and Stouffer, 1997). It appears that, at the beginning of the late-
luteal phase, when progesterone production is falling, elements of the
steroidogenic pathway are still being expressed. At the end of the luteal phase,
expression of these elements, including LH receptors, appears to be reduced
(Bassett et al., 1991; Ravindranath et al., 1992b; Suzuki et al., 1993; Nishimori et
al., 1995). As the production of progesterone, and the maintenance of
steroidogenic enzyme expression, is dependant on LH (Hutchison and Zeleznik,
1984; Fraser et al., 1986; Ravindranath et al., 1992b), it is possible that, in the
late-luteal phase, LH action is being diluted at the level of the LH receptor
(Zeleznik and Hillier, 1996). As LH receptors are still present (Ravindranath et
al., 1992a; Duncan et al., 1996a), this effect may be at the level of coupling to
second messenger systems. Studies of the LH receptor have shown that
uncoupling does occur in some circumstances (Segaloff and Ascoli, 1993). It is
likely that the continued stimulation of the steroidogenic enzymes also stimulates
their continued expression.
In conclusion, the molecular mechanisms of the initiation of functional luteolysis
are still unknown. It is likely that a reduction in expression of the components of
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the steroidogenic pathway, particularly 3P-HSD, is involved in the continued fall
in progesterone production premenstrually. It is, however, unlikely that changes in
their expression initiates the initial reduction in progesterone production. In the
presence of logarithmically increasing concentrations of hCG, in early pregnancy,
the steroidogenic pathway is maintained, facilitating the continuing luteal
synthesis of progesterone. In the late-luteal phase, the fall in progesterone
production appears to occur in the presence of the major components of the
steroidogenic pathway, including StAR. The fall in progesterone production is
then associated with alterations in steroidogenic enzyme expression, particularly
3P-HSD. The mechanisms of the initial drop in progesterone production, and why
the expression of 3P-HSD appears to vary most throughout the luteal phase
remain unclear. It appears that further studies on luteal steroidogenesis in the
primate, focusing on the stimulation of second messenger signals in response to
LH receptor ligand binding, are required.
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Chapter 8
The human corpus luteum continues to expresses
the progesterone receptor during maternal
recognition of pregnancy
8.1 Abstract
It has been suggested that progesterone may have an autocrine role in the
maintenance of luteal function. This study aimed to localise progesterone
receptors in the human corpus luteum and endometrium, and to investigate the
effect of luteal 'rescue' with exogenous hCG. Corpora lulea and endometrial
biopsies were collected from women undergoing hysterectomy throughout the
luteal phase and after luteal 'rescue' with exogenous hCG. Progesterone receptors
were detected by immunohistochemistry using monoclonal antibodies which
recognised both 'A' and 'B' isoforms, or solely the 'B' isoform, of the receptor.
Steroidogenic cells were identified by immunohistochemistry for 3P-HSD. In the
endometrium, the strong glandular epithelial staining present in early-luteal tissue
did not persist beyond this stage (p<0.005). Stromal staining persisted throughout
the luteal phase. Progesterone receptors were much more difficult to
immunolocalise in the corpus luteum. They could be localised to the steroidogenic
cells and some cells in the surrounding stroma. The localisation or intensity of
immunostaining did not change across the luteal phase or after luteal 'rescue' with
hCG, or when the antibody recognising the 'B' isoform was used. In conclusion,
the corpus luteum continues to express progesterone receptors, particularly the 'B'
isoform, in the presence of increasing progesterone concentrations during luteal
'rescue'. The low levels of luteal progesterone receptors and the lack of change in
relation to luteal function, does not add support to the hypothesis that progesterone
has a major autocrine role in the human corpus luteum.
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8.2 Introduction
The molecular mechanisms of luteolysis and luteal 'rescue' in the human corpus
luteum remain unclear (Behrman et al., 1993). It is clear, however, that the major
function of the corpus luteum is the secretion of progesterone, to prepare the
endometrium for blastocyst implantation, and to support early pregnancy (Knobil,
1973; Behrman et al., 1993; Zeleznik and Fairchild Benyo, 1994). Progesterone is
synthesised from cholesterol by the action of steroidogenic enzymes (Strauss et
al., 1981), under the control of pituitary LH (Hutchison and Zeleznik, 1984), and
secreted by the steroidogenic cells of the corpus luteum. Progesterone acts on its
target tissues through a specific nuclear hormone receptor (Grody et al., 1982). To
date, three isoforms of the nuclear progesterone receptor have been described 'A',
'B' (Horwitz et al., 1985; Kastner et al., 1990) and 'C' (Wei et al., 1990). The 'A'
form of the receptor is a slightly truncated version of the 'B' form, and the 'C' form
is more truncated still (Wei et al., 1990). Although not fully characterised, it has
become apparent that these different forms of the receptor may have different
functional properties (Kastner et al., 1990; Vegeto et al., 1993; Tung et al., 1993;
Graham and Clarke, 1997).
The main site of progesterone action is the uterine endometrium (Lessey et al.,
1988; Press et al., 1988) and myometrium (Kawaguchi et al., 1991), but there are
many extra-uterine sites of action. Progesterone receptors have been localised in
the brain (Press and Greene, 1988), blood vessels (Perrot-Applanat et al., 1994),
breast (Clark et al., 1983), lung (Press and Greene, 1988) and luteinising
granulosa cells (Greenberg et al., 1990). However, of particular interest is the
detection of progesterone receptors in the corpus luteum itself. Specific nuclear
progesterone receptors have been detected in the corpus luteum of non-human
primates (Hild-Petito et al., 1988) and women (Iwai et al., 1990; Horie et al.,
1992; Suzuki et al., 1994). However, other species, such as the rat, do not appear
to express luteal progesterone receptors (Park-Sarge et al., 1995). The finding of
specific progesterone receptors in progesterone-producing cells gives new support
to a theory, put forward many years ago, that progesterone is involved in
controlling its own synthesis and secretion (Rothchild, 1981; Rothchild, 1996).
We postulated that if progesterone had a significant autocrine effect in the corpus
luteum, the expression of luteal progesterone receptors may vary throughout its
functional lifespan. We investigated the expression and localisation of
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progesterone receptors in the human corpus luteum by immunohistochemistry
throughout the luteal phase and after luteal 'rescue' with exogenous hCG to mimic
the hormonal changes of early pregnancy. We identified steroidogenic cells in
serial sections using an antibody to the steroidogenic enzyme 3(3-HSD. In
addition, we investigated the nature of progesterone receptor by looking
specifically for the 'B' isoform. The expression and localisation of the
progesterone receptor in a known, hormonally-regulated, progesterone target site,
the endometrium, was also studied throughout the luteal phase and after luteal
'rescue'.
8.3 Specific Materials and Methods
8.3.1 Tissues Studied
Corpora lutea and endometrial biopsies from 25 women were studied (2.2). Part of
each corpus luteum and the endometrial biopsy was fixed for 24 hours in 4%
paraformaldehyde and embedded in paraffin wax (2.2.3), In addition, part of the
corpus luteum was frozen in embedding medium for the preparation of frozen
sections (2.2.3). Each tissue was classified according to the date of the urinary LH
surge (2.2.4). Six samples were classified as early-luteal, six as mid-luteal, six as
late-luteal and six were classified as luteal 'rescue' (2.2.4). One sample was
classified as periovulatory and consisted primarily of luteinised granulosa cells.
Haematoxylin and eosin stained sections of each corpus luteum and endometrial
biopsy were prepared (3.2.8).
8.3.2 Immunohistochemistry
Immunohistochemistry was initially performed on paraformaldehyde-fixed
sections of corpus luteum and endometrium (3.2.2). Sections (5 pm), cut onto
poly-L-lysine-coated slides (3.2.1), were used. As preliminary experiments showed
that microwave antigen retrieval was required, this was performed as described
previously (3.2.4). Immunohistochemistry was performed using NRS to block
non-specific binding (3.2.6). The mouse anti-human progesterone receptor
antibody (Battifora and Mehta, 1993) (3.1.2) was used at a dilution of 1:20 in
TBS. This antibody recognises both the 'A' isoform and the 'B' isoform of the
receptor and has no cross-reactivity with other steroid-hormone receptors.
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Specific antibody binding was visualised using biotinylated rabbit anti-mouse
immunoglobulins and an AB-AP detection system (3.2.6). As negative controls,
the primary antibody was replaced by mouse immunoglobulins, at the same
concentration, in serial sections (3.2.9). Colouration was achieved by incubation
with NBT (3.2.7). This gives a stable blue end-product. Care was taken to ensure
that all slides were processed identically and were exposed to each step of the
protocol for exactly the same time, under the same conditions. The sections were
not counterstained with haematoxylin as the progesterone receptor is a nuclear
protein. The slides were washed, dehydrated and mounted (3.2.8) prior to analysis.
Steroidogenic cells were identified on serial sections using a specific polyclonal
rabbit antibody to human 3(3-HSD (3.1.2) as described previously (7.3.5). Briefly,
fixed sections were prepared as described (3.2.2) and incubated with the primary
antibody in a dilution of 1:1000. NGS was used to block non-specific binding, and
specific antibody binding was detected using biotinylated goat anti-rabbit
immunoglobulins (3.2.6) and visualised with an AB-HRP reaction which turned
the substrate (DAB) into a stable brown end-product (3.2.7).
Immunohistochemistry for progesterone receptor isoforms was performed on
frozen sections (3.2.3). Mouse monoclonal antibodies which recognised both 'A'
and 'B' isoforms of the progesterone receptor, or solely the 'B' isoform of the
receptor were used (3.1.2). The monoclonal antibody to the 'B' isoform of the
receptor had no cross-reactivity with the A' isoform. Primary antibodies were used
at a concentration of 1:50 and mouse IgG at the same concentration was used in
place of the primary antibody as a negative control (3.2.9). NRS was used to block
non-specific binding and specific antibody binding was detected using biotinylated
rabbit anti-mouse immunoglobulins (3.2.6) and visualised with an AB-AP
reaction which turned the substrate (NBT) into a stable blue end-product (3.2.7).
8.3.3 Analysis of Results
Progesterone receptors were quantified on immunostained sections by computer-
aided nuclear densitometry (Koh et al., 1995). Only sections from the same run
performed in carefully controlled conditions were analysed together. Grey-scale
densitometric analysis was performed after image capture using an image analysis
program (NIH Image 1.55) using a stratified random sampling technique. The
average grey scale reading on at least fifty nuclei in three fields of view per section
was calculated, and the results monitored with reference to the running mean.
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Background readings, taken from the cytoplasm of the same cells, were subtracted
from the average grey scale reading to give a more objective measurement of
staining intensity.
The validity of the technique was monitored by analysis of different
immunohistochemistry runs and by repeating the measurements on the same
sections at a later date. In the endometrium, nuclear staining glandular and stromal
compartments varied little within the compartment: thus all identified nuclei were
analysed. In the steroidogenic compartment of the corpus luteum, only a
proportion of nuclei immunostained. In this case, the percentage of positive nuclei
were counted, and densitometry was only performed on the positive nuclei.
Results were analysed statistically by one-way ANOVA using a commercial
software package (StatView 4.0). Where differences existed, with a 5% level of
significance, pairwise comparisons were performed using the Bonferroni/Dunn
method.
8.4 Results
8.4.1 Plasma Progesterone Concentrations
Mean plasma progesterone concentrations were 32.4 ±9.6 nmol/1 in the early-
luteal phase, 40.9 ±9.9 nmol/1 in the mid-luteal phase, and 19.2 ±12.6 nmol/1 in
the late-luteal phase. Plasma progesterone concentrations in women receiving
hCG rose from a mean of 38.2 ±3.4 nmol/1 to a mean of 52.7 ±1.1 nmol/1 at the
time of surgery, confirming luteal 'rescue' in each case. The classification of the
corpora lutea by serial urinary LH measurement agreed with the luteal phase
dating of endometrial biopsies using the method of Li et al. (1988).
8.4.2 Endometrial Progesterone Receptor Immunostaining
Immunostaining for the progesterone receptor was exclusively nuclear in all
sections investigated (Fig. 8.1a). No specific immunostaining was detected in
serial negative control sections, where the primary antibody was replaced by non¬
specific immunoglobulins at the same concentration (Fig. 8.\b). Nuclear
progesterone receptor immunostaining was seen in the glandular and stromal
compartments of early-luteal phase endometrium (Fig. 8.1a). In contrast,
progesterone receptor immunoreactivity was exclusively stromal in the mid- (Fig.
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Figure 8.1
Progesterone receptor immunostaining in human endometrium
Immunohistochemistry for progesterone receptors in endometrium: a) early-luteal
phase endometrium showing specific nuclear staining in the glandular (G) and
stromal (S) compartments; b) negative control serial section of (a), where the
primary antibody was replaced with non-specific immunoglobulins, showing no
specific staining in the glands (G) or stroma (S); c) mid-luteal endometrium
showing nuclear progesterone receptor immunostaining in the stroma (S) but not
the glands (G); d) continued stromal (S) immunostaining and absence of glandular
(G) staining in late-luteal endometrium; e) the same pattern of glandular (G) and
stromal (S) immunostaining seen in the endometrium after luteal 'rescue' with
exogenous hCG; f) haematoxylin and eosin stained section of 'rescued'
endometrium showing some decidualisation of the stroma (S) and early Arias-
Stella reaction of pregnancy in the glands (G). Scale bar = 100 pm.
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8.1c) and late-luteal phase endometrium (Fig. 8.1c/). After luteal 'rescue' with
exogenous hCG, to maintain endometrial progesterone exposure in the late-luteal
phase, progesterone receptor immunoreactivity remained exclusively stromal (Fig.
8.1c). After luteal 'rescue', the endometrium showed morphological evidence of
decidualisation and the Arias-Stella reaction of pregnancy (Fig. 8.1/).
There was no change in the intensity of stromal nuclear progesterone receptor
immunostaining throughout the luteal phase or after luteal 'rescue' with exogenous
hCG (Fig. 8.2). However, there was a significant change in the intensity of
glandular progesterone receptor immunostaining (Fig. 8.2). Glandular nuclear
immunoreactivity was much lower (p<0.005) in the mid- and late-luteal
endometrium than in the early-luteal endometrium. There was no difference in
endometrial progesterone receptor immunostaining in the late-luteal phase, when
progesterone exposure is declining, and the endometrium from simulated early
pregnancy, when progesterone exposure is increasing (Fig. 8.2).
8.4.3 Luteal Progesterone Receptor Immunostaining
Nuclear progesterone receptor immunostaining could clearly be identified in
luteinised periovulatory granulosa cells (Fig. 8.3a). In the mature corpus luteum
progesterone receptors could be detected on a proportion of luteal cells (Fig. 8.3b).
Comparison with serial sections immunostained for the steroidogenic enzyme 3p-
HSD confirmed that progesterone-producing cells can express specific nuclear
receptors to progesterone (Fig. 8.3c). Progesterone receptor immunoreactivity in
some steroidogenic cells was seen in all sections studied. Progesterone receptor
immunoreactivity was also present in cells of the surrounding stroma which was
often more intense than the steroidogenic cell immunostaining (Fig. 8.3d,e).
When the intensity of steroidogenic cell progesterone receptor immunostaining
was analysed, there were no significant differences throughout the luteal phase
and after luteal 'rescue' with exogenous hCG (Fig. 8.4). In addition, there were no
differences in the proportion of cells demonstrating immunodetectable
progesterone receptors throughout the luteal phase or after luteal 'rescue' (Fig.
8.4). Immunohistochemistry for progesterone receptors resulted in a much lower
intensity stain in the corpus luteum than in the endometrium under identical
conditions (Fig. 8.5).





Stage of the luteal phase
Figure 8.2
Quantification of endometrial progesterone receptor immunostaining
The intensity of progesterone receptor immunostaining as measured by nuclear
densitometry in the glandular and stromal compartments of endometrium from the
early- (LH+1 to LH+5), mid- (LH+6 to LH+10) and late-luteal (LH+11 to LH+14)
phases, and after luteal 'rescue' (hCGx5 to hCGx8) to mimic early pregnancy (n=6
per group; values are mean ±S.E.M.). Immunostaining in the glandular nuclei was
highest in the early-luteal phase (p<0.005; ANOVA). There was no difference in
the staining of glandular and stromal nuclei in the early-luteal phase but in the
mid- and late-luteal phases, and after luteal 'rescue' with exogenous hCG stromal
immunoreactivity was greater than glandular (p<0.001; ANOVA). There was no
difference in stroma cell nuclear progesterone receptor immunostaining across the
luteal phase or after luteal 'rescue'.
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Figure 8.3
Progesterone receptor immunostaining in human corpora lutea
Immunohistochemistry for progesterone receptors in corpora lutea: a) luteinised
granulosa cells, collected just prior to follicular rupture, showing specific nuclear
immunostaining for progesterone receptors (arrows); b) mid-luteal corpus luteum
showing scattered nuclear progesterone receptor staining (arrows) within the
granulosa-lutein cell layer (G); c) section from the same corpus luteum as (b)
immunostained for the steroidogenic enzyme 3(3-HSD, showing these cells, in the
granulosa-lutein layer (G), to be steroidogenic in nature; d) late-luteal corpus
luteum showing specific nuclear progesterone receptor immunostaining in the
non-steroidogenic stromal tissue (S) surrounding the steroidogenic granulosa-
lutein cells (G) and theca-lutein (T) cells, which display less marked nuclear
progesterone receptor immunostaining; e) section from the same corpus luteum as
(d) stained with haematoxylin and eosin to clarify the architecture of the
steroidogenic granulosa-lutein cells (G), theca-lutein cells (T) and the surrounding
stromal tissue (S). Scale bar =100 pm.
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Figure 8.4
Quantification of luteal progesterone receptor immunostaining
The mean number of nuclei demonstrating specific progesterone receptor
immunoreactivity per high power field, in the steroidogenic cells of human
corpora lutea, and their mean intensity of immunostaining measured by nuclear
densitometry are shown (n=6 per group; values are mean ±S.E.M.). There were no
differences in the number or intensity of stained nuclei in corpora lutea from the
early- (LH+1 to LH+5), mid- (LH+6 to LH+10) and late-luteal (LH+11 to LH+14)
phases or after luteal 'rescue' with exogenous hCG (hCGx5 to hCGx8) to simulate
the hormonal changes of early pregnancy (ANOVA).
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Figure 8.5
Comparison of immunostaining intensity in the endometrium and corpus
luteum
The intensity of progesterone receptor immunostaining as measured by nuclear
densitometry in endometrial stroma (Endometrium, n=24) and granulosa-lutein cells
of corpora lutea (Corpus Luteum, n=24). These are compared to nuclear
densitometry of granulosa-lutein cells of the control sections where mouse
immunoglobulins were used in place of the primary antibody (Control, n=24). This
shows the nuclear progesterone receptor immunoreactivity to be much greater in
endometrium than corpora lutea under these conditions (values are means
±S.E.M.).
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8.4.4 Identification of the 'B' Isoform of the Progesterone Receptor
Immunohistochemistry for the 'B' isoform of the progesterone receptor was
performed on frozen sections of corpora lutea. Specific nuclear immunostaining
for the 'B' progesterone receptor could be detected in luteal steroidogenic cells
(Fig. 8.6a). Comparison of serial sections immunostained with the same
concentration of a monoclonal antibody, prepared under the same conditions,
which recognised both the 'A' and 'B' forms of the receptor showed a similar
pattern and intensity of staining (Fig. 8.6b). This pattern of immunostaining was
repeated in all sections throughout the luteal phase and after luteal 'rescue' with
exogenous hCG (Fig. 8.6c,d). Immunoreactive nuclear progesterone receptors
appeared to localise to a greater proportion of steroidogenic luteal cells when
frozen sections were analysed with these antibodies. However, as tissue definition
was much poorer, quantitative analysis was not performed.
8.5 Discussion
This study reports the expression and localisation of the progesterone receptor in
human endometrium and corpora lutea throughout the luteal phase and after luteal
'rescue' with exogenous hCG. Expression of the progesterone receptor in human
endometrium has been well documented previously (Press et al., 1988; Lessey et
al., 1988). The localisation of specific progesterone receptor immunoreactivity in
our study agrees with these reports. These data suggest that the progesterone
receptor in stromal cells of the endometrium is regulated differently from the
progesterone receptor in endometrial glands. Whereas the glandular receptor
appears to be down-regulated by progesterone, this is not true of the stromal
receptor during the normal secretory phase. Progesterone receptor
immunoreactivity has been reported in the stromal cells of decidua of early
pregnancy (Perrot-Applanat et al., 1994). Using a luteal 'rescue' model, which
allows prolonged exposure to progesterone in the absence products from the
conceptus, we have confirmed the continued expression of the stromal cell
progesterone receptor in the presence of increasing progesterone concentrations.
There is increasing evidence for the expression of progesterone receptors in the
steroidogenic cells of the primate corpus luteum. Press and Greene (1988) first
used immunohistochemistry to detect progesterone receptors in the human corpus
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Figure 8.6
Immunolocalisation of the 'B' isoform of the progesterone receptor in
corpora lutea
Immunohistochemistry for progesterone receptor isoforms in the granulosa-lutein
cells of human corpora lutea: a) early-luteal corpus luteum showing specific
nuclear reactivity after immunostaining with an antibody which solely recognises
the 'B' isoform of the progesterone receptor; b) serial section of (a) showing the
same pattern of nuclear immunoreactivity after staining with an antibody which
recognises both the 'A' and the 'B' isoforms of the progesterone receptor; c) section
of a corpus luteum after luteal 'rescue' with exogenous hCG, immunostained for
the 'B' isoform of the progesterone receptor showing continued nuclear
immunoreactivity; d) serial section of (c) after staining for both the 'A' and 'B'
isoforms of the progesterone receptor showing the same pattern of nuclear
immunoreactivity. Scale bar =100 (am.
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luteum. Since then, several studies have systematically immunolocalised
progesterone receptors to the steroidogenic cells of the corpus luteum of the
human (Iwai et al., 1990; Horie et al., 1992; Suzuki et al., 1994), rhesus monkey
(Hild-Petito et al., 1988) and baboon (Hild-Petito and Fazleabas, 1997). Other
techniques have been used to confirm luteal progesterone receptor expression in
the primate, including radioligand binding assays (Slayden et al., 1994), western
blotting (Duffy et al., 1997), RT-PCR (Chandrasekher et al., 1994), northern
blotting (Hild-Petito and Fazleabas, 1997) and RNAse protection assay (Duffy and
Stouffer, 1995). We have again immunolocalised progesterone receptors to the
primate corpus luteum. This study continues the line of evidence that the
progesterone-producing cells of the corpus luteum have the potential to respond to
that progesterone in an autocrine fashion.
As well as confirming the expression of progesterone receptors in the corpus
luteum, this study gives some additional pieces of information. Firstly, we found
that the progesterone receptor was much harder to immunolocalise in the corpus
luteum than in the endometrium, a classical progesterone-responsive tissue. In the
one study where progesterone receptors were immunolocalised in a variety of
tissues, the immunostaining of the ovary and endometrium were not compared or
contrasted (Press and Greene, 1988). This suggests that either progesterone
receptors are expressed in low levels by the corpus luteum or that tissue fixation
differences affect the tissues' immunostaining properties. Whereas, tissue antigen
accessibility may well be involved, there is indirect evidence that this may not be
the case. We found no differences in immunostaining properties in the same
endometrial and luteal tissues when bcl-2 localisation was investigated (Rodger et
al., 1995; Koh et al., 1995). In addition, progesterone receptor immunostaining
was easier to detect in the surrounding stroma than the steroidogenic cells of the
same corpus luteum. Immunostaining of luteal stromal cells has previously been
well documented (Press and Greene, 1988; Suzuki et al., 1994). Western blotting
(Duffy et al., 1997) and RNAse protection assays (Duffy and Stouffer, 1995) for
progesterone receptors recently demonstrated much lower expression than in an
equivalent amount of endometrium. It is probable that steroidogenic cells of the
corpus luteum express much lower levels of progesterone receptors than classical
progesterone target tissues.
We found that the 'rescued' corpus luteum continued to express progesterone
receptors. Previous studies of luteal progesterone receptors in the human (Iwai et
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al., 1990, Horie et al., 1992; Suzuki et al., 1994) and monkey (Hild-Petito et al.,
1988) looked at corpora lutea from normal ovarian cycles. Prior to ovulation, LH
stimulates the expression of progesterone receptors in granulosa cells
(Chandrasekher et al., 1991). In vitro, it has been suggested that hCG also
increases the expression of progesterone receptor mRNA in luteinised monkey
granulosa cells (Duffy et al., 1996). We used exogenous hCG to simulate the
luteal events of early pregnancy in the human. The increased progesterone
receptor expression seen after the LH surge does not follow exposure to hCG in
the corpus luteum. The luteal progesterone receptor is not up-regulated or down-
regulated by prolonged exposure to progesterone during luteal 'rescue'. A recent
study has confirmed the continued expression of progesterone receptors in baboon
corpora lutea collected during early pregnancy (Hild-Petito and Fazleabas, 1997).
The corpus luteum of early pregnancy, therefore, maintains the potential to
respond to the progesterone it continues to produce.
We looked at the expression of progesterone receptor isoforms in the corpus
luteum. There is evidence that different isoforms of the human progesterone
receptor have different functional properties (Graham and Clarke, 1997). It is
thought that the 'B' isoform of the progesterone receptor mediates the stimulatory
effects of progesterone in classical target tissues (Vegeto et al., 1993). The 'A'
isoform can inhibit the ability of the 'B' isoform of the progesterone receptor to
stimulate transcription (Vegeto et al., 1993; Tung et al., 1993). Although it is not
possible to specifically immunolocalise the 'A' isoform of the receptor, we found it
likely that the main isoform in the corpus luteum was the 'B' progesterone
receptor. Recently, using western blotting Duffy et al. (1997) confirmed that the
'B' progesterone receptor was the main isoform in the monkey corpus luteum,
particularly in the late-luteal phase. This suggests that it is the receptor isoform
associated with classical progesterone action that is primarily present in the corpus
luteum.
There has been some controversy about changes in progesterone receptor
expression in the corpus luteum throughout the luteal phase. Some studies have
suggested that progesterone receptor expression is reduced in the late-luteal phase
(Hild-Petito et al., 1988; Iwai et al., 1990; Suzuki et al., 1994). We did not find
any change in the level of progesterone receptor immunoreactivity throughout the
luteal phase. It is uncertain why this discrepancy is present. It may relate to the
classification of corpora lutea, which has previously been morphological in basis.
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We have used carefully controlled urinary tracking to accurately date each corpus
luteum on the basis of the urinary LH surge. Indeed, it has been reported that
progesterone receptor mRNA is present in the corpus luteum throughout the luteal
phase (Chandrasekher el al., 1994; Duffy and Stouffer, 1995; Hild-Petito and
Fazleabas, 1997), as is the protein as detected by western blotting (Duffy et al.,
1997). Although not fully resolved, it appears that progesterone receptors can be
detected in primate corpora lutea throughout their functional lifespan.
It is unclear whether all, or a proportion of the steroidogenic cells of the corpus
luteum express progesterone receptors. In this study, only a proportion of luteal
cells had immunodetectable progesterone receptors. This has also been seen in
other immunohistochemical studies (Press and Greene, 1988; Duffy et al., 1994;
Hild-Petito and Fazleabas, 1997). Other studies have demonstrated specific
immunostaining in a greater proportion of steroidogenic cells (Hild-Petito et al.,
1988; Suzuki et al., 1994; Slayden et al., 1994). We found a greater percentage of
luteal cells expressed progesterone receptors, when we used frozen sections and
different primary antibodies. This difference is likely to be due to different
sensitivities of the various immunohistochemical techniques. It is therefore likely
that progesterone receptors are expressed by the majority of the steroidogenic cells
in the corpus luteum.
The role of the luteal progesterone receptor is still not clear. Rat corpora lutea do
not express progesterone receptors (Parke-Sarge et al., 1995). The physiology of
luteolysis and maternal recognition of pregnancy is markedly different in rats
(Niswender and Nett, 1994). As progesterone receptors are present in the primate,
this may mean that they are required for a specific functional role. It is not fully
established whether other non-primate species, with alternate mechanisms to
control luteal function, express progesterone receptors in their corpora lutea. There
has however been a preliminary report that the ovine corpus luteum expresses
progesterone receptors (Smith et al., 1995b). Although the reasons are not clear,
this species difference in luteal progesterone receptor expression may give us
clues as to its function.
Several approaches have been used to determine whether progesterone has a
functional role in the primate corpus luteum. The effect of administration of the
antigestogen RU486 on luteal function was studied initially. It has been shown
that RU486 can inhibit normal luteal function in women (Schaison et al., 1985;
Garzo et al., 1988). However, this is likely to be directly related to its effects of
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pituitary gonadotrophins (Schaison et al., 1985; Garzo et al., 1988; Batista et al.,
1994). When the corpus luteum is supported by exogenous hCG in the presence of
RU486, normal luteal progesterone production continues, in spite of uterine
bleeding (Croxatto et al., 1989). In addition, in vivo, RU486 administration had no
effect on progesterone production from cultured luteinised granulosa cells, which
expressed immunodetectable progesterone receptors (Greenberg et al., 1990). It
seems that either progesterone has little effect on luteal function directly or other
techniques are required to dissect its role.
One novel approach to study the local effects of progesterone is to administer
trilostane, a 3P-HSD inhibitor. Duffy et al. (1994) administered trilostane to
rhesus monkeys during the luteal phase. They found no effect on serum
gonadotrophin levels but low progesterone levels, which did not recover after
trilostane withdrawal. They concluded progesterone may be required for the
maintenance of the functional and structural integrity of the primate corpus luteum
(Duffy et al., 1994). However, in this model oestrogen production was
unexpectedly maintained, as was the production of other luteal products, such as
relaxin (Duffy et al., 1995; Duffy et al., 1996). Although there is some evidence
from this model that progesterone may modulate the expression of its receptor
(Duffy and Stouffer, 1995), we did not see a change in progesterone receptors
across the luteal phase in the presence of different progesterone concentrations. It
is possible that progesterone has direct effects on LH receptor expression. In vitro
progesterone treatment of bovine luteal cells resulted in increased LH receptor
expression (Jones et al., 1992). The LH receptor, however, is expressed in the
human corpus luteum throughout the luteal phase in the presence of differing
progesterone concentrations (Duncan et al., 1996a). The concept of a local effect
of progesterone on luteal function is attractive (Rothchild, 1981; Rothchild, 1996),
but at present there are no direct functional data to fully explain the role of the
luteal progesterone receptor.
In conclusion, we have shown that the progesterone receptor can be
immunolocalised to the human corpus luteum throughout the luteal phase and
after luteal 'rescue' with exogenous hCG. It is likely that the level of expression of
these receptors is less than that in the classical progesterone-responsive tissues,
but the isoform is that associated with a functional effect. The functional role of
the progesterone receptor of the corpus luteum is not known. It is possible that
progesterone has a role in regulating its own synthesis. Our findings, that the low
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levels of progesterone receptors do not vary in the different functional stages of
the lifespan of the corpus luteum, despite varying progesterone concentrations, do
not support the hypothesis that progesterone receptors have a major functional role
in regulating luteal progesterone production.
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Chapter 9
Experimental Section II: Structural Effects
9.1 General Introduction
This second section explores the structural remodelling of the corpus luteum at
different stages of its lifespan. The mid-luteal corpus luteum is an extraordinarily
active endocrine gland. It synthesises and secretes large amounts of steroids, non¬
steroid hormones and growth factors (Behrman et al., 1993). It is, weight for
weight the most active endocrine gland in the body (Rothchild, 1981) with a blood
supply per unit mass many times that of the kidney (Ford et al., 1992). However,
the corpus luteum is a transient structure, with a life-span, under normal
conditions, of little more than 14 days (Lenton and Woodward, 1988). At the time
of menstruation, it is difficult to find the residual corpus luteum on the human
ovary.
During its short lifespan the corpus luteum changes greatly from a structural point
of view. Before ovulation, the dominant follicle is largely a fluid-filled cystic
structure on the ovary measuring somewhere between 15 to 22 mm in diameter
(Adashi, 1994). The granulosa cells lining the follicle are avascular in nature and
obtain their nutrients by diffusion from blood vessels in the adjacent theca cell
layer (Gougeon, 1996). This limits the thickness of the granulosa cell layer to five
or six cells (Zeleznik and Fairchild Benyo, 1994). After ovulation, the follicular
remnants are transformed into the highly vascular corpus luteum. The granulosa
cell layer undergoes hypertrophy and is invaded by endothelial cells, supporting
fibroblasts and connective tissue (Behrman et al., 1993; Zeleznik and Fairchild
Benyo, 1994). This stage of luteal development is associated with intense
angiogenesis (Reynolds et al., 1992) and endothelial cell proliferation (Rodger et
al., 1997). In the mid-luteal phase, the corpus luteum is a solid ball of tissue on the
ovarian surface, around 15 mm in diameter. During luteolysis, this changes into a
small relatively avascular fibrous remnant in a matter of days (Corner, 1956). The
cell and tissue debris generated during the luteolytic process are thought to be
removed by tissue macrophages (Paavola, 1979; Norman and Brannstrom, 1994).
The numbers of macrophages are thought to increase in the corpus luteum during
luteolysis (Best et al., 1996), but the effect of luteal 'rescue' is not known.
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As well as intense tissue remodelling around the time of ovulation, when the
corpus luteum is formed, there is marked tissue remodelling during luteolysis
(Luck and Zhao, 1995). It is becoming increasingly clear that the remodelling
associated with luteolysis involves the loss of cells from the corpus luteum
(Spencer et al., 1996). It is now thought that this cell loss involves the death of
both steroidogenic and endothelial cells by apoptosis (Juengel et al., 1993; Fraser
et al., 1995b; Shikone et al., 1996; Young et al., 1997). This cell death is not seen
during early pregnancy (Shikone et al., 1996), and there is preliminary evidence
that rates of luteal cell death are inhibited by hCG (Dharmarajan et al., 1994).
Much less is known about the remodelling of the ECM throughout the luteal phase
and the effect of hCG during luteal 'rescue' on ECM synthesis and breakdown.
The connective tissue of a gland is made up primarily ofECM. The ECM consists
of structural proteins such as collagen, proteoglycans, laminin, elastin and
fibronectin which hold the cellular components of the gland together. It also
supports the blood and lymph vessels, transient cell populations and forms a
repository for growth factors (Hulboy et al., 1997). Any change in the structure of
a tissue involves synthesis and breakdown of the ECM. Little is known about
tissue remodelling in the corpus luteum. Proteolytic breakdown of the ECM
requires the action of powerful enzymes. The enzymes capable of denaturing
fibrillar collagens are a group of zinc-dependent enzymes known as the MMPs
(Matrisian, 1990; Woessner, 1991; Birkendal-Hansen, 1995). Indeed, studies of
tissue remodelling in tumours during tissue invasion (Naylor et al., 1994), the
endometrium at menstruation (Salamonsen and Woolley, 1996; Hulboy et al.,
1997), and the follicle wall at ovulation (Reich, 1991; Curry et al., 1992), have all
implicated MMP action. It is therefore likely that MMPs are involved in the
remodelling associated with luteolysis.
The MMPs are a group of at least 17 structurally related enzymes (Hulboy et al.,
1997) which are tightly controlled under physiological conditions (Birkedal-
Hansen, 1995). Although most are secreted into the ECM (Woessner, 1991), the
most recently described MMPs are transmembrane enzymes expressed on cellular
membranes (Hulboy et al., 1997). Although, there are several different enzymes,
only a few have been extensively studied. These are the enzymes which can
degrade the major structural proteins, and include MMP-1, MMP-2 and MMP-9
(Hulboy et al., 1997). There is some preliminary evidence that these enzymes can
be detected in infraprimate corpora lutea (Tsang et al., 1995; Nothnick et al.,
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1996), and luteinised human granulosa cell cultures (Puistola et al., 1995; Aston et
al., 1996a). Indeed, one study suggested that their expression may be increased
during prolactin-induced luteolysis in the rat (Endo et al, 1993a). However, at
present, there are only limited data about MMP expression and control in the
corpus luteum, and no data about their expression in the primate, or the effect of
maternal recognition of pregnancy. If their expression is important during
luteolysis, it is important to determine if they are inhibited during luteal 'rescue'.
More is known about the expression of TIMPs in the corpus luteum. At present
there are four members of the TIMP family. TIMP-1 and TIMP-2 are secreted
proteins which are widely expressed (Hulboy et al., 1997). TIMP-3 is found in
association with the basement membrane (Uria et al., 1994), and TIMP-4 has only
recently been reported, and therefore much less well defined (Hulboy et al., 1997).
TIMPs bind to and inhibit MMP enzymes with a one-to-one stoichiometry
(Woessner, 1991). TIMP-1 is thought to be a major secretory product of the
corpus luteum. Although nothing is known of its expression in primate corpora
lutea, it is produced in large amounts by the corpus luteum of pigs (Smith MF et
al., 1994), sheep (Smith GW et al., 1994), cows (Juengel et al., 1994) and rats
(Nothnick et al., 1995). It can also be detected in cultures of luteinised human
granulosa cells (Rapp et al., 1990; Morgan et al., 1994). In addition, it is now
clear that TIMP-2 can also be detected in infraprimate corpora lutea (Nothnick et
al., 1995; Smith et al., 1995a; Smith et al., 1996a). It is therefore likely that
TIMPs have significant roles in the control of luteal structure or function.
These roles are not entirely clear. It is likely that TIMPs inhibit MMP activity in
the corpus luteum (Salamonsen, 1996). However, there is no clear evidence for a
reduction in TIMP expression during luteolysis (Juengel et al., 1994). There may
be other reasons why TIMPs are highly expressed by corpora lutea. TIMP-1 has
been shown to have growth factor-like activity (Hayakawa et al., 1992), share a
degree of structural homology with bovine StAR (Hartung et al., 1995), and act as
a stimulator of steroidogenesis in the testicular cell cultures (Boujrad et al., 1995).
It is possible that these are also important roles for TIMP-1 in the corpus luteum.
In addition, although it is clear that there are large amounts of TIMP-1 in the
corpus luteum, it is not immediately clear how MMPs can function in the presence
these large amounts of specific inhibitor.
There are therefore some major questions still to be answered about remodelling
in the corpus luteum. Nothing is known about MMP and TIMP expression in the
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primate corpus luteum. Nothing is known about the effect of luteal 'rescue' during
maternal recognition of pregnancy on TIMP and MMP expression. Nothing is
known about the localisation ofMMPs and TIMPs in relation to each other in the
corpus luteum and which cell types are responsible for their production. In
addition, the role of TIMP-1 expression in the corpus luteum is unclear. Is it
principally to inhibit MMPs or are there other roles? For example, does TIMP-1
act as a steroidogenic factor? Clearly, the investigation of structural remodelling in
the corpus luteum is important. At present little is known, and this area has great
potential for study.
9.2 Scope of the Section
This section aims to investigate the factors involved in tissue remodelling in the
corpus luteum during luteolysis and during luteal 'rescue'. The following four
chapters aim to systematically address the factors involved in structural
remodelling of the ECM of the primate corpus luteum, throughout its functional
lifespan, with particular emphasis on luteal 'rescue'. Like the previous
experimental section, each chapter is written in the form of a scientific paper. The
conclusions of this section will be drawn together at the end of this thesis. As
mentioned previously, the results of the chapters in both the experimental sections
of this thesis will be drawn together in Chapter 14 in an attempt to describe a
unifying paradigm.
The first area to be addressed in this section is the expression of TIMP-1 in the
primate corpus luteum. TIMP-1 specifically inhibits the MMP enzymes involved
in tissue remodelling processes throughout the body. Chapter 10 addresses
whether TIMP-1 can be localised to human corpora lutea and whether the
inhibition of structural luteolysis during luteal 'rescue' is associated with an
alteration in the expression of TIMP-1. The potential alteration of TIMP-1
expression during luteolysis is further investigated in Chapter 11. The ontogeny
of TIMP-1 expression in the corpus luteum is also addressed in Chapter 11 by
studying its expression in the steroidogenic cells of the follicle during their growth
and development. A potential steroidogenic role for TIMP-1 is addressed in
Chapter 11 by studying its expression in a variety of steroidogenic and non-
steroidogenic tissues.
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The second area of remodelling to be investigated is the expression of MMP
enzymes in the human corpus luteum. Chapter 12 assesses the expression and
activity of the major MMPs in the corpus luteum, throughout the luteal phase and
after luteal 'rescue' with hCG to prevent structural luteolysis. Chapter 12 also
addresses the expression of the other members of the TIMP family in relation to
the MMPs. The mechanism whereby MMPs can function in an environment
containing TIMPs are also addressed in Chapter 12 by studying the tissue
localisation of these enzymes and their specific inhibitors.
The third factor in the remodelling process to be investigated is the involvement of
immune cells. Chapter 13 investigates the main immune cell in the corpus
luteum, the macrophage. The numbers, and specific tissue localisations, of
macrophages in the corpus luteum are assessed throughout the functional luteal
phase. Chapter 13 also reports the effect of hCG, during luteal 'rescue', on the
number of macrophages in the corpus luteum. The mechanism of the effect of
hCG on macrophage numbers is therefore investigated, by comparing the
localisation ofmacrophages with that of the LH/hCG receptor.
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Chapter 10
Expression of TIMP-1 in the human corpus luteum after
luteal 'rescue'
10.1 Abstract
TIMP-1 is a specific inhibitor of a group of proteolytic enzymes known as MMPs.
These enzymes have been widely implicated in the process of tissue remodelling.
Extensive remodelling occurs in the corpus luteum during luteolysis unless hCG is
produced by the early conceptus. This study aimed to investigate the expression
and localisation of TIMP-1 in human corpora lutea during the luteal phase of the
cycle and after luteal 'rescue' with exogenous hCG, to mimic the changes of early
pregnancy. Human corpora lutea from the early- (n=4), mid- (n=4) and late- (n=4)
luteal phases, and after luteal 'rescue' by hCG (n=4), were obtained at the time of
hysterectomy. Expression of TIMP-1 was investigated in these tissues by western
blotting, immunohistochemistry, northern blotting and in situ hybridisation. Luteal
cells of thecal origin were distinguished from those of granulosal origin by
immunostaining for 17a-hydroxylase. A 30 kilodalton protein consistent with
TIMP-1 was detected in human corpora lutea. This protein was localised to the
granulosa-lutein cells in all tissues examined. TIMP-1 mRNA was found in large
quantities in all glands examined and this again localised to the granulosa-lutein
cells. The expression and localisation of TIMP-1 did not change throughout the
luteal phase and was not altered by luteal 'rescue'. The function of this uniform
expression of TIMP-1 in the corpus luteum is not clear but these data suggest that
the inhibition of structural luteolysis during maternal recognition of pregnancy is
not mediated by regulation of TIMP-1 expression.
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10.2 Introduction
The human corpus luteum will undergo functional and structural luteolysis unless
hCG is produced by the implanting blastocyst (Behrman el ah, 1993). Although
this process is fundamental to ovarian function, the molecular mechanisms of
luteolysis and luteal 'rescue' in the human are still uncertain. During structural
luteolysis the gland rapidly changes from the most active endocrine gland in the
body, with a greater blood flow per unit mass than the kidney (Ford et al., 1982),
to a small fibrous remnant.
Such a process is likely to involve extensive remodelling of the ECM that is
controlled by MMPs, a group of zinc-dependant proteolytic enzymes. Alterations
in MMP activity have been implicated in the spread of neoplastic tissues (Naylor
et al., 1994) as well as in remodelling of reproductive tissues such as the
endometrium at menstruation (Hampton and Salamonsen, 1994) and the follicle
wall at ovulation (Reich et al., 1985). The activity of MMPs is rigorously
controlled at several levels, including synthesis as a pro-enzyme, requiring
activation, and the production of specific inhibitors: TIMP-1, TIMP-2 and TIMP-
3. TIMP-1 is of particular interest as it has recently been demonstrated that it is
the major secretory product of the ovine corpus luteum (Smith et al., 1993) and
that its expression is transiently increased during PGF2a induced luteolysis
(Juengel et al., 1994). Other studies have reported that TIMP-1 expression
increases markedly in preovulatory granulosa cells around the time of the
gonadotrophin surge (Smith GW et al., 1994).
This study aimed to investigate the role of TIMP-1 in the human corpus luteum by
studying the expression in the corpus luteum through both the normal luteal phase
and during early pregnancy simulated by the administration of hCG in
logarithmically increasing doses.
10.3 Specific Materials and Methods
10.3.1 Tissues Studied
Corpora lutea were enucleated at the time of hysterectomy in 16 women
undergoing surgery for benign conditions (2.2.3). Four corpora lutea were
classified as early-luteal, four as mid-luteal and four as late-luteal (2.2.4). Four
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corpora lutea were obtained after exogenous hCG administration to 'rescue' the
corpus luteum (2.2.2). Two pieces of each corpus luteum were stored at -70 °C for
subsequent RNA and protein extraction (2.2.3). One piece was fixed in 4%
paraformaldehyde and embedded in paraffin wax (2.2.3) for subsequent
immunohistochemistry (3.2) and another piece was frozen in embedding medium
for the preparation of frozen sections (2.2.3), In each case an endometrial biopsy
was also fixed in paraformaldehyde (2.2.3) and plasma was taken before surgery
for estimation of progesterone concentration (2.2.2).
10.3.2 Immunohistochemistry
Paraffin wax sections (5 qm) on poly-L-lysine-coated slides (3.2.1) were de-waxed
and rehydrated (3.2.2). As preliminary experiments indicated that microwave
antigen retrieval was necessary for the detection of TIMP-1, all sections were
therefore microwaved (3.2.4). Non-specific binding was blocked by NRS
containing 5% (w/v) BSA (3.2.6). Sections were incubated overnight at 4 °C with
a 1:20 dilution of monoclonal mouse anti-TIMP-1 antibody (3.1.2) in TBS (3.2.6).
This antibody has less than 0.01% cross-reactivity with TIMP-2 protein. Antibody
binding was indicated using AB-AP (3.2.7) with substrate to give a red end
product (3.2.7). As negative controls, serial sections were incubated with mouse
IgG in place of the primary antibody at the same concentration (5 qg/ml) (3.2.9)
and in further control sections the primary antibody was omitted (3.2.9). The
intensity of staining was graded by an observer blinded to the tissue identity.
Staining was classified as, - if absent, + if weakly present, ++ if moderate and +++
if strong.
Serial sections were also stained for 17a-hydroxylase using a polyclonal rabbit
antibody (3.1.2) at 1:750 dilution in TBS. In this case, after microwave antigen
retrieval (3.2.4), NGS was used to block non-specific binding and specific binding
was detected using biotinylated goat anti-rabbit immunoglobulins (3.2.6).
10.3.3 Western Blotting
Two hundred micrograms of protein (3.3.1) was denatured, separated by
electrophoresis on an 11% polyacrylamide gel (3.3.1) and electrophoretically
transferred onto nitrocellulose membrane (3.3.1). Primary antibody (3.1.2) was
used in a concentration of 2 pg/ml in TBST (3.3.2). Specific antibody binding was
visualised with biotinylated goat anti-rabbit immunoglobulins and AB-AP using a
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red chromogen (3.3.2). Molecular weight markers were run in an adjacent lane to
calculate the weight of the detected proteins. Ovine luteal cell conditioned
medium was used as a positive control for TIMP-1 (3.1.1). The intensity of each
band was determined by computer aided densitometric image analysis (NIH Image
1.55) after image capture.
10.3.4 Northern Blotting
Thirty micrograms of total RNA was denatured, electrophoresed in a 1.5%
formaldehyde-agarose gel, transferred to a nylon membrane and fixed by u.v.
cross-linkage (3.6.1). Membranes were pre-hybridised for 5 hours in hybridisation
buffer (3.6.2), The human TIMP-1 cDNA probe (3.1.3) was labelled with 50 pCi
32P dCTP by the random priming method (3.5.5). Hybridisation was performed at
65 °C for 20 hours (3.6.2). The membranes were washed (3.6.3), laid down to a
phosphor screen for 24 hours and developed and quantified using a
phosphorimager computer (3.6.3). To correct for minor differences in RNA
loading the blots were stripped (3.6.4) and reprobed in the same manner with a
cDNA probe to human (3-actin (3.1.3). We found no differences in the level of (3-
actin expression during the different stages of the luteal phase. The molecular size
of the transcripts was determined by running RNA markers in an adjacent lane
(3.6.1). The ratio of relative intensities for TIMP-1 to P-actin, after normalisation
by logarithmic transformation, was used for data analysis.
10.3.5 In situ Hybridisation
In situ hybridisation was performed on frozen sections using an antisense TIMP-1
35S-labelled riboprobe (3.7). The antisense probe was generated from the vector
(3.1.3) linearised by BamHl (3.5.3) using T7 RNA polymerase (3.7.2). The sense
probe, which was used as the negative control, was generated from the vector
(3.7.1) linearised by EcoRl (3.5.3) using SP6 RNA polymerase (3.7.2). Frozen
sections (6 pm) on poly-L-lysine-coated slides (3.2.1) were initially prepared as
described previously (3.7.3). After acetylation the sections were treated using a
different in situ hybridisation protocol than that described. In this case, the
sections were washed in 2x SSC before dehydration and delipation through graded
alcohols and chloroform.
The slides were air dried and incubated with pre-hybridisation buffer [50%
formamide, 10 mM DTT, lx Denhardt's solution, 4x STE (lx STE is 0.1 M NaCl,
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10 mM Tris HC1 pH 8, 1 mM EDTA), 125 pg/ml yeast tRNA, 125 pg/ml salmon
sperm DNA] for one hour at 45 °C. Excess pre-hybridisation buffer was removed
and slides were incubated with 1 x 106 c.p.m. of radio-labelled probe in 40 pi of
hybridisation buffer [pre-hybridisation buffer containing 10% (v/v) dextran
sulphate], sealed under hydrophobic film (3.7.4) and incubated overnight at 45 °C
in a moist chamber. Sections were washed in 2x SSC/ 2 mM DTT prior to RNAse
A treatment (30 pg/ml in RNAse buffer [10 mM Tris, 1 mM EDTA, 0.5M NaCl,
pH 8]) for 30 min at 37 °C. The sections were sequentially washed in RNAse
buffer/ 1 mM DTT and 2x SSC/ 1 mM DTT at room temperature before washing
in O.lx SSC/ 1 mM DTT at 45 °C in a shaking water bath. Sections were rinsed in
O.lx SSC then dehydrated through graded alcohols containing 0.3 M ammonium
acetate and air-dried.
The sections were then dipped in photographic emulsion (3.7.6) and incubated in
light-tight boxes at 4 °C for 21 days (3.7.6). The slides were then developed,
fixed, counterstained with haematoxylin and mounted (3.2.8). The distribution of
grains was analysed by dark field microscopy, after image capture, using a
computer based image analysis system (Cue-2). The cellular composition of each
field was identified by light field microscopy.
10.4 Results
10.4.1 Plasma Progesterone Concentrations
Classification of the corpora lutea by serial urinary LH measurement agreed with
luteal phase dating of endometrial biopsies using the method of Li et al. (1988) in
all cases. Plasma progesterone concentrations were 36.36 ±9.28 nmol/1 for the
early luteal tissue, 40.35 ±9.88 nmol/1 for the mid luteal samples and 18.80 ±12.81
nmol/1 for the late luteal samples. After luteal 'rescue' by exogenous hCG the
plasma progesterone concentrations had increased to 52.75 ±1.09 nmol/1.
10.4.2 Immunohistochemistry
Immunostaining for TIMP-1 was present in corpora lutea of all stages of the luteal
cycle and after luteal 'rescue'. As can be seen in Fig. 10.1a, staining was localised
to the steroidogenic cells of the gland and absent from the negative controls (Fig.
10.1/>). There were no differences in the localisation of immunostaining for TIMP-
V
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Figure 10.1
TIMP-1 immunostaining in human corpora lutea
Immunostaining of human corpora lutea: a) TIMP-1 protein in the early corpus
luteum (red), staining is present in the steroidogenic cells (G) and absent from the
surrounding stroma (S) (Scale bar =100 pm); b) negative control serial section of
(a) showing no staining of the steroidogenic cells (G) and the stroma (S) (Scale
bar =100 pm); c) Immunostaining for 17a-hydroxylase enzyme in a late-luteal
corpus luteum (red). The theca-lutein cells are seen in discrete clumps (T) at the
periphery of the granulosa-lutein cells (G); (Scale bar = 50 pm); d) Serial section
of (c) stained for TIMP-1. The theca-lutein cells (T) are relatively free from
staining and the granulosa-lutein cells (G) show specific TIMP-1 immunostaining
(red); (Scale bar = 50 pm).
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1 during the luteal cycle or after luteal 'rescue'. In particular, the regressing corpus
luteum of the late-luteal phase showed no local areas of altered TIMP-1
immunostaining within the tissue section. The intensity of staining in all sections
was classified as ++ or +++ with no obvious pattern of variation throughout the
luteal cycle or after luteal 'rescue'. The steroidogenic cells derived from the theca
were identified by immunostaining serial sections for the enzyme 17a-
hydroxylase. Fig. 10.1c shows the theca-lutein cells to be present in discrete
clumps along the periphery of the granulosa-lutein cells. This pattern of staining is
similar to that reported by Tamura et al. (1992). The theca cells were relatively
free from immunostaining for TIMP-1 as can be seen in Fig. 10.Id.
10.4.3 Western blotting
Western blotting showed a single band at 30 kilodaltons (kDa) as shown in Fig.
10.2. This is consistent with the molecular weight of TIMP-1 which has
previously been reported (Smith GW et al., 1994), and the same band could be
detected in ovine luteal cell conditioned medium known to contain TIMP-1. This
protein was detected in protein samples from human luteal tissue from all stages
of the cycle. The intensity of the detected protein band in luteal cell extracts was
similar at all stages of the luteal cycle and after luteal 'rescue'. The width of the
detected band suggested there may be a heterologous population of TIMP-1
proteins, with different glycosylation patterns. We however found no consistent
differences in protein band width during the different stages of the luteal phase.
10.4.4 Northern Blotting
A single band approximately 0.9 kb in length was detected in total RNA extracted
from human corpora lutea by northern blotting. This size is consistent with TIMP-
1 message reported in humans (Rapp et al., 1990) and sheep (Smith GW et al.,
1994). As shown in Fig. 10.3, TIMP-1 mRNA was abundant and could be found
at all stages of the luteal cycle and after luteal 'rescue'. Densitometric
quantification of the intensity of the message standardised for tissue P-actin
expression demonstrated no differences of level of TIMP-1 message during the
luteal cycle and after luteal 'rescue' (Fig. 10.4).
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Western blot for TIMP-1 in human corpora lutea
Western blot for TIMP-1 protein in luteal tissue homogenates from different
stages of the luteal phase and after luteal 'rescue' by exogenous hCG. Ovine luteal
cell conditioned medium known to contain large quantities of TIMP-1 was used as
a positive control. The migration of molecular weight markers is indicated at the
right of the figure.















Stage of luteal phase
Figure 10.3
Northern blot of TIMP-1 mRNA in human corpora lutea
Northern blot of TIMP-1 mRNA using total RNA extracted from corpora lutea at
different stages of the luteal phase and after luteal 'rescue' by exogenous hCG. The
positions of the ribosomal 28S and 18S bands are indicated. The control bands
detected after stripping the blot and re-probing for P-Actin are indicated below the
TIMP-1 blot.
Chapter 10 TIMP-1 in human corpus luteum 168
10-
Early Mid Late Resc
Stage of luteal phase
Figure 10.4
Expression of TIMP-1 mRNA in human corpora lutea
TIMP-1 mRNA in corpora lutea from different stages of the luteal phase and after
luteal 'rescue' by exogenous hCG. Message for TIMP-1 detected by northern
blotting was quantified by computer-aided densitometry corrected for minor
loading variations by comparison of p-actin levels.
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10.4.5 In situ Hybridisation
As shown in Fig. 10.5a, message for TIMP-1 was uniformly distributed
throughout the granulosa-lutein cells of the corpus luteum. This distribution was
only seen in the sections incubated with the antisense probe and was absent from
control sections incubated with the sense probe (Fig. 10.56). The localisation of
TIMP-1 mRNA in luteal cells is consistent with the localisation of TIMP-1
protein (Fig. 10.1a). Luteal cells of thecal origin had much lower grain
concentrations than those granulosal cell origin (Fig. 10.5c,d). The localisation of
TIMP-1 mRNA did not change throughout the luteal cycle or after luteal 'rescue'.
10.5 Discussion
This study is the first to demonstrate the expression and localisation of TIMP-1 in
the human corpus luteum. TIMP-1 mRNA has previously been demonstrated in
the corpus luteum of a number of other species including the sheep (Smith GW et
al., 1994), the cow (Juengel et al., 1994) and the pig (Smith MF et al., 1994).
Indeed it has previously been shown that TIMP-1 is one of the major products of
the ovine corpus luteum, and our data suggest that TIMP-1 is similarly abundant
in the luteal cells of the human ovary. The immunohistochemistry and
immunoblotting demonstrate specific binding to a protein of the appropriate
molecular weight while the Northern analysis and in situ hybridisation
experiments confirmed the source of specific mRNA expression.
The TIMP-1 protein and mRNA were found to be present specifically in the
granulosa-lutein cell-types of the corpus luteum. Human pre-ovulatory granulosa
cells have previously been shown to produce metalloproteinase inhibitor activity
in vitro (Morgan et al., 1994) and contain abundant TIMP-1 mRNA (Rapp et al.,
1990). TIMP-1 is expressed in the granulosa cells of the pre-ovulatory follicle in
the sheep at a 15 fold higher level than in the theca cells of the same follicle
(Smith GW et al., 1994). We identified the steroidogenic cells of thecal origin in
the corpus luteum by immunostaining with an antibody to 17a-hydroxylase. This
enzyme is not present in the granulosa-lutein cells and has been used to identify
cells of thecal origin in human corpora lutea (Tamura et al., 1992; Rodger et al.,
1995). We found that there was little if any immunostaining, or in situ
hybridisation for TIMP-1 in the theca-lutein cells of the human corpus luteum. As
the localisation of TIMP-1 appeared to be confined to the large steroidogenic cells
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Figure 10.5
In situ hybridisation of TIMP-1 mRNA in human corpora lutea
In situ hybridisation of human corpora lutea for TIMP-1 mRNA: a) dark-field of
TIMP-1 mRNA in the early corpus luteum. Grains are found in the steroidogenic
cells (G) at much higher levels than the surrounding stroma (S); (Scale bar = 100
pm); b) dark-field negative control serial section of (a) using sense TIMP-1. There
are no differences in grain localisation in the steroidogenic cells (G) and the
stroma (S); (Scale bar = 100pm); c) dark-field of luteal TIMP-1 mRNA showing
uneven distribution of grains within the steroidogenic cell layer (Scale bar = 50
pm); d) light-field of (c) showing the granulosa-lutein cells (G) and the theca¬
lutein cells (T). Grains are present at much higher levels in the granulosa-lutein
cells (G) than the theca-lutein cells (T); (Scale bar = 50 pm).
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of the corpus luteum it is unlikely that non-steroidogenic cells present in the
corpus luteum such as macrophages, T-lymphocytes (Brannstrom et al., 1994a)
and endothelial cells (Rodger et al., 1997) contribute to TIMP-1 production, but
this remains to be established.
No change was found in either the site or intensity of expression of TIMP-1
during the luteal phase or following luteal 'rescue' with hCG. This was surprising
as luteal expression of TIMP-1 has previously been shown to rise for up to eight
hours during PGF2a induced luteolysis in the cow (Juengel et al., 1994). The same
group localised TIMP-1 mRNA by in situ hybridisation during luteolysis and
found that scattered individual cells within the steroidogenic tissue expressed
much higher levels than the surrounding cells (Smith GW et al., 1994). This
pattern of expression was unlike the uniform grain distribution seen within ovine
follicular granulosa cells (Smith GW et al., 1994). In the human corpus luteum we
found that expression of TIMP-1 is uniform in the granulosa-lutein cell population
and this distribution is maintained throughout the luteal cycle. The different
patterns of expression are probably due to a more gradual luteolytic process in
women. Although we studied four corpora lutea from the late-luteal phase, all the
corpora lutea studied were still functional, in that progesterone secretion was
continuing. Unlike the ruminant, luteolysis in women does not result from a surge
of uterine prostaglandin and is therefore likely to be a more gradual process
(Auletta and Flint, 1988). In contrast in cattle, prostaglandin treatment produces
co-ordinated luteolysis which allows changes induced in a proportion of cells,
such as apoptosis, to be detected more easily (Juengel et al., 1993). The more
gradual fall in luteal function in women may mask the increased TIMP-1
expression seen within individual cells during luteolysis in the ovine gland.
Luteal involution is inhibited during maternal recognition of pregnancy by hCG
acting through the LH receptor (Behrman et al., 1993). Expression of TIMP-1 in
preovulatory granulosa cells increases during luteal formation at the time of the
gonadotrophin surge (Smith GW et al., 1994). At this stage the granulosa cells
contain LH receptors (Richards and Midgley, 1976), and it is possible that the
increase in TIMP-1 is partially mediated through stimulation of this receptor. In
the rat, LH stimulates a TIMP-like protein in granulosa cell culture media and
TIMP-1 mRNA is increased by LH (Mann et al., 1991; Morgan et al., 1994).
However, it does not appear that further stimulation of the corpus luteum by hCG,
as occurs in normal pregnancy, provokes any further increase in TIMP-1
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synthesis. This may be a species-related difference as Morgan et al. (1994) were
unable to show any increase in TIMP-1 in response to LH in cultured human
granulosa cells. TIMP-1 expression in women may be controlled by other
hormones such as progesterone. Progesterone receptors have been identified in the
human corpus luteum (Suzuki et al., 1994) and the progesterone antagonist
RU486 can reduce TIMP activity in granulosa cell cultures (Morgan et al., 1994).
The significance of the TIMP-1 produced by the human corpus luteum remains
unclear but its production in large quantities throughout the luteal cycle suggests
an important role. In view of this, Juengel et al., (1994) have suggested that
TIMP-1 expression reflects the production of endogenous MMPs and acts as a
protective mechanism to limit specific protease action. However, as described in
this paper, TIMP-1 mRNA is abundant in the corpus luteum. It is one of the most
abundant mRNAs in luteinised granulosa cells (Rapp et al., 1990) and TIMP-1 is
the major protein product of the ovine corpus luteum (Smith et al., 1993). In
contrast, recent results suggest that the mRNAs for MMPs are present in far lower
concentrations than that of TIMP-1 (Nothnick et al., 1995; Nothnick et al., 1996).
As TIMP-1 binds to and inactivates MMPs in a 1:1 ratio (Matrisian, 1990) it is
probable that in the corpus luteum, MMPs are functioning in an environment
containing a high level of specific inhibitor. For MMPs to function in this
environment it is likely that the interaction between MMPs and TIMPs is at a local
cellular rather than a tissue-wide level. It may be that local tissue remodelling is
regulated by the expression of proMMPs and their subsequent activation to active
MMPs, rather than control of inhibition. It is consequently difficult to assess the
function of TIMP-1 in isolation, when the activity and production of MMPs and
other inhibitors such as TIMP-2 remain unclear during the luteal cycle,
particularly as it has recently been reported that TIMP-2 is also produced by the
ovine corpus luteum (Smith et al., 1995a).
TIMP-1 has other properties which may contribute to a critical role in
maintenance of the corpus luteum as well as the inhibition of metalloproteinase
activity. TIMP-1 promotes the proliferation of fibroblasts and endothelial cells and
may be a paracrine or autocrine growth factor (Hayakawa et al., 1992). This may
be important to facilitate the high levels of angiogenesis during corpus luteum
formation (Reynolds et al., 1992). It is also possible that TIMP-1 has a role in cell
migration (Smith GW et al., 1994) or protection against neoplastic stimuli during
periods of tissue growth and neovascularisation. A recent publication has raised
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the possibility that TIMP-1 particularly in combination with procathepsin-L may
be involved in regulating steroidogenesis (Boujrad et al., 1995). Boujrad et al.,
(1995) found that a locally produced FSH-responsive factor which stimulates both
Leydig and granulosal cell steroidogenesis is the TIMP-1-procathepsin-L
complex. Both TIMP-1 and this complex were found to stimulate steroidogenesis
in a cAMP-independent manner with a bioactivity similar to saturating amounts of
hCG. Although the effect of TIMP-1 and the procathepsin-L complex on luteal
steroidogenesis are not yet known, it is notable that the corpus luteum has a very
high level of synthesis of both TIMP-1 and steroids.
In summary, TIMP-1 is an abundant secretory product of the human corpus
luteum during both the normal menstrual cycle and in simulated early pregnancy.
The physiological role of the TIMP-1 is unclear but may involve the facilitation of




Expression of TIMP-1 in the primate ovary during
induced luteal regression
11.1 Abstract
Although TIMP-1 is one of the major secretory products of the corpus luteum, the
functional significance of this is not clear. In addition to its role as a specific
inhibitor of the MMPs involved in tissue remodelling, it has recently been
suggested that TIMP-1 is also a potent stimulator of steroidogenesis in vitro.
However, in the ruminant, TIMP-1 expression increases during luteal regression.
This study sought to determine (i) the effect of induced luteal regression on
ovarian TIMP-1 expression in the primate and (ii) the expression of TIMP-1 in
other steroidogenic and non-steroidogenic tissues. Marmoset ovaries were studied
on day 10 of the normal luteal phase, and 12 and 24 hours after induced luteolysis,
with either GnRHant or PGF2a analogue. Ovaries from different stages of the
normal ovarian cycle were also studied. Expression of TIMP-1 was investigated
by isotopic in situ hybridisation. TIMP-1 expression was also examined in a wide
range of other marmoset tissues by northern blotting and in situ hybridisation.
TIMP-1 was found to be highly expressed in the marmoset corpus luteum.
Induced luteolysis, with either PGF2a or GnRHant, was associated with a
significant fall in TIMP-1 expression in luteal tissue. TIMP-1 mRNA was also
localised to ovarian follicles throughout the ovarian cycle. Expression occurred in
the thecal layer of smaller follicles (<1.5 mm) and the granulosal layer of larger
preovulatory follicles. In atretic follicles, TIMP-1 was highly expressed at the
interface between the thecal and granulosal cells. TIMP-1 was found to be
predominantly expressed in steroidogenic tissues, particularly the ovary, adrenal
and placenta. These data support a role for changes in TIMP-1 expression in
tissue remodelling in the ovary and are consistent with an additional function of
TIMP-1 as a facilitator of steroidogenesis.
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11.2 Introduction
Unless chorionic gonadotrophin is produced by the implanting blastocyst, the
primate corpus luteum will stop secreting progesterone and become a small
fibrous remnant. The mechanisms of functional and structural luteolysis in the
primate are still poorly understood (Behrman et al., 1993). The highly vascular
corpus luteum is formed from the dominant follicle and in turn becomes the
avascular corpus albicans in a matter of weeks. This process involves extensive
tissue remodelling (Luck and Zhao, 1995). The MMPs are a group of zinc-
dependent proteolytic enzymes which have been implicated in remodelling of the
ECM (Birkedal-Hansen, 1995). The activity of these enzymes is controlled at
several levels, including their synthesis as pro-enzymes, enzyme activation, and
the production of specific inhibitors (Matrisian, 1990). The corpus luteum is
known to produce specific TIMPs (Smith et al., 1993; Smith et al., 1995a). One
of these, TIMP-1, is of particular interest as it is one of the major products of the
corpus luteum of many species, including the sheep (Smith et al., 1993), cow
(Jeungel et al., 1994), pig (Smith MF et al., 1994) and, as shown in Chapter 10,
the human (Duncan et al., 1996c).
The role of TIMP-1 in the corpus luteum has yet to be elucidated. Jeungel et al.
(1994) found that the expression of TIMP-1 increased after PGF2oc-induced
luteolysis in the cow, and postulated that it may have an important role in tissue
remodelling during luteolysis. However, it is not known whether TIMP-1
expression is increased during luteolysis in the primate. We did not observe any
change in TIMP-1 expression over the functional lifespan of the human corpus
luteum (Duncan et al., 1996c), implying that TIMP-1 may have other functions in
the primate corpus luteum. Boujrad et al. (1995) found that a locally produced
FSH-responsive factor, which stimulated both Leydig and granulosal cell
steroidogenesis, was the TIMP-1-procathepsin-L complex. Both TIMP-1 and this
complex were found to stimulate steroidogenesis in a cAMP-independent manner
with a bioactivity similar to saturating amounts of hCG. It is therefore possible
that one role of TIMP-1 is to facilitate steroidogenesis.
This study aimed to investigate the expression of TIMP-1 during luteolysis in the
primate corpus luteum. The marmoset monkey was used as a model, as luteolysis
can be induced by both PGF2a and LH withdrawal (Fraser et al., 1995b). As
whole primate ovaries were studied, we were also able to describe the localisation
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of TIMP-1 mRNA in ovarian follicles. In order to investigate the possibility of a
general role for TIMP-1 in steroidogenesis, TIMP-1 expression was studied in a
wide range of endocrine and non-endocrine tissues.
11.3 Specific Materials and Methods
11.3.1 Tissues Studied
Captive-bred common marmoset monkeys were studied (2.3.1). To confirm
normal ovulatory cycles, plasma samples were assayed for progesterone to
determine the date of ovulation and the luteal phase duration (2.3.1). Ovaries were
collected on day 10 of the luteal phase (2.3.3). Ovaries were collected from
untreated control animals (n=4) and animals treated with either PGF2ct analogue
(2.3.2), 12 hours (n=3) or 24 hours (n=3) previously or GnRHant (2.3.2), 12 hours
(n=3) or 24 hours (n=3) previously. Whole ovaries were fixed in 4%
paraformaldehyde and embedded in paraffin wax (2.3.3), In addition, some
marmoset ovaries were available which had been frozen in embedding medium
after removal (2.3.3). These included follicular phase ovaries (n=4), luteal phase
ovaries (n=3), and other ovaries where luteolysis had been induced as described
above (n=8).
A bank of normal marmoset tissues, collected from this and other experiments,
was also utilised (2.3.3). These tissues were removed immediately post-mortem.
A piece of each tissue was snap frozen in liquid nitrogen and stored at -70 °C for
subsequent RNA extraction. Another piece was frozen in embedding medium, and
stored at -70 °C until frozen sections were prepared (2.3.3).
11.3.2 In situ Hybridisation
Isotopic in situ hybridisation was performed on both fixed and frozen sections
using 35S-labelled riboprobes (3.7). Antisense and sense riboprobes, incorporating
35S-labelled UTP, were generated (3.7.2) from the full-length human TIMP-1
cDNA construct (3.1.3). The antisense probe was generated from the plasmid
vector (3.7.1) linearised by Kpnl (3.5.3) using T7 RNA polymerase (3.7.2). The
sense probe was used as the negative control. This was generated from the
plasmid vector (3.1.3) linearised by Hindlll (3.5.3) using SP6 RNA polymerase
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(3.7.2), Sections ofmid-luteal human corpus luteum (2.2) were used as a positive
control in each experiment.
Fixed sections (5 prn) on poly-L-lysine-coated slides (3.2.1) were prepared (3.7.3)
and incubated with proteinase K (3.7.3). Frozen sections were quickly thawed and
fixed in 4% paraformaldehyde (3.7.3), All slides were then washed, acetylated,
dehydrated and dried under vacuum (3.7.3). One hundred microlitres of
hybridisation buffer (3.7.4) containing 1 x 106 c.p.m. radiolabeled probe was
added to each section. The slides were covered with a hydrophobic coverslip and
hybridised overnight at 55 °C in a moist chamber (3.7.4).
The coverslips were washed off (3.7.5) and the slides were treated with RNAse A
(3.7.5). After increasingly stringent washes (3.7.5), the slides were washed for 30
minutes in 0.1 x SSC at 70 °C (3.7.5). They were then dehydrated through graded
alcohols and allowed to dry (3.7.5), The slides were then dipped in photographic
emulsion (3.7.6) and stored at 4 °C for 18 days in the dark. After developing and
fixing (3.7.6), the slides were washed, counterstained in haematoxylin and
mounted (3.2.8).
11.3.3 Northern Blotting
Twenty micrograms of total RNA (3.6.1) was denatured, electrophoresed in a
1.5% formaldehyde-agarose gel, transferred to a nylon membrane (3.6.1) and
fixed to the membrane by u.v. cross-linkage (3.6.1). After pre-hybridisation for
two hours (3.6.2), the membranes were hybridised for 20 hours at 65 °C (3.6.2)
with a full-length human TIMP-1 cDNA probe (3.1.3) labelled with 50 pCi 32P
dCTP (3.5.5). After washing (3.6.3) the blots were laid down to a phosphor screen
for 48 hours and visualised using a phosphorimager computer (3.6.3). To confirm
accurate loading of RNA, the blots were stripped (3.6.4) and reprobed with a 32P
end-labelled oligonucleotide (3.1.3) which hybridises to 18S RNA (3.6.4),
11.3.4 Analysis of Results
Sections were viewed by dark-field microscopy and analysed after image capture
by computer-aided image analysis (NIH Image 1.55). To investigate the grain
distribution over the corpus luteum, only fixed sections, which had undergone in
situ hybridisation in carefully controlled conditions in the same run, were
analysed. The corpora lutea in each section were identified and the grain density
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in five fields were analysed by the same observer, blinded to the tissue identity,
using a technique of stratified random sampling, and monitoring the running
mean. Any acellular areas, or areas of the section without the corpus luteum were
ignored. This was repeated at a later date by the same observer to confirm the
reproducibility of the results. As TIMP-1 is highly expressed in the corpus luteum,
the area proportion of grains was measured, after binary conversion, rather than
the absolute grain count. Differences in the area proportion of grains between
different groups were investigated by one way ANOVA. Where an overall
statistically significant difference, at the 5% level, was detected, pairwise
comparisons between groups were performed using Bonferroni/Dunn multiple
range tests.
As TIMP-1 was also localised to the follicle, the expression of TIMP-1 was
analysed in each follicle. All of the different ovarian sections, fixed and frozen,
were analysed after in situ hybridisation. In order to obtain an idea of the
localisation of TIMP-1 as the follicle developed, a technique was devised to
classify individual follicles in accordance with their size. Each follicle was
measured in light-field using an eyepiece graticule calibrated with a standard
micrometer slide. The maximal dimension of the follicle from the outside edge of
the thecal layer was calculated. As grains were only seen in follicles >200 pm,
only these follicles were counted. These were classified as i) pre-antral, if there
was no antrum visible in the plane of section, ii) antral, if an antrum was visible
and the follicle measured <600 pm, iii) small, if the follicle measured <1 mm, iv)
medium, if the follicle measured <1.5 mm and v) large, if the follicle measured
1.5 mm or greater. The appearance of each follicle was then classified by
morphology as normal or atretic (Grimes et al., 1987). The grain distribution over
the thecal and granulosal layer of each follicle was observed in dark-field of the
same slides and recorded as absent or present.
11.4 Results
11.4.1 Plasma Progesterone Concentrations
Progesterone concentrations in the control animals were 330 ±69 nmol/1 (mean
±S.E.M.). Functional luteal regression was observed in all animals treated with
either the GnRHant or the PGF2a analogue, as described previously (Fraser et al.,
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1995b). PGF2a treatment resulted in a decline in progesterone concentrations to
20 ±5 nmol/1 after 12 hours and 22 ±6 nmol/1 after 24 hours, and treatment with
GnRHant resulted in progesterone concentrations of 13 nmol/1 after 12 hours and
23 ±11 nmol/1 after 24 hours. All progesterone concentrations after induced
luteolysis were within the normal range of follicular phase levels in the marmoset
(Smith et al., 1990).
11.4.2 TIMP-1 in the Corpus Luteum
TIMP-1 mRNA was expressed in the granulosa-lutein cells of the human corpus
luteum (Fig. 11.1a). The human corpus luteum had been included as a positive
control as it expresses large amounts of TIMP-1 (Duncan et al. 1996c). This grain
distribution was absent from all negative control sections, which had been
incubated with the sense probe (Fig. 11.16).
TIMP-1 message was localised to the corpus luteum in luteal-phase marmoset
ovaries (Fig. 11.1 c,d). TIMP-1 mRNA could also be localised to the cells of the
corpora lutea, 12 and 24 hours after induced luteolysis (Fig. 11.1 ef). However,
the silver grains over the corpus luteum were lower in number and more patchily
distributed after induced luteolysis (Fig. 11.1ef). The area proportion of grains
decreased significantly after both PGF2a (p<0.05) and GnRHant (p<0.05)
treatments (Fig. 11.2). When specific time points were analysed, grain density was
significantly lower 24 hours after PGF2a treatment (p<0.05), and both 12 (p<0.05)
and 24 hours (p<0.01) after GnRHant treatment (Fig. 11.2). Treatment with
GnRHant or PGF2a analogue produced similar changes in the appearance of the
corpora lutea and the localisation of TIMP-1 mRNA.
11.4.3 TIMP-1 in the Follicle
TIMP-1 mRNA was also identified in ovarian follicles (Fig. 11.3a,b). TIMP-1
expression was absent from the oocyte, the primordial follicle and the small pre-
antral follicle <200 pm in diameter. Follicles 200 pm or greater in diameter
expressed TIMP-1 in the thecal cell layer (Fig. 11.3a,b,c,d). In the healthy
follicles, TIMP-1 was absent from the granulosal cell layer at this stage. In larger
pre-ovulatory follicles (>1.5 mm) TIMP-1 was noted to be absent from the thecal
layer and present in large amounts in the granulosal cell layer (Fig. 11.3ef). When
the follicle was atretic, a specific localisation of TIMP-1 was noted. TIMP-1
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Figure 11.1
TIMP-1 mRNA in the marmoset corpus luteum
In situ hybridisation for TIMP-1 mRNA in the primate corpus luteum: a) dark-
field of TIMP-1 mRNA in the mid-luteal human corpus luteum. Many more
grains are seen over the granulosa-lutein cells (G) than the theca-lutein cells (T);
b) dark-field negative control serial section of (a) showing very few grains with
no difference between the granulosa-lutein cells (G) and the theca-lutein cells (T);
c) light-field of a mid-luteal marmoset ovary showing the position of the corpus
luteum (CL); d) dark-field of section (c) showing TIMP-1 grains localised to the
corpus luteum (CL); e) dark-field of TIMP-1 mRNA in the corpus luteum (CL) of
a marmoset ovary 12 hours after treatment with GnRHant; f) dark-field of TIMP-1
mRNA in the marmoset corpus luteum (CL) 24 hours after GnRHant treatment.
(Scale Bar = 200 pm).
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Figure 11.2
Expression of TIMP-1 mRNA after induced luteolysis
TIMP-1 mRNA in the marmoset corpus luteum after induced luteolysis as
measured by grain density after in situ hybridisation. Luteolysis had been induced
by PGF2a analogue (PG) or GnRHant (GnRH), 12 or 24 hours previously. Values
are means ±S.E.M., significant differences from the control group are indicated
for each experimental group: *=p<0.05; **=p<0.01.
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Figure 11.3
TIMP-1 mRNA expression in follicles
In situ hybridisation for TIMP-1 mRNA in marmoset follicles: a) light-field of a
normal luteal phase marmoset ovary showing a small follicle, with its granulosal
(G) and thecal (T) layers next to a corpus luteum (CL); b) dark-field of section (a)
showing localisation of TIMP-1 mRNA by in situ hybridisation. Grains are seen
over the thecal cells (T) and corpus luteum (CL) but are absent from the
granulosal cells (G); c) light-field of a follicular phase ovary showing a medium-
sized follicle with the thecal cells (T), granulosal cells (G) and oocyte (O) clearly
visible; d) dark-field of section (c) showing TIMP-1 localised, to the thecal cells
(T) but absent from the granulosal cells (G) and the oocyte (O); e) light-field of
large pre-ovulatory follicle taken from another follicular phase marmoset ovary
showing the thecal layer (T), the granulosal layer (G) and the cumulus granulosa
cells (C) surrounding the oocyte; f) dark-field of section (e) showing TIMP-1
mRNA grains over the granulosa (G) and cumulus cells (C) but absent from the
thecal cells (T); g) light-field of an atretic follicle in an ovary collected 12 hours
after treatment with PGF2a analogue, showing the thecal (T) and granulosal (G)
layers; h) dark-field of section (g) showing some TIMP-1 expression in the thecal
cells (T), patchy expression in the granulosal cells (G) and marked expression at
the thecal-granulosal interface. (Scale bar = 200 pm).
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mRNA was found to be localised to theca cells and individual granulosa cells, and
was intensely expressed at the thecal-granulosal interface (Fig. l\3g,h). The
changing pattern of TIMP-1 localisation noted in the follicle was remarkably
consistent in all the follicles analysed (Table 11.1). The pattern of TIMP-1
expression by the follicles of different sizes appeared to be independent of the
stage of the cycle at which the ovary was obtained and was thus identical in
ovaries obtained from the follicular phase, the luteal phase, or following induced
luteolysis.
11.4.4 TIMP-1 in Other Tissues
TIMP-1 was found to be expressed in a wide range of marmoset tissues (Fig.
11.4). A single band, approximately 0.9 kb in length, was detected in total RNA
extracted from marmoset tissues. This size is consistent with that reported for
human TIMP-1 mRNA (Rapp et al., 1990; Duncan et al., 1996c). The highest
levels of expression were seen in steroidogenic tissues, particularly the ovary,
adrenal and placenta. Other tissues had low levels ofTIMP-1 expression, although
specific expression was noted in the thyroid and prostate glands. However, when
the localisation of TIMP-1 message was investigated, in these tissues, by in situ
hybridisation, the grain density was found to be much less than that seen in the
ovary. It became apparent, using in situ hybridisation, that TIMP-1 was also
expressed in the testis, specifically in the Sertoli cells and interstitial cells (Fig.
11.5a,b). Specific hybridisation was seen over the steroidogenic cells of the
adrenal cortex (Fig. 11.5c), but not the adrenal medulla. Very few grains were
seen over the kidney (Fig. 11.5d,e), myometrium and endometrium of the uterus,
endocrine and exocrine cells of the pancreas, spleen, liver and thymus. Specific
areas of TIMP-1 expression were seen in the placenta (Fig. 11.5fg), in the
parafollicular cells of the thyroid (Fig. 11.5/2,/) and in the glandular cells of the
prostate.
11.5 Discussion
This is the first study to localise the expression of TIMP-1 mRNA in whole
primate ovaries. In common with previously studied species, such as the human
(Duncan et al., 1996c) and the ruminant (Smith GW et al., 1994), the marmoset
corpus luteum expresses large amounts of TIMP-1 message. As TIMP-1 protein
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Localisation of TIMP-1 message
None Thecal Granulosal Both Interface
Pre-Antral 4 19 0 0 1
Antral 0 47 1 2 1
Small 0 43 2 2 1
Medium 0 33 1 6 1
Large 0 0 9 2 0
Atretic 1 0 0 2 31
Table 11.1
Localisation of TIMP-1 mRNA in marmoset follicles
Localisation of TIMP-1 message in marmoset follicles after in situ hybridisation.
The grain distribution over the thecal and granulosal layers of each follicle >200
(am was recorded. The numbers are the number of follicles with grains over the
thecal layer only, the granulosal layer only, no specific grains, grains over both
layers and grains over both layers with particular localisation to the granulosal-
thecal interface. Follicles were classified as atretic or normal and normal follicles
were classified by size as pre-antral/antral (<600 pm), small (<1 mm), medium
(<1.5 mm) or large (>1.5 mm). The shaded box is the modal category for each
follicle class.





Expression of TIMP-1 in different marmoset tissues
Northern blot of TIMP-1 mRNA in different organs from the marmoset. The
positions of the ribosomal 28S and 18S bands are indicated. The 18S bands are
shown to demonstrate equal RNA loading between lanes. Ovary 1 was from the
luteal phase and ovary 2 was from the follicular phase of the ovarian cycle.
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Figure 11.5
Localisation of TIMP-1 mRNA in different marmoset tissues
In situ hybridisation for TIMP-1 mRNA in various primate organs: a) dark-field
of marmoset testis after in situ hybridisation for TIMP-1 with grains seen at the
outside of the tubules (T); b) light-field of (a) showing the tubules (T) and the
basal Sertoli cells; c) dark field of the marmoset adrenal gland after TIMP-1 in
situ hybridisation showing a general increased grain distribution over the cortex
(C); d) light-field of the marmoset kidney; e) dark-field of section (d) showing
few grains over the tissue; f) light-field of the placenta with cells at the periphery
of the trophoblast layer highlighted (arrows); g) dark-field of section (f) showing
TIMP-1 to be localised to specific areas of the section (arrows); h) light-field of
the marmoset thyroid gland with the some of the parafollicular cells highlighted
(arrows); i) dark-field of section (h) showing TIMP-1 to localise to these
parafollicular cells (arrows) by in situ hybridisation. (Scale bar =100 pm).
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synthesis has been demonstrated in these species (Smith et al., 1993; Jeungel et
al., 1994; Duncan et al., 1996c), it is likely that TIMP-1 is also a major secretory
product of the marmoset corpus luteum.
Induction of luteolysis resulted in a marked fall in the level of TIMP-1 expression
in the marmoset corpus luteum. The mechanism and control of this fall, and its
role in tissue remodelling is unclear. The fall in TIMP-1 expression may facilitate
increased metalloproteinase digestion of the luteal matrix during regression.
However, although rat and bovine corpora lutea express metalloproteinases (Endo
et al., 1993a; Tsang et al., 1995), and TIMP-2 is also expressed in ovine corpora
lutea (Smith et al., 1995a), detailed information about the expression of these
factors, their localisation, and relationship to TIMP-1 during induced luteolysis is
not yet available.
The timing of the fall in TIMP-1 expression in association with the drop in
progesterone concentration would also be consistent with a recently proposed
steroidogenic role for TIMP-1 (Boujrad et al., 1995). There is, however, no
indication from these data as to whether the observed changes in TIMP-1
expression are a cause or a consequence of the reduced steroid synthesis. A
further consideration is that significant changes in luteal morphology can be seen
by 24 hours after induced luteal regression in the marmoset (Fraser et al., 1995b).
The fall in TIMP-1 expression may therefore be related to the death of viable
luteal cells in the corpus luteum at this time (Fraser et al., 1995c; Young et al.,
1997).
These findings are contrary to previous observations of the effects of induced
luteolysis in the cow (Juengel et al., 1994). TIMP-1 expression in the bovine
corpus luteum was found to increase up to 24 hours post-PGF2a injection and
then return to pre-treatment levels within 48 hours. This occurs at a time when
increasing cell death is observed in the bovine corpus luteum (Jeungel et al.,
1993). We have examined TIMP-1 expression at 12 and 24 hours after induced
luteolysis, and found a marked and persistent fall in TIMP-1 expression.
However, the luteolytic processes of the primate and the ruminant are different in
both nature and time-span (Auletta and Flint, 1988) and this study provides
further evidence of these differences.
We have shown that TIMP-1 is also expressed by follicles in the primate ovary
and that the localisation changes relative to the apparent size of the follicle. These
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data are limited in that two-dimensional interpretation of three-dimensional pre¬
ovulatory follicles may lead to an underestimation of the size and nature of some
follicles. Volume changes may also result from processing and sectioning of the
tissue. In spite of these deficiencies, a consistent pattern was observed in the
follicular localisation of TIMP-1 mRNA relative to the size of the follicle.
TIMP-1 is first expressed in the thecal cell layer of preantral follicles which are
larger than 200 pm in diameter. This is the stage when the follicle becomes
gonadotrophin-dependent (Zeleznik and Fairchild Benyo, 1994), and LH receptors
can first be detected in the theca (Richards and Midgley, 1976). In the rat, LH
stimulates the secretion of a TIMP-like protein and increases TIMP-1 mRNA
(Mann et al., 1991; Morgan et al., 1994). It is therefore possible that TIMP-1
expression in the thecal cells is related to the action of LH. In the testis, TIMP-1
production by the Sertoli cells is induced by FSH (Ulisse et al., 1994, Boujrad et
al., 1995). Although the granulosa cells express FSH receptors at this stage, and
respond to FSH (Zeleznik and Fairchild Benyo, 1994), they do not express TIMP-
1 mRNA. It is therefore likely that the control of TIMP-1 expression by FSH is
different in the ovarian follicle and the testicular tubule.
In contrast, all the large pre-ovulatory follicles (>1.5 mm) expressed TIMP-1 in
the granulosa cells. Smith GW et al. (1994) showed that the ovulatory
gonadotrophin surge induced granulosa cell TIMP-1 expression in the sheep. Our
results are consistent with a similar preovulatory induction of TIMP-1 in the
granulosa cells of the primate ovary. As the granulosa cells express the LH
receptor at this stage (Richards and Midgley, 1976), the increased TIMP-1
expression may be directly induced by LH. It is not clear why the theca cells stop
expressing TIMP-1, but this pattern of TIMP-1 expression is seen in the
granulosa-derived and the theca-derived cells of the human corpus luteum
throughout its functional life-span (Duncan et al., 1996c).
The expression of TIMP-1 in the atretic follicles was very different. This was
independent of luteolytic treatment or stage of the ovarian cycle. There was a
patchy expression in the thecal and granulosal cell layers but marked expression
around the basal lamina at the cellular interface. During follicular atresia, the
steroidogenic cells degenerate (Hay et al., 1976) and the basal lamina breaks
down (Bagavandoss et al., 1983). These data are consistent with a role for MMP
involvement in the tissue remodelling associated with follicular atresia. The
expression of TIMP-1 may be induced to control local metalloproteinases
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involved in the breakdown of the basal lamina. However, the expression of
metalloproteinases in the atretic follicle has not yet been described, but they have
been shown to be expressed during the breakdown of the follicle wall during
ovulation (Reich et al., 1985; Russell et al., 1995).
The physiological role of TIMP-1 in the steroidogenic cells of the follicle is not
clear. It is likely that it is involved in the regulation of the matrix remodelling
which occurs during follicular growth and development. TIMP-1 has been shown
to have proliferative effects on cells in vitro (Hayakawa et al., 1992), but it
remains to be established whether it can function as a growth factor in vivo. In
addition, the pattern of TIMP-1 expression is similar to the localisation of several
steroidogenic enzymes in different sizes of follicle (Richards et al., 1995). This is
consistent with a role for TIMP-1 as a steroidogenic agent.
TIMP-1 was also found to be expressed in other tissues. This is not surprising as
TIMP-1 is involved in tissue remodelling throughout the body (Salamonsen,
1996). The luteal phase ovary expressed far higher levels of TIMP-1 mRNA than
any of the other tissues investigated. Expression in the placenta and adrenal has
previously been noted in the ewe (Hampton et al., 1995). TIMP-1 expression has
previously been reported in human endometrium (Hampton and Salamonsen,
1994), but we did not detect it in the marmoset endometrium. This may be
because the marmoset monkey does not have a menstrual cycle and lacks cyclical
endometrial remodelling. Sertoli cell expression of TIMP-1 has been reported in
the rat (Boujrad et al., 1995). As the vast majority of total testicular RNA is of
germ cell origin, we were best able to confirm its expression in the marmoset
testis by in situ hybridisation.
TIMP-1 was particularly expressed by steroidogenic tissues such as the ovary,
placenta, testis and adrenal. This expression was generally localised to the
steroidogenic cells of these organs. Although the ovary and placenta undergo
extensive remodelling during their life-span, the adult adrenal and testis do not.
Whether TIMP-1 has any role in these tissues other than specific inhibition of
metalloproteinases has yet to be determined. However, these data are consistent
with an additional role for TIMP-1 as a facilitator of steroidogenesis in vivo. The
ontogeny and the role of TIMP-1 in endocrine glands requires further
investigation and functional studies of TIMP-1 are required.
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In conclusion, the fall in TIMP-1 expression in association with primate
luteolysis, and its changing localisation during the life-span of the follicle support
a role for modulation of TIMP-1 in the control of tissue remodelling. In addition,
these data and the predominant expression of TIMP-1 in steroidogenic tissues,




The effect of luteal 'rescue' on the expression and
localisation of MMPs and TIMPs in the human
corpus luteum
12.1 Abstract
Luteolysis is associated with tissue remodelling likely to involve the MMPs and
their specific tissue inhibitors, the TIMPs. This study investigated the expression
and localisation of the major MMPs and TIMPs in the human corpus luteum
throughout the luteal phase and after luteal 'rescue' with hCG. Corpora lutea (n=9)
were collected at hysterectomy and dated by serial urinary LH estimation. In
addition, corpora lutea (n=3) were collected from women who had received daily
doubling doses of hCG to mimic the hormonal changes of early pregnancy. MMP-
1, MMP-2, MMP-9, TIMP-1, TIMP-2 and TIMP-3 were investigated by
zymography, reverse zymography, northern blotting and in situ hybridisation.
There was no change in the expression of MMP-1, TIMP-1 and TIMP-2
throughout the luteal phase or after luteal 'rescue'. Little TIMP-3 could be detected
in the corpus luteum. MMP-9 activity peaked in the early and late-luteal phase.
The expression and activity of MMP-2 was maximal in the late-luteal phase.
Exposure to hCG during luteal 'rescue' in vivo was associated with a reduction
(p<0.05) in the expression and activity of MMP-2. Messenger RNA for MMP-1,
MMP-2 and TIMP-2 were localised to the connective tissue stroma and the theca¬
lutein cells of the corpus luteum. In contrast, TIMP-1 mRNA was localised to the
granulosa-lutein cells and MMP-9 mRNA was expressed in scattered cells within
the steroidogenic and non-steroidogenic cell layers. In conclusion, during maternal
recognition of pregnancy, hCG prevents the normal increase in MMP-2 in the late-
luteal phase. MMPs can function in an environment containing large amounts of
TIMP-1 as they have a different cellular localisation.
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12.2 Introduction
Unless hCG is secreted from the implanting blastocyst, the human corpus luteum
will undergo structural and functional luteolysis (Behrman et al., 1993). The
corpus luteum changes from the most active endocrine gland in the body, with a
blood flow per unit mass much greater than the kidney (Ford et al., 1982), to a
small fibrous remnant in a matter of days. This extensive tissue remodelling is
likely to involve a group of zinc-dependent proteolytic enzymes known as the
MMPs (Luck and Zhao, 1995; Salamonsen, 1996; Hulboy et al., 1997). These
enzymes have been implicated in a wide variety of biological processes which
involve remodelling of the ECM such as ovulation, menstruation, angiogenesis,
and tumour growth and metastasis (Reich et al., 1985; Hampton and Salamonsen,
1994; Naylor et al., 1994).
The activity of MMPs is controlled at several levels, including synthesis as pro¬
enzymes, enzyme activation, and the production of specific tissue inhibitors
(Matrisian, 1990; Birkedal-Hansen, 1995). TIMPs are of particular interest as
TIMP-1 is one of the major products of the corpus luteum. It is produced in large
amounts by the corpus luteum ofmany species, including the rat (Nothnick et al.,
1995), sheep (Smith GW et al., 1994), cow (Juengel et al., 1994), pig (Smith MF
et al., 1994), monkey, as shown in Chapter 11, (Duncan et al., 1996b) and the
human, as shown in Chapter 10, (Duncan et al., 1996c). In addition, it has
recently been reported that TIMP-2 is also produced by corpora lutea of rats
(Nothnick et al., 1995), sheep (Smith et al., 1995a) and cows (Smith et al.,
1996b), and that TIMP-3 can also be detected in rat ovaries (Nothnick et al.,
1995).
TIMPs bind to and inhibit MMP enzymes with a one-to-one stoichiometry
(Birkedal-Hansen, 1995). As TIMP-1, in particular, is produced in large amounts
throughout the normal luteal phase (Duncan et al., 1996c), it is not clear how
metalloproteinase enzymes function in an environment containing large amounts
of specific inhibitor. This study aimed to investigate the expression and
localisation of the common MMPs and TIMPs in the human corpus luteum
throughout the normal luteal phase and the effect of luteal 'rescue' with exogenous
hCG, to mimic the hormonal changes of early pregnancy, on these enzymes and
their inhibitors.
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12.3 Specific Materials and Methods
12.3.1 Tissues Studied
Corpora lutea were enucleated at the time of hysterectomy in women undergoing
surgery for benign conditions (2.2). On the basis of urinary LH estimation (2.2.4),
three corpora lutea classified as early-luteal, three as mid-luteal and three as late-
luteal were investigated. Three corpora lutea obtained after luteal 'rescue' with
hCG (2.2.2) were also studied. A further corpus luteum was obtained (2.2.3) from
a woman who had received hCG for 8 days to achieve luteal 'rescue' (2.2.2) but
the operation was postponed. This corpus luteum was collected 3 days after the
final hCG injection.
Two pieces of each corpora lutea were stored at -70 °C for subsequent protein and
RNA extraction (2.2.3). One piece was frozen in embedding medium and stored at
-70 °C (2.2.3). Serial frozen sections (6 pm) were cut onto RNAse-free slides
coated with poly-L-lysine (3.2.1) and stored at -70 °C until use. In each case, an
endometrial biopsy was fixed in 4% paraformaldehyde and processed into paraffin
wax for luteal phase-dating (3.2.8). Fresh human placental tissue was obtained
from the local maternity hospital.
12.3.2 Gelatine Zymography
Protein was extracted from corpora lutea in 0.1% (w/v) SDS at 4 °C. The protein
content of the sample after sonication was measured using the method of Bradford
(1976). Seventy-five micrograms of protein in sample buffer [10% (v/v) glycerol,
1% (w/v) SDS and 0.04% (v/v) bromophenol blue] were applied, without heating
or reduction, to an 11% (w/v) polyacrylamide gel containing 1 mg/ml gelatine and
0.1% (w/v) SDS. After electrophoretic separation of proteins, the gels were
incubated in 2.5% triton X-100 for 30 min to remove the SDS. The gels were then
incubated for 16 hours at 37 °C in 50 mM Tris-HCl (pH 7.6), containing 0.2 M
NaCl, 5 mM CaCl2 and 0.02% (w/v) Brij 35. The gels were stained in staining
solution [30% (v/v) methanol, 10% glacial acetic acid, 0.5% (w/v) Coomassie
brilliant blue G250] and then destained in the same solution in the absence of dye.
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12.3.3 Reverse Zymography
Reverse zymography using 75 pg of each protein sample was performed using a
commercial kit (3.1.1). Briefly, 12% (w/v) polyacrylamide gels containing 0.1%
(w/v) SDS, 1 mg/ml gelatine and a solution of secreted MMPs (as supplied) were
prepared. After electrophoresis, the gels were washed overnight in a solution of
2.5% Triton X-100, 50 mM Tris-HCl (pH 7.5) and 5 mM CaCl2. The gels were
rinsed in water and incubated in 50 mM Tris-HCl (pH 7.5) and 5 mM CaCl2, with
gentle shaking, for 24 h at 37 °C. Staining and destaining were carried out as
described above (12.3.3), and bands corresponding to TIMP-1, TIMP-2 and
TIMP-3 were identified by reference to the standards supplied with the kit (3.1.1).
12.3.4 Northern Blotting
Total RNA (20 pg) was denatured, electrophoresed in a 1.5% formaldehyde-
agarose gel, transferred to a nylon membrane and fixed by u.v. cross-linkage
(3.6.1). Northern blot analysis was conducted using 32P dCTP-labelled cDNA
probes (3.5.5) for MMP-1, MMP-2, MMP-9, TIMP-1, TIMP-2 and TIMP-3
(3.1.3) as described previously (3.6.2). After washing (3.6.3), the blots were laid
down to a phosphor screen for 48-72 h and visualised using a phosphorimager
computer (3.6.3). The blots were then stripped (3.6.4) and then reprobed with a
32P end-labelled oligonucleotide which hybridises to 18S RNA (3.6.4), The
molecular size of the bands was calculated with reference to standard RNA
molecular weight markers run in an adjacent lane (3.6.1).
12.3.5 In situ Hybridisation
Isotopic in situ hybridisation was performed on frozen sections using 35S-labelled
riboprobes (3.7). Antisense and sense riboprobes incorporating 35S-labelled UTP
were prepared (3.7.2) from the appropriate plasmids (3..1.3). The riboprobes were
generated from the above plasmids (3.7.1) using the following restriction enzymes
(3.5.3) and RNA polymerases (3.7.2): MMP-1, Hindlll with T7 polymerase
(antisense) and NotI with T3 polymerase (sense); MMP-2, EcoRl with T7
polymerase (antisense) and Hindlll with SP6 polymerase (sense); MMP-9, EcoRl
with T7 polymerase (antisense) and Pstl with SP6 polymerase (sense); TIMP-1,
Kpnl with T7 polymerase (antisense) and Hindlll with SP6 polymerase (sense);
TIMP-2, Hindlll with SP6 polymerase (antisense) and EcoRl with T7 polymerase
(sense).
Chapter 12 MMPs and TIMPs in the human corpus luteum
The sections were prepared as described previously (3.7.3) and hybridisation was
conducted at 55 °C using 1 x 106 c.p.m 35S-labelled antisense riboprobe (3.7.4).
The 35S-labelled sense riboprobe (1 x 106 c.p.m.) (3.7.2) was added to serial
sections as a negative control (3.7.4). After washing in increasingly stringent
conditions (3.7.5), the slides were dipped in photographic emulsion (3.7.6) and
incubated at 4 °C for 21 days in the dark. After developing and fixing (3.7.6), the
sections were washed, counterstained with haematoxylin and mounted (3.2.8).
12.3.6 Immunohistochemistry
Frozen sections on poly-L-lysine-coated slides (3.2.1) were prepared as described
previously (3.2.3), Non-specific binding was blocked using NGS with 5% (w/v)
BSA. The primary antibody to 17a-hydroxylase (3.1.2) was diluted to a
concentration of 1:1500 in TBS and applied to the section for 20 hours at 4 °C
(3.2.6). Antibody binding was visualised with an AB-AP complex using
biotinylated goat anti-rabbit immunoglobulins as the secondary antibody (3.2.6).
Colouration was achieved using a substrate to give a red end-product (3.2.7).
Sections were then counterstained with haematoxylin, dehydrated, and mounted
(3.2.8).
12.3.7 Analysis of Results
The intensities of the 92 kDa and 66 kDa bands detected by zymography were
measured by computer-aided densitometric image analysis (NIH Image 1.55) after
image capture and inversion. Northern blot band intensity was measured using the
phosphorimager computer. To correct for minor differences in loading, the ratio of
the band intensity relative to the 18S band was used for data analysis. One-way
ANOVA was used to investigate differences in expression throughout the luteal
phase. The 'rescued' corpora lutea were compared to the late-luteal corpora lutea
using an unpaired t-test. A commercial software package was used for statistical
analysis (StatView 4.0).
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12.4 Results
12.4.1 Plasma Progesterone Concentrations
The classification of the corpora lutea by serial urinary LH measurement agreed
with the luteal-phase dating of endometrial biopsies using the method of Li et al.
(1988). The plasma progesterone concentrations were 35.3 ±9.8 nmol/1 in the
early-luteal samples, 41.0 ±9.9 nmol/1 in the mid-luteal samples and 19.2 ±12.9
nmol/1 in the late-luteal samples. After luteal 'rescue' by exogenous hCG the
plasma progesterone concentrations had increased to 52.6 ±1.5 nmol/1. The
plasma progesterone concentration in the post-'rescue' sample was 9.16 nmol/1.
12.4.2 Identification ofMetalloproteinases and their Tissue Inhibitors
Three distinct bands of gelatinase activity at 92 kDa, 72 kDa and 66 kDa were
detected in the human corpus luteum by gelatine zymography (Fig. 12.1). These
are consistent with MMP-9, and the latent and active form ofMMP-2 respectively
(Endo et al., 1993a; Salamonsen, 1996). Reverse zymography demonstrated a
band of inhibition of gelatinase activity at approximately 28 kDa and a lighter
band at 21 kDa (Fig. 12.2). These correspond to TIMP-1 and TIMP-2 respectively
(Hampton et al., 1995; Salamonsen, 1996). A further band at 24 kDa was seen in
human placental tissue, but was absent from corpora lutea. This is consistent with
TIMP-3 (Hampton et al., 1995) which is produced by decidual tissue (Higuchi et
al., 1995). TIMP-1 and TIMP-2 could be detected in samples taken from different
stages of the luteal phase and after luteal 'rescue' with exogenous hCG (Fig. 12.2).
The activities of MMP-2 and MMP-9 changed over the luteal phase (Fig. 12.3).
MMP-9 activity peaked in the early- and late-luteal phase and was lowest in the
mid-luteal phase (p<0.05), In contrast, MMP-2 activity increased throughout the
luteal phase to a maximum in the late-luteal phase (p<0.05). Luteal 'rescue' with
hCG resulted in lower MMP-2 activity than during the late-luteal phase in the
absence of hCG (p<0.05). When the corpus luteum was 'rescued' with hCG, and
then the trophic support was withdrawn (in the post-'rescue' sample), large
amounts ofMMP-2 activity was clearly identified by zymography (Fig. 12.1).
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Figure 12.1
Gelatine zymogram from human corpora lutea
Representative gelatine zymogram of human corpora lutea extracts from the early-
(LH+1 to LH+5), mid- (LH+6 to LH+10) and late- (LH+11 to LH+14) luteal
phase and after luteal 'rescue' by hCG (hCGx6 to hCGx8). The extract marked (*)
is taken from a corpus luteum which was 'rescued' with hCG for 8 days and then
collected 3 days after the final exposure to hCG. The bands are bright against a
dark background and the molecular size of each band in kDa is indicated on the
right.
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Figure 12.2
Reverse zymogram from human corpora lutea
Representative reverse zymogram of protein extracts from human placenta (P) and
corpora lutea collected in the early- (E) (LH+1 to LH+5), mid- (M) (LH+6 to
LH+10) and late-luteal (L) (LH+11 to LH+14) phase, and after luteal 'rescue' (R)
with exogenous hCG (hCGx6 to hCGx8) in vivo. The bands are seen as dark
against a lighter background and the molecular size of each band in kDa is
indicated on the right.
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Figure 12.3
i
Activities of MMP-2 and MMP-9 in human corpora lutea
Activities ofMMP-2 and MMP-9 in human corpora lutea. The inverse intensity of
the bands for MMP-9 (92 kDa) and the active form of MMP-2 (66 kDa) on
gelatine zymography in the early- (LH+1 to /LH+5), mid- (LH+6 to LH+10) and
late-luteal (LH+11 to LH+14) phase and after luteal 'rescue' with hCG (hCGx6 to
hCGx8). Values are means ± standard deviation (S.D.) (n=3 per group).
Differences (p<0.05) in mean activities are shown (a: t-test; b: ANOVA).
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12.4.3 Expression of Metalloproteinases and their Tissue Inhibitors
A single band of approximately 0.9 kb corresponding to TIMP-1 (Rapp et al.,
1990; Duncan et al., 1996c) was detected in human corpora lutea by northern
blotting (Fig. 12.4). This confirms our previously reported results, in Chapter 10,
(Duncan et al., 1996c). Northern blotting for TIMP-2 resulted in a single band of
3.6 kb (Fig. 12.4). This is consistent with the transcript size for TIMP-2 mRNA in
the human (Stetler-Stevenson et al., 1990). Several mRNA species corresponding
to TIMP-3 (Higuchi et al., 1995) were detected in the placenta but were not seen
in the human corpus luteum (data not shown). As we have previously reported
(Duncan et al., 1996c), there were no significant differences in the level of TIMP-
1 expression throughout the luteal phase or after luteal 'rescue' with hCG (Fig.
12.5). Likewise TIMP-2 expression did not appear to change throughout the luteal
phase or after luteal 'rescue' (Fig. 12.5).
Specific mRNA transcripts of 3.5 kb were detected in corpora lutea after Northern
blotting for MMP-2. This is consistent with the reported transcript size ofMMP-2
(Hoeben et al., 1996). In addition, northern blotting for MMP-1 demonstrated
transcripts of 3.6 kb and approximately 1.0 kb in human corpora lutea (data not
shown). Little MMP-9 expression could be detected by northern blotting in spite
of clear identification by zymography. Messenger RNA for MMP-2 was lower
(p<0.05) in 'rescued' corpora lutea that in the late-luteal phase in the absence of
hCG (Fig. 12.6). There were no differences in MMP-1 expression throughout the
luteal phase or after luteal 'rescue' with exogenous hCG (Fig. 12.6).
12.4.4 Localisation ofMetalloproteinases and their Tissue Inhibitors
Messenger RNA for TIMP-1, TIMP-2, MMP-1, MMP-2 and MMP-9 was
localised in human corpora lutea by isotopic in situ hybridisation. Each of these
mRNA species had a specific pattern of localisation which persisted throughout
the normal luteal phase and after luteal 'rescue' with exogenous hCG. In agreement
with our previous findings, reported in Chapter 10, TIMP-1 was highly expressed
in the granulosa-lutein cells of the corpus luteum (Fig. 12.7a,h) (Duncan et al.,
1996c). In contrast, TIMP-2 was localised to different regions of the corpus
luteum. TIMP-2 was expressed at the periphery of the granulosa-lutein cells (Fig.
12.7c). Comparison with serial sections immunostained for 17a-hydroxylase, to
identify the theca-lutein cells, showed that TIMP-2 was expressed by the theca-









Northern blot for TIMP-1, TIMP-2 and MMP-2 in human corpora Iutea
Representative northern blot for TIMP-1, TIMP-2 and MMP-2 in human corpora
lutea in the early- (LH+1 to LH+5), mid- (LH+6 to LH+10) and late-luteal
(LH+11 to LH+14) phase and after luteal 'rescue' with hCG (hCGx6 to hCGx8).
Specific hybridisation bands are dark against a lighter background. The
approximate size in kb of the bands are indicated and the 18S RNA bands are
shown to demonstrate equal RNA loading.
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Figure 12.5
Expression of TIMP-1 and TIMP-2 in human corpora lutea
Expression of TIMP-1 and TIMP-2 in the human corpus luteum. The intensity of
TIMP-1 and TIMP-2 mRNAs, corrected for 18S intensity, in the early- (LH+1 to
LH+5), mid- (LH+6 to LH+10) and late- (LH+11 to LH+14) luteal phase and after
luteal 'rescue' with exogenous hCG (hCGx6 to hCGx8) in vivo, are shown. Values
are means ±S.D. (n=3 per group). There were no significant differences in the
level of expression throughout the luteal phase (ANOVA) or after luteal 'rescue'
(t-test).
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Figure 12.6
Expression ofMMP-l and MMP-2 in human corpora lutea
Expression of MMP-l and MMP-2 mRNA in the human corpus luteum. The
intensities of the major MMP-l and MMP-2 mRNA bands, corrected for 18S
intensity, in the early- (LH+1 to LH+5), mid- (LH+6 to LH+10) and late- (LH+11
to LH+14) luteal phase and after luteal 'rescue' with exogenous hCG (hCGx6 to
hCGx8) in vivo, are shown. Values are means ±S.D. (n=3 per group). Significant
differences are shown (a; p<0.05) (ANOVA).
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Figure 12.7
Localisation of TIMP-1 and TIMP-2 mRNA in the human corpus luteum
Localisation of TIMP-1 and TIMP-2 mRNA in the human corpus luteum: a) dark-
field of TIMP-1 in situ hybridisation in the early-luteal corpus luteum showing
expression in the granulosa-lutein cells; b) negative control of (a) showing few
silver grains with no specific distribution; c) serial section of (a) showing dark-
field of TIMP-2 in situ hybridisation: expression of TIMP-2 is in a different
cellular compartment to TIMP-1; d) serial section of (a) immunostained for 17a-
hydroxylase to localise the theca-lutein cells. (G)= granulosa-lutein cells; (T)=
theca-lutein cells; (S)= connective tissue stroma. Scale bar = 100 pm.
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lutein cells (Fig. \2.1d). In addition, TIMP-2 was also expressed in the fibrous
connective tissue surrounding the steroidogenic cells (Fig. 12.7c).
MMP-1 was heavily expressed by the cells of the stroma and connective tissue of
the corpus luteum (Fig. 12.8a). Only very low levels of expression were seen in
the area of the gland containing steroidogenic cells (Fig. 12.8a,b). MMP-2 was
localised to the theca-lutein cells and surrounding connective tissue (Fig. 12.8c).
MMP-2 could also be detected around the vasculature, and occasionally in cells
within blood vessels. Little MMP-2 expression could be detected in the granulosa-
lutein cell population. The distribution of MMP-9 was different, as expression
was localised to individual cells within the gland (Fig. 12.8d). Although these
cells were concentrated along the theca-lutein cell layer and vascular connective
tissue, some cells within the granulosa-lutein compartment were also found to
express MMP-9 (Fig. 12.8d). This pattern of expression ofMMPs and TIMPs was
consistent, and seen in all serial sections examined (Fig. 12.9).
12.5 Discussion
This paper demonstrates the expression and localisation of the MMPs and their
specific tissue inhibitors in the human corpus luteum. TIMP-1 has already been
described as a major product of the corpus luteum of several species (Smith GW
et al., 1994; Juengel et ah, 1994; Smith MF et al., 1994) and we have previously
reported its expression in the human (Duncan et al., 1996c) and non-human
primate (Duncan et al., 1996b). We have now found that TIMP-2 is also expressed
by the human corpus luteum. This agrees with the observation of Smith et al. who
described TIMP-2 expression in ovine (Smith et al., 1995a) and bovine (Smith et
al., 1996b) follicles and corpora lutea. In contrast to TIMP-1 and TIMP-2, TIMP-3
is a not thought to be a secreted molecule but a component of the extracellular
matrix (Leco et al., 1994; Salamonsen, 1996). Although we detected TIMP-3
mRNA in the human placenta, where it has previously been described (Higuchi et
al., 1995), we found little expression in the corpus luteum. Similarly Uria et al.
(1994) did not detect TIMP-3 expression in the human ovary. However, TIMP-3
mRNA has recently been reported in the ovary of the pseudo-pregnant rat
(Nothnick et al., 1995). As TIMP-3 expression was inversely related to TIMP-1
expression, which decreased in the pseudo-pregnant ovary, this discrepancy may
reflect the different time-spans examined, or it may be a species difference.
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Figure 12.8
Localisation of MMP-1, MMP-2 and MMP-9 mRNA in the human corpus
luteum
Localisation ofmRNA for the major MMPs in the human corpus luteum: a) dark-
field of in situ hybridisation for MMP-1 in the mid-luteal phase corpus luteum
showing expression in the connective tissue stroma with minimal expression in
the granulosa-lutein cell layer; b) serial section of (a) immunostained for 17a-
hydroxylase to localise the theca-lutein cells; c) dark-field in situ hybridisation
showing the localisation of MMP-2 mRNA and d) MMP-9 mRNA in the same
corpus luteum. (G)= granulosa-lutein cells; (T)= theca-lutein cells; (S)=
connective tissue stroma. Scale bar = 100 pm.




Differential localisation of MMPs and TIMPs in the corpus luteum
Relationship between the localisation of the major MMPs and TIMPs in the late-
luteal corpus luteum. A composition of serial sections after in situ hybridisation
for MMP-1, MMP-2, MMP-9, TIMP-1 and TIMP-2, and immunohistochemistry
for 17a-hydroxylase arranged around the light-field section of the corpus luteum
showing the pattern of expression of MMPs and TIMPs. (G)= granulosa-lutein
cells; (T)= theca-lutein cells; (S)= connective tissue stroma. Scale bar = 200 pm.
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Indeed, species differences in luteal TIMP-1 expression during luteolysis have
already been described (Juengel et al., 1994; Duncan et al., 1996b; Duncan el al.,
1996c). In the human it seems that TIMP-1 and TIMP-2 are the major luteal
TIMPs.
In the small numbers we analysed, the expression TIMP-2 did not change during
the functional luteal phase or after luteal 'rescue' with exogenous hCG. TIMP-2
expression was found to change during the luteal phase in ovine corpora lutea
(Smith et al., 1995a). Smith et al. (1995a) reported that TIMP-2 expression was
maximal in the early-luteal phase and significantly lower in the late-luteal phase.
This is likely to be another example of species difference in the physiology of the
corpus luteum. In the cow, TIMP-2 expression was reported to increase
significantly from the early- to the mid-luteal phase (Smith et al., 1996b) and
expression was increased after prostaglandin-induced luteolysis (Juengel et al.,
1994). Further evidence of species difference is that the primary TIMP-2 transcript
size in the sheep corpus luteum is 1.0 kb (Smith et al., 1995a), whereas in the
human corpus luteum and other tissues (Stetler-Stevenson et al., 1990) the size is
3.5-kb. In the human corpus luteum, control of tissue remodelling during the
functional luteal phase does not appear to be related to alterations in the levels of
expression of TIMPs.
MMP-1, MMP-2 and MMP-9 are expressed in the human corpus luteum. MMP-2
and MMP-9 have previously been detected by zymography in homogenates of rat
ovaries (Endo et al., 1993a), bovine corpus luteum (Tsang et al., 1995) and
luteinised human granulosa-cells (Puistola et al., 1995; Aston et al., 1996a).
MMP-1, MMP-2 and MMP-9 mRNAs have recently been described in the
pseudo-pregnant rat ovary (Nothnick et al., 1996). Collagen and other components
of the ECM are an integral part of the structure of the corpus luteum (Luck and
Zhao, 1995; Zhao and Luck, 1996). The human corpus luteum expresses enzymes
with the capacity to proteolytically break-down these components of the ECM.
The expression and activity of MMPs in the corpus luteum changed during the
luteal phase. MMP-2 expression and activity was maximal in the late-luteal
corpus luteum. This is consistent with a role in tissue remodelling associated with
luteolysis. In the rat, prolactin-induced structural luteolysis was associated with
the activity of metalloproteinase enzymes, particularly MMP-2 (Endo et al.,
1993a). Interestingly, Aston et al. (1996a) have recently reported that MMP-2
activity increased with length of time of culture of luteinised granulosa cells. The
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major MMP secreted from ovine luteal explants was MMP-2 (Russell et al.,
1995). Expression of MMP-2 in the corpus luteum may be associated with the
tissue remodelling at the time of luteolysis.
In contrast, high levels of MMP-9 activity were also detected in the early-luteal
phase. It is possible that MMP-9 is involved in the extensive tissue remodelling
that occurs during the formation of the corpus luteum from the ruptured follicle
(Luck and Zhao, 1995). A role ofMMP-9 in the formation of the corpus luteum is
supported by the finding that it is the primary metalloproteinase detected in
follicle explants (Russell et al., 1995). In addition, MMP-9 is the major MMP
secreted into the culture medium of luteinised bovine (Zhao and Luck, 1996) and
human granulosa cells (Puistola et al., 1995; Aston et al., 1996a). Dispersed luteal
cells from four-day-old bovine corpora lutea had both MMP-2 and MMP-9
activity, but MMP-9 activity decreased with duration of culture (Tsang et al.,
1995) and MMP-9 was seen in the media of cultured human granulosa cells only
during the first two days of culture (Puistola et al., 1995). This provides
preliminary evidence that MMP-9 may have a role in ovulation and the tissue
remodelling associated with the formation of the corpus luteum.
When compared to the late-luteal phase, exposure of the corpus luteum to hCG
during luteal 'rescue' was associated with reduced expression and activity of
MMP-2. This is clearly different from the process of ovulation when LH/hCG
stimulates an increase in MMP-1 and MMP-2 expression (Curry et al., 1992;
Tadakuma et al., 1993; Hulboy et al., 1997). Follicular levels ofMMP-2 increase
between the LH surge and ovulation (Russell et al., 1995). In cultures of luteinised
granulosa cells, hCG also was shown to reduce the expression of MMP-2 and
MMP-9 (Aston et al., 1996a; Stamouli et al., 1996). Human granulosa cells
cultured on a thin layer of ECM are lost from culture in the absence of
gonadotrophin (Aston et al., 1996a). These cells are released from culture, not as a
result of cell death, but via an active process suppressed by hCG (Aston et al.,
1996b). One of the effects of hCG during maternal recognition of pregnancy
appears to be the inhibition ofmetalloproteinase expression.
MMP-1 and MMP-2 had a similar cellular localisation in the human corpus
luteum. They were expressed in the connective tissue stroma, the vascular pedicles
and within the theca-lutein cell layer. Fibroblasts and endothelial cells are sources
ofMMPs (Woessner, 1991) and they are likely to express MMP-1 and MMP-2 in
the corpus luteum. In the endometrium (Hampton and Salamonsen, 1994) and in
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ovarian cancers (Naylor et al., 1994) cells of the stroma also have been shown to
express these enzymes. Although the expression of MMP-2 was maximal in the
late-luteal phase, its localisation in the corpus luteum was not affected. This
suggests the source for MMP during luteolysis is the periphery of the gland. In
contrast, MMP-9 mRNA was localised to single cells in the steroidogenic and
non-steroidogenic cell layers. The identity of these cells is uncertain but they are
likely to be white blood cells. Polymorphonuclear leukocytes express MMP-9
(Murphy et al., 1989) and we found that expression was often associated with
blood vessels. Cells of the immune system, including macrophages, are found in
the human corpus luteum (Brannstrom et al., 1994a) and may be a source, or
stimulator, ofMMP expression.
It is unclear if MMPs are expressed by the granulosa-lutein cells of the corpus
luteum. Few grains were localised to this cell layer and when present, they were in
isolated individual cells. This finding is contrary to reports using cultures of
luteinised granulosa cells (Puistola et al., 1995; Aston et al., 1996a). In vitro
MMP-9 expression falls with continuing culture. This has led some authors to
suggest that MMP-9 activity is related to leukocytes which accompany the
granulosa cells in the first few days of culture (Puistola et al., 1995). However, it
is thought that bovine and human granulosa cells and bovine luteal cell dispersates
in culture secrete MMP-2 (Tsang et al., 1995; Puistola et al., 1995; Zhao and
Luck, 1996). Although it is possible that MMP-2 activity in these cultures results
from white cell or thecal contamination, it is likely that granulosa-lutein cells have
the potential to express MMPs and are induced to do so in culture. However, it is
clear that the main site of MMP-2 expression in the corpus luteum is not the
granulosa-lutein cells.
TIMP-1 and TIMP-2 have different cellular localisations in the corpus luteum.
Comparison of serial sections immunostained for 17a-hydroxylase, to identify the
luteal cells of thecal origin, showed that TIMP-2 was localised to the theca-lutein
cells and the surrounding connective-tissue stroma. Smith et al. (1995a) found
TIMP-2 in the theca of the ovine follicle. This is consistent with the primary
localisation of TIMP-2 in the follicle being maintained in the mature corpus
luteum. The localisation of TIMP-2 was similar to the localisation ofMMP-1 and
MMP-2. This suggests that TIMP-2 may have a role in the local regulation of
these enzymes in the corpus luteum. Indeed, it has been suggested that TIMP-2
displays a preference for MMP-2 (Goldberg et al., 1989). However, as we have
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reported in Chapter 10 (Duncan et al., 1996c), the localisation of TIMP-1 is
different. It is possible that TIMP-1 has other roles in addition to inhibition of
metalloproteinases in the corpus luteum. It has been suggested that TIMP-1 has
growth factor activity (Hayakawa et al., 1992) and may function as a facilitator of
steroidogenesis (Boujrad et al., 1995; Duncan et al., 1996b). However, the lack of
significant ovarian disturbance in mice without a functional TIMP-1 gene
(Nothnick et al., 1997), means the role of high TIMP-1 expression in granulosa-
lutein cells is not clear.
It was not clear how MMPs could function in the corpus luteum which expresses
large amounts of the specific inhibitor, TIMP-1 (Juengel et al., 1994; Duncan et
al., 1996c). We have shown that MMPs are expressed in different areas of the
corpus luteum than TIMP-1. In addition, where MMPs were expressed in the
granulosa-lutein cellular layer, the expression was localised to foci of individual
cells. The localisation of MMPs seems to be a key factor in their activity in the
corpus luteum.
The control of MMP expression in the corpus luteum is not clear. The detection
and localisation of pro-MMP mRNA may not be related to the activity of MMPs.
MMPs have to undergo enzymatic activation (Matrisian, 1990). The increased
MMP-2 expression in the late-luteal phase parallels the increase in immune cells
(Brannstrom et al., 1994a). Immune cells may be the source of some MMPs,
immune cell cytokines and chemoattractants may be involved in stimulation of
MMP expression. MMP-9 is induced by IL-1 in the rat ovary (Hurwitz et al.,
1993), however IL-1 also stimulates TIMP expression (Nothnick and Curry,
1996). Prostaglandins, which are likely to be involved in the luteolytic process
(Behrman et al., 1993), may modulate MMP expression (Reich, 1991).
Steroid and trophic hormones may influence MMP expression (Hampton and
Salamonsen, 1994; Salamonsen, 1996; Stamouli et al., 1996; Hulboy et al., 1997).
Oestrogen induces a significant increase in MMP-2 activity in vitro (Puistola et
al., 1995). The primate corpus luteum does not express oestrogen receptors
(Chandrasekher et al., 1994) but does contain progesterone receptors
(Chandrasekher et al., 1994; Suzuki et al., 1994). LH/hCG receptors are localised
to different regions of the corpus luteum (Duncan et al., 1996a) than MMPs. It is
therefore likely that steroidogenic cell products inhibit the expression ofMMPs in
a paracrine fashion. The nature of these products is still unclear and more work is
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required to dissect out the control of MMP expression and activity in the corpus
luteum.
In conclusion, the expression of MMP-2 in the late-luteal phase may indicate a
role for this enzyme in the tissue remodelling associated with luteolysis. One
function of hCG during luteal 'rescue' is to prevent this increase in MMP
expression. As TIMP-1 and TIMP-2 change little, it is likely that control ofMMP
activity in the corpus luteum involves changing MMP rather than TIMP
expression. MMPs are localised in different areas than TIMP-1 and where they are
expressed in the same area they are expressed in foci. This may explain how
MMPs can function in the background of large amounts of TIMP-1.
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Chapter 13
The human corpus luteum: reduction in
macrophages during maternal recognition of
pregnancy
13.1 Abstract
It has been shown that immune cells, particularly macrophages, accumulate in the
corpus luteum during luteolysis. This study aimed to investigate the effect of
maternal recognition of pregnancy on the localisation and numbers of
macrophages in the human corpus luteum. Corpora lutea (n=12) were obtained
from normally cycling women at the time of hysterectomy and were dated on the
basis of serial urinary LH estimation. In addition, corpora lutea (n=4) were
collected from women who had received daily doubling doses of hCG to mimic
the hormonal changes of early pregnancy. Macrophages were localised by
immunohistochemistry using an anti-CD68 antibody. Steroidogenic cells,
steroidogenic cells of thecal origin and endothelial cells were identified on serial
sections by immunohistochemistry for 3P-HSD, 17a-hydroxylase and von
Willebrand factor respectively. The luteal cells capable of responding directly to
hCG were identified by isotopic in situ hybridisation for mRNA encoding
LH/hCG receptors. Macrophages were primarily localised to the vascular
connective tissue and theca-lutein areas of the corpus luteum although some were
found in the granulosa-lutein cell layer. Macrophage numbers increased
throughout the luteal phase to a maximum in the late-luteal phase (p<0.05). Luteal
'rescue' with hCG was associated with a marked reduction in the numbers of
tissue macrophages when compared to the late-luteal phase (p<0.001). One of the
effects of hCG during maternal recognition of pregnancy is to prevent the normal
influx of macrophages into the corpus luteum. As LH/hCG receptors localised to
the steroidogenic cells, this implies a fundamental role for steroidogenic cell
products in the control ofmacrophage influx into the human corpus luteum.
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13.2 Introduction
In a non-conception cycle, the primate corpus luteum undergoes luteolysis with a
loss of functional and structural integrity. The molecular events involved in
luteolysis and how they are prevented by exposure to hCG during maternal
recognition of pregnancy remain unclear (Behrman et al., 1993). One feature of
luteolysis, however, is the marked accumulation of immune cells in the corpus
luteum. This increase in the number of immune cells has been reported in a
variety of species, including rodents (Brannstrom et al., 1994b), rabbits (Naftalin
et al., 1997), ruminants (Murdoch, 1987; Lei et al., 1991), and women (Wang LJ
et al., 1992; Best et al., 1996; Takaya et al., 1997). As these species use disparate
mechanisms to control their corpus luteum (Auletta and Flint, 1988), this common
increase implies a fundamental role for immune cells, or their cytokine products
(Brannstrom and Norman, 1993), in the luteolytic process.
The main immune cell to be localised in the human corpus luteum during
luteolysis is the macrophage (Wang LJ et al., 1992; Brannstrom et al., 1994a;
Best et al., 1996). However, macrophage products have been shown to have both
positive and negative effects on progesterone secretion. Macrophage products
have been reported to have pro-steroidogenic effects in cell culture (Kirsch et al.,
1981; Kirsch et al., 1983; Halme et al., 1985). In addition, in the early stages of
luteal function, macrophages are thought to have primarily luteotrophic effects
(Brannstrom and Norman, 1993). Other macrophage products, however, such as
TNFa, PGF2a, reactive oxygen species and NO, have been shown to have
negative effects on steroidogenesis (Fairchild Benyo and Pate, 1992; Grusenmeyer
and Pate, 1992; Vega et al., 1995; Kato et al., 1997; Van Voorhis et al., 1994).
Whereas macrophages are likely to be involved in the phagocytic clearance of cell
debris (Paavola, 1979; Takaya et al., 1997) after functional luteolysis, it is still not
clear role tissue macrophages have in the functional corpus luteum.
We hypothesised that the primary role of macrophages in the human corpus
luteum was luteolytic, rather than luteotrophic, and that macrophage numbers
would not increase in the 'rescued' corpus luteum of early pregnancy. To test this
hypothesis, we investigated the number of macrophages in the human corpus
luteum throughout the functional luteal phase by immunohistochemistry. We
compared the numbers of macrophages in corpora lutea in the late-luteal phase,
where progesterone output is falling, with corpora lutea 'rescued' with exogenous
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hCG, where progesterone output is increasing. We also hypothesised that any
increase in macrophages within the corpus luteum was by de novo influx, rather
than local changes in cellular localisation. To test this hypothesis, we identified
the structural architecture of the corpus luteum by immunohistochemistry and
compared the localisation of macrophages throughout the luteal phase and after
luteal 'rescue' with exogenous hCG. In the final part of the study, we investigated
the site of action of hCG on macrophages during luteal 'rescue' by localising
LH/hCG receptors in the corpus luteum by isotopic in situ hybridisation.
13.3 Specific Materials and Methods
13.3.1 Tissues Studied
Corpora lutea were enucleated at the time of hysterectomy in 16 women
undergoing surgery for benign conditions (2.2) and dated on the basis of serial
urinary LH measurements (2.2.4). Four corpora lutea were classified as early-
luteal, four as mid-luteal and four as late-luteal (2.2.4). Four 'rescued' corpora
lutea were collected from women who had been treated with exogenous hCG to
mimic the hormonal changes of early pregnancy (2.2.2). One piece of each corpus
luteum was fixed in 4% paraformaldehyde (2.2.3) and embedded in paraffin wax
for immunohistochemistry (3.2) and another piece was frozen in embedding
medium to allow frozen sections to be prepared (2.2.3). In each case an
endometrial biopsy was also fixed in paraformaldehyde and processed into
paraffin wax for luteal phase dating by tissue morphometry (3.2.8).
13.3.2 Immunohistochemistry
Paraffin wax sections (5 pm) on poly-L-lysine-coated slides (3.2.1) were prepared
(3.2.2). As preliminary experiments indicated that antigen retrieval using
trypsinisation was necessary for the detection of the CD68 antigen and von
Willebrand factor, this was then performed (3.2.4). Endogenous peroxidase
activity was then blocked (3.2.5). Immunohistochemistry was performed as
described (3.2.6) using NRS containing 4% (w/v) BSA to block non-specific
binding. Sections were incubated with the primary antibody, monoclonal mouse
anti-human macrophage CD68 antigen (3.1.2) diluted 1:50 in TBS, or the mouse
anti-human von Willebrand factor (3.1.2) diluted 1:25, for one hour at room
Chapter 13 Macrophages in the human corpus luteum 217
temperature (Rodger et al., 1997) (3.2.6). Mouse IgG at an equivalent antibody
concentration was used as a negative control (3.2.9). Antibody binding was
indicated by an AB-HRP reaction with a biotinylated rabbit anti-mouse secondary
antibody at a dilution of 1:100 in TBS (3.2.6). The reaction was developed with
DAB to give a stable brown end-product (3.2.7).
Steroidogenic cells were identified in serial sections by immunohistochemistry for
3P-HSD. Here, polyclonal rabbit anti-human 3P-HSD (3.1.2) was used in a
dilution of 1:1000 (Riley et al., 1992). Immunohistochemistry was performed as
described above, without trypsinisation, using NGS to block non-specific binding
(3.2.6) and biotinylated goat anti-rabbit immunoglobulins to detect specific
binding (3.2.6). Steroidogenic cells of thecal origin were identified in serial
sections by immunohistochemistry for 17a-hydroxylase as described previously
(Rodger et al., 1995) (10.3.2). Briefly, the polyclonal rabbit anti-human 17a-
hydroxylase antibody (3.1.2) was used at a 1:750 dilution, NGS was used to block
non-specific binding, and biotinylated goat anti-rabbit immunoglobulins were
used as the secondary antibody. Rabbit serum with an equivalent immunoglobulin
concentration was used as a negative control (3.2.9).
13.3.3 In situ Hybridisation
Isotopic in situ hybridisation for LH/hCG receptors was performed using
antisense and sense 35S-labelled riboprobes (3.7). The antisense probe,
incorporating 35S-labelled UTP was generated from the plasmid vector (3.1.3)
linearised by Hindlll (3.5.3) using T3 RNA polymerase (3.7.2). The 35S-labelled
sense probe was used as a negative control. This was generated from the plasmid
vector (3.7.1) linearised by ECoRl (3.5.3) using T7 RNA polymerase (3.7.2).
As preliminary experiments with fixed serial sections gave technically poor
results, LH/hCG receptor mRNA was localised in frozen sections from the same
corpora lutea. Frozen sections (2.2.3) were fixed, acetylated, dehydrated and dried
under vacuum (3.7.3). One hundred microlitres of hybridisation buffer containing
1 x 106 c.p.m. radiolabeled riboprobe (3.7.2) was added to each section and the
slides were incubated overnight at 55 °C in a moist chamber (3.7.4), The
following day the slides were treated with RNAse A, and washed in increasingly
stringent conditions (3.7.5). The sections were then dehydrated, allowed to dry
and dipped in photographic emulsion (3.7.6). After incubation in the dark for 21
days, they were developed and fixed (3.7.6). The sections were then rinsed,
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counter-stained with haematoxylin and mounted (3.2.8), They were viewed under
dark-field illumination and the localisation of the silver grains was determined by
reference to the image viewed under light-field illumination.
13.3.4 Analysis of Results
The number of macrophages was counted by an observer blinded to the tissue
identity and repeated the following week to confirm the reproducibility of the
results. Macrophage numbers in all sections during the repeat count were within
5% of the initial count. Macrophages were identified by intense brown staining on
tissue sections. Only positive cells where the nuclei could be identified were
counted in order to avoid counting tiny fragments of cells present in the tissue
section. Sections were analysed using a stratified random sampling technique
using a graticule lens. The stratified random sampling technique involved taking
random fields from a grid of 24 fields arranged around a fixed, non-random, point
(the centre of the section). At least five fields of each section were counted and
the running mean was monitored to confirm adequate sampling. The granulosa-
lutein cell layers, the theca-lutein cell layers and the surrounding stroma were
identified by morphology and by comparison with serial sections immunostained
for 3(3-HSD and 17a-hydroxylase. In addition to the total number of
macrophages, the number ofmacrophages in these layers was also recorded.
The number of macrophages at different stages of the luteal phase, and the
number in the different cellular layers, were analysed by one way ANOVA with a
5% level of significance. Where significant differences were found to exist,
pairwise comparisons using the Bonferroni/Dunn method were performed using
commercial computer software (StatView 4.0).
13.4 Results
13.4.1 Plasma Progesterone Concentrations
The classification of the corpora lutea by serial urinary LH measurement agreed
with the luteal-phase dating of endometrial biopsies using the method of Li et al.
(1988). The plasma progesterone concentrations were 36.36 ±9.28 nmol/1 in the
early luteal samples, 40.35 ±9.88 nmol/1 in the mid-luteal samples and 18.80
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±12.81 nmol/1 in the late luteal samples. After luteal 'rescue' by exogenous hCG
the plasma progesterone concentrations had increased to 52.75 ±1.09 nmol/1.
13.4.2 Functional Anatomy of the Corpus Luteum
Steroidogenic cells were identified in human corpora lutea by the
immunolocalisation of 3P-HSD (Fig. 13.1a). Luteal cells of both thecal and
granulosal origin express this enzyme. The theca-lutein cells were specifically
identified by immunolocalisation of 17a-hydroxylase (Fig. 13.16). These cells
formed clearly distinct populations, located around the peripheral margin of the
granulosa-lutein cells. Vascular endothelial cells were localised by
immunohistochemistry for von Willebrand factor (Fig. 13.1c). The theca-lutein
cell layer had a rich blood supply. Endothelial cells were also scattered throughout
the granulosa-lutein cell layers, particularly in the radial invaginations from the
theca-lutein cell layer (Fig. 13.lt/). LH receptors were localised by isotopic
mRNA in situ hybridisation (Fig. 13.1c). As described previously, in Chapter 5,
they were localised to the steroidogenic cell population (Duncan et al., 1996a).
When compared to immunostained sections, no hybridisation signal could be
detected in endothelial cells, stromal cells or cells without the morphological
characteristics of steroidogenic cells.
13.4.3 Localisation of Tissue Macrophages
Macrophages, as described by immunohistochemical localisation of the CD68
antigen, could be localised in all corpora lutea studied (Fig. 13.2a). No staining
was present in negative control sections where the primary antibody was replaced
with an equivalent concentration of IgG (Fig. 13.26). Many more macrophages
could be detected in late-luteal corpora lutea (Fig. 13.2c) than after luteal 'rescue'
with exogenous hCG (Fig. 13.2d). The numbers of macrophages in the corpora
lutea at different stages of the luteal phase were counted. The macrophage content
of the corpus luteum increased throughout the luteal phase reaching a maximum
in the late-luteal phase (p<0.05) (Fig. 13.3). Luteal 'rescue' with hCG was
associated with a reduction in the number ofmacrophages (Fig. 13.3), which were
significantly lower that the late-luteal phase (PO.OOl).
Macrophages were particularly prominent in the theca-lutein cell layer at all
stages (Fig. 13.1/; Fig. 13.2a). In the granulosa-lutein cell layer, they were usually
seen in association with the vascular in-foldings, particularly in the late-luteal
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Figure 13.1
Functional anatomy of the human corpus luteum
Functional anatomy of the human corpus luteum: a) mid-luteal corpus luteum
immunostained for 3|3-HSD showing staining of the steroidogenic cells in the
granulosa-lutein (G) and theca-lutein (T) cell layers and no staining of the
connective tissue core (arrow); b) the same corpus luteum as (a) immunostained
for 17a-hydroxylase showing staining in the theca-lutein (T) cells around the
periphery of the granulosa-lutein cells (G), which, like the connective tissue core
(arrow) show no immunoreactivity; c) the same corpus luteum as (a)
immunostained for von Willebrand factor to demonstrate the endothelial cells
which are abundant in the theca-lutein cell layer (T) and connective tissue
invaginations (arrow) and also found in the granulosa-lutein cell layer (G); d) a
closer view of the granulosa-lutein cell layer (G) of another mid-luteal corpus
luteum immunostained for von Willebrand factor showing strong endothelial cell
immunostaining in the vascular connective tissue invaginations (arrow); e) dark-
field view of a mid-luteal corpus luteum after isotopic in situ hybridisation for LH
receptor mRNA showing grains distributed over the granulosa-lutein cell layer
(G); f) the same corpus luteum as (e) after immunohistochemistry for
macrophages (CD68 +ve cells) showing the distribution of macrophages around
the periphery of the granulosa-lutein cell layer (G), an entirely different
localisation to LH receptor mRNA. Scale bar =100 pm.
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Figure 13.2
Localisation ofmacrophages in the human corpus luteum
Macrophage localisation in the human corpus luteum: a) mid-luteal corpus luteum
with macrophages (CD68 +ve cells, brown) localised to the periphery of the
steroidogenic cells in the theca-lutein layer (T) and also to the granulosa-lutein
cell layer (G) and surrounding connective tissue stroma; b) negative control serial
section of (a) showing the theca-lutein (T) and granulosa-lutein (G) cell layers
with no specific staining visible; c) increased numbers of macrophages (CD68
+ve cells, brown) in the theca-lutein (T) and granulosa-lutein (G) cell layers in a
late-luteal corpus luteum; d) corpus luteum after luteal 'rescue' with hCG showing
fewer macrophages (CD68 +ve cells, brown) in the theca-lutein (T) and
granulosa-lutein (G) cell layers. Scale Bar =100 pm.
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Figure 13.3
Numbers ofmacrophages in human corpora lutea
Macrophage numbers in corpora lutea: numbers of CD68 +ve cells in sections of
human corpus luteum in the early- (LH+1 to LH+5), mid- (LH+6 to LH+10) and
late- (LH+11 to LH+14) luteal phase and after luteal 'rescue' with hCG (hCGx5 to
hCGx8). Values are mean +S.E.M. (n=4 per group). Values were analysed by
ANOVA and where significant differences at the 5% level were observed
pairwise comparisons were conducted using the Bonferroni/Dunn method
(*=p<0.05, **=p<0.001).
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phase (Fig. 13.2c). The numbers of macrophages specifically located within the
granulosa cell layer showed the same pattern as the overall macrophage content
throughout the luteal phase (Fig. 13.4). There were no differences in the
percentages of macrophages specifically located to the granulosa-lutein cell layer
at any stage of the luteal phase. The localisation of the LH receptor (Fig. 13.1e) in
the human corpus luteum was clearly different from the localisation of CD-68
positive tissue macrophages (Fig. 13.1f).
13.5 Discussion
We have compared the macrophage content in the corpus luteum of women who
received exogenous hCG at concentrations equivalent to that of early pregnancy
with corpora lutea obtained from untreated women at clearly defined stages of the
luteal phase. We found that the macrophage content was significantly lower in the
hCG-treated women than in the untreated women from the same stage of the
luteal phase. This suggests that macrophage accumulation is associated with the
loss of luteal integrity during luteolysis and that one of the effects of hCG during
luteal 'rescue' is to prevent the accumulation ofmacrophages in the corpus luteum.
In this study we have concentrated on the numbers and localisation of
macrophages in the corpus luteum. Various other immune cells have also been
identified in the corpus luteum, including polymorphonuclear leukocytes
(Brannstrom et al., 1994a) and T-cells (Best et al., 1996). However, it is clear that
macrophages are the predominant immune cell subpopulation in the human and
rabbit corpus luteum (Wang LJ et al., 1992; Best et al., 1996; Bagavandoss et al.,
1990). In addition, unlike other immune cells, macrophages have clearly been
shown to vary in number during the lifespan of the corpus luteum, being
particularly abundant in the regressing corpus luteum (Best et al., 1996;
Brannstrom et al., 1994a). Although other immune cells may be affected during
luteal 'rescue', it is likely that the clearest and most predominant effect is that on
tissue macrophage content.
Our study confirms that macrophage influx increases during the functional
lifespan of the corpus luteum. Macrophage accumulation in the corpus luteum is a
feature of luteolysis in a variety of animal species, including rats (Brannstrom et
al., 1994b), rabbits (Bagavandoss et al., 1990; Naftalin et al., 1997), pigs (Hehnke
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Figure 13.4
Numbers ofmacrophages in the granulosa-cell layer of human corpora lutea
Macrophage numbers within the granulosa-lutein cell layer: numbers of CD 68
+ve cells in sections of human corpus luteum in the early- (LH+1 to LH+5), mid-
(LH+6 to LH+10) and late- (LH+11 to LH+14) luteal phase and after luteal
'rescue' with hCG (hCGx5 to hCGx8). Values are mean ±S.E.M. (n=4 per group).
Values were analysed by ANOVA and where significant differences at the 5%
level were observed pairwise comparisons were conducted using the
Bonferroni/Dunn method (*=p<0.05).
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et al., 1994), sheep (Murdoch, 1987) and women (Brannstrom et al., 1994b; Best
et al., 1996; Takaya et al., 1997). Macrophages are clearly present in large
numbers in the regressing corpus luteum after menstruation in women (Wang LJ
et al., 1992; Brannstrom et al., 1994a; Takaya et al., 1997). However, there has
been some debate about the accumulation ofmacrophages in the late-luteal phase
when the corpus luteum is still producing progesterone. Brannstrom et al. (1994a)
failed to find an increase in luteal macrophages in the late-luteal phase. In
contrast, other studies (Lei et al., 1991; Best et al., 1996) reported increased
macrophages in the functional corpora lutea in the late-luteal phase. It is likely
that the discrepant findings of Brannstrom et al. (1994a) are explained by their
more extended definition of the late-luteal phase (from LH+8) and that
macrophage influx is a feature of luteal ageing.
The role of macrophage accumulation in the late-luteal phase is not fully
established. It is not clear whether it is a cause or consequence of falling
progesterone synthesis. Clearly macrophage products can inhibit steroidogenesis
in vitro. NO (Van Voorhis et al., 1994), TNFa (Fairchild Benyo and Pate, 1992;
Wang HZ et al., 1992), PGF2a (Grusenmeyer and Pate, 1992), reactive oxygen
species (Vega et al., 1995; Kato et al., 1997) and interleukins (Sjogren et al.,
1991) have all been shown to inhibit the steroidogenic pathway. In addition, cell
death by apoptosis is a feature of luteolysis in many species (Dharmarajan et al.,
1994; Zheng et al., 1994; Shikone et al., 1996) and apoptosis can be promoted by
macrophage products, such as free oxygen radicals, TNFa and some interleukins
(Hale et al., 1996; Jacobson, 1996; Spencer et al., 1996). Macrophages may have
a role in structural luteolysis, they can clear cellular debris by phagocytosis
(Paavola, 1979) and activate the MMP enzymes (Hurwitz et al., 1993; Hulboy et
al., 1997) which have been implicated in the remodelling associated with
luteolysis (Endo et al., 1993a; Luck and Zhao, 1995). Whether it is cause or
consequence of falling progesterone synthesis, it is likely that the accumulation of
macrophages in the late-luteal phase has a negative effect on the structure and
function of the corpus luteum.
Macrophages however have been shown to have both pro-steroidogenic and
luteotrophic properties under some conditions. It remains possible that the
macrophage accumulation in the functional luteal phase is a luteotrophic response
to failing progesterone synthesis. Macrophage-derived products have been shown
to enhance progesterone output from luteal cells in culture (Kirsch et al., 1983;
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Halme et al., 1985), and macrophages may secrete factors important for
angiogenesis and tissue reorganisation. Brannstrom and Norman (1993)
postulated a luteotrophic effect of macrophages in the early luteal phase. In
addition, as macrophages could enhance progesterone synthesis (Kirsch et al.,
1981; Kirsch et al., 1983) and promote proliferation of granulosa cells
(Fukumatsu et al., 1992), Bukovsky et al. (1995) also proposed a luteotrophic role
ofmacrophages. In the rat corpus luteum, non-steroidogenic cells, probably white
blood cells, have also been shown to have potent stimulatory effects on luteal cell
steroidogenesis (Nelson et al., 1992). It is therefore not clear whether the
accumulation of macrophages in the corpus luteum would always be associated
with a fall in progesterone synthesis.
We have demonstrated that luteal 'rescue' with exogenous hCG to mimic the early
stages of pregnancy is associated with a reduction in the numbers ofmacrophages
in the late-luteal corpus luteum. This supports the hypothesis that macrophages
have a primarily luteolytic, rather than luteotrophic role, in the human corpus
luteum. Our findings are different to those of some sub-primate species.
Brannstrom et al. (1994b) found particularly high concentrations of macrophages
in the rat corpus luteum during the early stages of pregnancy and
pseudopregnancy. They found six-fold more macrophages in the corpus luteum of
early pregnancy than during luteolysis (Brannstrom et al., 1994b). This
accumulation of macrophages is also seen in the corpus luteum of pregnant
rabbits (Bagavandoss et al., 1990). In the rabbit corpus luteum, oestrogen
withdrawal induces macrophage invasion, but subsequent oestrogen replacement
maintained progesterone production and did not necessarily reduce macrophage
numbers (Naftalin et al., 1997). Indeed, in that model system, the relative
numbers of macrophages had no apparent relationship to progesterone synthesis.
They concluded that the presence of macrophages did not preclude the
continuation of progesterone production (Naftalin et al., 1997). It is not known
whether the human corpus luteum can continue to function in the presence of
increasing numbers of macrophages, but clearly, macrophage influx is not a
feature of luteal 'rescue' with hCG.
What promotes the influx of macrophages into the failing corpus luteum? Several
chemoattractant and macrophage stimulatory molecules have now been identified,
including cytokines such as IL-8 (Norman and Brannstrom, 1994), granulocyte-
macrophage colony stimulating factor (GM-CSF) (Nicola, 1989) and monocyte
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chemoattractant protein 1 (MCP-1) (Leonard and Yoshimura, 1990). These
molecules can be detected in the ovary (Robertson and Seamark, 1990; Zhao et
al., 1995; Arici et al., 1997). Recently, Townson et al. (1996) reported increased
expression of MCP-1 in the corpus luteum during luteal regression in rats. This
increase preceded the appearance of macrophages in the corpus luteum and they
concluded that MCP-1 may have a prominent role in the immunological process
of luteal regression. Induction of structural luteolysis by prolactin in rat corpus
luteum (Bowen et al., 1996), and by oestrogen withdrawal in the rabbit corpus
luteum (Naftalin et al., 1997), is associated with macrophage accumulation and
expression of MCP-1. MCP-1 can be stimulated by cytokines (Oppenheim et al.,
1991; Arici et al., 1997) which can be found in the corpus luteum during
luteolysis (Brannstrom and Norman, 1993). However, MCP-1 expression can also
be stimulated by hCG in granulosa-lutein cell culture (Arici et al., 1977). Data on
the expression of these chemoattractant molecules in the human corpus luteum
throughout the luteal phase is not yet available, but would clearly be of great
interest.
How does exposure to hCG during luteal 'rescue' prevent the influx of
macrophages into the corpus luteum? HCG exerts its biological actions by
binding to, and activating, LH receptors (Cole et al., 1973). LH receptors are
localised to the steroidogenic cells of the corpus luteum (Nishimori et al., 1995;
Duncan et al., 1996a) and we have shown the localisation of these receptors is
different to the localisation of macrophages. Although we were not able to co-
localise macrophages and LH receptors on the same tissue section, it is unlikely
that macrophages themselves express the LH receptor. The effect of hCG on
macrophage accumulation therefore seems to be mediated through the
steroidogenic cells. This effect is likely to be associated with the production or
withdrawal of steroid or non-steroid molecules from the cells expressing LH/hCG
receptors. Progesterone itself may function as a signal molecule as progesterone
receptors can be localised to the human corpus luteum (Suzuki et al., 1994).
While these receptors appear to be present on steroidogenic cells (Suzuki et al.,
1994; Hild-Petito and Fazleabas, 1997), they can also be found on other cells
within the connective tissue stroma (Suzuki et al., 1994). It is not known whether
luteal macrophages express progesterone receptors or whether luteal sex steroids
can directly affect migration.
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In our study, macrophages were found associated with the theca-lutein cell layer
and the vasculature of the corpus luteum. An early study reported that
macrophages were predominant in the granulosa-lutein cell layer of the human
corpus luteum (Gillim et al., 1969). However, later studies found a predominance
in the theca-lutein layer (Wang LJ et al., 1992; Brannstrom et al., 1994a). We
have used steroidogenic markers to confirm this observation. Brannstrom et al.
(1994a) reported that macrophages were more abundant in the theca-lutein layer
and were particularly associated with blood vessels. The relationship with blood
vessels may suggest a recruitment of monocyte/macrophages from the circulation.
In our study macrophage numbers increased during the late-luteal phase, in all
cellular compartments. This is consistent with recruitment from the circulation
rather than local migration. Interestingly, MCP-1 is secreted by several cell types
including endothelial cells and fibroblasts (Leonard and Yoshimura, 1990). In the
rat corpus luteum, luteal vascular cells appear to be a source ofMCP-1 (Townson
et al., 1996). The endothelial cells and their communication with the
steroidogenic cells of the corpus luteum may play a major role in the control of
macrophage recruitment.
In conclusion, this study has shown that macrophages accumulate in the human
corpus luteum during the luteal phase and are maximal in the late-luteal phase.
One of the effects of hCG during luteal 'rescue' is to prevent this influx of
macrophages into the corpus luteum. As macrophages do not express LH/hCG
receptors this effect is mediated indirectly through factors produced by the
steroidogenic cells. Further work is needed to study the expression of
chemoattractant molecules in the human corpus luteum throughout the luteal




This thesis has presented the results of a series of investigations into the
properties of the primate corpus luteum at different stages of its functional
lifespan. These results are contained in the eight experimental chapters. Each
chapter has been deliberately written in the form of a complete scientific paper
that can be read in isolation. Each chapter, therefore, ends with a specific
discussion and a set of conclusions. The role of this chapter is not to rehash these
specific discussions and conclusions but to examine the results, in the context of
the whole thesis, in order to attempt to synthesise a speculative paradigm for the
molecular mechanisms involved in the control of the human corpus luteum.
This chapter begins with a careful examination of the experimental models
utilised. Clearly, an extrapolation of the results to normal primate luteal
physiology depends of the validity of the models used. The next part of the
discussion is concerned with potential improvements in experimental design that
would allow additional information to be collected. In the next section, the
conclusions of the experimental work in this thesis are revisited and an attempt
made to unify them in an extended paradigm for primate luteal function. This
raises further questions and areas of study which are then addressed and a strategy
for the further investigation of the corpus luteum is developed. This chapter will
hopefully form the introduction to a continuing programme of research in the
human corpus luteum.
14.1 Are the Models Valid?
14.1.1 General Validity
What is the rationale for studying the corpus luteum? There are several answers to
this question, as the corpus luteum has properties of general interest to cell
biologists and specific interest to reproductive biologists. The human corpus
luteum is a very dynamic gland, with high levels of natural cellular growth, death,
angiogenesis and tissue remodelling (Behrman et al., 1993). Understanding how
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these processes occur, and are controlled, is likely to have direct relevance to
other dynamic tissue processes including neoplasia, wound healing and
menstruation. In addition, the corpus luteum is a highly active steroidogenic gland
(Zeleznik and Fairchild Benyo, 1994). Understanding how luteal cells achieve
such high levels of steroidogenesis, at a molecular level, may give us insights
about general cellular metabolism, relevant to other endocrine and non-endocrine
cell types. The corpus luteum is a valuable resource that is likely to have validity
in a number of fields outwith general reproductive biology.
14.1.2 Specific Validity
General validity aside, the main rationale for these studies was the investigation of
the molecular mechanisms important during the lifespan of the corpus luteum
itself. Clearly, these studies aimed to broaden and expand our knowledge of the
physiology of the corpus luteum. The reason that we want to specifically
understand how the corpus luteum works, is that an increased understanding of
how it functions may facilitate the development of novel approaches to the
prevention or promotion of human fertility. The validity of all the conclusions
reached in this thesis depends on how representative the models used are of
normal luteal physiology. One of the most important aspects of luteal models,
therefore, relates to their direct relevance to the human.
Most reported studies on the corpus luteum use rodent, rabbit or ruminant models
(Niswender et al., 1985; Auletta and Flint, 1988; Behrman et al., 1993;
Niswender and Nett, 1994). These models are convenient, accessible, easily
manipulated, and in some cases of direct agricultural relevance (Niswender et al.,
1985). While it is likely that the molecular characteristics of different mammalian
corpora lutea have many common elements, it is clear that there are many
fundamental differences between infraprimate and primate corpora lutea (Auletta
and Flint, 1988; Niswender and Nett, 1994; Zeleznik and Fairchild Benyo, 1994).
Several of these major structural, regulatory and functional differences have
already been discussed in this thesis. Whereas important insights into the
molecular mechanisms involved in the control of primate luteal function can be
gained by studying infraprimate species, the nature of the primate corpus luteum
can only be elucidated by studying primate tissue. The major relevance of these
studies, when trying to understand the human corpus luteum, is that human and
non-human primate models were utilised.
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The use of human models to study the primate corpus luteum is not unique by any
means. Many observational studies on human luteal tissue have been reported
(Bramley et al., 1987; Bukovsky et al., 1995; Nishimori et al., 1995; Shikone et
al., 1996; Best et al., 1996), although when compared with the number of studies
on infraprimate and non-human primate species, human tissue is studied
uncommonly. Indeed, because of the difficulty in obtaining human corpora lutea,
small numbers are often studied, and most of these studies report the use of
archival corpora lutea, or corpora lutea collected on an ad-hoc basis. One of the
problems with previous human studies is the lack of facilities for the systematic
collection of corpora lutea.
14.1.3 Accurate Dating of Corpora Lutea
One of the strengths of the studies reported in this thesis (Koh el al., 1995;
Duncan et al., 1996a; Duncan et al., 1996b; Duncan et al., 1996c; Duncan et al.,
1998a; Duncan et al., 1998b; Duncan et al., 1998c) is that all the corpora lutea
investigated had been carefully dated. For the first time, the stage of the luteal
phase has been accurately defined, on the basis of the urinary LH peak. In
addition, only corpora lutea in which the urinary LH peak agreed with the LMP,
and the morphological luteal phase dating (Li et al., 1988) were used. This has
ensured a robust and valid classification of functional human corpora lutea. As no
other human studies have been as rigorous in luteal phase dating and
classification, it is likely that the studies reported here are at least as valid as
previous observational human studies. Indeed, it is possible that less robust dating
measures could skew observational results obtained throughout the menstrual
cycle. This suggests that the human model system reported in this thesis is as
valid as possible in the classification of luteal phase.
14.1.4 Are these Corpora Lutea Representative?
It is reasonable to conclude that the results in this thesis are reliable, as far as the
validity of the model system and the robust nature of the dating classification are
concerned. However, their relevance to normal luteal physiology depends on how
representative of normal, the human corpora lutea were. Clearly, the corpora lutea
were obtained from women with gynaecological problems, and this is a potential
source of bias. The selection criteria tried to minimise this bias by excluding those
with systemic disease, those exposed to recent hormonal preparations and those
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with a history of infertility. In addition, all women studied had regular menstrual
cycles, which implies normal folliculogenesis and ovulation (Cowan, 1997).
However, these women did require hysterectomy for benign conditions. It is
possible that the group of patients undergoing surgery were in some way different
from the normal fertile population, or that the pathological process, that
necessitated surgery, affected the corpus luteum. It is also possible that the stress
involved in the run up to surgery, augmented the release of factors which directly
or indirectly altered the corpus luteum.
There are other potential sources of bias. The women in these studies tended to be
older, and towards the end of their reproductive life, as well as having benign
gynaecological disease. There is some evidence for subtle and overt ovarian
dysfunction increasing with age, and being present in women with benign
gynaecological conditions (Stouffer, 1990; Olive, 1991; Dawood, 1994;
Bukovsky et al., 1996). It remains possible that the results were biased by these
factors. However, the women were all ovulatory with normal menstrual cycle
length. Although the clinical relevance of luteal dysfunction has been widely
debated (Balasch and Vanrell, 1987; Olive, 1991; Jones, 1991; Dawood, 1994;
Hinney et al., 1996), there is no convincing evidence for luteal dysfunction, in the
presence of normal folliculogenesis, in normally cycling fertile women. Indeed,
these women had all been pregnant, implying normal luteal function in the past. It
is likely that the tissues studied were as representative as possible of normal
human corpora lutea.
14.1.5 Other Human Models
Since the advent of assisted conception, luteinised granulosa cells have been
increasingly used to study luteal function. As these cells produce progesterone in
culture, and exhibit a dose-response stimulation with hCG, they have been
advocated as a model system to study the corpus luteum (Soto et al., 1984; Wang
et al., 1991; Aston et al., 1996a; Stamouli et al., 1996). While these models have
proven useful, and increased our understanding of the molecular mechanisms of
luteal function (Abayasekara et al., 1993; Endo et al., 1993b), their use is limited.
This is because, cellular connections, transient cells, supporting matrix,
fibroblasts and theca-lutein cells, in correct anatomical relationships, are missing.
All these elements are thought to contribute to normal luteal function (Behrman et
al., 1993; Zeleznik and Fairchild Benyo, 1994). The same problems are also
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present when cultures of luteal cells (Stouffer et al., 1977; Brannian et al., 1992;
Devoto et al., 1995) are studied. Another approach to the in vitro analysis of the
cellular function of luteal cells has been to use luteal slices (Girsh et al., 1996;
Hagstrom et al., 1996; Fairchild Benyo and Zeleznik, 1997). This has the
advantage of maintaining tissue architecture and cellular communications.
However, the extent to which the tissue response is modified by mechanical
sectioning is unknown. It is likely that luteinised granulosa cell, luteal cell and
luteal slice cultures are valuable tools, but it has to be accepted that data
interpretation is difficult, and the results have to be validated in whole corpora
lutea.
14.1.6 Non-Human Primate Models
Most of our understanding of the primate corpus luteum has come from
observational, functional and interventional studies involving new world monkeys
(Stouffer, 1988; Behrman et al., 1993). There is little evidence that these species
differ significantly from the human in terms of their ovarian cycle. Monkey
models allow careful dating and collection of tissue. However, the numbers used
tend to be low, for humanitarian and expense reasons. In addition, all observations
require to be tested on the human to ensure their complete validity. Primate
models have proved very useful (Hutchison and Zeleznik, 1984; Hutchison et al.,
1986; Stouffer, 1988; Duffy et al., 1994; Auletta and Kelm, 1994), particularly
where interventions are required. However for observational studies, it is likely
that human tissue represents the most appropriate investigative modality.
14.1.7 Maternal Recognition of Pregnancy
As enucleation of corpora lutea in the early stages of pregnancy causes
miscarriage (Csapo et al., 1973), it is unethical to collect corpora lutea from early
human pregnancy. In the past, human luteal tissue from ectopic pregnancies has
been studied (Rao et al., 1977b; Bramley et al., 1987; Dawood and Khan-
Dawood, 1994; Nishimori et al., 1995). However, this tissue is unlikely to be
representative of normal early pregnancy, as the diagnosis is made at a gestation
when placental progesterone is becoming increasingly important (Hearn, 1986;
Zeleznik and Fairchild Benyo, 1994), and hCG production, and luteal function, is
failing (Barnea et al., 1986; Ledger et al., 1994; Duncan et al., 1995). This
problem has been tackled in the past using primate models. Corpora lutea can be
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collected from monkeys in the early stages of pregnancy and studied (Webley et
al., 1990; Hild-Petito and Fazleabas, 1997). In addition, exogenous hCG can be
administered to 'rescue' the corpus luteum (Ottobre and Stouffer, 1986; Stouffer et
al., 1987; Christenson and Stouffer, 1996a). Such studies have given valuable
insights but their use has been limited to the non-human primate (Stouffer, 1988).
A model has been developed, and validated, to 'rescue' the corpus luteum and
mimic the hormonal changes of early pregnancy in women (Illingworth et al.,
1990). This model has been used for the first time in the studies reported in this
thesis, to study the molecular effects of maternal recognition of pregnancy in the
human corpus luteum. Its novelty clearly makes this tool a unique and valuable
addition to the investigation of the human corpus luteum. Its validity is assured, as
far as the accurate simulation of the hormonal changes of early pregnancy is
concerned (Illingworth et al., 1990; Illingworth et al., 1996). However, its specific
validity depends on whether it is only hCG that is involved in luteal 'rescue' and
pregnancy recognition. Some authors have postulated that other molecules from
the uterus or embryo are involved (Johnson et al., 1993; Lower et al., 1993).
However, the available evidence is limited, and most researchers accept, as far as
current data are concerned, that hCG appears to be the sole factor involved in
maternal recognition of pregnancy in higher primates (Behrman et al., 1993;
Zeleznik and Fairchild Benyo, 1994).
14.1.8 Induced Luteolysis in the Marmoset
How representative is the marmoset model of induced luteolysis? There are
several areas which should be discussed in relation to this. The first concerns how
representative the marmoset is of normal primate physiology. The marmoset is a
small primate with an ovarian cycle similar to higher primates. There are some
differences however. The length of the marmoset luteal phase tends to be longer
than the human (Lunn, 1998). In addition, the marmoset monkey often ovulates
two follicles (Heam et al., 1978). The proportion of luteal tissue in the ovary
during the luteal phase is greater than that seen in women (Webley et al., 1990).
Indeed, there are some differences in the microanatomy of the corpus luteum.
Specific theca-lutein and granulosa-lutein cells are difficult to identify (Webley et
al., 1990), and marmoset ovaries contain accessory areas of luteinised tissue
which are steroidogenically active (Fraser et al., 1995a; Torii et al., 1996), and
may behave differently to corpora lutea. It is not clear if structural luteolysis is as
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intimately linked to functional luteolysis in the marmoset (Young et al., 1997), as
it is in the human (Corner, 1956).
These concerns mean that it is not clear how representative the marmoset is of
normal human ovarian physiology. However, the marmoset is a primate, and its
corpus luteum appears to be controlled in the same way during the luteal phase
(Lunn, 1998), during maternal recognition of pregnancy (Hearn and Webley,
1987) and, as far as we can tell, during functional luteolysis, as the human.
Although, the model has some deficiencies, it is a more valid model than
infraprimate species. Where the marmoset has its benefit, is in its size, ease of
husbandry, time to ovarian maturity (Hearn et al., 1978; Lunn, 1998), and ease of
luteolytic manipulation (Webley et al., 1991; Fraser et al., 1995b). Luteolysis can
easily be induced in the marmoset (Webley et al., 1991), and this gives us the
potential of studying closely co-ordinated changes. In addition, the fact that
disparate mechanisms can be used to induce luteolysis (Webley et al., 1991),
ensures that the effects are not specific to one treatment modality.
How representative of natural luteolysis is induced luteolysis? Things are clearly
different. In infraprimate species, induced luteolysis in frequently used in the
study of the corpus luteum (Ji et al., 1991; Endo et al., 1993a; Hehnke et al.,
1994; Smith et al., 1996b). However, due to species difference in the control of
luteolysis (Auletta and Flint, 1988), in these species, induced luteolysis mirrors
more closely what happens naturally. Induced luteolysis induces cell death and
morphological changes (Fraser et al., 1995b; Fraser et al., 1995c; Young et al.,
1997) in the marmoset. These are very dramatic, but recent studies have shown
that early follicular corpora lutea, in advanced stages of luteolysis, show similar
levels of cell death and morphological changes, albeit less marked (Young et al.,
1997). Although differences clearly exist, there appear to be parallels of induced
luteolysis with natural luteolysis (Auletta et al., 1995). The model can be
criticised, but there are advantages in studying co-ordinated luteolysis, and as far
as induced luteolysis in the primate is concerned, the marmoset is the most
studied primate model. No alternative, or more valid models, are regularly used or
are currently available.
14.1.9 Conclusions
In conclusion, the models can be criticised. However, as far as human tissue is
concerned, the model used is at least as valid as other human studies and offers
Chapter 14 General Discussion 237
the advantage of accurate dating. In addition, the use of luteal 'rescue' with
exogenous hCG gives a novel and exciting mechanism to systematically study the
corpus luteum of early pregnancy in women for the first time. The bank of human
corpora lutea is unparalleled elsewhere as a model system. There are more
deficiencies with the marmoset model. However, the model of induced luteolysis
in the marmoset is well defined (Webley et al., 1991; Fraser et al., 1995b) and,
currently, is the most used model for primate luteolysis available. The models
studied are at'least as valid as the models used in the past, from which our current
understanding of primate luteal physiology are derived.
14.2 Improvements in the Collection of Tissue
While the research reported in this thesis was underway, it became clear that
improvements were possible in the collection of tissue, and in the types of tissue
collected. It is likely that such improvements would increase the information
obtained from the molecular investigations. However, in order to ensure a
comparable set of tissues, collected with the same protocols, these improvements
were not incorporated into the protocols. However, the following changes should
be considered for future, or continuing studies.
14.2.1 Collection of Menstrual Corpora Lutea
One of the deficiencies in these studies is the lack of menstrual corpora lutea.
Clearly, luteolysis is a dynamic process, and although functional luteolysis is
complete at the end of the luteal phase, it is likely that remodelling continues
through the early follicular phase. Previous studies have looked at menstrual
corpora lutea on an ad-hoc basis (Ravindranath et al., 1992a; Brannstrom et al.,
1994a; Nishimori et al., 1995; Best et al., 1996). It has been shown that regressive
changes can be seen in early follicular corpora lutea (Young et al., 1997).
Although, the data collected on functional corpora lutea are clearly of primary
importance, studies on menstrual corpora lutea have the potential to add to the
picture, particularly when studying regression. In the future, it is suggested that
early follicular corpora lutea should also be collected.
The collection of menstrual, or early follicular, corpora lutea, however, may be
more difficult than it sounds. During the late-luteal phase, there is marked
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remodelling of the corpus luteum (Corner, 1956). It is often difficult to clearly
identify the luteal remnant macroscopically in follicular phase ovaries. Indeed,
when identified, it may be more difficult to enucleate the corpus luteum at this
time, as it is less delineated (Baird et al., 1984). These factors aside, it is likely
that menstrual corpora lutea could be collected successfully, and their inclusion
would broaden these studies, and give additional information about normal
luteolysis.
14.2.2 Tissue Fixation
It was clear from the studies reported in this thesis, that fixed tissue allowed better
morphological clarity, and thus greater ease of interpretation, than frozen tissue
sections. However, in most cases, some form of antigen retrieval was required to
allow the detection of antigens by immunohistochemistry. Often, the
immunohistochemical protocols required extensive refining to give reliable, and
reproducible results. In addition, antigen retrieval was found to reduce the
histological quality of the tissue. The fixative regimen used was quite harsh, and
different fixatives were not explored. It is possible that optimal fixation was used
in the protocol, but it remains possible that the tissues were over-fixed. Clearly,
the fixation procedures could not be changed mid-experiments, but in the future
there may be a role for an extended trial of different fixatives and different times
of fixation. This may broaden the immunohistochemical uses of the tissues.
14.2.3 Alternative Sources of Tissue
Assuming there may be a small bias in the type of luteal tissue collected, is there
any way that luteal tissue could be collected from younger women, with no
gynaecological conditions that may be hormonally related? Unfortunately, there
are very few alternative approaches to the collection of carefully dated human
corpora lutea. An approach involving the collection of corpora lutea from
normally cycling women having abdominal operations for non-gynaecological or
non-uterine pathology would be impractical for several reasons. Firstly, such
surgery would involve different surgeons and specialities, revised ethical
approval, and a much more complex identification procedure. In addition, planned
abdominal operations in young women of reproductive age, with regular cycles
are uncommon. Emergency surgery, such as that required in acute appendicitis,
would eliminate urinary dating, which is one of the strengths of the current study.
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It is possible that the rigorous screening used in hysterectomy patients would not
be as robust in general surgery patients, as gynaecological information is often
missing from the notes.
Other major gynaecological operations are not suitable. Laparotomy for reversal
of sterilisation or tubal surgery are much more infrequent procedures, and it is
known that adhesions after ovarian surgery (Dabirashrafi el al., 1991; Naether and
Fischer, 1993-; Duncan et al., 1994) may impair fertility (Weinstein and Polishuk,
1975; Toaff et al., 1976). However, there is another potential gynaecological
source. The group of patients that would form the best source of normal human
corpora lutea are those patients undergoing elective sterilisation. They are all of
proven fertility, and thus proven normal luteal function, they tend to be younger
(Wilcox et al., 1991) than women having hysterectomy, and the theoretical risk of
peri-ovarian adhesions affecting fertility would not apply. In addition, this is a
common operation, potential subjects are plentiful, and operation dates are more
flexible.
Over the period of the study, when 598 sets of pre-operative hysterectomy case
notes were examined, over 2000 female sterilisation operations were performed in
the Royal Infirmary of Edinburgh. Human luteal tissue, collected at sterilisation,
has been used by other groups (Hagstrom et al., 1996). There are, however,
several considerations which makes these patients unsuitable at present. Firstly,
the majority of women undergoing sterilisation are using hormonal rather than
barrier forms of contraception, but more importantly, the vast majority of these
operations are done laparoscopically (Penney et al., 1997). Laparoscopic surgical
skills are increasing, and laparoscopic ovarian cystectomies, and treatment of
ectopic pregnancies (Alper et al., 1992), are common-place. Although
laparoscopic luteectomy or luteal biopsy is certainly possible, it is difficult, and
not common practice.
At present, it is impractical, and probably unethical, to perform laparoscopic
luteal biopsy. The operation time would be significantly increased. This, coupled
with the potential of the highly vascular corpus luteum (Ford et al., 1982) to
bleed, (Raziel et al., 1993) and the potential requirement for an open procedure
(Raziel et al., 1993), would increase the morbidity of the operation unacceptably.
In addition, advanced laparoscopic surgery is a skill with a steep learning curve,
and not all surgeons are competent at performing it. Therefore, while it should be
remembered that sterilisation patients are a potential source of luteal tissue, with
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present skills and equipment, it is not practical or safe to consider collecting such
tissue. Whether things may change in the future is uncertain. It is therefore likely
that there is little we can do to improve the numbers, or types, of corpora lutea
collected.
14.2.4 Alternative Treatments in the Human Model
In the future, the techniques to develop a model for luteolysis in the human may
be available. More and more data on the clinical use of GnRHant in humans is
being collected. These drugs are currently being used in assisted conception
research programmes. It is possible that GnRHant could be used safely to induce
luteolysis in the human, in order to investigate co-ordinated luteolysis and allow
the discontinuation of the marmoset model.
One of the fortuitous, but unexpected, findings of this thesis is that it may be
possible to induce co-ordinated luteolysis using hCG withdrawal. One sample was
collected three days after the final hCG injection, during a 'rescue' programme.
Although this treatment excluded the sample from analysis, MMP expression was
investigated in it by gelatine zymography (Chapter 12; Duncan et al., 1998b).
Although, only this one sample was available, it appeared that the increase in
MMP activity during the late-luteal phase was accentuated. This model has never
been used before, but it should be investigated as a potential model of co¬
ordinated luteolysis, both morphologically, functionally and structurally.
Other stages of luteal development are of interest, once an understanding of the
luteal changes during the functional luteal phase have been investigated. Corpora
lutea from ectopic pregnancies have been used to imply the luteal changes of early
pregnancies. Although this can be criticised, an investigation of these corpora
lutea may give information about the failing corpus luteum or the corpus luteum
of later pregnancy. Whether used to improve the investigation, or merely to
discredit luteal tissue from ectopic pregnancy, collection of this tissue should be
considered in combination with the other tissues available. Although ectopic
pregnancies are common (Li et al., 1991b; Duncan et al., 1995), the increasing
use of laparoscopic surgical treatment may make the collection of tissues more
infrequent, and difficult than it was previously (McNeilly et al., 1980; Bramley et
al., 1987).
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Another stage of the luteal lifespan which has not been well investigated is the
corpus luteum after the luteo-placental shift. Interestingly, the luteal remnant can
sometimes be identified on one of the ovaries at caesarean section at term, and
may even be functional (Emmi et al., 1991; Sherwood, 1994). A collection of
these corpora lutea may provide valuable information about the corpus luteum in
pregnancy (Zeleznik and Fairchild Benyo, 1994).
14.3 The Findings of this Thesis
This thesis has reported several novel findings. The LH receptor and other
elements of the steroidogenic pathway are maintained, and not down-regulated,
during maternal recognition of pregnancy in women (Chapter 5; Duncan et al.,
1996a). It has shown that induced luteolysis involves a rapid loss of the LH
receptor and other elements of the steroidogenic pathway (Chapter 6; Duncan et
al., 1998a). Luteolysis is therefore clearly associated with a loss of the
steroidogenic pathway. However, the data reported here support the hypothesis
that progesterone levels decline before the changes in the steroidogenic pathway
can be detected (Chapter 7). It appears that the loss of the steroidogenic pathway
may be a consequence of the falling progesterone levels rather than the cause.
However, once progesterone levels fall, the reduction in the steroidogenic
pathway is likely to augment this decline.
Remodelling of the corpus luteum is of major importance to its structure and
function. TIMP-1 is a major product of the human (Chapter 10; Duncan et al.,
1996b) and non-human primate (Chapter 11; Duncan et al, 1996c) corpus
luteum. It appears that it may have a role in preventing MMP action, because
expression of TIMP-1 declines during induced luteolysis (Duncan et al., 1996c).
However, this effect is not seen in functional corpora lutea during natural
luteolysis in women (Duncan et al., 1996b). Here it seems likely that remodelling
is controlled by an alteration in MMP expression (Chapter 12; Duncan et al.,
1998b). MMPs can work in an environment containing large amounts of TIMPs
as they have different cellular localisations (Duncan et al., 1998b). The MMPs
seem to effect remodelling from the outside of the gland in. It is not sure why
TIMP-1 is produced in large amounts by the corpus luteum; it is possible that it
works as a facilitator of steroidogenesis (Duncan et al., 1996c). MMP expression
and action are inhibited during maternal recognition of pregnancy, by the action of
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hCG. This effect is directly on MMP rather than TIMP expression (Duncan et al.,
1996b; Duncan et al., 1998b).
Luteolysis in the functional luteal phase is associated with an influx of
macrophages (Chapter 13; Duncan et al., 1998c). This is inhibited by hCG
during maternal recognition of pregnancy (Duncan et al., 1998c). It is interesting
that hCG acts through the LH receptor. The distribution of LH receptor expression
indicates that it is unlikely that macrophages, or the cells involved in MMP
production, express these receptors (Duncan et al., 1996a). LH/hCG receptors are
found on steroidogenic cells. It is therefore likely that steroidogenic cell products
are involved in controlling macrophage influx and MMP expression. The nature
of these products are not clear. One of the potential products is progesterone itself.
Progesterone receptors can be found on the stroma and steroidogenic cells of the
corpus luteum (Chapter 8), indicating that progesterone may have an autocrine
role in the corpus luteum, and that it may be involved in controlling its own
production. However, although the progesterone receptors present are those
associated with classical hormone action, their role is unclear as they are present
in small amounts, and at constant levels, despite changing ligand concentrations.
14.4 Speculative Paradigms
How can these findings be developed into a model of how the human corpus
luteum works? The corpus luteum is a dynamic gland and models, therefore, have
to take this into account. However, for the purpose of paradigm development, the
corpus luteum can thought of in four main stages: the mid-luteal phase with
maximal progesterone production; the late-luteal phase when progesterone
production declines; the end of the late-luteal phase when progesterone
production ceases; and during luteal 'rescue' when progesterone production is
maintained. The following models are speculative, but encompass the general
understanding of primate luteal function (Behrman et al., 1993; Zeleznik and
Fairchild Benyo), combined with the new information presented in this thesis.
14.4.1 The Mid-Luteal Corpus Luteum
The mid-luteal corpus luteum is illustrated diagramatically in Fig. 14.1. A small
amount of LH is required to stimulate steroidogenesis. LH binds to its receptor
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Figure 14.1
The mid-luteal corpus luteum
Speculative cartoon of the mid-luteal corpus luteum. LH binds to its receptor on
the luteal cell membrane. This stimulates second messenger cascades. These
messengers stimulate the production of progesterone and alter factors that result in
a relative inhibition of macrophage influx, and MMP expression. The second
messengers also facilitate continued synthesis of LH receptors, and other elements
of the steroidogenic pathway.
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and activates second messenger pathways. These molecules, particularly cAMP,
stimulate the steroidogenic enzymes to synthesis progesterone. They also cause
the continued synthesis of LH receptors and other elements of the steroidogenic
pathway. The luteal cells are maximally functional, producing progesterone, and
altering the synthesis of other products, that inhibit MMP expression and
macrophage influx. The luteal cells also produce TIMP-1 which stabilises the
local ECM, promotes interaction of the luteal cell with its local matrix, and
neighbours, and inhibits tissue remodelling by MMPs. The functionality of the
steroidogenic cell is improved by these actions, and progesterone synthesis is
facilitated.
14.4.2 The Late-Luteal Phase
The late-luteal corpus luteum is illustrated in Fig. 14.2. The small amount of LH
binds to the LH receptors and activates the second messenger pathways. However
the same amount of LH stimulates a reduced amount of second messenger
molecules. There is evidence of changes in the enzyme, adenylyl cyclase (Eyster
et al., 1985; Rojas et al., 1989), and a functional uncoupling of the LH receptor
(Segaloff and Ascoli, 1993). This thesis speculates that the LH receptor
increasingly uncouples from the second messenger pathways. Several authors
have suggested that the corpus luteum, when formed, is programmed to die
(Behrman et al., 1993; Zeleznik and Hillier, 1996). It is possible that the
increasing uncoupling of the LH receptor is a function of the maturation of the
corpus luteum throughout the luteal phase.
The resulting reduced concentrations of second messengers, notably cAMP,
stimulates less progesterone output. In addition, it is postulated that less LH
receptors and other elements of the steroidogenic pathway are synthesised. This
will reduce the components of, as well as the stimulation of, the steroidogenic
pathway. One of the effects of this is to start a cycle of reduced generation of
cAMP, reduced progesterone synthesis, reduced synthesis of the components of
the steroidogenic pathway, and therefore reduced ability to respond to cAMP. The
result of this cycle, is that progesterone concentrations increasingly decline and
the corpus luteum heads inexorably towards its luteolytic fate. As well as the
declining progesterone, the production of other luteal cell products change. It is
not known whether it is the reduced production of luteal products, or the increased
production of some factors, during luteolysis, that effects macrophage influx.
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Figure 14.2
The late-iuteal corpus luteum
Speculative cartoon of the late-luteal corpus luteum. Here, LH binds to its
receptor on the luteal cell membrane but, because of increasing receptor
uncoupling, less second messenger molecules are produced. This results in less
progesterone being synthesised, and less replenishment of LH receptors and other
elements of the steroidogenic pathway. This further reduces progesterone output.
Factors synthesised by the corpus luteum are altered to favour increasing
macrophage influx and MMP expression and activity.
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However, there is an associated influx of macrophages and induction of MMP
expression and activity.
The role of the macrophages is not entirely clear. Their products may inhibit
steroidogenesis further (Brannstrom and Norman, 1993). It is also likely that
macrophage products are involved in increasing the remodelling of the ECM
(Hurwitz et al., 1993; Hulboy et al., 1997). There is clearly some ECM
remodelling and increased activity of MMPs at this stage. This is likely to be
secondary to a change in MMP/TIMP ratios. Cells which lose their contact with
the ECM are more likely to die by apoptosis (Pullan et al., 1996). It is possible
that cell death is instigated by this remodelling. It is also possible that the cells,
with their failing progesterone production, are producing more death factors and
less survival factors (Fraser et al., 1995b; Rodger et al., 1995; Spencer et al.,
1996; Rodger et al., 1998). Macrophages can begin the process of phagocytosis of
cellular and tissue debris (Paavola, 1979).
14.4.3 The End of the Late-Luteal Phase
At the end of the functional luteal phase, there is little response to the ambient
LH. This is because there is little second messenger stimulation from the LH
receptor, and the components of the steroidogenic pathway are increasingly
depleted (Fig. 4.3). Studies have shown that menstrual primate corpora lutea do
not contain LH receptors (Ravindranath et al., 1992a; Nishimori et al., 1995), or
other elements of the steroidogenic pathway (Doody et al., 1990; Bassett et al.,
1991). In addition, the speculative factors inhibiting macrophage influx or MMP
expression are also reduced. Macrophages are present in large amounts in this
stage. They are likely to produce MMPs or stimulate MMP expression. The
MMP/TIMP ratio increases, as MMPs are increasingly expressed (Duncan et al.,
1998b), and it is likely that, with the demise of steroidogenic cells, TIMP-1 levels
decline (Duncan et al., 1996c). The ECM is increasingly being remodelled,
primarily from the outside of the gland inwards, but also in small islands within
the steroidogenic cell layer (Duncan et al., 1998b).
At this stage, luteal cells begin to die by apoptosis and the gland shrinks. The
stimulus to apoptotic cell death is not clear, but it is likely to involve several
factors. The loss of cell contact with the ECM (Pullan et al., 1996; Aston et al.,
1996b) is likely to play some role. In addition, proto-oncogene expression can be
detected in the corpus luteum (Rodger et al., 1995; Fraser et al., 1995b; Rodger et
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Figure 14.3
The corpus luteum at the end of the luteal phase
Speculative cartoon of the corpus luteum at the end of the luteal phase. There are
few LH receptors and other elements of the steroidogenic pathway. Progesterone
synthesis has therefore ceased. The balance of cell products now favours the
marked influx ofmacrophages and the expression and activity ofMMPs.
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al., 1998). Although significant differences in proto-oncogene expression,
throughout the luteal phase, have not been consistently reported. It is possible
that, like in the atretic follicle (Tilly, 1996; Spencer et al., 1996; Gougeon, 1996),
an alteration in the expression of cellular survival and death genes (Tilly, 1996) is
involved in initiating luteal cell death. Clearly the macrophage is involved in the
phagocytosis of apoptotic bodies and the clearance of cellular debris. It is also
possible that endothelial cells, as well as steroidogenic cells, die (Fraser et al.,
1995c; Modlich et al., 1996). This would block local capillary blood flow
(Modlich et al., 1996), and reduce the blood supply to the corpus luteum. The net
effect of these processes is a reduction in the size of the gland, increased tissue
remodelling, and a marked reduction in its vascularity.
14.4.4 Luteal 'Rescue'
The cellular events surrounding luteal 'rescue' are illustrated in cartoon form in
Fig. 14.4. The reduced stimulation of the second messenger system, possibly
second to functional uncoupling of the LH receptor, is still present. As the corpus
luteum matures, as postulated above, this uncoupling increases. However, there
are increasing amounts of hCG in the circulation (Lenton and Woodward, 1988).
This hCG acts through the LH receptor. As the primate LH receptor does not
down-regulate in the presence of an excess of its ligand (Duncan et al., 1996a),
this results in an increased stimulus to the second messenger pathways. The
increasingly high ligand levels, in the presence of increasingly uncoupled
receptors, maintains a similar amount of second messenger molecules. This
maintains the production of progesterone and the synthesis of each element of the
steroidogenic pathway.
As well as maintaining the production of progesterone, the factors inhibiting
MMP expression and macrophage influx are maintained. This maintains, or
reduces, the MMP/TIMP ratio. The ECM is stabilised, and in the presence of a
stable ECM, and a potential excess of survival factors, apoptosis of the luteal cells
is inhibited. There is no proliferation of the endothelial cells during luteal 'rescue'
(Christenson and Stouffer, 1996a; Rodger et al., 1997), but luteal blood flow is
clearly maintained (Glock and Brumsted, 1995; Kupesic and Kurjak, 1997). The
increasing LH receptor uncoupling requires logarithmically increasing hCG to
maintain adequate adenylyl cyclase stimulation, and progesterone production.
However, the life of the corpus luteum can only be prolonged in the short term,
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Figure 14.4
Luteal 'rescue' during maternal recognition of pregnancy
Speculative cartoon of the cellular mechanisms in luteal cells at the time of luteal
'rescue' by hCG, during maternal recognition of pregnancy. The presence of large
amounts of hCG causes increased stimulation of the LH receptors on the luteal
cell membranes. Although, the LH receptor is increasingly uncoupled, this
increased receptor stimulation maintains the levels of intracellular second
messengers. These molecules maintain steroidogenesis and stimulate the
continued synthesis of LH receptors and other elements of the steroidogenic
pathway. The continued function of the luteal cells, changes the balance of
products to prevent macrophage influx and MMP expression.
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and by the time of the luteo-placental shift, the increasing synthesis of hCG
cannot be maintained and, as the corpus luteum is now relatively unreactive to
hCG, regression begins.
14.5 Strategy for Further Investigation
It is not known how accurate the above paradigms are. However, it is likely that
there is some degree of relevance to how the human corpus luteum works. What
the above paradigms do achieve, is the development of hypotheses, that can be
validated or refuted by further study. The corpus luteum has been likened to an
unfinished jigsaw. Many of the pieces are still missing. However, the
development of the speculative pathways, outlined above, has highlighted several
key areas that need to be defined and explored. The following section focuses on
some of these areas, and begins the search for some crucial missing pieces.
14.5.1 Luteal LH/hCG Action
When considering the speculative paradigms above, there are several assumptions
that are made. The first premise is the functional uncoupling of the LH receptor as
the corpus luteum matures. This is fundamental to the theories about the control
of the primate corpus luteum presented in this thesis. Such uncoupling has
previously been suggested by in vitro studies of the LH receptor (Ezra and
Salomon, 1980; Segaloff and Ascoli, 1993). However, previous strategy for the
study of the LH receptor, has involved the study of these receptors in mouse cell
lines, or in rat tissues (Segaloff and Ascoli, 1993). This approach has its
problems. It is clear that there are fundamental differences in the behaviour of the
LH receptor in rodent and primate luteal tissues, particularly with reference to
down-regulation (Caldwell et al., 1980; Peegel et al., 1994; Duncan et al., 1996a).
Clearly studies of the coupling of the LH receptor are required in human cells
expressing the human LH receptor.
Studies on the LH receptor, and the coupled enzymatic complex, may be possible
on luteinised granulosa cells (Soto et al., 1984; Sjogren et al., 1991; Lopez Bernal
et al., 1995; Takao et al., 1997). Indeed, this may be the best way to investigate
the human LH receptor in the first instance. However, one of the major questions
to be answered involves the nature of the differences between the behaviour of the
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rat LH receptor and that of the primate. Why does the human LH receptor not
down-regulate? It is difficult to envisage how this question can be addressed. A
comparison of human and rat LH receptor gene response elements, and functional
studies involving transient gene expression of these receptors in rat and human
cells, may give additional information.
An investigation of LH receptors, and their coupled intercellular responses,
requires careful in vitro studies of luteal cells. The response on luteal cells to
LH/hCG in vitro, at different stages of the luteal phase, has been investigated in
the past (Stouffer et al., 1977). However, these experiments should be repeated
with the newer molecular, and cell imaging, techniques now available. Clearly, a
careful study of the numbers and availability of LH receptors (Cameron and
Stouffer, 1982; Ottobre et al., 1984; Bramley et al., 1987; Segaloff and Ascoli,
1993), coupled with the ability of ligand to stimulate second messenger
molecules, in vitro, would be of great interest. There is, therefore, a role for
continuing in vitro studies of luteal cell function.
It is possible to investigate luteal steroidogenic cells in vitro. In general,
individual luteal cells are obtained by enzymatic digestion of corpora lutea (Lei et
al., 1991; Brannian et al., 1993). However, enzymatic digestion can effect the
integrity of membrane proteins, including the LH receptor. It has therefore been
suggested that mechanical separation and elutriation of individual cells may be a
more useful technique to obtain intact luteal cells (McLean et al., 1992). It has
been noted, however, that other cells, particularly white cells, that contaminate
cultures (Spanel-Borowski and Ricken, 1997), can affect steroidogenesis (Kirsch
et al., 1981; Kirsch et al., 1983; Halme et al., 1985). This may be a problem in the
assessment of primary cultures from different stages of the luteal phase, as the
immune cell content of corpora lutea changes throughout the luteal phase (Wang
LJ et al., 1992; Brannstrom et al., 1994a; Best et al., 1996; Duncan et al., 1998c).
In addition, primary cell culture involves a breakdown in intercellular
communications, and an alteration in the cellular composition, and relationships,
that may be of fundamental importance to normal luteal function. One solution, to
this problem, may be the use of thin luteal slices (Girsh et al., 1996; Hagstrom et
al., 1996; Fairchild Benyo and Zeleznik, 1997). This technique has the potential
to be more accurate than single cell culture, in that cells remain intimately
associated with their natural neighbours. However, the effects of the inevitable
tissue damage, and cytokine release, during slicing, remain uncharacterised.
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It is possible that there is a change in the nature of the LH receptor itself that
effects its ability to couple to G-proteins. The LH receptor is known to undergo
alternate splicing, and several splice variants have been detected. LH receptor
splice variants have been reported in rodents (Aatsinki et al., 1992), sheep (Bacich
et al., 1995), and pigs (VuHai-LuuThi et al., 1992). Indeed, it is thought that the
full length receptor is only a minority of the LH receptor mRNA synthesised
(Bacich et al., 1995). These splice variants tend to lack varying amounts of the
mRNA which codes for the transmembrane domains (Themmen et al., 1994).
Indeed, once translated, different splice variants appear to have different
functional characteristics. It is likely that changes in the levels of different splice
variants may effect the overall functionality of the LH receptor. It is not known,
though, if these variants change throughout the luteal phase. However, it has
recently been shown that both marmoset testicular, and human luteal, tissues do
express LH receptor splice variants (Zhang et al., 1997; Minegishi et al., 1997).
Clearly studies on the functionality, distribution, and ontogeny, of these splice
variants in the human corpus luteum are required.
There is, therefore, still a place for the continued study of LH/hCG receptor in
human corpora lutea. Clearly though, a robust model of LH receptor expression
and coupling to second messenger pathways, is required. This, for practical
purposes, is likely to be a cell culture based system. Techniques for the estimation
of cAMP formation in vitro have been developed (Lopez Bernal et al., 1995). In
addition, calcium imaging can be used to look at intracellular effects of receptor
action in hormone sensitive tissues (Anderson et al., 1996). It is therefore possible
to study the stimulation of second messengers in response to LH binding. These
experiments should, in addition, be combined with an investigation of the
steroidogenic effects of membrane permeable formulations of cAMP, in vitro
(Jordan, 1981; Soto et al., 1984). This has the potential to dissect the
contributions of receptor uncoupling to adenylyl cyclase, and the down-stream
actions of cAMP, during functional luteolysis. It is likely that we have not heard
the last about the LH receptor of the primate corpus luteum.
14.5.2 Paracrine Molecules
It is not clear what factors control the local effects of hCG in the corpus luteum,
postulated in the paradigms described above. There are many different potential
paracrine molecules in the corpus luteum (Behrman et al., 1993; Nappi et al.,
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1994; Zeleznik and Fairchild Benyo, 1994). Clearly, each potential regulatory
molecule needs to be detected and localised in primate corpora lutea in the first
instance. Once identified and characterised, the effects of these molecules, and the
factors controlling their expression, need to be investigated. It is only then that the
contribution of each individual molecule can be mapped. As there are any number
of potential regulatory molecules, it is important to specifically target likely
molecules for the initial detailed studies. One of the groups of molecules worthy
of further investigation are the IGFs. This is because they have been shown to
have a major role in folliculogenesis (Hillier, 1991; Jones and Clemmons, 1995),
and they can be detected in the corpus luteum (Hernandez et al., 1992; Johnson et
al„ 1996).
A systematic investigation of the expression, localisation, and source, of the IGFs
in the human corpus luteum throughout the luteal phase and after luteal 'rescue' is
indicated. In addition, the cellular localisation of IGF receptors, in the same
circumstances, would be of interest. It is now clear that the actions of IGFs can be
modified by IGFBPs (Jones and Clemmons, 1995). It is also clear that the ECM
can form a repository for these molecules (Jones and Clemmons, 1995; Hulboy et
al., 1997), and that any agent which modifies the ECM can alter local IGF
bioavailability. One of the most interesting recent developments is the localisation
of IGFBP-3 to the vascular endothelial cells of the corpus luteum (Fraser et al.,
1997). The role of IGFBP-3, and its expression throughout the luteal phase, are
clearly an important area for study.
There is increasing interest in the role of glucocorticoids in ovarian function (Daly
et al., 1984; Wang et al., 1993; Waddell et al., 1996; Lopez Diaz and Bosu,
1997). A variety of sex steroid receptors can be localised to the corpus luteum
(Horie et al., 1992; Suzuki et al., 1994), and it appears that glucocorticoid
receptors are no exceptions (Sugino et al., 1997). In addition, corticotrophin
releasing factor (CRF) may have a role in ovarian function (Apa et al., 1995;
Asakura et al., 1997; Erden et al., 1998). The role of adrenal steroids in the corpus
luteum is not known. However, an interesting observation is the expression of
1 lp-hydroxysteroid dehydrogenase (llp-HSD) in rodent (Waddell et al., 1996),
and human corpora lutea (Ricketts et al., 1998) This enzyme is involved in the
conversion of Cortisol to cortisone, and it serves to reduce a tissue's exposure to
Cortisol (Waddell et al., 1996). There is some evidence that the expression of this
enzyme changes during the luteal phase (Waddell et al., 1996). A review of the
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ability of the corpus luteum to synthesise local corticosteroids, respond to them,
and alter their local bioavailability is therefore indicated. This investigation could
start with a detailed analysis of the expression of nuclear glucocorticoid receptors,
and 11 p-HSD, in the corpus luteum, throughout the luteal phase and after luteal
'rescue' with exogenous hCG.
14.5.3 Inhibins and Activins
It is likely that inhibins and activins have major roles in the corpus luteum. It is
only now that these potential roles are coming to light. Messenger RNA for the
subunit building blocks of inhibin and activin are expressed in the primate corpus
luteum (Fraser et al., 1993; Roberts et al., 1993). In addition, inhibin and activin
proteins can be detected in the corpus luteum (Cuevas et al., 1987; Smith et al.,
1991; Wada et al., 1996), and in the peripheral circulation during the luteal phase
of the ovarian cycle (Groome et al., 1996; Muttukrishna et al., 1996). It is likely
that these proteins have an endocrine effect on pituitary FSH secretion (Burger
and Igarashi, 1988; Fraser and Lunn, 1993). However, it is possible that they have
paracrine effects in the corpus luteum. Inhibin and activin, in particular, have the
potential to modulate luteal cell steroidogenesis (Hillier et al., 1991a; Miro and
Hillier, 1992; Brannian et al., 1992). Indeed, expression of inhibin and activin
changes during the luteal phase. Serum studies have suggested that inhibin A
declines in the late-luteal phase (Groome et al., 1996), at a time when activin A
tends to increase (Muttukrishna et al., 1996).
In vitro studies, and observational studies in vivo, have suggested that luteal cell
inhibin, particularly the a-subunit, is stimulated by LH/hCG (Eramaa et al., 1994;
Illingworth et al., 1996). It is therefore possible that gonadotrophin-stimulated
expression of the a-subunit, promotes inhibin A expression in the functional
corpus luteum, during the mid-luteal phase, and after luteal 'rescue' (Illingworth et
al., 1990; Illingworth et al., 1996). It is also possible that a relative reduction in
gonadotrophin action, in the late-luteal phase, reduces a-subunit expression
(Fraser et al., 1995a). This means that the relative concentrations of the p-
subunits, which are less affected, increase. This serves to facilitate the synthesis of
activin. Indeed, it appears that luteal activin A concentrations increase at the end
of the luteal phase (Roberts et al., 1993; Muttukrishna et al., 1996). Activin A can
promote cell death, and can directly inhibit steroidogenesis (Brannian et al., 1992;
Miro and Hillier, 1992; Nishihara et al., 1995; Wang et al., 1996).
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This potential local role of activin in the corpus luteum during the luteolytic
process, is highly speculative. Activin secretion at the end of the luteal phase may,
solely, be an endocrine stimulus to pituitary FSH secretion in preparation for the
early follicular phase (Baird and Smith, 1993). However, activin receptors have
now been identified at a molecular level (Shinozaki et al., 1992; Cameron et al.,
1994; Eramaa et al., 1995), and they can be detected in luteinised granulosa cells
(Eramaa et al., 1995). There is, therefore, a role for the further investigation of
activins and inhibins in the human corpus luteum throughout the luteal phase.
Clearly classic endocrine and paracrine studies should be performed in vivo, when
agonists and antagonists are available in large enough doses. However, in the first
instance, a quantitative analysis ofmRNA expression of each subunit throughout
the luteal phase, and after luteal 'rescue', is indicated. In addition, molecular and
functional studies to identify the expression, type and localisation of activin
receptors in the human corpus luteum would also be of interest.
14.5.4 Prostaglandins
Further studies of the potential effector molecules, involved in primate luteolysis,
are required. It is clear that prostaglandins, particularly PGF2a, have local roles in
luteolysis in infraprimate species (Auletta and Flint, 1988; Niswender and Nett,
1994). In some primate species, notably the marmoset monkey, systemic PGF2a is
also luteolytic (Webley et al., 1991; Fraser et al., 1995b). In addition, there is
evidence that prostaglandins may have a local role during luteolysis in the primate
(Patwardhan and Lanthier, 1980; Auletta et al., 1984a; Auletta et al., 1984b;
Auletta et al., 1990; Zelinski-Wooten and Stouffer, 1990). It is certainly possible
that primates and infraprimate species have similar local mediators of luteolysis.
These mediators are likely to include PGF2a.
The PGF2a receptor has now been cloned (Lake et al., 1994; Graves et al., 1995).
Several studies have therefore reported the expression of these receptors in
infraprimate corpora lutea (Rueda et al., 1995b; Juengel et al., 1996; Olofsson et
al., 1996; Mamluk et al., 1998). Crude early binding studies reported PGF2cc
receptors in human corpora lutea (Powell et al., 1974; Rao et al., 1977a), and
recently receptor mRNA has been described in luteinised granulosa cells
(Ristimaki et al., 1997). It is not just PGF2a that may be involved in controlling
luteal function, other PGs have also been implicated (Zelinski-Wooten and
Stouffer, 1990; Olofsson and Leung, 1994). It is now possible for an extended
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molecular investigation of PG receptors in the human corpus luteum. The
expression and localisation of PG receptors should be investigated throughout the
luteal phase and after luteal 'rescue' with exogenous hCG in women, and
throughout the luteal phase, and after induced luteolysis, in the marmoset.
The synthesis of prostaglandins, and how their synthesis is controlled, is also
likely to be important. It is now possible to investigate the expression and the
localisation of the major enzymes involved in PG synthesis and metabolism.
Although the COX enzymes, and prostaglandin dehydrogenase (PGDH), have
been studied in different systems, a systematic study of their expression in the
human corpus luteum is required. The time is right for a revisitation of the effects
of prostaglandins in the primate corpus luteum using current molecular
technologies.
14.5.5 Progesterone
One of the most intriguing questions, about the control of the corpus luteum,
remains unanswered. Does progesterone regulate its own synthesis, or the
integrity of the gland, at a local level? It has been postulated that paracrine actions
of progesterone are involved in controlling steroidogenesis (Rothchild, 1981;
Duffy et al., 1994; Rothchild, 1996). The initial technique used to investigate
progesterone action in the corpus luteum utilised the progesterone antagonist,
RU486. This approach had problems, as RU486 had direct effects on the secretion
of luteotrophic gonadotrophins from the pituitary (Schaison et al., 1985; Batista et
al., 1994). Newer, elegant techniques, using 3p-HSD inhibitors, are now being
used to investigate the local effects of progesterone in the corpus luteum.
Although these experiments are generating useful data, they also have associated
problems, which makes full interpretation of the results difficult. Although the
morphology of the corpus luteum is markedly altered (Duffy et al., 1994), it
appears that the corpus luteum continues to synthesise normal amounts of some
hormones, notably relaxin (Duffy et al., 1995; Duffy et al., 1996). In addition,
oestrogen synthesis was unexpectedly, and inexplicably, maintained during
treatment with trilostane, in this experimental model (Duffy et al., 1994). The
results and conclusions of these studies remain controversial.
It may be that progesterone precursor molecules, accumulate in the corpus luteum
after trilostane treatment. The build up of these steroids, using this method, may
interfere with the structure and function of the corpus luteum per se. Although the
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use of 3P-HSD inhibitors in vivo, has generated interesting results (Duffy et al.,
1994; Slayden et al., 1994; Duffy and Stouffer, 1995; Duffy et al., 1996), it is
likely that other approaches are required. One approach may be to add back LH
during treatment with RU486. An earlier study used hCG in addition to RU486,
and found that RU486 had little effect on luteal function (Croxatto et al., 1989).
However, this was a crude and unphysiological approach. It may be that a more
sophisticated control of pituitary LH after RU486 treatment is required.
One approach may be to use pulsatile LH, or GnRH, infusions to stimulate the
corpus luteum, as used previously in the classic endocrinological experiments
(Hutchison et al., 1986; Zeleznik and Fairchild Benyo, 1994). This would allow
physiological LH concentrations to be present in the presence of RU486 or excess
additional exogenous progesterone. The effect of this regimen on the corpus
luteum should be studied both functionally and structurally. Parameters for study
should include secretory products of the corpus luteum. If the progesterone
concentrations cannot be adequately assessed, other hormones such as relaxin
(Sherwood, 1994) and inhibin A (Groome et al., 1996), should be investigated. In
addition, corpora lutea should be collected for structural and functional
investigation in vitro. Morphological indicators of luteal function, such as LH
receptor and steroidogenic enzyme expression, MMP expression, and macrophage
influx should be studied. It is of interest that rodent models cannot be used for
such studies as, unlike primates, they do not express luteal progesterone receptors
(Parke-Sarge etal., 1995).
There is continuing debate about specific non-genomic progesterone receptors in
the corpus luteum (Rae et al., 1998). Non-genomic actions of progesterone may
be secondary to non-specific membrane effects, or specific membrane associated
receptors. It is not known whether these receptors exist as distinct entities, but
there is quite convincing evidence, from sperm studies, that progesterone has
actions that cannot be explained by the presence of classical nuclear progesterone
receptors (Luconi et al., 1998; Revelli et al., 1998). Indeed, there is an increasing
body of evidence for membrane-associated progesterone binding sites, in
infraprimate corpora lutea (Bramley and Menzies, 1988; Bramley and Menzies,
1994; Rae et al., 1998). The corpus luteum may, therefore, prove a source of
tissue in the molecular search for the non-genomic progesterone receptor. The
local effects of progesterone, at genomic and membrane levels, on cellular
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function in the corpus luteum are not fully understood. However, they are likely to
be important, and suitable for further study.
14.5.6 Cellular Connections and Fine Structure
It is increasingly clear that cellular connections, with each other and the ECM, are
very important for normal tissue function. There is recent evidence about the
expression of adhesion molecules, integrins, connexins and gap junction
molecules in the corpus luteum (Okuma et al., 1996; Khan-Dawood et al., 1996b;
Khan-Dawood et al., 1996c; Simon et al., 1997; Honda et al., 1997). One of the
potential ways that MMPs may effect tissue remodelling and affect luteal
function, is by catalysing the alteration, or destruction, of these molecules. Indeed,
if these molecules are of primary importance in luteal function, one of the
functions of TIMPs may be to stabilise, and maintain them. Clearly, a systematic
investigation of these molecules, throughout the luteal phase, and after luteal
'rescue' in the primate, would be timely.
One of the most powerful tools in the analysis of dynamic tissue processes, is
snap shot studies at the morphological level. Such studies have clarified the tissue
processes surrounding ovulation (Pederson, 1951; Tsafriri and Dekel, 1994; Espey
and Lipner, 1994), and increased our basic understanding of how ovulation occurs
(Espey, 1994). There have been careful studies on the histological structure
(Corner, 1956), and fine structure (Gillim et al., 1969), of the human corpus
luteum throughout the luteal phase. However, these studies are now several
decades old. There is clearly a role to reassess the morphology and ultrastructure
of the corpus luteum, as additional information could now be collected. This is
because: there have been marked improvements in the quality ofmicroscopes, and
higher power light magnification; the corpus luteum could be assessed in light of
current knowledge; clear endocrinological dating of the corpus luteum is possible;
additional immunohistochemical techniques are now available for cellular
identification and clarification; and it is now possible to use the luteal 'rescue'
model to investigate the changes of early pregnancy.
A systematic morphological study of the human corpus luteum would be of great
interest in the present climate. Indeed, there has been a move towards more
morphological studies of the corpus luteum (Kim-Bjorklund et al., 1991a; Kim-
Bjorklund et al., 1991b; Retamales et al., 1994; Khan-Dawood et al., 1996a; Torii
et al., 1996). A simple re-analysis of the morphological changes in luteolysis and
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luteal 'rescue' may give pointers to future areas of study. In addition, it is easier to
understand the distribution ofmRNA and protein species in the corpus luteum, if
a clear description of its detailed morphology, and dynamic morphological and
temporal changes, is available. There is still a role for simple morphological
analysis of the corpus luteum.
14.5.7 Tissue Remodelling
This thesis has provided the first evidence about MMP and TIMP expression in
the primate corpus luteum. There are several potential areas of study to expand
these observations. The first area, is an investigation of the nature of the cells
expressing MMP-9 in the human corpus luteum. MMP-9 is expressed is
individual cells in the granulosa-lutein cell layer. Good antibodies for MMP-9 are
now available (Nikkari et al., 1996). It should now be possible to investigate the
cellular localisation of MMP-9 by immunohistochemistry, in sections of human
corpus luteum. Indeed, it is possible that this immunohistochemistry could be
performed on fixed sections, with improved morphological definition.
If better morphological definition is not sufficient to allow the identification of
these cells, then dual staining immunohistochemistry (Rodger et al., 1995), with
white cell, and steroidogenic cell markers may help. Now techniques exist for a
combination of isotopic mRNA in situ hybridisation with immunohistochemistry
(Millar et al., 1995), and these techniques may be valuable assets in the
investigation of the cellular localisation of MMP-9. However, one of the
confusing aspects of MMP localisation in the corpus luteum, is whether
granulosa-lutein cells themselves are able to synthesise and secrete MMPs. It is
certainly thought they can in culture (Puistola et al., 1996a; Aston et al., 1996a).
However, in tissue sections, investigation of MMP expression by mRNA in situ
hybridisation, revealed only minimal levels of expression in these cell types
(Duncan et al., 1998b). Whereas it is likely that luteinised granulosa cells,
deprived of normal cellular connections, in culture, themselves secrete MMPs, it
is possible that the results are influenced by white cell contamination of these
cultures (Spanel-Borowski and Ricken, 1997). Immunocytochemistry on cytospin
granulosa cell cultures, using white cell, and steroidogenic cell markers, may help
identify the cellular source ofMMPs in these experiments.
Another interesting area highlighted is the role of TIMP-1 as a facilitator of
steroidogenesis. Further work requires to be done on the expression of TIMP-1 in
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non-luteal steroidogenic tissues. In addition, its direct steroidogenic effects in
culture (Boujrad et al., 1995), need to be confirmed in different culture
conditions, in various endocrine systems, and by other groups. The mechanism of
the steroidogenic effects of TIMP-1, in culture, requires dissection, especially in
light of the finding that bovine TIMP-1 has sequence homology with StAR
(Hartung et al., 1995). The steroidogenic effect of TIMP-1 is thought to occur in
combination with procathepsin-L (Boujrad et al., 1995). The expression and
localisation of procathepsin-L in the primate corpus luteum, and in other TIMP-
expressing tissues, has not yet been studied. This needs to be documented.
There are at least 17 forms of MMP (Hulboy et al., 1997). This thesis has
investigated the more common ones. It remains possible that other MMPs have a
major role in the function and structure of the corpus luteum, throughout the luteal
phase and during maternal recognition of pregnancy. Further studies on the other
MMPs, particularly matrilysin (MMP-7) and the stromelysins 1,2 and 3 (MMP-3,
MMP-10, MMP-11), are required. They appear to have roles in menstruation
(Salamonsen and Woolley, 1996; Hulboy et al., 1997), a process with many
parallels with luteolysis. Serine proteinases have been implicated in the local
activation ofMMPs (Hulboy et al., 1997). Indeed, plasminogen activator has been
identified in the ruminant and rat corpus luteum (Liu et al., 1996; Smith et al.,
1997). Clearly, information on its expression in the human corpus luteum is
required.
One of the problems with the interpretation of MMP expression is that the
detection of mRNA and protein, does not necessary mean active remodelling.
These proteins require to be activated from their pro-enzyme precursors
(Woessner, 1991; Birkedal-Hansen, 1995), and in their active form, they are
inhibited by TIMPs. It is difficult to assess, in individual areas of the tissue,
whether local MMP/TIMP ratios favour MMP action, or MMP inhibition. It is
therefore difficult to accurately predict the action of MMPs in the presence of
TIMPs. One of the ways to tackle this problem is to use a novel technique known
as in situ zymography (Galis et al., 1995). This technique allows the assessment
ofMMPs in their native environment. It allows for the detection ofMMP activity
in tissue sections containing the normal local levels of TIMPs. In addition, it does
not result in the artificial activation of MMP pro-enzymes, that is evident when
gelatine zymography is used (Salamonsen, 1996). This technique would give
Chapter 14 General Discussion
valuable information about how the MMPs effect local tissue remodelling during
luteolysis.
14.5.8 Endothelial Cells and Angiogenesis
In order to gain access to luteal steroidogenic cells, from the circulation,
molecules have to cross the endothelial cell layer (Ghinea and Milgrom, 1995).
The endothelial cells therefore have the potential to influence luteal function. The
finding of IGFBP-3 in endothelial cells suggests they may be involved in the local
control of IGF availability (Fraser et al., 1997). In addition, luteal cells may
influence endothelial cells. It is likely that the steroidogenic luteal cells are
responsible for the production of angiogenic factors such as VEGF (Redmer et al.,
1996; Gordon et al., 1996). It is also likely that luteal cells can produce vasoactive
products such as NO and endothelin (Flores et al., 1995; Kamada et al., 1995;
Magini et al., 1996; Shiels et al., 1996), that may have direct effects on
endothelial function (Gross, 1995).
It is also possible that endothelial cell death can influence the survival and
function of other luteal cells (Modlich et al., 1996). As over 50% of cells in the
mature corpus luteum are endothelial cells (Dharmarajan et al., 1985), factors
influencing their function have the ability to profoundly affect luteal cell function.
To investigate luteal endothelial cells, several groups are now looking at these
cells in primary culture (Spanel-Borowski, 1991; Bagavandoss and Wilks, 1991;
Christenson and Stouffer, 1996b). Such an approach, combined with a
steroidogenic cell co-culture, may reveal information about the endothelial-
steroidogenic cell interaction and co-dependence.
Luteal angiogenesis is very marked (Reynolds et al., 1992; Redmer and Reynolds,
1996), and groups involved in studying angiogenesis during neoplasia, are now
increasingly aware of the corpus luteum as a model for angiogenesis. Recent
studies have confirmed the high levels of angiogenesis and endothelial cell
division during the early-luteal phase (Christenson and Stouffer, 1996; Rodger et
al., 1997). Indeed angiogenesis is fundamental to luteal function (Ferrara et al.,
1998). Disruption to angiogenesis has profound effects on luteal function in some
models (Ferrara et al., 1998). It is therefore useful to use the corpus luteum as a
model to study luteal angiogenesis, angiogenesis in general, and the effects of
inhibitors of angiogenesis (Folkman, 1985; Reynolds et al., 1992). It is likely that
luteal angiogenesis will be one of the most important areas of study in the future.
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14.5.9 Novel Molecules
These approaches to studying the corpus luteum focus on recognised molecules. It
is possible that novel, or unrecognised molecules are vital to the structure and
function of the corpus luteum. At present, studies of the corpus luteum investigate
molecules, and molecular processes, that have been shown to be important in
other cellular systems, or relevant cell culture models. It is possible that the
corpus luteum has some pathways or proteins which are either unique to the
corpus luteum, or are much more important in the corpus luteum than in other
systems. One method of detecting such proteins is to use comparative protein
gels, at different, clearly defined, stages of the luteal phase. This is possible, by
using the technique of two dimensional protein gel electrophoresis (McLaren et
al., 1994). This technique is commonly used to look at changes in protein
production after damage to spermatogenesis (Turner et al., 1996). Consistent
changes in unspecified proteins throughout the luteal phase and after luteal
'rescue' can therefore by identified, and the proteins characterised.
In addition, total mRNA expression can be analysed, at different stages of the
luteal phase, by differential display and subtractive hybridisation (Shima et al.,
1995; Wolf et al., 1997; Jin et al., 1997). This allows consistent differences in
mRNA expression across the stages of the luteal phase to be detected and
analysed. Using this technique, it is relatively straightforward to identify the
nature of the consistently changing mRNA species. One of the attractive features
of this approach is that, experiments using the well-characterised human luteal
'rescue' model, often reveal little change in protein, or mRNA, expression
throughout the luteal phase (Rodger et al., 1995; Duncan et al., 1996a; Duncan et
al., 1996c; Rodger et al., 1998). It is therefore likely that most mRNA species will
not change consistently, and resources can be focused towards the ones which do.
The disadvantages of these techniques, includes the fact that they are technically
difficult, and expensive in terms of time, materials and equipment. Indeed,
preliminary studies reveal some problems with reproducibility. In addition,
funding bodies often look less favourably on techniques that are less clearly
focused and involve more trial and error. Although these techniques are powerful,
with great potential, it is likely that their application to the corpus luteum would
be difficult.
However, although difficult, these techniques have the potential to highlight
unexpected gene expression of fundamental import to luteal physiology, and even
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general cellular biology. However, it remains possible that no helpful results
would be detected. Subtractive hybridisation and differential display are novel
methods for exploring the corpus luteum that may become increasingly important
with continued technique refining. In addition, there is a clear role for the
preparation of human luteal libraries. This would provide a necessary resource for
the identification, and characterisation, of novel genes expressed in the corpus
luteum. In addition, as the corpus luteum is a dynamic tissue, that has many
globally important properties, it would would be an ideal source to form the basis
of a powerful human library with general application.
14.6 Research Priorities
This thesis has described some elements which clearly change over the functional
luteal phase. This is important, as many previous experiments have found little
change in a variety of molecules studied (Rodger et al., 1995; Duncan el al.,
1996a; Duncan et al., 1996c; Rodger et al., 1998). Therefore, these changes form
a starting point to allow characterisation of the molecular changes controlling
luteal function. An investigation into the nature of these changes, and a dissection
of the causes, and their controls, should therefore be priorities for future related
research. The two main areas of change were the influx of macrophages into the
corpus luteum (Duncan et al., 1998c), and the increased expression and activity of
MMP-2 (Duncan et al., 1998b). It is these areas which form the research priorities
for the continuation of the work in the thesis.
14.6.1 Macrophage Influx
There is certainly an influx of macrophages into the human corpus luteum during
luteolysis (Wang LJ et al., 1992; Best et al., 1996; Takaya et al., 1997; Duncan et
al., 1998c), and this influx begins during the functional luteal phase. It is also
likely that these macrophages have inhibitory effects on the function and structure
of the corpus luteum (Norman and Brannstrom, 1994). However, it is not known
what factors are involved in this influx of macrophages. What is now known, is
that hCG during luteal 'rescue' prevents this influx (Duncan et al., 1998c). As
LH/hCG receptors are localised to the steroidogenic cells, it appears that
steroidogenic cell products are involved in controlling macrophage influx. It is not
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known whether hCG stimulates inhibitors of macrophage chemotaxis, or hCG
inhibits the formation of chemotactic molecules.
Although many molecules, including IL-8 (Critchley et al., 1994), are known to
be chemoattractant, one of the major molecules involved in macrophage influx is
MCP-1 (Leonard and Yoshimura, 1990). Studies on infraprimate corpora lutea
have found the expression of MCP-1 (Townson et al., 1996), and it seems to be
elevated during macrophage influx (Bowen et ah, 1996; Naftalin et al., 1997). At
the moment MCP-1 is the best candidate molecule involved in macrophage
influx. However, its expression in the primate remains to be fully investigated. A
preliminary report has recently suggested that MCP-1 can, indeed, be detected in
the human corpus luteum (Senturk et al., 1997). However, a clear research priority
is the systematic assessment of the expression and localisation of MCP-1 in the
human corpus luteum, throughout the luteal phase and after luteal 'rescue' with
exogenous hCG.
14.6.2 MMP-2 Expression
One of the factors which clearly changes during the transition between luteolysis
and luteal 'rescue' is the expression ofMMP-2 (Duncan et al., 1998b). Expression
of MMP-2 is, therefore, likely to have a role in the remodelling associated with
luteolysis. However, the factors involved in its production are not clear. As MMP-
2 distribution (Duncan et al., 1998b) differs from that of the LH receptor (Duncan
et al., 1996a), it is likely that luteal cell products, rather than hCG, are involved in
the control of its expression. It is also likely that the source ofMMP-2 is the non-
steroidogenic cells at the periphery of the corpus luteum (Duncan et al., 1998b).
One approach to the investigation ofMMP-2 expression, is the utilisation of a cell
culture system. Establishment of luteal cells with the potential to express MMP
would be important in this case. This has been achieved with luteinised granulosa
cell culture (Puistola et al., 1995; Aston et al., 1996a). However, an attempt to
culture non-steroidogenic stromal fibroblast-like cells from the corpus luteum
may prove more useful. The effect of various luteal cell products including
progesterone, IGFs, inhibin, activin and cytokines could be investigated. In
addition, a search for steroid response elements in the MMP-2 gene, and the
presence of steroid and protein receptors on the MMP-2-producing cells would
give valuable additional information. The nature of the factors controlling MMP-2
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expression should be one of the priorities for research on the primate corpus
luteum.
14.7 Overall Conclusion
This thesis has used novel models of primate luteal function to investigate the
corpus luteum throughout the luteal phase, after luteal 'rescue' with exogenous
hCG, to simulate the hormonal changes of early pregnancy, and after induced
luteolysis. Together, these models are unique, and have resulted in a bank ofwell
characterised human, and non-human primate, luteal tissue, unsurpassed
anywhere in the world. The use of these tissues has allowed insight into the
changing nature of the steroidogenic and remodelling pathways throughout the
primate luteal phase.
The findings reported in this thesis have been published in several peer reviewed
journals (Duncan et al., 1996a; Duncan et al., 1996b; Duncan et al., 1996c;
Duncan et al., 1998a; Duncan et al., 1998b; Duncan et al., 1998c). In addition,
tissues collected using this regimen, have given valuable information in
supplementary studies (Rodger et al., 1995; Koh et al., 1995; Illingworth et al.,
1996; Rodger et al., 1997; Rodger et al., 1998). In conclusion, the models used in
these studies have provided valuable insights into the molecular control of the
primate corpus luteum. They are powerful models which are unique. Research
using these methods should continue. Speculative paradigms and new important
areas of research have been developed and identified as a result of the studies
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Luteal progesterone production is dependent on luteinizing
hormone (LH) from the pituitary gland. Despite continuing
LH secretion, the human corpus luteum undergoes func¬
tional luteolysis unless it is 'rescued' by human chorionic
gonadotrophin (HCC), produced by the implanting blasto¬
cyst. As LH and HCG act through a common receptor,
this study sought to determine the expression of the LH/
HCG receptor in the corpus luteum during maternal
recognition of pregnancy. Corpora lutea were collected at
hysterectomy from women in the normal luteal phase and
after luteal 'rescue' with exogenous HCG. In each case the
corpus luteum was classified according to the date of the
LH surge measured in daily urine samples. The expression
of the LH receptor was investigated by Northern blotting,
in-situ hybridization and in-situ ligand binding. LH recep¬
tor mRNA and ligand binding activity were detected in
corpora lutea from all stages of the luteal phase. LH
receptor expression and binding were maintained during
maternal recognition of pregnancy in the presence of
exponentially increasing HCG concentrations. These data
show that the LH receptor is maintained throughout the
functional life-span of the human corpus luteum and is not
down-regulated during maternal recognition of pregnancy.
Key words: corpus luteum/human chorionic gonadotrophin/
luteinizing hormone/pregnancy/receptor
Introduction
Progesterone production by the primate corpus luteum is
dependent on circulating luteinizing hormone (LH) from the
pituitary gland (Hutchison and Zeleznik, 1984; Fraser et al.,
1986). Withdrawal of circulating LH results in both structural
and functional luteolysis. However, despite the continued
secretion of LH, functional luteolysis occurs after 14 days
unless human chorionic gonadotrophin (HCG) is secreted by
the implanting blastocyst (Hutchison et al., 1986). Both LH
and HCG exert their luteotrophic actions through a common
receptor (Cole et al., 1973). The human LH/HCG receptor
cDNA has now been cloned and sequenced (Minegish et al.,
1990). It is part of a family of G-protein-coupled receptors.
with seven transmembrane regions and a large glycosylated
extracellular domain (Segaloff and A-scoli, 1993).
In the presence of increasing HCG, during maternal recogni¬
tion of pregnancy in women, luteal progesterone production
increases and circulating progesterone concentrations rise
(Lenton and Woodward, 1988; Tovanabutra et al., 1993).
However, in other species the LH receptor has been shown to
undergo desensitization and down-regulation after exposure to
its ligand (Niswender et al., 1985; Segaloff and Ascoli, 1993;
Peegel et al., 1994). In addition, previous studies investigating
the LH receptor in the human corpus luteum have reported
low levels of receptor in the corpus luteum of ectopic pregnancy
(Rao et al., 1977; Bramley et al., 1987; Yamoto et al., 1988).
It is therefore not clear how the human corpus luteum is
able to augment progesterone production during maternal
recognition of pregnancy.
This study aimed to investigate the luteal LH/HCG receptor
during the process of maternal recognition of pregnancy at the
time of menstrual delay. We studied LH/HCG receptor mRNA
expression and ligand binding in carefully dated human corpora
lutea from throughout the normal luteal phase and after luteal




All reagents were obtained from Sigma Chemical Company (Poole,
UK), unless otherwise stated. A 1.5 kb cDNA construct, corresponding
to nucleotide 542 to the last nucleotide of the open reading frame
(2124) of the human LH receptor in pBluescript (Stratagene, Cam¬
bridge, UK), was kindly supplied by Dr M.Atger of the Faculte de
Medecine de Bicetre, Universite Paris-Sud, Le Kremlin-Bicetre,
France. 125I-labelled LH was obtained commercially from the Depart¬
ment of Chemical Pathology, Hammersmith Hospital, London, UK.
The specific activity of the [i25I]LH was 100 (iCi/pg, and 10 000
c.p.nr. is equivalent to 45 pg.
Collection of tissue
Corpora lutea were enucleated at the time of hysterectomy in women
undergoing surgery for benign conditions, typically heavy and/or
painful menses. All women were healthy, aged 32^45 years, with
regular menstrual cycles and had not received any form of hormonal
treatment for at least 3 months prior to taking part in the study.
The date of the LH surge was determined by estimating the LH
concentrations in serial early morning urine samples collected prior
to the operation (Djahanbakhch et al., 1981a). On this basis, four
corpora lutea were classified as early luteal (LH+1 to LH+5), four
as mid-luteal (LH+6 to LH+10) and four as late luteal (LH+11 to
LH+ 14). In addition, four women were given i.m. injections of HCG
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(Protasi; Serono Laboratories. Welwyn Garden City, UK) from day
LH+7 in daily doubling doses, starting at 125 IU. for 5-8 days until
surgery. This regimen has been shown to reproduce the hormonal
changes of early pregnancy (Illingworth et al.. 1990).
As described previously (Duncan et al., 1996), the whole corpus
luteurn was enucleated from the ovary by blunt dissection and the
ovary oversewn. The tissue was divided immediately into radial
blocks to ensure that the whole thickness of the gland was represented
in any piece. A piece of tissue was rapidly snap frozen in liquid
nitrogen and stored at -70°C for subsequent RNA extraction. Another
piece of the biopsy was frozen in embedding medium (Tissue-Tek
OCT compound: Miles Inc., Elkhart, IN, USA) and stored at -70°C
until frozen sections were cut. Frozen sections were stored at -70°C
until required. In each case, an endometrial biopsy was also fixed in
4% paraformaldehyde and processed into paraffin wax for luteal
phase dating by tissue morphometry (Li et al., 1988). Blood was
taken before surgery and the plasma progesterone concentration was
measured by a standard radioimmunoassay (Djahanbakhch et al.,
1981b). This study was approved by the local Reproductive Medicine
Ethics Committee, and informed consent was obtained from all
patients prior to tissue collection.
Northern blotting
Total RNA was isolated by the method of Chomczvnski and Sacchi
(1987) using a commercial kit. Its concentration was determined by
absorption at 260 nm. Total RNA (25 jig) was denatured, electro-
phoresed in a 1.5% formaldehyde-agarose gel and transferred to a
nylon membrane (Amersham International pic. Aylesbury, UK) by
capillary action in 20X SSC (IX SSC is 150 mM NaCl, 15 mM
sodium citrate, pH 7.0). The RNA was fixed onto the membranes by
UV cross-linkage (Spectronics Corporation. New York. NY, USA).
Membranes were prehybridized for 3 h in 15 ml hybridization buffer
[0.5 M sodium phosphate, 1 mM EDTA. 1% (w/v) bovine serum
albumin (BSA). 7% (w/v) sodium dodecyl sulphate, 6.7% (v/v)
deionized formamide] at 65°C.
A human LH receptor probe (provided by Dr M.Atger) was labelled
with 50 jiCi [j:P]dCTP by the random priming method using a
commercial kit (Amersham International pic) and added to the
hybridization buffer. The membranes were hybridized overnight at
65°C. The following day the membranes were washed twice with
2x SSC and once with 2X SSC/0.1% SDS for 15 min at 65°C. They
were laid onto a phosphor screen for 36 h and visualized using a
phosphorimager computer (Molecular Dynamics, Maidstone, UK).
To correct for minor differences in RNA loading, the blots were
stripped in stripping buffer (5 mM Tris, pH 8.0, 0.3 mM EDTA,
0.1X Denhardt's reagent) for 2 h at 65°C. The blots were then probed
for 18S RNA using an oligonucleotide probe as described previously
(Brooks et al.. 1992). The molecular size of the transcripts was
determined by running commercial RNA markers (Promega, South¬
ampton, UK) in an adjacent lane.
In-situ hybridization
Isotopic in-situ hybridization was performed on frozen sections using
35S-labelled riboprobes. Antisense and sense riboprobes incorporating
35S-Iabelled UTP (Amersham International pic) were synthesized
using a commercial kit (Promega). The antisense probe was generated
from the plasmid vector linearized by Hindlll (Promega) using T3
RNA polymerase (Promega). The sense probe was used as a negative
control. This was generated from the plasmid vector linearized by
fcoRI (Promega) using T7 RNA polymerase (Promega).
Frozen sections (5 urn) on poly-L-lysine (50 |ig/l)-coated slides
were thawed quickly and fixed in 4% paraformaldehyde for 5 min at
room temperature. After washing in 0.1 M sodium phosphate, slides
were rinsed firstly in water and then in 0.1 M triethanolamine (TEA).
pH 8.0. The slides were then acetylated in 0.25% (v/v) acetic
anhydride (BDH Laboratory Supplies, Poole, UK) in TEA. After
acetylation. the slides were washed in 2X SSC and dehydrated
through graded alcohols. The slides were then dried under a vacuum
in a desiccator for 1 h at room temperature. In all. 100 (il of
hybridization buffer [50% deionized formamide. 10% dextran
sulphate. IX Denhardt's solution. 0.5 mg/ml yeast tRNA. 10 ntM
dithiothreitol (DTT). 0.3 M NaCl. 10 mM Tris. 1 mM EDTA, pH
8.0] containing IX 106 c.p.m. radiolabelled probe were added to each
section. The slides were covered with a hydrophobic coverslip (Gel
Bond: 1CN Biomedical Ltd, High 'Wycombe, UK) and incubated
overnight at 55°C in a moist chamber.
The following day the coverslips were washed off in 4X SSC.
After several rinses in 4X SSC, the slides were treated with RNAse
A (20 jig/ml) in RNAse buffer (10 mM Tris, 1 mM EDTA. 0.5 M
NaCl. pH 8.0) for 30 min at 37°C. The sections were desalted by
rinsing in 2X SSC/1 mM DTT. followed by IX SSC/1 mM DTT
and 0.5 X SSC/1 mM DTT at room temperature. The slides were
then washed for 30 min in 0. IX SSC at 70°C in a shaking water
bath. After rinsing in 0. IX SSC/1 mM DTT at room temperature,
the sections were dehydrated through graded alcohols containing
1 mM DTT and 0.08X SSC, washed in pure ethanol and allowed to
dry. These slides were then dipped in Kodak NTB-2 photographic
emulsion (IBI Ltd. Cambridge. UK) and incubated in the dark for 21
days. They were developed (Kodak D-19) and fixed (Kodak Unifix)
at 15°C in the dark. After rinsing in running tap water, sections were
counterstained with haematoxylin and mounted in Pertex mounting
medium (Cellpath. Hemel Hempstead, UK).
In-situ ligand binding
In-situ ligand binding was performed using a modification of the
method described by Molenaar et al. (1993). Frozen sections of 5
jim were cut onto poly-L-lysine-coated slides and stored at -70°C
until use. They were thawed quickly and incubated in binding buffer
[50 mM HEPES, 5 mM MgCL, 0.3% (w/v) BSA, pH 7.4] at room
temperature for 20 min. Excess buffer was removed and 10 000
c.p.m. [i25I]LH (Chelsea Reagent; Hammersmith Hospital, London.
UK) or 10 000 c.p.m. [I25I]LH with an excess (20 IU) of cold HCG
(Profasi; Serono Laboratories), in binding buffer, were added to each
slide for 2 h at room temperature. The slides were washed briefly
four times in 0.05 M Tris, pH 7.4, at 4°C, dipped in distilled water
and allowed to dry for 3 h at 4°C. They were then dipped in
photographic emulsion (Kodak NTB-2) and stored at 4°C for 3 days
in the dark. After developing (Kodak D-19) and fixing (Kodak Unifix)
at 15°C in the dark, the slides were washed in water, counterstained
with haematoxylin. dehydrated through graded alcohols and mounted
in Pertex mounting medium.
Analysis of the sections
The distribution and number of silver grains were analysed by dark-
field microscopy after image capture using computer-based image
analysis systems. To quantify the results of the in-situ hybridization,
the area proportion of silver grains over the steroidogenic cells was
measured in five random fields for each section using an image
analysis program (NIH Image 1.55; NIH. Bethesda, MD, USA).
Acellular areas or areas without the steroidogenic cells were ignored.
Only sections from the same run. performed under carefully controlled
conditions, were analysed. The results of the in-situ ligand binding
were analysed in a similar fashion except that the grain distribution
in this case allowed the measurement of absolute numbers of grains.
Grains were counted using the Cue-2 image analysis system (Olympus
Optical Co. UK Ltd. London, UK). In each case the grain density
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Figure I. Northern blotting for luteinizing hormone (LH) receptor
in human corpora lutea. The positions ot' the 28S and 18S
ribosomal RNA bands are indicated on the right. The expression of
I8S RNA is shown to control for differences in RNA loading. LH
receptor mRNA could be detected in corpora lutea from all stages
of the luteal phase [early (LH+l to LH + 5). mid- (LH+6 to
LH + 10). late (LH+ 11 to LH-t-14) | and after luteal rescue with
exogenous human chorionic gonadotrophin (Resc).
was compared at each stage of the luteal phase using an analysis of
variance with a 5% level of statistical significance.
Results
Plasma progesterone concentrations
The classification of the corpora lutea by serial urinary LH
measurements agreed with the luteal phase dating of endomet¬
rial biopsies using the method of Li et al. (1988). As reported
previously (Duncan et al.. 1996). the plasma progesterone
concentrations were 36.4 ± 9.3 nmol/l in the early luteal
samples. 40.4 ± 9.9 nmol/l in the mid-luteal samples and 18.8
± 12.8 nmol/l in the late luteal samples. After luteal rescue
by exogenous HCG the plasma progesterone concentrations
had increased to 52.8 ± l.l nmol/l.
Detection of LH/HCG receptor mRNA
A major 4.5 kb band and minor 6.8-7.2 kb bands were detected
by Northern blotting in the human corpus luteum (Figure I).
These are consistent with the size of the major LH receptor
transcripts reported previously in the corpus luteum of primates
(Ravindranath et al.. 1992; Nishimori et al.. I995). LH/HCG
receptor mRNA could be detected in corpora lutea from all
stages of the luteal phase and after luteal rescue with HCG.
The LH/HCG receptor mRNA was localized to the steroido¬
genic cells of the corpus luteum by in-situ hybridization (Figure
2a). No specific localization was seen in any of the control
sections incubated with the sense probe (Figure 2b). Messenger
RNA for the LH/HCG receptor could be detected, by in-situ
hybridization at all stages of the functional luteal phase and
alter luteal 'rescue' with exogenous HCG (Figure 2c and d).
No significant differences in the level of LH/HCG receptor
expression, as measured by grain density, were found between
different stages of the luteal phase (Figure 3). The expression
of LH/HCG receptor mRNA during luteal rescue was similar
to that seen in mid-luteal phase corpus luteum.
Detection of LH binding sites
Specific binding sites for LH were detected in the steroidogenic
cells of the normal corpus luteum (Figure 4a and b). These
binding sites were detected in all corpora lutea from each
stage of the luteal phase. In addition, they could also be found
after exposure to logarithmically increasing doses of HCG
in vivo to simulate maternal recognition of pregnancy (Figure
4c). No specific binding of LH was observed in the negative
control sections (Figure 4d). When the binding sites were
quantified, using grain counting, no significant differences
were observed at any stage of the luteal phase or after luteal
rescue with HCG (Figure 5). The LH/HCG receptor protein,
as measured by specific binding, was maintained during
maternal recognition of pregnancy at similar levels to the mid-
luteal phase.
Discussion
This paper describes the expression of the LH/HCG receptor
in human corpora lutea throughout the functional luteal phase
and after luteal 'rescue' with exogenous HCG. Messenger RNA
for the LH/HCG receptor has been demonstrated previously in
primate corpus luteum at different stages of the luteal phase
(Ravindranath et al.. 1992: Nishimori et al., 1995).
Ravindranath et al. (1992) studied the expression of the LH
receptor in corpora lutea of cynomolgus monkeys. They
reported that LH receptor mRNA increased in the early luteal
phase and was continually expressed in the corpus luteum
throughout the luteal phase. Our data confirm that the LH/
HCG receptor is expressed throughout the functional life-span
of the primate corpus luteum.
These observations differ slightly from those of Nishimori
et al. (1995), who reported a significant reduction in the
expression of LH receptor mRNA in the late luteal phase.
Although levels of LH receptor mRNA tended to be lower in
the late luteal corpus luteum. this did not reach statistical
significance in our study. This is unlikely to be explained by
the number of corpora lutea examined because the same
number were investigated in each study. We studied the
expression of the LH receptor by quantifying the grain density
over steroidogenic cells after in-situ hybridization. Nishimori
et al. (1995) used Northern blotting of whole gland mRNA to
quantify LH receptor expression, and the difference may reflect
these different techniques. However, as the LH receptor is not
expressed in the corpus luteum after menstruation
(Ravindranath et al., 1992; Nishimori et al., 1995). it is clear
that its expression is switched off at the completion of
functional luteolysis. As the definition of the late luteal phase
differs in each study, it is possible that the late luteal glands
studied by Nishimori et al. (1995) were closer to the completion
of functional luteolysis than in our study.
It has been suggested that the stability of transcribed LH
receptor mRNA may be decreased to prevent translation into
the receptor protein (Lu et al.. 1993). We used in-situ ligand
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Figure 2. ln-situ hybridization for luteinizing hormone (LH) receptor mRNA in the human corpus luteum. (a) Dark field of corpus luteum
from the early luteal phase. Many more grains are seen over the steroidogenic cells (C) than the surrounding stroma (S). fb) Negative
control dark-field serial section of (a) after in-situ hybridization with the sense riboprobe. showing no difference in background
hybridization between the steroidogenic cells (C) and the surrounding stroma (S). (c) Dark-field late luteal corpus luteum showing LH
receptor mRNA in the steroidogenic cells (C) but not in the stroma (S). (d) Dark field of LH receptor mRNA in a corpus luteum after
rescue with exogenous human chorionic gonadotrophin. Expression is maintained in the steroidogenic cells (C) and is absent from the
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Figure 3. Luteinizing hormone (LH) receptor mRNA in the human
corpus luteum as measured by grain density after in-situ
hybridization. No differences were seen in the expression of L.H
receptor message in the early, mid- and late luteal phases or after
luteal rescue with exogenous human chorionic gonadotrophin.
Values are means i SEM.
binding to identify the LH receptor protein in human corpus
luteum. Numerous studies have demonstrated the presence of
LH/HCG receptors in human corpus luteum using ligand
binding assays (Rao et al., 1977; McNeilly el al., 1980; Shima
el al.. 1987). Although these studies reported that LH receptor
binding was reduced in the late luteal phase, it has subsequently
become clear that when receptor occupancy was taken into
account, levels of total receptor are similar throughout the
luteal phase (Brantley el al.. 1987; Yeko el al.. 1989). We
have confirmed that the LH receptor protein, in addition to
mRNA, is maintained in the corpus luteum throughout its
functional life-span.
The cause of functional luteolysis in the primate is not clear
(Behrman et al.. 1993). The decline in progesterone secretion
in the late luteal phase is not associated with falling serum
LH concentrations (Hutchison ei al., 1986). This suggests that
the corpus luteum is becoming increasingly insensitive to
LH. Expression of the LH/HCG receptor is regulated both
transcriptionally and post-transcriptionally (Segaloff and
Ascoli. 1993). However, the continued presence of both the
receptor mRNA and protein, as measured by ligand binding,
suggests that the luteal LH/HCG receptor is maintained while
progesterone production is falling. This is consistent with the
findings of Cameron and Stouffer (1982), who compared
cell membrane LH binding with progesterone production in
macaque corpus luteum. These data suggest that functional
luteolysis may be associated with an increasing block to
steroidogenesis downstream of LH/HCG receptor binding.
We found that LH receptor mRNA and protein were main¬
tained during maternal recognition of pregnancy with exo¬
genous HCG. Previous studies have investigated the luteal
LH/HCG receptor by binding assays early in human pregnancy
(Rao el a!.. 1977; McNeilly et al.. 1980; Brantley et al., 1987;
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Figure 4. Demonstration of the luteinizing hormone (LH) receptor in the human corpus luteum by in-situ ligand binding, (a) Dark field of
corpus luteum from the mid-luteal phase. Many more grains are seen over the steroidogenic cells (C) than the surrounding stroma (S). (b)
Light field of section (a) showing the localization of the steroidogenic cells (C) and the surrounding stroma (S). (c) Dark field of the LH
receptor in the corpus luteum after rescue with exogenous human chorionic gotiadotrophin. showing continued LH binding in the
steroidogenic cells <C) but not in the stroma (S). (d) Dark field of negative control serial section of (c) showing no specific binding to the
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Figure 5. Luteinizing hormone (LH) receptors in the human corpus
uteum as measured by grain counting after in-situ ligand binding.
Mo differences were seen in the number of LH binding sites in the
;arly. mid- and late luteal phases or after luteal rescue with
:xoaenous human chorionic gonadotrophin. Values are means
± SEM.
Davvood and Khan-Dawood, 1994). Concentrations of LH
•eceptor were variable but were much lower than in mid-luteal
:orpus luteum. In addition. LH/HCG receptor mRNA has now
oeen identified in the corpus luteum of pregnant women
Nishimori et al., 1995). Like receptor binding, levels of
nRNA expression were much lower than in mid-cycle corpus
luteum. However, in each case, material from the corpus
luteum of ectopic pregnancies was investigated. In established
pregnancies, maternal recognition of pregnancy has taken
place, and although luteal progesterone production is continu¬
ing. it is beginning to decline (Tovanabutra et al., 1993). In
addition, ectopic pregnancies have suboptimal serum HCG
and progesterone concentrations (Barnea et al.. 1986; Ledger
et al.. 1994) and are usually associated with vaginal bleeding
(Li et al., 1991). It appears that luteal LH/HCG receptor
expression is maintained to a greater degree during maternal
recognition of uterine pregnancy than in established ectopic
pregnancy.
These data are in agreement with those of Ottobre and
Stouffer (1986). who studied LH binding to homogenates of
rhesus monkey corpora lutea after exogenous HCG administra¬
tion. They found that, although the number of available
receptors dropped, the total number of receptors remained the
same. However, it was not clear if these receptors were
membrane bound or if recycling of receptors was occurring.
Using in-situ hybridization in association with in-situ ligand
binding, we have confirmed the continued presence of the LH/
HCG receptor and demonstrated the continued transcription
of receptor mRNA. These data provide strong evidence that
the LH receptor is not down-regulated during maternal recogni¬
tion ot pregnancy in the primate.
In contrast, there is considerable evidence for ligand-induced
down-regulation of the LH receptor in other cellular systems.
In cell lines expressing the LH receptor, exposure to ligand
causes a down-regulation of LH receptor binding (Segaloff
and Ascoli. 1993). This loss of ligand binding activity is
W.C.Duncan et al.
associated with a loss of LH receptor mRNA (Hoffman et al.,
1991). In rat corpus luteum, LH receptor mRNA could not be
detected 24 h after ligand-induced down-regulation (Peegel
et al., 1994). LH receptor mRNA expression in the same
corpora lutea recovered, but not until 72 h after a single
exposure to ligand. In addition, in adult rat testis, exposure to
HCG resulted in a prolonged down-regulation of the LH
receptor message (Pakarinen et al., 1990). In ruminants, the
administration of HCG was also associated with a marked
down-regulation of luteal LH receptors (Niswender et al.,
1985). Although the LH receptor can be up-regulated in the
growing follicle of the rat (LaPolt et al., 1990), this has not
been described in the corpus luteum. In the corpus luteum of
non-primate species, it is clear that LH receptors are down-
regulated both in vitro and in vivo by exposure to HCG.
Thus it seems likely that the effect of HCG on the LH
receptor is species specific. Caldwell et al. (1980) treated
luteal phase rats and women with equivalent doses of HCG.
In the rat, both progesterone production and LH receptor
content fell significantly, whereas in women, luteal progester¬
one production increased. The mechanisms of luteolysis and
maternal recognition of pregnancy differ in primates and non-
primate species (Auletta and Flint, 1988). It appears that,
by using an LH-like chorionic gonadotrophin to maintain
progesterone production from the corpus luteum, primates
have adapted to overcome down-regulation of the LH/HCG
receptor during maternal recognition of pregnancy.
The LH receptor is regulated by other mechanisms in
addition to transcription and translation. Desensitization of the
receptor to its ligand, with uncoupling from second messenger
systems, has been reported in vitro and in vivo (Segaloff and
Ascoli. 1993). Such desensitization may explain why increasing
doses of HCG are required to maintain progesterone production
during pregnancy. In addition, there are multiple transcripts of
the LH receptor regulated by alternative splicing (Themmen
et al., 1994). Bacicn et al. (1994), using an ovine model,
showed that full-length receptor mRNA was a minority of the
LH receptor mRNA species detected in the corpus luteum.
Most mRNA species coded for truncated or non-functioning
receptors. This alternative splicing of the LH receptor has also
been reported in other species (Aatsinki et al., 1992; VuHai-
LuuThi et al., 1992). However, the functional significance of
these transcripts is not yet clear and it is not known whether
they are expressed in corpora lutea of primates.
In summary, this study shows that both LH receptor mRNA
and protein are maintained in human corpus luteum during
maternal recognition of pregnancy. The lack of down-regulation
is further evidence that primates and non-primates exhibit
different mechanisms to control the function of the corpus
luteum.
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The molecular mechanisms involved in luteolysis are still
unclear in the primate. This study aimed to investigate the
effect of induced luteolysis on the ovarian luteinizing
hormone (LH) receptor and the steroidogenic enzyme, 3(3-
hydroxysteroid dehydrogenase (3p-HSD) in the marmoset
monkey. Luteolysis was induced in the mid-luteal phase
either directly by systemic prostaglandin F2c( (PGF2a), or
indirectly by LH withdrawal using systemic gonadotrophin
releasing hormone antagonist (GnRHant) treatment. The
LH receptor was studied by isotopic mRNA in-situ hybrid¬
ization and in-situ Iigand binding and 3p-HSD expression
was studied using isotopic mRNA in-situ hybridization and
immunohistochemistry. Induced luteolysis was associated
with a reduction in the expression of LH receptor (P <
0.0001) and 3P-HSD mRNA, closely followed by a reduction
in the LH receptor (P < 0.05) and 3P-HSD protein concen¬
trations within 24 h. There were no differences in the
findings whether luteolysis was induced with PGF2{X or
GnRHant. This study shows that disparate mechanisms to
induce luteolysis in the primate result in an identical rapid
loss of the LH receptor and 3p-HSD. In conclusion, induced
luteolysis leads to rapid loss of the steroidogenic pathway
in luteal cells.




The molecular mechanisms of luteolysis in the primate and of
how the functional and structural integrity of the corpus luteum
are lost, are still unclear (Auletta and Flint, 1988; Behrman etal.,
1993). It has recently been shown that cell death by apoptosis
(Juengel et al., 1993; Fraser et al., 1995a; Young et al., 1997)
and remodelling of the extracellular matrix by matrix metallo-
proteinase enzymes (Endo et al., 1993), are likely to contribute
to the loss of the structural integrity of the corpus luteum during
luteolysis. The molecular mechanisms responsible for the loss
of its functional integrity and its falling progesterone output,
however, are still not fully understood.
The primate corpus luteum is dependent.on the trophic support
of luteinizing hormone (LH) from the pituitary gland. LH binds
specifically to the LH receptor, a seven transmembrane region
G-protein-coupled receptor (Segaloff and Ascoli, 1993) on the
surface of luteal cells, to stimulate steroidogenic enzymes to
produce progesterone. Withdrawal of LH results in luteolysis
(Fraser et al., 1986), whereas human chorionic gonadotrophin
(HCG), from the implanting blastocyst, acts through the LH
receptor to maintain steroidogenesis and 'rescue' the corpus
luteum. We have previously shown that during luteal 'rescue',
the LH receptor is maintained and is not down-regulated by its
ligand (Duncan et al., 1996a).
There is a significant reduction in luteal LH receptors preceded
by reduced receptor mRNA concentrations after prostaglandin
F2a (PGF2a)-induced luteolysis in ruminants (Guy et al., 1995;
Smith etal., 1996). This is thought to contribute to the functional
decline of the ruminant corpus luteum. However, in the monkey,
LH receptor mRNA increased during the late-luteal phase (Rav-
indranath et al., 1992a) when progesterone output declined.
Similarly, in the human, LH receptormRNA and binding activity
can be detected in the late-luteal corpus luteum (Nishimori etal.,
1995; Duncan et al., 1996a), but not in the corpus luteum after
menstruation (Ravindranath et al., 1992a; Nishimori et al.,
1995). In the primate, functional luteolysis is thought to occur
initially in the presence of normal concentrations of LH
receptors.
The primate corpus luteum is capable of recovering from a
transient withdrawal of gonadotrophic support (Hutchison and
Zeleznik, 1985) but not from natural functional luteolysis
(Stouffer et al., 1977). This study investigated the effect of co¬
ordinated induced luteolysis on LH receptor and 3P-hydroxy-
steroid dehydrogenase (3p-HSD) expression in the primate. The
marmoset monkey was used, as luteolysis can be induced by
systemic PGF2ct, although uterine PGF2a is not the natural luteo-
lysin in this species. In addition, luteolysis can be induced by LH
withdrawal using gonadotrophin releasing hormone antagonist
(GnRHam). We aimed to discover whether PGF2a had the same
effect on luteal LH receptors in the primate as the ruminant,
and whether induced luteolysis by withdrawal of gonadotrophic
support had the same effect.
Materials and methods
Collection of tissue
Captive-bred common marmoset monkeys (Callithrixjacchusjacchus)
were maintained in a colony which has been closed since 1973. All
experiments were carried out in accordance with the Animals (Scientific
Procedures) Act 1986. To confirm normal ovulatory cycles, plasma
samples were collected by femoral venepuncture on alternate days
2532 © European Society for Human Reproduction and Embryology
LH receptor in in<l;",eci luteotysis
Figure 1. Luteinizing hormone (LH) receptor in the mid-luteal marmoset corpus luteum: (a) dark-field in-situ hybridization of LH receptor
mRNA in the control mid-luteal corpus luteum (CL), no signal is seen in the stroma and tiny follicles (F): (b) light-field section of (a),
showing the position of the corpus luteum (CL), stroma and tiny follicles (F); (c) dark-field serial negative control section of (a) using the
sense probe for LH receptor mRNA, no signal can be seen in the corpus luteum (CL) or the tiny follicles (F); (d) light field higher power
(scale bar = 25 um) section of corpus luteum showing silver grains in steroidogenic cells (S) but not in endothelial-like cells (E): (e) dark-
field serial section of (a) after LH binding studies showing binding over the corpus luteum (CL) and not over the stroma and tiny follicles
(F). Scale bar = 200 pm.
and stored at -20°C until required. These samples were assayed for
progesterone to determine the date of ovulation and the luteal phase
duration (Smith et al., 1990). The marmoset normally ovulates two to
three follicles and has a functional luteal phase of 18-21 days.
Ovaries were collected on day 10 of the luteal phase as previously
described (Fraser et al., 1995a; Duncan et al., 1996b). Ovaries were
collected from untreated control animals (n = 4) and animals treated
with: PGFja analogue, cloprostenol (1 jig i.m. injection; Planate.
Coopers Animal Health Ltd, Crewe, Cheshire, UK), 24 h (n = 4)
previously; GnRHant, antarelix ([/V-Ac-D-Nal1, D-pCI-Phe2, D-Pal3, D-
(Hic)6, Lys(iPr)8, D-Ala'°]GnRH (Deghenghi et al., 1993), 500 pg/kg
s.c. injection, Europeptides (GEIE), Argenteuil, Val-D'Oise. France),
12 h (n = 2) and 24 h (n = 4) previously. Whole ovaries were snap-
frozen in embedding medium (Tissue-Tek OCT compound: Miles Inc..
Elkhart, IN, USA) and stored at-70°C until sectioning. Frozen sections
(5 Jim) were prepared from these ovaries and stored at -70°C until use.
In addition, ovaries were also available from control (n = 4) and treated
animals (n = 6) which had been fixed in 4% paraformaldehyde for 24 h
and embedded in paraffin wax (Fraser et al., 1995a). Five-micrometer
sections were cut onto poly-L-lysine (50 jtg/l)-coated slides for immuno-
histochemical analysis.
Source of reagents
All reagents used were obtained from Sigma Chemical. Poole.
Dorset, UK unless otherwise indicated. A 1.5 kb cDNA construct.
corresponding to nucleotide 542 to the last nucleotide of the open
reading frame (2124), of the human LH receptor in pBluescript
(Stratagene. Cambridge. Cambs. UK) was kindly supplied by Dr M.
Atger of the Faculte de Medecine de Bicetre, Universite Paris-Sud.
Le Kremlin-Bicetre, France. lodinated LH (Chelsea Reagent) was
obtained commercially from Department of Chemical Pathology,
Hammersmith Hospital, London, UK. The specific activity of the
iodinated LH is 100 (iCi/jtg and 10 000 c.p.m. is equivalent to
45 pg. A 1.2 kb cDNA construct of human 3j3-HSD in pIB125 (Prof.
J. I. Mason, Dept. of Chemical Biochemistry, University of Edinburgh,
Edinburgh, UK) and a polyclonal antibody to human type I 3P-HSD
was kindly supplied by Professor Van Luu-The, The CHUL Research
Centre, Quebec, Canada. All restriction enzymes and RNA poly¬
merases were obtained from Promega, Southampton. Hants. UK.
In-situ hybridization
Isotopic in-situ hybridization was performed on frozen sections using
S35-labelled riboprobes as described previously (Duncan etai. 1996a).
Antisense and sense LH receptor riboprobes incorporating SJ>5-labelled
UTP (Amersham International pic, Aylesbury, Bucks, UK) were
synthesized using a commercial kit (Promega). The antisense probe
was generated from the plasmid vector linearized by Hindlll using
T3 RNA polymerase. The sense probe was used as a negative control.
This was generated from the plasmid vector linearized by ECoRl
using T7 RNA polymerase. The antisense riboprobe for 3p-HSD
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Figure 2. Luteinizing hormone (LH) receptor mRNA in the marmoset ovary after induced luteolysis: (a) light-field section of a mid-luteal
marmoset ovary showing the corpus luteum (CL) and the theca (T) and granulosa cells of an antral follicle; (b) dark-field section of (a)
after in-situ hybridization for LH receptor mRNA showing specific signal in the corpus luteum (CL) and theca (T) cells of the follicle, but
not the granuolsa cells (G) of the follicle; (c) light-field section of a marmoset ovary 24 h after induced luteolysis with GnRHant showing
the corpus luteum (CL) and the theca (T) and granulosa (G) cells of an antral follicle; (d) dark-field section of (c) after in-situ hybridization
for LH receptor mRNA showing no signal in the corpus luteum (CL) and granulosa cells (G) but maintenance of the signal in the theca
cells (T) of the antral follicle. Scale bar = 200 um. Insert shows higher power view of the follicle showing the grains to be localized to the
theca (T) rather than granulosa (G) cells.
mRNA was generated by T7 RNA polymerase after plasmid lineariz¬
ation by Sstl.
Frozen sections (5 pm) on poly-L-lysine (50 pg/l)-coated slides
were quickly thawed and fixed in 4% paraformaldehyde for 5 min at
room temperature. After washing in 0.1 M sodium phosphate, slides
were rinsed firstly in water and then in 0.1 M triethanolamine (TEA)
pH 8. The slides were then acetylated in 0.25% (v/v) acetic anhydride
(BDH Laboratory Supplies, Poole, Dorset. UK) in TEA. After
acetylation. the slides were washed in 2XSSC (IXSSC is 150 raM
NaCl. 15 mM sodium citrate) pH 7, and dehydrated through graded
alcohols. The slides were then dried under vacuum in a desiccator
for 1 h at room temperature. An aliquot of 100 ul of hybridization
buffer (50% deionized formamide, 10% dextran sulphate,
IXDenhardt's solution, 0.5 mg/ml yeast tRNA, 10 mM dithiothreitol
(DTT). 0.3 M NaCl, 10 mM Tris, I mM EDTA pH 8) containing
1X106 c.p.m. radiolabelled probe was added to each section. The
slides were covered with a hydrophobic coverslip (Gel Bond; ICN
Biomedical Ltd, High Wycombe, Bucks, UK) and incubated overnight
at 55°C in a moist chamber.
The following day the coverslips were washed off in 4XSSC.
After several rinses in 4XSSC, the slides were treated with RNase
A (20 ,ug/ml) in RNase buffer (10 mM Tris, 1 mM EDTA, 0.5 M
NaCl, pH 8) for 30 min at 37°C. The sections were de-salted by
rinsing in 2XSSC/1 mM DTT, followed by 1XSSC/1 mM DTT and
0.5XSSC/1 mM DTT at room temperature. The slides were then
washed for 30 min in 0.1XSSC at 70°C in a shaking water bath.
After rinsing in 0.1XSSC/1 mM DTT at room temperature, the
sections were dehydrated through graded alcohols containing 1 mM
DTT and 0.08 XSSC, washed in pure ethanol and allowed to dry.
These slides were then dipped in photographic emulsion (Kodak
NTB-2; IBI Ltd, Cambridge, Cambs, UK) and stored at 4°C for 18
days in the dark. After developing (Kodak D-19) and fixing (Kodak
Unifix) at 15°C in the dark, the slides were washed in water,
counterstained in haematoxylin, dehydrated through graded alcohols
and mounted in Pertex mounting medium (Cellpath, Hemel
Hempstead. Herts, UK).
In-situ ligand binding
In-situ ligand binding was performed as described previously (Duncan
et al., 1996a). Frozen sections (5 pm) were quickly thawed and
incubated in binding buffer [50 mM HEPES, 5 mM MgCL, 0.3%
(w/v) BSA. pH 7.4] at room temperature for 20 min. Excess buffer
was removed and 10 000 c.p.m. of iodinated LH or 10 000 c.p.m.
iodinated LH with excess (20 IU) of cold HCG (Profasi; Serono
Laboratories, Welwyn Garden City, Herts. UK), in binding buffer
was added to each slide for 2 h at room temperature. The slides were
briefly washed four times in 0.05 M Tris pH 7.4 at 4°C. dipped in
distilled water and allowed to dry for 3 h at 4°C. They were then
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Figure 3. Luteinizing hormone (LH) receptor in marmoset corpora
lutea after induced luteolysis. Grain density of LH receptor mRNA
and grain counts of LH receptor binding in marmoset corpora lutea
in the mid-luteal phase (control) (n — 4), 12 h after induced
luteolysis with GnRHam (GnRH 12 h) (n = 2), 24 h after induced
luteolysis with GnRHant (GnRH 24 h) (n = 4) and 24 h after
induced luteolysis with PGFya (PG 24) (n — 4). Values are
mean ± SEM: *P < 0.05, **P < 0.0001 (ANOVA).
dipped in photographic emulsion (Kodak NTB-2) and stored at 4°C
for 3 days in the dark. After developing (Kodak D-19) and fixing
(Kodak Unifix) at 15°C in the dark, the slides were washed in water,
counterstained in haematoxylin, dehydrated through graded alcohols
and mounted in Pertex mounting medium.
Immunohistochemistry
Sections were dewaxed in xylene, then rehydrated through graded
alcohols to water. Sections then underwent microwave antigen retrieval
at full power in four 5 min cycles in 0.01 M sodium citrate, pH 6.0.
After standing for 20 min at room temperature, the slides were
washed in 0.05 M Tris buffered saline, pH 8.0 (TBS) for 10 min.
The sections were then incubated overnight at 4°C with the polyclonal
rabbit anti-human 3(3-HSD antiserum diluted 1:300 in TBS. On the
following day, the sections were washed with TBS and then incubated
with biotinylated goat anti-rabbit immunoglobulins (Dako Ltd, High
Wycombe, Bucks, UK), diluted 1:500 in 20% normal goat serum
(NGS) (SAPU, Carluke, Lanarkshire, UK), 5% BSA in TBS, for 1 h
at room temperature. After being washed with TBS, sections were
incubated with avidin-biotin alkaline phosphatase complex (Dako
Ltd) for 1 h at room temperature, then washed again with TBS and
developed with chromagen to give a red end product (Alkaline
Phosphatase Substrate Kit I; Vector Laboratories, Peterborough,
Cambs, UK). Sections were counterstained with haematoxylin, dehyd¬
rated through graded alcohols and cleared in xylene prior to mounting.
Polyclonal rabbit IgG (Dako Ltd) at the same antibody concentration
was used in place of the primary antibody, in serial sections, as a
negative control.
Analysis of sections
The distribution and number of silver grains was analysed by dark-
field microscopy after image capture, using computer-based image
analysis systems. To quantify the results of the in-situ hybridization,
the area proportion of silver grains over the steroidogenic cells was
measured in five random fields for each section using an image
analysis program (NIH Image 1.5; NIH Bethseda, MD. USA).
Acellular areas or areas without the steroidogenic cells were ignored.
Only sections from the same run, performed under carefully controlled
conditions, were analysed. The results of the in-situ ligand binding
were analysed in a similar fashion except that the grain distribution
in this case allowed measurement of absolute numbers of grains. In
each case, the grain density was compared in each treatment group
using analysis of variance (ANOVA) with a 5% level of significance
using a commercial statistics computer program (StatView 4.0; Abacus
Concepts Inc.. Berkeley, CA, USA).
Results
Progesterone concentrations
As described previously (Duncan et al., 1996b), progesterone
concentrations in the control animals were 330 ± 69 nmol/1
(mean ± SEM). Functional luteal regression was observed in
all animals treated with either the GnRH antagonist or the
prostaglandin analogue (Fraser et al., 1995b). Prostaglandin
treatment resulted in a decline in progesterone concentrations
to 22 ± 6 nmol/1 after 24 h, and treatment with GnRH
antagonist resulted in progesterone concentrations of 13 nmol/
1 after 12 h and 23 ± 11 nmol/1 after 24 h. All progesterone
concentrations after induced luteolysis were within the normal
range of follicular phase concentrations in the marmoset (Smith
et al., 1990).
LH receptor after induced luteolysis
Messenger RNA for the LH receptor was detected by in-situ
hybridization in corpora lutea of marmoset ovaries from the
mid-luteal phase (Figure la.b). No specific signal was present
in the negative control sections incubated with the sense
riboprobe (Figure lc). LH receptors were localized to individual
steroidogenic cells within corpora lutea. No hybridization
signal could be seen in cells without the morphological
appearance of steroidogenic cells which expressed 3P-HSD,
including endothelial cells (Figure Id). The localization of LH
receptor binding corresponded to the localization of LH recep¬
tor mRNA (Figure le). No specific binding was seen in
negative control sections where excess cold HCG was added.
Messenger RNA for the LH receptor was also expressed in
the theca cell layer of antral follicles in ovarian tissue from
the mid-luteal phase (Figure 2a,b). After induced luteolysis,
by PGF2a or GnRH.lnt administration, LH receptor mRNA
disappeared from corpora lutea but was maintained in the
theca cell layer of antral follicles (Figure 2c,d). Luteal LH
receptor mRNA concentrations fell after treatment to very low
concentrations 12 and 24 h (P < 0.0001) after induced
luteolysis (Figure 3). Luteal LH receptor binding was similar
to controls 12 h after induced luteolysis but was significantly
reduced by 24 h (P < 0.05) (Figure 3). Although the small
numbers at 12 h precluded accurate statistical analysis, the
loss of LH binding appeared to lag behind the loss of LH
receptor mRNA (Figures 3, 4a-f). There were no differences
in luteal LH receptor mRNA or binding where luteolysis was
induced with PGF2a or GnRHant.
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Figure 4. Luteinizing hormone (LH) receptor in the marmoset corpus luteum 12 and 24 h after induced luteolysis: (a) dark-field section of a
mid-luteal marmoset ovary after in-situ hybridization for LH receptor mRNA showing signal in the corpus luteum (CL) but not in the
surrounding stroma (S); (b) dark-field section of a marmoset ovary 12 h and (c) 24 h after luteolysis was induced with GnRH.m[ after in-situ
hybridization for LH receptor mRNA showing no signal in the corpus luteum (CL) or stroma (S); (d) dark-field serial section of (a)
showing LH binding in the corpus luteum (CL) but not the surrounding stroma (S); (e) dark-field serial section of (b), showing persistence
of LH binding in the corpus luteum (CL) and its absence from the surrounding stroma (S); (f) dark-field serial section of (c) showing
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3f5-HSD after induced luteolysis
Both mRNA (Figure 5a) and protein (Figure 5b) for 3P-HSD
could be detected in corpora lutea of mid-luteal phase ovaries.
Twenty-four hours after induced luteolysis, with either PGF2a
or GnRHant no mRNA for 3(3-HSD could be detected in
corpora lutea (Figure 5c) although it could still be detected in
the theca cell layer of developing follicles. 24 h after induced
luteolysis, 3P-HSD protein could still be detected by immuno-
histochemistry (Figure 5d), however, the immunostaining was
more patchy and less intense (Figure 5d) in each ovary studied.
Discussion
This study reports the expression of the LH receptor and the
steroidogenic enzyme 3P-HSD after induced luteolysis in the
primate. We have previously reported the expression and
localization of the LH receptor in the human corpus luteum
throughout the functional luteal phase and during simulated
early pregnancy (Duncan et al., 1996a). In that study, it was
not clear that LH receptor mRNA fell during the late-luteal
phase. Other studies have suggested either an increase
(Ravindranath et al.. 1992a) or a fall (Nishimori et al., 1995;
Minegishi et al., 1997) in luteal LH receptor mRNA during
the late-luteal phase in the primate. We therefore used a well
established model (Fraserefa/., 1995a,b; Duncan et al., 1996b)
of induced luteolysis in the primate in this follow-up study, to
investigate the effect of luteolysis of LH receptor expression.
It is now clear that induced luteolysis in the primate is
associated with a rapid loss of LH receptors from the corpus
luteum.
Induced luteolysis has been shown to result in a fall in LH
receptor expression in rodents (Bjurulf and Selstam, 1996) and
ruminants (Guy et al., 1995; Smith et al., 1996). In these
animals, PGF2a is an important physiological luteolysin. In
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Figure 5. 3(3-HSD in the marmoset corpus luteum after induced luteolysis: (a) dark-field section of a mid-luteal marmoset ovary after in-situ
hybridization for 3|3-HSD mRNA showing signal in the corpus luteum (CL) but not the surrounding stroma (S); (b) section of a mid-luteal
marmoset ovary after immunohistochemistry for 3(3-HSD showing staining of the corpus luteum (CL) but not the surrounding stroma (S);
(c) dark-field section of a marmoset ovary 24 h after luteolysis was induced with PGF2ct after in-situ hybridization for 3(3-HSD mRNA
showing no signal in the corpus luteum (CL) and stroma (S); (d) section of a marmoset ovary 24 h after luteolysis was induced with PGF2a
after immunohistochemistry for 3(3-HSD, showing patchy staining of the corpus luteum (CL) but not the surrounding stroma (S). Scale
bar = 100 pm.
rats, luteal prostaglandin increases during the last days of
the luteal phase (Olofsson et al., 1990) and inhibition of
prostaglandin synthesis by indomethacin prolongs the natural
life-span of the corpus luteum (Bjurulf et al., 1994). In sheep
and cows, natural luteolysis is clearly attributed to the uterine
synthesis and secretion of PGF2a (Niswender et al., 1985;
Auletta and Flint, 1988). In these species, it is thought that
PGF2a has a direct effect on luteal LH receptor mRNA
expression (Bjurulf and Selstam, 1996; Smith et al., 1996).
Although it is not clear in this study whether the reduced LH
receptor mRNA is due to decreased transcription or decreased
mRNA stability (Segaloff and Ascoli, 1993), it is clear that,
despite different mechanisms of luteolysis in primates (Auletta
and Flint, 1988), the effect of PGF2o( of LH receptor mRNA
concentrations appears to be the same.
There is evidence that locally produced PGF2a may have a
role in primate luteolysis (Auletta et al., 1984; Auletta and
Flint. 1987; Behrman etal., 1993). Prostaglandins are produced
by the human corpus luteum and PGF2a receptors can be
detected in the human corpus luteum (Challis et al., 1976).
Pharmacological doses of prostaglandins can reduce progester¬
one secretion from the primate corpus luteum (Wentz and
Jones, 1973; Auletta et al., 1984). In addition, some studies
have reported increased intra-luteal PGF2oc during the end of
the functional human luteal phase (Shutt et al., 1976; Patward-
han and Lanthier, 1980). As LH receptors cannot be detected
in follicular phase primate corpora lutea (Ravandranath et al.,
1992a; Nishimori et al., 1995; Takao et al., 1997), it is clear
that they disappear with functional luteolysis. Local PGF2a
may be involved in the inhibition of LH receptor expression
at the end of the primate luteal phase.
The steroidogenic pathway can also be affected at other sites
by PGF2a. In vitro, PGF2a inhibits LH-stimulated progesterone
production, and this is thought to be a post-cAMP-mediated
effect (Auletta and Flint, 1988; Abayasekara et al., 1993;
Michael et al., 1994). PGF2a is known to activate protein
kinase C (PKC) (Niswender et al., 1994), which has several
effects on the steroidogenic pathway. It inhibits cholesterol
transport to cytochrome P450 side chain cleavage enzyme
(P450scc) (Wiltbank et al., 1993), which suggests an inhibitory
effect on sterol carrier protein-2 (SCP-2) (McLean et al., 1995)
or steroidogenic acute regulatory protein (StAR) (Stocco and
Clark, 1996). In addition it has been shown that expression of
3(3-HSD can also be inhibited in vitro (Hawkens et al., 1993).
We have shown that 3P-HSD mRNA and protein expression
are inhibited during PGF2a-induced luteolysis in the primate.
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This confirms that the multiple sites of inhibition of steroido¬
genesis during PGF2a-induced luteolysis are also seen in
the primate.
Induced luteolysis using LH withdrawal had the same effects
on luteal LH receptor and 3J3-HSD expression. It has previously
been shown that removal of LH support in monkeys caused a
dramatic down-regulation of mRNA for both P450scc and 3(3-
HSD (Ravindranath et al., 1992b). Indeed, concentrations of
3(3-HSD have been shown to decline during natural luteal
regression in the primate (Doody et al., 1990). We have
confirmed the fall in 3(3-HSD message and shown that this is
associated with a fall in LH receptor mRNA. The similarity
of the effects of the disparate ways to induce luteolysis in the
marmoset suggests common final pathways of action. It is not
known whether LH withdrawal induces local PGF2(X formation.
However, it has been shown that HCG. acting through the LH
receptor, has an inhibitory effect on luteolysis induced by
PGF2a (Auletta and Kelm. 1994). It is therefore likely that LH
withdrawal and PGF2cc activate a common final pathway to
induce luteolysis.
That common pathway might be progesterone withdrawal.
It is clear that acute administration of PGF2tx can inhibit
progesterone synthesis in the absence of changes in the
expression of steroidogenic enzymes (Michael et al., 1994).
Its effects on cAMP stimulation and progesterone output
precede the observed decrease in mRNA concentrations (Khan
and Rosberg, 1979; Bjurulf and Selstam, 1996). Likewise,
withdrawal of LH results in rapid cessation of progesterone
output (Fraser et al., 1986). It is possible that progesterone
itself has an autocrine role in the corpus luteum. The primate
corpus luteum possesses receptors to the progesterone it
produces (Chandrasekher et al., 1994; Suzuki et al., 1994).
Recent work using trilostane to inhibit progesterone synthesis
suggests that progesterone may indeed have a major role in
the function of the corpus luteum (Duffy et al., 1994; Duffy
and Stouffer, 1995). However, it is not yet clear if progesterone
maintains the enzymes responsible for its production. Evidence
from the rat, where PGF2ct only induces a transient decline in
LH receptor and 3(3-HSD mRNA suggests that their recovery
occurs in the presence of follicular phase concentrations of
progesterone (McLean etal., 1995; Bjurulf and Selstam, 1996).
The fact that we did not see this recovery, and that the rat
does not appear to express luteal progesterone receptors (Parke-
Sarge et al., 1995) suggests that this may be a species effect.
Progesterone therefore remains a potential candidate in the
control of luteal function during luteolysis.
The effect of induced luteolysis on mRNA was evident
before the effect on protein concentrations. We could detect
little LH receptor and 3p-HSD mRNA 12 h after induced
luteolysis. In sheep. Smith et al. (1996) reported that this
reduction was evident within 6 h of induced luteolysis. We
found continued LH receptor binding 12 h after induced
luteolysis and could detect some 3J3-HSD protein 24 h after
induced luteolysis in the absence of mRNA. The patchy
appearance of 3P-HSD we observed after induced luteolysis
is similar to that seen during natural luteolysis in the monkey
(Sanders and Stouffer, 1997). This time difference of effects
on mRNA and protein concentrations was also seen in ovine
corpora lutea after induced luteolysis with PGF2a (Smith et al.,
1996). This is consistent with protein having a longer turnover
time than mRNA. However, as progesterone concentrations
were at follicular concentrations, 12 h after induced luteolysis,
it appears that this protein is not stimulated enough to be
functional at this stage. It therefore needs to be stressed
that at the first time point studied (12 h), the progesterone
concentrations were already at follicular concentrations. It is
not clear whether the decline in progesterone precedes the
inhibition of LH and 3P-HSD expression, is secondary to it.
or related through another common factor. It would be interes¬
ting to dissect the pathway at time points earlier than 12 h.
Induced luteolysis in the marmoset monkey is associated
with cell death and disruption of the cellular architecture
(Fraser et al., 1995a). Indeed it has been suggested that PGF2a
can directly cause apoptotic cell death (Sawyer et al., 1990).
It is possible that the fall in mRNA and protein for the LH
receptor and 3P-HSD reflects a general loss of cell viability
within the corpus luteum rather than being specific to functional
luteolysis. This is unlikely, as the loss of mRNA clearly
precedes the loss of protein for both the LH receptor and 3(3-
HSD, and other mRNA species are still present in the corpus
luteum 12 h after induced luteolysis (Duncan et al., 1996b).
In addition, some proteins have been shown to increase in the
corpus luteum after induced luteolysis in the marmoset (Woad
et al., 1996). This suggests that the steroidogenic pathway is
specifically and rapidly switched off during induced luteolysis.
The rapid loss of LH receptor mRNA in the corpus luteum
was not seen in the thecal layers of antral follicles after induced
luteolysis. This LH receptor will be equally starved of its
ligand after GnRHam-induced luteolysis. The inhibitory effects
on LH receptor and 3J3-HSD mRNA was clearly not seen in
the thecal cells. This suggests that the common luteolytic
pathway is not found in follicular thecal cells. It is not known
whether these cells express PGF2a receptors. In the sheep
corpus luteum. PGF2a receptors are located on the large luteal
cells, and not the small luteal cells, that are thought to be of
thecal origin (Fitz et al., 1982). This may be one of the
differences. Thecal cells of the follicle, however, may express
progesterone receptors (Suzuki et al., 1994). Clearly studying
the differences between follicular thecal cells and luteal cells
may aid understanding of the luteolytic process.
In conclusion, the rapid reduction of LH receptors and the
steroidogenic enzyme 3(3-HSD during induced luteolysis in the
primate suggests an inhibition to synthesis of the components of
the steroidogenic pathway as well as their function during
luteolysis. It is still not clear if this is a cause or effect of low
progesterone concentrations, but it is likely to contribute to
the continued inhibition of progesterone synthesis during
luteoiysis. The similarity of effect of PGF2a treatment and LH
withdrawal, however, suggests a common inhibitory pathway.
Dissection of this pathway may give more information about
the continuing enigma of primate luteolysis.
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Immunolocalization of bcl-2 protein in human endometrium in the
menstrual cycle and simulated early pregnancy
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Cell death by apoptosis is now regarded as an important feature of normal endometrial physiology. Recent
reports have suggested that bcl-2, a proto-oncogene responsible for the suppression of apoptosis, is expressed
in endometrium and may be involved in the regulation of menstruation. Using standard immunohistochemical
procedures, the immunoreactivity of bcl-2 and progesterone receptors has been investigated in normal human
endometrium throughout the menstrual cycle (n = 25) as well as endometrium exposed to continued
oestradiol and progesterone stimulation by 'rescue' of corpus luteum (n = 4) with exogenous human chorionic
gonadotrophin (HCG) administration (pseudopregnancy). Marked immunoreactivity, consistent with previous
reports, was noted in the glandular epithelium during the proliferative phase of the cycle. Immunostaining
persisted in the glandular epithelium during the secretory phase, although the percentage and intensity of
staining was markedly reduced. Staining in the stromal compartment was only noted during the late secretory
phase of the cycle. Co-localization with an antibody against CD56 demonstrated that this immunoactivity
largely reflected the presence of lymphocytes in the stroma. Endometrium from subjects who underwent
'luteal rescue' displayed limited immunostaining in either glands or stroma. The absence of significant bcl-2
expression in endocrinological^ maintained endometrium makes it highly unlikely that bcl-2 is important in
prolonging endometrial cell survival in the luteal phase of the menstrual cycle.
Key words: apoptosis/bcl-2/endometrium/immunohistochemistry/pseudopregnancy
Introduction
Apoptosis is a distinct mode of cell death that is responsible
for deletion of cells in normal tissues (Keir et al., 1972). This
process is quite distinct from cell death in response to toxic
effects (necrosis) and is characterized by specific morphological
features such as cell shrinkage, nuclear chromatin condensation
and fragmentation leading to the formation of membrane-
enclosed apoptotic bodies containing well-preserved organelles
(Kerr et al., 1994). Apoptosis has been noted to be involved
in the involution of some endocrine-dependent target organs
such as the adrenal gland (Wyllie et al., 1973), the ovary
(Hurwitz and Adashi, 1992) and the prostate (Kyprianou and
Isaacs, 1988). Apoptosis has also been reported in rabbit
endometrium after withdrawal of progesterone (Nawaz et al.,
1987) as well as human endometrium at the end of the luteal
phase (Hopwood and Levison, 1976). In addition to the detailed
morphological features of apoptosis, specific nuclear DNA
fragmentation has been demonstrated in human endometrium
by 3' end-labelling techniques (Tabibzadeh et al., 1994)
Apoptosis is known to be controlled by the expression of a
number of regulatory genes, including c-myc, p53, apo-l/fas
and particularly members of the expanding bcl-2 family. Bcl-2,
the product of a proto-oncogene, is localized in the inner
© Oxford University Press
mitochondrial membrane (Hockenbery et al., 1990) and has
been shown to prolong cell survival by suppressing apoptosis
in various cells (Vaux et al., 1992; Baer, 1994). Two recent
reports have described the expression of bcl-2 in normal human
endometrium (Gompel et al., 1994; Otsuki et al., 1994). Both
reports observe that the level of expression in the glandular
cells is maximal during the proliferative phase of the menstrual
cycle but while one report (Otsuki et al., 1994) suggests that
bcl-2 is present during the early part of the luteal phase, the
other (Gompel et al., 1994) found that bcl-2 disappeared from
the endometrium 2-3 days after the onset of secretory change,
with only weak immunoreactivity being evident later in the
luteal phase.
Only Gompel et al. (1994) made detailed reference to the
pattern of stromal immunoreactivity. In the proliferative phase,
stromal staining was scarce with only the occasional lympho¬
cyte (positive internal control) displaying positive immuno¬
reactivity. Stromal staining increased with predecidualization
of the stromal compartment and in association with the increase
in the presence of lymphocytes. However, the cell types
expressing bcl-2 were not characterized. This is important, as
bcl-2 plays a central role in lymphocyte selection in response
to an antigenic stimulus (Cohen and Duke, 1992). As it
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is likely that processes such as vasoconstriction in response
to endothelins or prostaglandins are more important than
glandular apoptosis per se in the turnover of the endometrium,
it is possible that stromal expression of bcl-2 may represent
an altogether different process.
From these data, it is unclear what role bcl-2 plays (if any)
in the processes leading up to menstruation in the non-pregnant
cycle or establishment of pregnancy in the pregnant cycle. To
investigate this further, we have studied the expression of
bcl-2 in carefully timed endometrial biopsies as well as biopsies
from women in whom the endocrinology of early pregnancy
has been simulated by injections of exogenous human chorionic
gonadotrophin (HCG). We have particularly investigated the
nature of the previously reported bcl-2 positive cells in the
stroma of the endometrium.
Materials and methods
Samples of endometrial tissue were collected from 29 women
aged between 25 and 45 years. Samples were either collected
from the uterine specimens of women undergoing elective
hysterectomy or by endometrial biopsy from women under¬
going laparoscopic sterilization. All subjects described regular
menstrual cycles of between 25 and 35 days and were of
proven fertility. No subject had received any drug or hormonal
therapy during the 3 months previous to the onset of their last
menstrual period.
The subjects were grouped according to the stage of the
menstrual cycle as follows: early proliferative phase (days
4—9 after onset of menses, n = 5); late proliferative phase
(days 10-14 after onset of menses, n = 3); early secretory
phase (days 1—4 after ovulation, n = 5); mid-secretory phase
(days 5-8 after ovulation, n = 3); late secretory phase (days
11-14 after ovulation, n = 8). Eighteen of the subjects whose
operation took place during the luteal phase of the menstrual
cycle had collected daily urine samples throughout the cycle
of operation. The luteinizing hormone (LH) concentration was
subsequently assayed in these samples and the day of ovulation
taken as the day of the urinary LH peak (Djahanbakhch et al.,
1981a). Progesterone concentration was measured in these
subjects by standard radioimmunoassay (Djahanbakhch et al.,
1981b) in a single plasma sample collected on the morning of
the operation and expressed as mean ± SE. The endocrine
dating was supported by histological dating on haematoxylin
and eosin sections according to the criteria of Noyes et al.
(1950).
Four subjects, where the operation was due to fall between
12 and 16 days after ovulation, agreed to receive HCG (Profasi,
Serono) to maintain the lifespan of the corpus luteum. The
HCG was administered by i.m. injection for between 6 and 8
days in incremental doses beginning with 125 IU per day then
doubling daily to a maximum of 16 000 IU per day. Plasma
samples were collected on alternate days during HCG adminis¬
tration. The concentrations of HCG as well as the ovarian
hormones, oestradiol, progesterone and inhibin produced by
this regime are similar to those seen in normal pregnancy
(Illingworth et al., 1990).
All tissue specimens were fixed in either 10% neutral
buffered formalin or 4% paraformaldehyde (the method of
fixation did not affect bcl-2 immunoreactivity) and thereafter
routinely embedded in paraffin wax. Tissue sections (5 pm)
were cut, dried overnight at 55°C and processed for (i)
haematoxylin and eosin staining for routine histological dating,
(ii) immunohistochemistry for expression of bcl-2 protein,
progesterone receptor and CD56 antigen.
Immunohistochemistry
bcl-2
The bcl-2 protein was immunoiocalized with a monoclonal
mouse antibody (bcl-2—124, Dako Ltd, High Wycombe, Bucks,
UK) raised against a synthetic peptide sequence comprising
amino acids 41-54 of bcl-2 protein (Tsujimoto and Croce,
1986). The immunohistochemical detection of bcl-2 was con¬
ducted on de-paraffinized sections using an avidin biotin
peroxidase detection system (Vector Laboratories, Peterbor¬
ough, UK). Briefly, sections were de-paraffinized and rehy-
drated through graded alcohols, followed by microwaving at
high power in 0.01 M sodium citrate buffer (pH 6) for 15
min. Endogenous peroxidase immunostaining was blocked by
treatment with 0.3% hydrogen peroxide in methanol for 30
min at room temperature. Thereafter, non-specific binding was
blocked by incubation with normal rabbit serum. Tissue
sections were then successively incubated with anti-human
bcl-2 mouse monoclonal antibody for 60 min at 37°C, then with
a horse biotinylated anti-mouse antibody (Vector Laboratories,
Peterborough, UK), and finally with an avidin-biotin peroxid¬
ase complex (ABC, Vector Laboratories, Peterborough, UK).
Sections were incubated with diaminobenzidine (DAB) and
lightly counterstained with haematoxylin prior to permanent
mounting. Tonsil tissue was included as a positive control.
As negative controls, mouse immunoglobulin of the same
immunoglobulin class and concentration as the primary anti¬
body was used.
Progesterone receptor (PR)
A monoclonal mouse antibody, raised against a synthetic
peptide towards the amino end of the human PR molecule,
was used to immunolocalize the PR (PGR Paraffin, Novocastra
Laboratories, Newcastle, UK). This antibody recognizes both
A and B forms of receptor as well as bound and unbound
receptor. PR was immunoiocalized using the avidin-biotin
peroxidase detection system described above using a 1:20
dilution of the primary antibody (0.6 pg/ml). Normal goat
serum (SAPU, Carluke, Lanarkshire, UK) was used to block
non-specific binding and a 1:100 dilution of biotinylated goat
anti-mouse (Dako Ltd, High Wycombe, Bucks, UK) was used
as the secondary antibody. As PR is a nuclear protein, these
sections were not counterstained with haematoxylin.
CD56
CD56 positive cells were immunoiocalized with a mouse
monoclonal antibody (Zymed Laboratories, San Francisco,
CA, USA). Primary antibody was used at a dilution of 1:250.
As a negative control, the primary antibody was replaced with
mouse immunoglobulin of the same concentration. An avidin
biotin peroxidase detection system was employed (Vector
1558
Endometrial bcl-2 in pseudopregnancy




Immunoreactivity was assessed using light microscopy and
the intensity of immunostaining for bcl-2 in all tissue sections
was semi-quantitatively scored on a five point scale where
0 = no staining, 1 = mild staining, 2 = moderate staining,
3 = intense staining and 4 = very intense staining. The
percentage of positively stained cells in each tissue section
was estimated in the gland, stromal and surface epithelial
compartments.
Progesterone receptor
Computer-aided nuclear densitometry was performed on sec¬
tions from the same carefully controlled experimental run.
Grey-scale densitometry was performed after image capture
using an image analysis program (Image 1.52, NIH, Maryland,
USA) on a Macintosh IICX computer. The average grey-scale
reading of 50 random nuclei in three fields of view was
calculated for the nuclei of the glands and stroma on each
section. Background readings (taken from the cytoplasm of
the same cells) were subtracted from the average grey-scale
reading to give a more objective measurement of staining
intensity in both stromal and glandular tissue.
Informed consent was obtained from all volunteers. Ethical
approval for this study was granted by the Lothian Ethics of




In all women who received HCG, menses was postponed. The
mean progesterone concentrations in the luteal phase subjects
were: early 16.77 ± 4.28 nmol/1; mid 34.04 ±6.73 nmol/1;
late 28.01 ±7.37 nmol/1; HCG treated, 54.76±2.45 nmol/1.
Positive control (tonsil)
Intense brown staining for bcl-2 protein was observed in the
follicular mantle and the majority of cells within the germinal
centre of the tonsil displayed negative immunostaining (Figure
la). The negative control (primary antibody replaced with
normal mouse immunoglobulin) showed an absence of specific
staining in the follicular mantle. In tonsil tissue and all
endometrial biopsies, bcl-2 positive immunostaining was con¬
sistently cytoplasmic.
Proliferative phase endometrium
Positive immunostaining for bcl-2 protein was observed in the
glandular cells of proliferative phase endometrium. The stroma
and surface epithelium occasionally also displayed positive
immunoreactivity (Figure lb). Immunoreactivity was most
marked in mid- and late proliferative phase glandular epithe¬
lium (Figure 2a). Stromal immunoreactivity was minimal with
occasional isolated cells (presumed lymphocytes) displaying
positive immunoreactivity (Figure 2b). A serial section, where
Figure 1. (a) Immunoperoxidase staining (brown reaction product)
for bcl-2 in human tonsil, scale bar = 100 pm;
(b) immunolocalization of bcl-2 protein in mid-proliferative
endometrium, scale bar = 200 pm; (c) negative control, note the
absence of specific bcl-2 immunoreactivity, scale bar = 200 pm;
(d) late secretory phase endometrium displaying marked
immunoreactivity in glandular epithelium and also isolated stromal
cells, scale bar = 200 pm; (e) late secretory phase endometrium
showing co-localization of bcl-2 protein (brown) in stromal cells
and CD56 antigen (purple, arrows), scale bar = 25 pm; (f) HCG
rescued endometrium (pseudopregnant) displaying nuclear (arrow)
immunoreactivity for progesterone receptor (brown) in the stromal
compartment (note the absence of glandular staining), scale bar =
25 pm.
the primary antibody had been replaced with normal mouse
immunoglobulin, displayed a complete absence of immuno¬
staining in all cells (Figure lc).
Secretory endometrium
The early secretory phase endometrium displayed weak
immunoreactivity in both glandular and surface epithelium
with infrequent stromal positive immunoreactivity. Both the
intensity of staining in the glandular epithelium and the
percentage of cells stained were reduced in the luteal phase
endometrium (Figure ld,e). The intensity of staining was very
variable (Figure 2a) but in late secretory phase endometrium,
bcl-2 immunostaining was noted to be higher in both glandular
and surface epithelium (data not shown). The mean percentage
of cells exhibiting positive staining for bcl-2 was 9% in the
early luteal phase, 13% in the mid-luteal phase and 36% of
cells in the late luteal phase. The late secretory biopsies were
the only sections to show high levels of immunoreactivity in
the stromal compartments (Figure 2b).
Co-localization with CD56 showed that many, although not
all, of the cells in the stromal compartment that were bcl-2
positive were also positive for CD56. In particular, lymphoid
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Figure 2. Density of staining for bcl-2 in proliferative and
secretory phase endometrium (density estimated by arbitrary
scoring system), plotted against the number of days since the
urinary luteinizing hormone (LH) surge in (a) glandular tissue and
(b) stroma.
bcl-2 (Figure le). The immunoreactivity for the PR in the
glandular epithelium present in the early secretory phase is
not present in the mid- or late secretory phase as shown in
Figure 3a. There are no differences in the stromal immunoreac¬
tivity for the PR in the early, mid- and late secretory phases
(Figure 3b).
HCG rescued endometrium (pseudo-pregnancy)
The morphology of these glands was found to be very similar
to that observed in the mid-luteal phase sections with tortuous
glands exhibiting intraluminal secretion with loss of blebbing.
There was little morphological evidence of apoptosis in these
sections and no pre-decidual changes were evident. In one of
the subjects who had received HCG for 8 days, the Arias-
Stella phenomenon of pregnancy was evident.
Weak immunostaining for bcl-2 was found in a small
proportion of glandular cells. The level of immunostaining in
the stromal cells was similarly very limited in comparison
with the late luteal phase. These cells were also positive for
CD56. The pattern of localization of PR in pseudo-pregnant
endometrium shows a very similar pattern to that of the mid
and late secretory endometrium (Figures If, 3a,b).
Discussion
The present study supports the findings of previous studies
(Gompel et al., 1994; Otsuki et ai, 1994) that bcl-2 is
expressed in the glandular component of human endometrium.
10 i 1 ' 1
0 7 14 21
Days after urinary LH peak
Figure 3. Immunolocalization of progesterone receptors (arbitrary
densitometric units) in secretory phase endometrium, plotted against
the number of days since the urinary LH surge in (a) glandular
tissue and (b) stroma.
The finding in this study of maximal staining intensity during
the proliferative phase is entirely consistent with these earlier
reports. There was, however, a marked discrepancy between
the luteal phase observations of our study and those of the
two previous studies: Otsuki et al. (1994) finding very little
immunostaining for bcl-2 at any stage of the luteal phase while
Gompel et al. (1994) noted staining only in the early luteal
phase. In contrast, we observed staining in the glandular
component of endometrial samples from all stages of the luteal
phase, including the late luteal phase, although the pattern
and intensity of staining was very variable. Whether these
discrepancies in luteal phase are a reflection of endometrial
dysfunction (18 of the luteal phase subjects were undergoing
hysterectomy for abnormally heavy periods) is not clear.
However, the study of endometrial samples obtained from
women where the time of ovulation has been clearly defined
by serial urine estimation enables us more clearly to identify
the chronology of events towards the end of the luteal phase.
The pattern of staining seen in the stromal compartment of
the endometrium is entirely different from that seen in the
glandular compartment. Significant immunoreactivity was
absent in the proliferative phase and early secretory phase and
became evident only in the late luteal phase. Indeed, as the
time since ovulation increased so did the percentage of cells
in the endometrium exhibiting bcl-2 staining. Our observation
that most of these cells are CD56 positive lymphocytes suggests
that the bcl-2 immunoreactivity seen in this part of the gland
may represent the presence of immune cells which have been
selected for survival. The survival of these immune cells may
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be necessary for the secretion of cytokines such as IL-8 and
tumour necrosis factor-a (TNFa) to initiate the processes
leading to menstruation (Kelly, 1994).
Indeed we found that where the women had been treated
with increasing doses of HCG, the detectable immunoactivity
for bcl-2 was low. Treatment with HCG simulates pregnancy
in that progesterone concentrations are maintained (as in all
subjects studied here), although clearly may differ due to the
absence of cytokines and growth factors of embryonic origin.
In all cases, the process of menstruation has been inhibited,
and although the histological appearances of this tissue show
no clear evidence of decidualization this may simply reflect
the short duration of exposure to HCG/progesterone. The
model therefore enables us to compare the expression of bcl-
2 in sections where the progesterone concentration is falling
prior to menstruation with those where the progesterone
concentration has been maintained. We found that in both the
stroma and the glandular compartments, the proportion of cells
expressing bcl-2 was reduced in these sections. This argues
strongly against the hypothesis advanced by Otsuki et al.
(1994) that bcl-2 has an important role in regulating death
of glandular cells in the functional layer during the late
luteal phase.
These observations are entirely consistent with the view that
the expression of bcl-2 protein in the epithelium is under
steroid control, in that oestrogen up-regulated expression
while in the sections where progesterone concentrations were
maintained, progesterone exposure down-regulated expression.
However, the pattern of persistent immunostaining in some
sections where progesterone concentrations are elevated
implies that the regulation of endometrial bcl-2 expression
may be the result of a combination of endocrine and paracrine
signals. Tabibzadeh (1994) has suggested that T-cells and the
cytokine TNFa may be implicated in the regulation of apoptosis
of epithelial cells. In addition to T-cells, other cells in the
stroma and endometrial epithelium also exhibit both message
and protein of TNFa (Hunt et al., 1992). Thus alternative
sources of TNFa may be implicated in the processes of
apoptosis. Interestingly, there is a significant increase in TNFa
mRNA in the late secretory phase (Tabibzadeh et al., 1994),
and it has been suggested that excess production of TNFa in
association with oestrogen withdrawal may be associated with
the development of apoptosis in human endometrium. We are
not aware of any published data concerning TNFa message
or protein in 'pseudo-pregnant' endometrium, i.e. after
'luteal rescue'.
The nature and extent of apoptosis in the human endo¬
metrium at different stages of the female menstrual cycle has
recently been described in detail (Tabibzadeh et al., 1994).
Apoptosis was found to occur at a low frequency in proliferative
endometrium, then increased during the secretory phase in the
glandular cells (Tabibzadeh et al., 1994). No apoptosis was
found in the stroma, including the lymphoid aggregates. These
observations suggest that the localization of bcl-2 in the
glandular component of the late secretory endometrium does
not inhibit apoptosis at that'stage of the cycle, although it is
possible that the high intensity of bcl-2 in the glandular
epithelium during the proliferative phase may reflect this
function. Our observations that CD56 positive lymphocytes
express bcl-2 is in keeping with the absence of histological
evidence of apoptosis in that region.
Any discussion of the significance of the immunolocalization
of bcl-2 now has to be tempered by the observation that bcl-2
is only the prototype of an extended family of similar proteins
which inhibit apoptosis. In particular, it is now clear that the
action of bcl-2 depends acutely on the concentration of and
interaction with a potential antagonist protein, bax (Oltvai
et al., 1993). At present, nothing is known about the localization
or level of expression of bax within human endometrium, nor
are there any data about the level of expression of potential
bcl-2 effectors/antagonists such as bcl-xL or bcl-xS (Boise
et al., 1993). Until the nature and extent of interactions between
these genes in the endometrium is clarified, the physiological
significance of bcl-2 in the endometrium will remain un¬
resolved.
In summary, we conclude from these data that bcl-2 is
expressed in the human endometrium at all stages of the
menstrual cycle. We found no evidence to support a simple
relationship between bcl-2 expression and endometrial main¬
tenance. Further research into the level of expression of bcl-2
antagonists such as bax, bcl-x-1 and bcl-x-s will be required
before the role of this complex gene family in the endometrium
can be fully understood.
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Abstract
Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a
specific inhibitor of a group of proteolytic enzymes known
as matrix metalloproteinases. These enzymes have been
widely implicated in the process of tissue remodelling.
Extensive remodelling occurs in the corpus luteum
during luteolysis unless human chorionic gonadotropin!!
(hCG) is produced by the early conceptus. This study
aimed to investigate the expression and localisation of
TIMP-1 in human corpora lutea during the luteal phase of
the cycle and after luteal rescue with exogenous hCG to
mimic the changes of early pregnancy. Human corpora
lutea from the early (»=4), mid- (/<=4) and late (u=4)
luteal phases and after luteal rescue by hCG (u = 4) were
obtained at the time of hysterectomy. Expression of
TIMP-1 was investigated in these tissues by Western
blotting, immunohistochemistry, Northern blotting and in
situ hybridisation. Luteal cells of thecal origin were distin¬
guished from those of granulosa origin by immunostaining
for 17a-hydroxylase. A 30 kDa protein consistent with
TIMP-1 was detected in human corpora lutea. This
protein was localised to the granulosa lutein cells in all
tissues examined. TIMP-1 mRNA was found in large
quantities in all glands examined and this again localised to
the granulosa lutein cells. The expression and localisation
ofTIMP-1 did not change throughout the luteal phase and
was not altered by luteal rescue. The function of this
uniform expression ofTIMP-1 in the corpus luteum is not
clear but these data suggest that the inhibition ofstructural
luteolysis during maternal recognition of pregnancy is not
mediated by regulation of TIMP-1 expression.
Journal of Endocrinology (1996) 148, 59-67
Introduction
I he human corpus luteum will undergo functional and
structural luteolysis unless human chorionic gonadotropin!!
(hC.CI) is produced by the implanting blastocyst (Behrman
<t al. 1993). Although this process is fundamental to
ovarian function the molecular mechanisms of luteolysis
and luteal rescue in the human are still uncertain. During
structural luteolysis, the gland rapidly changes from the
most active endocrine gland in the body with a greater
bkxxl flow per unit mass than the kidney (Ford et al. 1982)
a small fibrous remnant.
Such a process is likely to involve extensive remodelling
"I the extracellular matrix which is controlled by a group
zmc-dependent enzymes, the matrix metalloproteinases
IMMPs). Alterations in metalloproteinase activity have
''veil implicated in the spread of neoplastic tissues (Naylor
t" a I. 1994) as well as in remodelling of reproductive
'ssties, such as the endometrium at menstruation
'Hampton & Salamonsen 1994) and the follicle wall at
ulation (Reich ct al. 1985). The activity of MMPs is
".eoiously controlled at several levels, including synthesis
•' Proenzyme requiring activation and the production of
I
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specific inhibitors, tissue inhibitors of metalloproteinases
(TIMP-1, TIMP-2 and T1MP-3). TIMP-1 is ofparticular
interest as it has recently been demonstrated that it is the
major secretory product of the ovine corpus luteum (Smith
ct al. 1993) and that its expression is transiently increased
during prostaglandin F2„ (PGF2u)-induced luteolysis
(Juengel ct al. 1994). Other studies have reported that
TIMP-1 expression increases markedly in preovulatory
granulosa cells around the time of the goiiadotrophin surge
(Smith GW ct al. 1994).
This study aimed to investigate the role ofTIMP-1 in
the human corpus luteum by studying its expression
in the corpus luteum throughout the normal luteal
phase and during early pregnancy simulated by the
administration of hCG in logarithmically increasing doses.
Materials and Methods
Collection of tissue
Corpora lutea were enucleated at the time of hysterectomy
in 16 women undergoing surgery for benign conditions.
All women were healthy, aged from 32 to 45 years with
w c Duncan and others TIMP-1 in human corpus luteum
regular menstrual cycles and had not received any form of
hormonal treatment for at least 3 months prior to taking
part in the study. The corpora lutea were dated on the
basis of serial urinary luteinizing hormone (LH) measure¬
ments on samples collected daily prior to operation
(Djahanbakhch et al. 1981 a). On this basis, four corpora
lutea were classified as early (LH+ 1 to LH+5), four as mid
(LH+6 to LH + 10) and four as late (LH+11 to LH+14). In
addition, four women received daily i.m. injections of
hCG (Profasi; Serono Laboratories, Welwyn Garden City,
Herts, UK) from LH+7 in daily doubling doses, starting at
125 1U, for 5 to 8 days until surgery. This regimen has
been shown to reproduce the hormonal changes of early
pregnancy (Illingworth ct ai 1990).
The whole corpus luteum was enucleated from the
ovary by blunt dissection and the ovary oversewn. The
tissue was immediately divided into radial blocks in order
to ensure that the whole thickness of the gland was
represented in any piece. Two pieces were rapidly snap
frozen in liquid nitrogen and stored at — 70 °C for
subsequent RNA and protein extraction. A biopsy was
fixed in 4% paraformaldehyde for 24 h and embedded in
paraffin wax for subsequent immunohistochemistry and
another biopsy was frozen in embedding medium (Tissue-
Tek OCT compound; Miles Inc., Elkhart, IN, USA) and
stored at — 70 °C until frozen sections were cut. In each
case an endometrial biopsy was also fixed in paraform¬
aldehyde and processed into paraffin wax for luteal-phase
dating by tissue morphometry (Li ct al. 1988). Plasma was
taken before surgery and progesterone concentration was
measured by a standard RIA (Djahanbakhch ct al. 1981/)).
This study was approved by the local Reproductive
Medicine Ethics Committee and informed consent was
obtained from all patients prior to tissue collection.
Immunohistochemistry
All reagents used were obtained from Sigma Chemical,
Poole, Dorset, UK unless indicated otherwise. Paraffin-
wax sections (5 pm) were cut onto poly-L-lysine
(50 pg/1)-coated slides and then dewaxed and rehydrated.
As preliminary experiments indicated that microwave
antigen retrieval (Shi et al. 1993) was necessary for the
detection ofTIMP-1, all sections underwent microwaving
at full power (1000 W) in 0-01 M citrate buffer pH 6 for
10 nun. After standing for 20 min, the sections were
washed in Tris-buffered saline (TBS) pH 8 and non¬
specific binding was blocked by normal rabbit serum
(Dako Ltd, High Wycombe, Bucks, UK) diluted 1:5 in
TBS containing 5% (w/v) BSA for 20 min. Sections were
incubated overnight at 4 °C with a 1:20 dilution of
monoclonal mouse anti-TIMP-1 antibody (TIMP-1
(Ab-1); Cambridge Bioscience, Cambridge, Cambs, UK)
in TBS. This antibody has less than 0-01% cross-reactivity
with TIMP-2 protein. Antibody binding was indicated by
an avidin—biotin alkaline phosphatase (Dako Ltd) reaction
with a biotinylated rabbit anti-mouse (Dako Ltd) second¬
ary antibody and substrate to give a red end product
(Alkaline Phosphatase Substrate Kit 1; Vector Laboratories,
Peterborough, Cambs, UK). Sections were washed in
water, counterstained with haematoxylin, dehydrated
through graded alcohols and mounted with pertex mount¬
ing medium (Cellpath, Hemel Hempstead, Herts, UK).
As negative controls, serial sections were incubated with
mouse IgG (Vector Laboratories) in place of the primary
antibody at the same concentration (5 pg/ml) and in
further control sections the primary antibody was omitted.
Serial sections were also stained for 17a-hydroxylase using
a polyclonal rabbit antibody (kindly provided by Professor
M R Waterman, Vanderbilt University, Nashville, TN,
USA) at a 1:750 dilution. In this case, after microwave
antigen retrieval, normal goat serum (SAPU, Carluke,
Strathclyde, UK) was used to block non-specific binding
and specific binding was detected using biotinylated goat
anti-rabbit immunoglobulins (Dako Ltd). The intensity of
staining was graded by an observer blinded to the tissue
identity. Staining was classified as — if absent, + ifweakly
present, ++ if moderate and ++ + if strong.
Western blotting
Protein was extracted on ice into 0-1% SDS and protein
content was estimated by the method of Bradford (1976).
Protein (200 pg) was denatured by boiling in sample buffer
containing p-mercaptoethanol and separated by electro¬
phoresis on an 1 1% polyacrylamide gel. Proteins were
electrophoretically transferred onto nitrocellulose mem¬
brane (Amersham International pic, Aylesbury, Bucks,
UK). After transfer the blot was washed briefly in TBS
containing 0-05% (v/v) Tween (TBST) and incubated in
10% (w/v) dried skimmed milk powder in TBST. Primary
antibody was used in a concentration of 2 pg/ml in TBST
and after washing in TBST the membrane was incubated)
with biotinylated goat anti-rabbit immunoglobulins
Streptavidin alkaline phosphatase (Dako Ltd) was
added after washing in TBST and after further washinc
visualisation was achieved using a red chromogen
(Alkaline Phosphatase Substrate Kit I; Vector Labora¬
tories). Molecular weight markers (Biorad Laboratories,
Hemel Hempstead, Herts, UK) were run in an adjacent
lane to calculate the weight of the detected proteins
Ovine luteal cell-conditioned medium (kindly pr0*
vided by Professor M F Smith, University of Missoun
Columbia, MO, USA) was used as a positive control fa
TIMP-1. The intensity of each band was determined by
computer aided densitometric image analysis (NIH Ima?
1-55; NIH, MD, USA).
Northern blotting
Total RNA was isolated by the method of Chomczytfa-
& Sacchi (1987) using a commercial kit (RNAz0"'
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Biogenesis, Bournemouth, Dorset, UK) and its concen¬
tration was determined by absorption at 260 nrn. Total
UNA (30 pg) was denatured, electrophoresed in a 1-5%
formaldehyde-agarose gel and transferred to a nylon mem¬
brane (Amersham International pic) by capillary action in
20 x SSC (1 x SSC is 150 mM NaCl, 15 mM sodium
ritrate) at pH 7. The RNA was fixed onto the membranes
bv u.v. cross-linkage (Spectronics Corporation, New
York, NY, USA). Membranes were prehybridised for 5 h
in 15 ml hybridisation buffer (0 5 m sodium phosphate,
I mM EDTA, 1% (w/v) BSA, 7% (w/v) SDS, 6-7% (v/v)
deionised formamide) at 65 °C. A human TIMP-1 cDNA
probe (kindly provided by Dr E Bone, British Biotech
l'liarmaceuticals Ltd, Oxford, Oxon, UK) was labelled
with 50 pCi 32P dCTP by the random priming method
using a commercial kit (Amersham International pic) and
added to the hybridisation buffer. Hybridisation was
performed at 65 °C for 70 h. The membranes were
washed twice at 65 °C with 2 x SSC for 15 nrin and once
more with 2 x SSC/01% SDS at 65 °C for 15 nun. The
blots were laid down to a phosphor screen for 24 h and
developed and quantified using a phosphorimager com¬
puter (Molecular Dynamics, Sevenoaks, Kent, UK). To
correct for minor differences in RNA loading the blots
were stripped in stripping buffer (5 mM Tris pH 8-0,
||'3 niM EDTA, 01 x Denhardt's reagent) for 2 h at 65 °C
and reprobed in the same manner with a cDNA probe to
human P-actin (Clontech, Palo Alto, CA, USA). We
found no differences in the level of P-actin expression
during the different stages of the luteal phase. The
molecular size of the transcripts was determined by run¬
ning commercial RNA markers (Promega, Southampton,
Hants, UK) in an adjacent lane. The ratio of relative
intensities for TIMP-1 to P-actin after normalisation by
logarithmic transfomiation was used for data analysis.
In situ hybridisation
In sitii hybridisation was performed on frozen sections
using an antisense TIMP-1 3:>S-labelled riboprobe. A
TIMP-1 cDNA construct in the transcription vector
pGEM 4-Z was obtained from Dr E Bone. Antisense
J"d sense riboprobes incorporating 35S-labelled UTP
'Amersham International pic) were synthesised using a
soniniercial kit (Promega). The antisense probe was
generated from the vector linearised by BamHI (Promega)
using T7 RNA polymerase. The sense probe which
^as used as the negative control was generated from the
uctor linearised by EcoRI (Promega) using SP6 RNA
Ipolymerase.
' rozen sections (6 pm) on poly-l-lysine-coated slides
usre quickly thawed and fixed in 4% paraformaldehyde
"r -"> nun at room temperature. After washing in OT m
luni phosphate, slides were transferred into 0T m
•nethanolamine (TEA) and acetylated in 0-25% (v/v)
anhydride (BDH Laboratory Supplies, Poole,
Dorset, UK) in TEA for 10 min. The sections were
washed in 2 x SSC before dehydration and delipation
through graded alcohols and chloroform. Slides were air
dried and incubated with prehybndisation buffer (50%
formamide, 10 nrM dithiothreitol (DTT), 1 x Denhardt's,
4 x STE (1 x STE is 01 m NaCl, 10 mM Tqs-HCl pH 8,
1 nrM EDTA), 125 pg yeast tRNA/ml, 125 pg salmon
sperm DNA/ml) for 1 h at 45 °C. Excess prehybridisation
buffer was removed and slides were incubated with
1 x 106 c.p.m. radiolabeled probe in 40 pi hybridisation
buffer (prehybridisation buffer containing 10% (v/v)
dextran sulphate), sealed under Gel Bond film (ICN
Biomedical Ltd, High Wycombe, Bucks, UK) and incu¬
bated overnight at 45 °C in a moist chamber. Sections
were washed in 2 x SSC/2 mM DTT prior to RNase A
treatment (30 mg/ml in RNase buffer (10 mM Tris, 1 mM
EDTA, 0-5 m NaCl, pH 8)) for 30 min at 37 °C. The
sections were sequentially washed in RNase buffer/1 mM
DTT and 2 x SSC/1 mM DTT at room temperature
before washing in 0T x SSC/1 mM DTT at 45 °C in a
shaking water bath. Sections were rinsed in OT x SSC
then dehydrated through graded alcohols containing 0-3 m
ammonium acetate and air-dried before dipping in Kodak
NTB-2 photographic emulsion (IBI Ltd, Cambridge,
Cambs, UK) in the dark. The emulsion was exposed in
light-tight boxes containing silica gel at 4 °C for 21 days
then developed (Kodak D-19) and fixed (Kodak Unifix)
at 15 °C in the dark. After rinsing in running tap
water, sections were counterstained with haematoxylin,
dehydrated through graded alcohols into xylene and
mounted in pertex mounting medium. The distribution of
grains was analysed by dark-field microscopy, after image
capture, using a computer-based image analysis system
(Cue-2, Olympus Optical Co. UK Ltd, London, UK).




Classification of the corpora lutea by serial urinary
LH measurement agreed with luteal-phase dating of
endometrial biopsies using the method of Li et al.
(1988) in all cases. Plasma progesterone concentrations
were 36-36 ± 9-28 nmol/1 for the early luteal tissue,
40-35 ± 9-88 nmol/1 for the mid-luteal samples and
18-80T 12-81 nnrol/l for the late luteal samples. After
luteal rescue by exogenous hCG the plasma progesterone
concentrations had increased to 52-75 ± 1-09 nmol/1.
Immunohistochemistry
Immunostaining for TIMP-1 was present in corpora lutea
of all stages of the luteal cycle and after luteal rescue. As
i Journal of Endocrinology (1996) 148, 59-67
Figure 1 Immunostaining of human corpora lutea: (a) TIMP-1 protein in the early corpus luteum (red), staining is present in the
steroidogenic cells (C) and absent from the surrounding stroma (S) (scale bar=100gm); (b) negative control serial section of (a) showing
no staining of the steroidogenic cells (C) and the stroma (S) (scale bar= 100 pm); (c) immunostaining for I 7u-hydroxylase enzyme in a lateluteal corpus luteum (red), the theca lutein cells are seen in discrete clumps (T) at the periphery of the granulosa lutein cells (G) (scalebar=50gm); (d) serial section of (c) stained for TIMP-1, the theca lutein cells (T) are relatively free from staining and the granulosa luteincells (G) show specific TIMP-1 immunostaining (red) (scale bar=50 gm).
can be seen in Fig. Ir7, staining was localised to the
steroidogenic cells of the gland and absent from the
negative controls (Fig. \b). There were no differences
in the localisation of immunostaining for TIMP-1 during
the luteal cycle or after luteal rescue. In particular, the
regressing corpus luteum of the late luteal phase showed
no local areas of altered TIMP-1 immunostaining within
the tissue section. The intensity of staining in all sections
was classified as ++ or + + + with 110 obvious pattern of
variation throughout the luteal cycle or after luteal rescue.
The steroidogenic cells derived from the theca were
identified by immunostaining serial sections for the en¬
zyme 17a.-hydroxylase. Figure If shows the theca lutein
cells to be present in discrete clumps along the periphery
of the granulosa lutein cells. This pattern of staining was
similar to that reported by Taniura el al. (1992). The theca
cells were relatively tree from immunostaining If
TIMP-1 as can be seen in Fig. IT
Western blotting
Western blotting showed a single band at 30 kl)a as shown
in Fig. 2. This is consistent with the molecular weight ol
TIMP-1 which has previously been reported (Smith
et al. 1994) and the same band could be detected in ovir.t
luteal cell-conditioned medium known to contain
TIMP-1. This protein was detected in protein sample
from human luteal tissue from all stages of the cycle. 'Th®
intensity of the detected protein band in luteal cell extrat°
was similar at all stages of the luteal cycle and after lute*
rescue. The width of the detected band suggested the"
may be a heterologous population of TIMP-1 prow"
Journal of Endocrinology (1996) 148, 59-67 i
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Figure 2 Western blot for TIMP-1 protein in luteal tissue homogenates from different
stages of the luteal phase and after luteal rescue by exogenous hCG. Ovine luteal
cell-conditioned medium known to contain large quantities of TIMP-1 was used as a
positive control. The migration of molecular weight markers is indicated at the right of
the figure.
with different glycosylation patterns. We found no
consistent differences in protein band width during the
different stages of the luteal phase however.
Vorlltcm blotting
A single band approximately 0-9 kb in length was detected
in total RNA extracted from human corpora lutea by
Northern blotting. This size was consistent with TIMP-1
message reported in humans (Rapp et cti 1990) and sheep
jSniith CI W et al. 1994). As shown in Fig. 3, TIMP-1
niKNA was abundant and could be found at all stages of
the luteal cycle and after luteal rescue. Densitometric
quantification of the intensity of the message standardised
'or tissue (3-actin expression demonstrated no differences
ot level of TIMP-1 message during the luteal cycle and
alter luteal rescue (Fig. 4).
hi situ hybridisation
As shown in Fig. 5a, message for TIMP-1 was uniformly
distributed throughout the granulosa lutein cells ot the
(orpiis luteum. This distribution was only seen in the
sections incubated with the antisense probe and was absent
Ironi control sections incubated with the sense probe (Fig.
I he localisation ofTIMP-1 mRNA in luteal cells was
"'"sistent with the localisation of TIMP-1 protein (Fig.
'J)- Luteal cells of thecal origin had much lower grain
'""centrations than those of granulosa cell origin (Fig. 5c
and d). The localisation ofTIMP-1 mRNA did not change
throughout the luteal cycle or after luteal rescue.
Discussion
This study is the first to demonstrate the expression and
localisation of TIMP-1 in the human corpus luteum.
TIMP-1 mRNA has previously been demonstrated in the
corpus luteum of a number of other species including the
sheep (Smith G W et al. 1994), the cow (Juengel ct al.
1994) and the pig (Smith M F ct al. 1994). Indeed it has
previously been shown that TIMP-1 is one of the major
products of the ovine corpus luteum and our data suggest
that TIMP-1 is similarly abundant in the luteal cells of the
human ovary. The immunohistochemistry and immuno-
blotting demonstrate specific binding to a protein of the
appropriate molecular weight while the Northern analysis
and in situ hybridisation experiments confirmed the source
of specific mRNA expression.
The TIMP-1 protein and mRNA were found to be
present specifically in the granulosa—lutein cell types of
the corpus luteum. Human preovulatory granulosa cells
have previously been shown to produce metalloproteinase
inhibitor activity in uitro (Morgan ct al. 1994) and contain
abundant TIMP-1 mRNA (Rapp et al. 1990). TIMP-1 is
expressed in the granulosa cells of the preovulatory follicle
in the sheep at a 15-told higher level than in the theca cells
of the same follicle (Smith G W ct al. 1994). We identified
journal ol Endocrinology (1996) 148, 59-67
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Figure 3 Northern blot of TIMP-1 mRNA using total RNA extracted from
corpora lutea at different stages of the luteal phase and after luteal rescue
by exogenous hCG. The positions of the ribosomal 28S and 18S bands are
indicated. The control bands detected after stripping the blot and
re-probing for P-actin are indicated below the TIMP-1 blot.
the steroidogenic cells of thecal origin in the corpus luteum
by immunostaining with an antibody to 17a-hydroxylase.
This enzyme is not present in the granulosa lutein cells and
has been used to identify cells of thecal origin in human
cotpora lutea (Tamura et al. 1992, Rodger et al. 1995). We
found that there was little if any immunostaining or in situ
hybridisation for TIMP-1 in the theca lutein cells of the
human corpus luteum. As the localisation of TIMP-1
appeared to be confined to the large steroidogenic cells of
the corpus luteum it is unlikely that non-steroidogenic
cells present in the corpus luteum, such as macrophages
and T-lymphocytes (Brannstrom et al. 1994), contribute to
TIMP-1 production but this remains to be established.
No change was found in either the site or the intensity
of expression of TIMP-1 during the luteal phase or
following luteal rescue with hCG. This was surprising, as
luteal expression ofTIMP-1 has previously been show
rise for up to 8 h during PGF2a-induced luteolysis it
cow (Juengel et al. 1994). The same group loca
TIMP-1 mRNA by in situ hybridisation during lutec
and found that scattered individual cells within the
oidogenic tissue expressed much higher levels than
surrounding cells (Smith G W et al. 1994). This patte
expression was unlike the uniform grain distribution
within ovine follicular granulosa cells (Smith G W
1994). In the human corpus luteum we found
expression of TIMP-1 is uniform in the granulosa 1
cell population and this distribution is maintained thrf
out the luteal cycle. The different patterns of expn
are probably due to a more gradual luteolytic proo
women. Although we studied four corpora lutea froi
late luteal phase, all the corpora lutea studied wer
journal of Endocrinology (1996) 148, 59-67
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lipure 4 TIMP-1 mRNA in corpora lutea from different stages of
Vie luteal phase and after luteal rescue by exogenous hCG.
Message for TIMP-1 detected by Northern blotting was quantified
!>\ computer-aided densitometry corrected for minor loading
sanations by comparison of (3-actin levels. Values are
eieans ± s.e.m., n—4.
'tunctional, in that progesterone secretion was continuing.
L'nlike the ruminant, luteolysis in women does not result
li'im a surge ofuterine prostaglandin and is therefore likely
to he a more gradual process (Auletta & Flint 1988). In
contrast, in cattle, prostaglandin treatment produces co¬
ordinated luteolysis which allows changes induced in a
proportion of cells, such as apoptosis, to be detected more
easily (Juengel et at. 1993). The more gradual fall in luteal
Junction in women may mask the increased TIMP-l
expression seen within individual cells during luteolysis in
»he ovine gland.
Luteal involution is inhibited during maternal recog-
luuon of pregnancy by hCG acting through the LH
fcccptor (Behrman et al. 1993). Expression of TIMP-1 in
J 'covulatory granulosa cells increases during luteal for-
•tution at the time of the gonadotrophin surge (Smith
W <l ill. 1994). At this sta?e the granulosa cells contain1994). t this stage the granulosa cells contain
receptors (Richards & Mtdgley 1976) and it is possiblethat the increase in TIMP-1 is partially mediated through
f'wulation of this receptor. In the rat, LH stimulates
fcA'ction ot a TIMP-like protein in granulosa cell cultures
riMP-1 mRNA is increased by LH (Mann et al.
f 1. Morgan et al. 1994). However, it does not appear
r' " further stimulation of the corpus luteum by hCG, as
V 'urs in normal human pregnancy, provokes any further
^urease in FIMP-1 synthesis. This may be a species-
related difference, as Morgan et al. (1994) were unable to
show any increase in TIMP-1 in response to LH in
cultured human granulosa cells. TIMP-1 expression in
women may be controlled by other hormones, such as
progesterone. Progesterone receptors have been identified
in the human corpus luteum (Suzuki et al. 1994) and the
progesterone antagonist RU486 can reduce TIMP activity
in granulosa cell cultures (Morgan ct al. 1994).
The significance of the TIMP-1 produced by the hu¬
man corpus luteum remains unclear but its production in
large quantities throughout the luteal phase suggests an
important role. In view of this, Juengel et al. (1994) have
suggested that TIMP-1 expression reflects the production
of endogenous metalloproteinases and acts as a protective
mechanism to limit specific proteinase action. However, as
described in this paper, TIMP-1 mRNA is abundant in the
corpus luteum, it is one of the most abundant mRNAs in
luteinised granulosa cells (Rapp et al. 1990) and TIMP-1 is
the major protein product of the ovine corpus luteum
(Smith et al. 1993). In contrast, preliminary results
(Duncan ct al. 1995) suggest that the nrRNAs for MMP-2
and MMP-9 are present in far lower concentrations than
that of TIMP-1. As TIMP-1 binds to and inactivates
MMPs in a 1:1 ratio (Matrisian 1990) it is probable that, in
the corpus luteum, MMPs are functioning in an environ¬
ment containing a high level of specific inhibitor. For
MMPs to function in this environment it is likely that the
interaction between MMPs and TIMPs is at a local cellular
rather than a tissue-wide level. It may be that local tissue
remodelling is regulated by the expression of proMMPs
and their subsequent activation to active MMPs, rather
than control ot inhibition. It is consequently difficult to
assess the function of TIMP-1 in isolation, when the
activity and production ofMMPs and other inhibitors such
as TIMP-2 remain unclear during the luteal cycle, particu¬
larly as it has recently been reported that TIMP-2 is also
produced by the ovine corpus luteum (Smith ct al. 1995).
TIMP-1 has other properties which may contribute to
a critical role in maintenance of the corpus luteum as well
as the inhibition of metalloproteinase activity. TIMP-1
promotes the proliferation of fibroblasts and endothelial
cells and may be a paracrine or autocrine growth factor
(Hayakawa et al. 1992). This may be important to facilitate
the high levels of angiogenesis during corpus luteum
formation (Reynolds et al. 1992). It is also possible that
TIMP-1 has a role in cell migration (Smith G W et al.
1994) or protection against neoplastic stimuli during
periods of tissue growth and neovascularisation. A recent
publication (Boujrad et al. 1995) has raised the possi¬
bility that TIMP-1, particularly in combination with
procathepsin-L, may be involved in regulating steroido¬
genesis. Boujrad et al. (1995) found that a locally produced
follicle-stimulating hormone-responsive factor which
stimulates both Leydig and granulosa cell steroidogenesis is
the TIMP-1—procathepsin-L complex. Both TIMP-1 and
this complex were found to stimulate steroidogenesis in a
journal of Endocrinology (1996) 148, 59-67
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Figure 5 In situ hybridisation of human corpora lutea for TIMP-1 mRNA: (a) dark field of TIMP-1 mRNA in the early corpus luteum,
grains are found in the steroidogenic cells (G) at much higher levels than the surrounding stroma (S) (scale bar=100gm); (/>) dark-fiel
negative control serial section of (a) using sense TIMP-1, there are no differences in grain localisation in the steroidogenic cells (G) an
the stroma (S) (scale bar=100 gm); (c) dark field of luteal TIMP-1 mRNA showing uneven distribution of grains within the steroidogen
cell layer (scale bar=50 gm); (d) light field of (c) showing the granulosa lutein cells (G) and the theca lutein cells (T), grains are preser
at much higher levels in the granulosa lutein cells (G) than the theca lutein cells (T) (scale bar=50 gm).
cyclic AMP-independeat manner with a bioactivity
similar to saturating amounts ofhCG. Although the effects
of TIMP-1 and the procathepsin-L complex on luteal
steroidogenesis are not yet known, it is notable that the
corpus luteum has a very high level of synthesis of both
TIMP-1 and steroids.
In summary, TIMP-1 is an abundant secretory product
of the human corpus luteum during both the normal
menstrual cycle and in simulated early pregnancy. The
physiological role of the TIMP-1 is unclear but may
involve the facilitation of steroidogenesis and the
protection of the ovary against the effects of local metallo-
proteinase production.
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Abstract
Although tissue inhibitor of metalloproteinases-1
(TIMP-1) is one of the major secretory products of the
corpus luteum, the functional significance of this is not
clear. In addition to its role as a specific inhibitor of
the matrix metalloproteinase enzymes involved in tissue
remodelling, it has recently been suggested that TIMP-1
is also a potent stimulator of steroidogenesis in vitro.
However, in the ruminant, TIMP-1 expression increases
during luteal regression. This study sought to determine (i)
the effect of induced luteal regression on ovarian TIMP-1
expression in the primate and (ii) the expression of
TIMP-1 in other steroidogenic and non-steroidogenic
tissues.
Marmoset ovaries were studied on day 10 of the normal
luteal phase and 12 and 24 h after induced luteolysis, with
either gonadotrophin-releasing hormone (GnRH) antag¬
onist or prostaglandin F2ct analogue. Ovaries from different
stages of the normal ovarian cycle were also studied.
Expression of TIMP-1 was investigated by isotopic in situ
hybridisation. TIMP-1 expression was also examined in a
wide range of other marmoset tissues by Northern blotting
and in situ hybridisation. TIMP-1 was found to be highly
expressed in the marmoset corpus luteum. Luteolysis
induced with either prostaglandin F2a or GnRH antagon¬
ist was associated with a significant tall in TIMP-1
expression in luteal tissue. TIMP-1 inRNA was also
localised to ovarian follicles throughout the ovarian cycle.
Expression occurred in the thecal layer of smaller follicles
(< T5 mm) and the granulosal layer of larger pre-ovulatory
follicles. In atretic follicles, TIMP-1 was highly expressed
at the interface between the thecal and granulosal cells.
TIMP-1 was found to be predominantly expressed in
steroidogenic tissues, particularly the ovary, adrenal and
placenta.
These data support a role for changes in TIMP-1
expression in tissue remodelling in the ovary and are
consistent with an additional function of TIMP-1 as a
facilitator of steroidogenesis.
Journal of Endocrinology (1996) 151, 203-213
Introduction
Unless chorionic gonadotrophin (CG) is produced by
the implanting blastocyst, the primate corpus luteum will
stop secreting progesterone and become a small fibrous
remnant. The mechanisms of functional and structural
luteolysis in the primate are still poorly understood
(Behrman et al. 1993). The highly vascular corpus luteum
is formed from the dominant follicle and in turn becomes
the avascular corpus albicans in a matter of weeks. This
process involves extensive tissue remodelling (Luck &
Zhao 1995). The matrix metalloproteinases are a group of
zinc-dependent proteolytic enzymes which have been
implicated in remodelling of the extracellular matrix
(Birkedal-Hansen 1995). The activity of these enzymes is
controlled at several levels, including their synthesis as
pro-enzymes, enzyme activation and the production of
specific inhibitors (Matrisian 1990). The corpus luteum is
lournal ot Endocrinology (1996) 151, 203-213 (j 1996 Journal of Endocrin<
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known to produce specific tissue inhibitors of metallo¬
proteinases (Smith et al. 1993, 1995). One of these, tissue
inhibitor ofmetalloproteinases-1 (TIMP-1), is ofparticular
interest as it is one of the major products of the corpus
luteum ofmany species, including the sheep (Smith et al.
1993), cow (Juengel et al. 1994), pig (Smith et al. 1994b)
and the human (Duncan et al. 1996).
The role of TIMP-1 in the corpus luteum has yet to be
elucidated. Juengel et al. (1994) found that the expression
ot TIMP-1 increased after prostaglandin F-,a-induced
luteolysis in the cow and postulated that it may have an
important role in tissue remodelling during luteolysis.
However, it is not known whether TIMP-1 expression is
increased during luteolysis in the primate. We did not
observe any change in TIMP-1 expression over the
functional lifespan of the human corpus luteum (Duncan
et al. 1996) implying that TIMP-1 may have other func¬
tions in the primate corpus luteum. Boujrad et al. (1995)
' Ltd Printed in Great Britain
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found that a locally produced follicle-stimulating hormone
(FSH)-responsive factor, which stimulated both Leydig
and granulosal cell steroidogenesis, was the TIMP-1 —
procathepsin-L complex. Both TIMP-1 and this complex
were found to stimulate steroidogenesis in a cAMP-
independent manner with a bioactivity similar to saturat¬
ing amounts ofhuman CG. It is therefore possible that one
role of TIMP-1 is to facilitate steroidogenesis.
This study aimed to investigate the expression of
TIMP-1 during luteolysis in the primate corpus luteum.
The marmoset monkey was used as a model, as luteolysis
can be induced by both prostaglandin F2u and luteinising
hormone (LH) withdrawal (Fraser ct al. 1995a). As whole
primate ovaries were studied, we were also able to
describe the localisation of TIMP-1 mRNA in ovarian
follicles. In order to investigate the possibility of a general
role for TIMP-1 in steroidogenesis, TIMP-1 expression




Captive-bred common marmoset monkeys (Callithrix
jacchus jacchus) were maintained in a colony which has been
closed since 1973. All experiments were carried out in
accordance with the Animals (Scientific Procedures) Act 1986.
To confirm normal ovulatory cycles, plasma samples were
collected by femoral venepuncture on alternate days and
stored at — 20 °C until required. These samples were
assayed for progesterone to determine the date of ovulation
and the luteal phase duration (Smith ct al. 1990). The
marmoset normally ovulates two or three follicles and has
a functional luteal phase of approximately 18 days.
Ovaries were collected on day 10 of the luteal phase, as
previously described (Fraser ct al. 1995a), from untreated
control animals (»=4) and animals treated with: the
prostaglandin F2(I analogue, cloprostenol (1 pg i.m.
injection; Planate (Coopers Animal Health Ltd, Crewe,
Cheshire, UK)) at 12 h (n=3) and 24 h (/;=3) previously;
the gonadotrophin-releasing hormone (GnRH) antagon¬
ist, antarelix ([N-Ac-d-Nal',d-pCl-Phe2,d-Pal3,d-(Hic)f',
Lys(iPr)h,d-Ala10]-GnRH (Deghenghi ct al. 1993)
(500 pg/kg s.c. injection; Europeptides (GEIE),
Argenteuil, Val-D'Oise, France) 12 h (n=3) and 24 h
(/?=3) previously. Whole ovaries were fixed in 4% para¬
formaldehyde for 24 h and embedded in paraffin wax. In
addition, some marmoset ovaries were available which had
been frozen in embedding medium (Tissue-Tek OCT
compound; Miles Inc., Elkhart, IN, USA) after removal.
These included follicular phase ovaries («=4), luteal phase
ovaries (»=3) and other ovaries where luteolysis had been
induced as described above (n=8). Frozen sections were
prepared trom these ovaries and stored at — 70 C until
use.
A bank of normal marmoset tissues, collected from this
and other experiments, was also utilised. These tissues
were removed immediately post-mortem. A piece of each
tissue was snap-frozen in liquid nitrogen and stored
at — 70 °C for subsequent RNA extraction. Another piece
was frozen in embedding medium, and stored at — 70 °C
until frozen sections were prepared. All reagents used were
obtained from Sigma Chemical Co.-, Poole, Dorset, UK
unless otherwise indicated.
In situ hybridisation
Isotopic in situ hybridisation was performed on both fixed
and frozen sections using 35S-labelled riboprobes. A full-
length human TIMP-1 cDNA construct in the transcrip¬
tion vector pGEM 4-Z was kindly supplied by British
Biotech Pharmaceuticals Ltd, Oxford, Oxon, UK. Anti-
sense and sense riboprobes, incorporating 35S-labelled
UTP (Amersham International pic, Aylesbury, Bucks,
UK), were synthesised using a commercial kit (Promega,
Southampton, Hants, UK). The antisense probe was
generated from the plasmid vector linearised by Kpnl
(Promega) using T7 RNA polymerase (Promega). The
sense probe was used as the negative control. This was
generated from the plasmid vector lineansed by Hindlll
(Promega) using SP6 RNA polymerase. Sections of mid-
luteal human corpus luteum (Duncan et al. 1996) were
used as a positive control in each experiment.
Fixed sections (5 pm) on poly-l-lysine (50 mg/l)-coated
slides were dewaxed in fresh xylene, and rehydrated
through graded alcohols. The slides were then incubated
with proteinase K (5 pg/ml) in buffer (100 mm Tris,
50 mm EDTA, pH 8) for 30 min at 37 °C. Where frozen
sections were used, 5 pm sections on polv-l-lysine-coated
slides were quickly thawed, fixed in 4% paraformaldehyde
for 5 min, at room temperature, and washed in 0-1 m
sodium phosphate. Both types of slide were then treated
identically. They were rinsed first in water and then in
0-1 m triethanolamine (TEA), pH 8.
After the rinsing, the slides were acetylated in 0 25%
(v/v) acetic anhydride (BDH Laboratory Supplies, Poole,
Dorset, UK) in TEA. They were then washed in 2 x
SSC (1 x SSC is 150 mM NaCl, 15 mM sodium citrate),
pH 7, and dehydrated through graded alcohols before
being dried under vacuum in a desiccator for 1 h at
room temperature. Then 100 pi hybridisation buffer
(50% deionised formamide, 10% dextran sulphate,
1 x Denhardt's solution (0-02% Ficoll 400/0-02%
polyvinylpyrrolidone/0-02% BSA), 0-5 mg/ml yeast
tRNA, 10 mM dithiothreitol (DTT), 0-3 m NaCl, 10 mM
Tris, 1 ntM EDTA, pH 8) containing 1 x 106 c.p.rn.
radiolabelled probe were added to each section. The
slides were covered with a hydrophobic coverslip
(Gel Bond; 1CN Biomedical Ltd, High Wycombe,
Bucks, UK) and incubated overnight at 55 °C in a moist
chamber.
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The following day the coverslips were washed oft in
4 x SSC. After several rinses in 4 x SSC, the slides were
treated with RNase A (20pg/ml) in RNase buffer
(10 niM Tns, 1 mM EDTA, 0-5 m NaCl, pH 8) for 30 min
at 37 °C. The sections were desalted by rinsing in
2 x SSC/1 mM DTT, followed by 1 x SSC/1 mM DTT
and 0-5 x SSC/1 mM DTT at room temperature. The
slides were then washed for 30 min in 0T x SSC at 70 °C
in a shaking water bath. After being rinsed in 0T x SSC/
1 mM DTT at room temperature, the sections were
dehydrated through graded alcohols containing 1 mM
DTT and 0-08 x SSC, washed in pure ethanol and
allowed to dry. These slides were then dipped in photo¬
graphic emulsion (Kodak NTB-2; IB I Ltd, Cambridge,
Cambs, UK) and stored at 4 °C for 18 days in the dark.
After being developed (Kodak D-19) and fixed (Kodak
Unifix) at 15 °C in the dark, the slides were washed
in water, counterstained in haematoxylin, dehydrated
through graded alcohols and mounted in Pertex mounting
medium (Cellpath, Hemel Hempstead, Herts, UK).
Northern blotting
Total RNA was isolated by the method ofChomczynski &
Sacchi (1987) using a commercial kit, and its concen¬
tration was determined by measuring absorbance at
260 nm. Total RNA (20 pg) was denatured, electro-
plioresed in a T5% formaldehyde-agarose gel and trans¬
ferred to a nylon membrane (Amersham International
pic) by capillary action in 20 x SSC. The RNA was fixed
on to membranes by u.v. cross-linkage (Spectronics
Corporation, New York, NY, USA). Membranes were
prehybridised for 2 h in 15 ml hybridisation buffer (0-5 m
sodium phosphate, 1 mM EDTA, 1% (w/v) BSA, 7%
(w/v) SDS, 6-7% (v/v) deionised formamide). The full-
length human TIMP-1 cDNA probe was labelled with
50 pCi [ "PJdCTP by the random priming method, using
a commercial kit (Amersham International pic), and added
to the hybridisation buffer. Hybridisation was performed
overnight at 65 °C.
The membranes were washed twice at 65 °C with
2 x SSC for 15 min and once more with 2 x SSC/0T%
SDS at 65 °C for 15 min (Duncan et al. 1996). The blots
were laid down to a phosphor screen for 48 h and
visualised using a Phosphorimager computer (Molecular
Dynamics, Maidstone, Kent, UK). To confirm accurate
loading of RNA, the blots were stripped in stripping buffer
(5 niM Fris, 0-3 uim EDTA, 0-1 x Denhardt's reagent) for
2 h at 65 C. The blots were then reprobed with a J2P
end-labelled oligonucleotide which hybridises to 18S
RNA as described previously (Brooks et al. 1992).
Analysis of sections
Sections were viewed by dark-field microscopy and
analysed after image capture by computer-aided image
analysis (NIH Image T55; NIH, Bethesda, MD, USA).
To investigate the grain distnbution over the corpus
luteum, only fixed sections, which had undergone in situ
hybndisation in carefully controlled conditions in the same
run, were analysed. The corpora lutea in each section were
identified and the grain density in five fields was analysed
by the same observer, blinded to the tissue identity, using
a technique of stratified random sampling and monitonng
the running mean. Any acellular areas or areas of the
section outwith the corpus luteum were ignored. This was
repeated at a later date by the same observer to confirm
the reproducibility of the results. As TIMP-1 is highly
expressed in the corpus luteum, the area proportion of
grains was measured, after binary conversion, rather
than the absolute grain count. Differences in the area
proportion of grains between different groups were
investigated by one-way ANOVA. Where an overall
statistically significant difference at the 5% level was
detected, pairwise comparisons between groups were
performed using Bonferrom/Dunn multiple range tests.
As TIMP-1 was also localised to the follicle, the
expression of TIMP-1 was analysed in each follicle. All of
the different ovarian sections, fixed and frozen, were
analysed after in situ hybridisation. In order to obtain an
idea of the localisation ofTIMP-1 as the follicle developed,
a technique was devised to classify individual follicles in
accordance with their size. Each follicle was measured
in light field using an eyepiece graticule calibrated using a
standard micrometer slide. The maximal dimension of the
follicle from the outside edge of the thecal layer was
calculated. As grains were only seen in follicles larger than
200 pm. only these follicles were counted. These were
classified as (i) pre-antral, if there was no antrum visible
in the plane of section, (ii) antral, if an antrum was visible
and the follicle measured less than 600 pm, (iii) small,
if the follicle measured less than 1 mm, (iv) medium, if
the follicle measured less than T5 mm and (v) large, if the
follicle measured T5 mm or more. The appearance of
each follicle was then classified by morphology as normal
or atretic (Grimes et al. 1987). The grain distribution over
the thecal and granulosal layer ofeach follicle was observed
in dark field of the same slides and recorded as absent or
present.
Results
TIMP-1 in the corpus luteiun
Progesterone concentrations in the control animals were
330 ± 69 nmol/1 (mean ± s.e.m.). Functional luteal re¬
gression was observed in all animals treated with either
the GnRH antagonist or the prostaglandin analogue, as
described previously (Fraser et al. 1995/;). Prostaglandin
treatment resulted in a decline in progesterone concen¬
trations to 20 ± 5 nmol/1 after 12 h and 22 ± 6 nmol/1
after 24 h, and treatment with GnRH antagonist resulted
journal of Endocrinology (1996) 151, 203-213
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Figure 1 In situ hybridisation for TIMP-1 mRNA in the primate corpus luteum. (a) Dark field of TIMP-1 mRNA in the mid-luteal human
corpus luteum; many more grains are seen over the granulosa-lutein cells (G) than the theca-lutein cells (T). (b) Dark field negative
control serial section of (a) showing very few grains with no difference between the granulosa-lutein cells (G) and the theca-lutein cells
(T). (c) Light field of a mid-luteal marmoset ovary showing the position of the corpus luteum (CL). (d) Dark field of section (c) showing
TIMP-1 grains localised to the corpus luteum (CL). (e) Dark field of TIMP-1 mRNA in the corpus luteum (CL) of a marmoset ovary 12 h
after treatment with a GnRH antagonist, (f) Dark field of TIMP-1 mRNA in the marmoset corpus luteum (CL) 24 h after GnRH antagonist
treatment. (Scale bar=200 gm.)
in progesterone concentrations of 13 nmol/1 after 12 h and
23 ± 11 nmol/1 after 24 h. All progesterone concentrations
after induced luteolvsis were within the normal range of
follicular phase levels in the marmoset (Smith et al. 1990).
TIMP-1 mRNA was expressed in the granulosa-lutein
cells of the human corpus luteum (Fig. la). The human
corpus luteum had been included as a positive control as it
expresses large amounts of TIMP-1 (Duncan ct al. 1996).
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Control PC 12 h PC 24 h GnRH 12 h GnRH 24 h
Treatment
Figure 2 TIMP-1 mRNA in the marmoset corpus luteum after induced luteolysis as
measured by grain density after in situ hybridisation. Luteolysis had been induced by
prostaglandin F2a analogue (PG) or GnRH antagonist (GnRH), 12 or 24 h previously.
Values are means ± s.e.m. Significant differences from the control group are indicated for
each experimental group: *P<0-05; **P<0-01.
This grain distribution was absent from all negative control
sections, which had been incubated with the sense probe
(Fig. lb).
TIMP-1 message was localised to the corpus luteum in
luteal phase marmoset ovaries (Fig. lc and d). TIMP-1
mRNA could also be localised to the cells of the corpora
lutea, 12 and 24 h after induced luteolysis (Fig. le and f).
However, the silver grains over the corpus luteum were
lower in number and more patchily distributed after
induced luteolysis (Fig. le and f). The area proportion of
grains decreased significantly after both prostaglandin
(P<0-05) and GnRH antagonist (P<0-05) treatments (Fig.
2). When specific time points were analysed, grain density
was significantly lower 24 h after prostaglandin treatment
(P<() ()5) and both 12 (P<(>05) and 24 h (P«M)1) after
GnRH antagonist treatment (Fig. 2). Treatment with
GnRH antagonist or prostaglandin analogue produced
similar changes in the appearance of the corpora lutea and
the localisation of TIMP-1 mRNA.
TIMP-1 in the follicle
TIMP-1 mRNA was also identified in ovarian follicles
(Fig. 3a and b). TIMP-1 expression was absent from the
oocyte, the primordial follicle and the small pre-antral
follicle less than 200 jam in diameter. Follicles 200 pm or
more in diameter expressed TIMP-1 in the thecal
cell layer (Fig. 3a, b, c and d). In the healthy follicles,
TIMP-1 was absent from the granulosal cell layer at this
journal of Endocrinology (1996) 151, 203-213
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Table 1 Localisation of TIMP-1 message in marmoset follicles after in situ hybridisation. The
grain distribution over the thecal and granulosal layers of each follicle larger than 200 pm
was recorded. The numbers are the number of follicles with grains over the thecal layer
only, the granulosal layer only, no specific grains, grains over both layers and grains over
both layers with particular localisation to the granulosal-thecal interface. Follicles were
classified as atretic or normal and normal follicles were classified by size as pre-antral/
antral (<600 pm), small (<1 mm), medium (<1.5 mm) or large (>1.5 mm). Asterisks
indicate the modal category for each follicle class
Localisation of TIMP-1 message
None Thecal Granulosal Both Interface
Pre-antral 4 19* 0 0 1
Antral 0 47* 1 2 1
Small 0 43* 2 2 1
Medium 0 33* 1 6 1
Large 0 0 9* 2 0
Atretic 1 0 0 2 31*
Figure 4 Northern blot of TIMP-1 mRNA in different organs from the marmoset. The
positions of the ribosomal 28S and 18S bands are indicated. The 18S bands are shown to
demonstrate equal RNA loading between lanes. Ovary 1 was from the luteal phase and
ovary 2 was from the follicular phase of the ovarian cycle.
stage. In larger pre-ovulatory follicles (> 1 -5 mm) TIMP-1
was noted to be absent from the thecal layer and present in
large amounts in the granulosal cell layer (Fig. 3e and f).
When the follicle was atretic, a specific localisation of
TIMP-1 was noted. TIMP-1 mRNA was found to
be localised to thecal cells and individual granulosal
cells, and was intensely expressed at the thecal—granulosal
interface (Fig. 3g and h). The changing pattern of
TIMP-1 localisation noted in the follicle was remark¬
ably consistent in all the follicles analysed (Table 1).
The pattern of TIMP-1 expression by the follicles of
different sizes appeared to be independent of the stage
of the cycle at which the ovary was obtained and
was thus identical in ovaries obtained from the follicu¬
lar phase, the luteal phase or following induced
luteolysis.
Figure 3 In situ hybridisation for TIMP-1 mRNA in marmoset follicles, (a) Light field of a normal luteal phase marmoset ovary showing a
small follicle, with its granulosal (G) and thecal (T) layers next to a corpus luteum (CL). (b) Dark field of section (a) showing localisation of
TIMP-1 mRNA by in situ hybridisation; grains are seen over the thecal cells (T) and corpus luteum (CL) but are absent from the granulosal
cells (G). (c) Light field of a follicular phase ovary showing a medium-sized follicle with the thecal cells (T), granulosal cells (G) and oocyte
(O) clearly visible, (d) Dark field of section (c) showing TIMP-1 localised to the thecal cells (T) but absent from the granulosal cells (G) and
the oocyte (O). (e) Light field of large pre-ovulatory follicle taken from another follicular phase marmoset ovary showing the thecal layer
(T), the granulosal layer (G) and the cumulus granulosa cells (C) surrounding the oocyte, (f) Dark field of section (e) showing TIMP-1
mRNA grains over the granulosa (G) and cumulus cells (C) but absent from the thecal cells (T). (g) Light field of an atretic follicle in an
ovary collected 1 2 h after treatment with prostaglandin F2a analogue, showing the thecal (T) and granulosal (G) layers, (h) Dark field of
section (g) showing some TIMP-1 expression in the thecal cells (T), patchy expression in the granulosal cells (G) and marked expression at
the thecal-granulosal interface. (Scale bar=200 pm.)
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Figure 5 In situ hybridisation for TIMP-1 mRNA in various primate organs, (a) Dark field of marmoset testis after in situ hybridisation
for TIMP-1 with grains seen at the outside of the tubules (T). (b) Light field of (a) showing the tubules (T) and the basal Sertoli cells.
Ic) Dark field of the marmoset adrenal gland after TIMP-1 in situ hybridisation showing a general increased grain distribution over the
cortex (C). (d) Light field of the marmoset kidney, (e) Dark field of section (d) showing few grains over the tissue, (f) Light field of the
placenta with cells at the periphery of the trophoblast layer highlighted (arrows), (g) Dark field of section (f) showing TIMP-1 to be
localised to specific areas of the section (arrows), (h) Light field of the marmoset thyroid gland with some of the parafollicular cells
highlighted (arrows), (i) Dark field of section (h) showing TIMP-1 to be localised to these parafollicular cells (arrows). (Scale
bar=100 pm.)
TIMP-1 in other tissues
TIMP-1 was found to be expressed in a wide range of
marmoset tissues (Fig. 4). A single band, approximately
0-9 kb in length, was detected in total RNA extracted
from marmoset tissues. This size is consistent with that
reported for human TIMP-1 mRNA (Rapp ct al. 1990,
Duncan ct al. 1996). The highest levels of expression were
seen in steroidogenic tissues, particularly the ovary, adrenal
and placenta. Other tissues had low levels of TIMP-1
expression, although specific expression was noted in the
thyroid and prostate glands. However, when the localis¬
ation of TIMP-1 message was investigated in these tissues
by in situ hybridisation, the grain density was found to be
much less than that seen in the ovary. It became apparent,
using in situ hybridisation, that TIMP-1 was also expressed
in the testis, specifically in the Sertoli cells and interstitial
cells (Fig. 5a and b). Specific hybridisation was seen over
the steroidogenic cells of the adrenal cortex (Fig. 5c), but
not the adrenal medulla. Very few grains were seen over
the kidney (Fig. 5d and e), myometrium and endo¬
metrium of the uterus, endocrine and exocrine cells of
the pancreas, spleen, liver and thymus. Specific areas of
TIMP-1 expression were seen in the placenta (Fig. 5f and g),
in the parafollicular cells of the thyroid (Fig. 5h and i) and
in the glandular cells of the prostate.
Discussion
This is the first study to localise the expression of TIMP-
1 mRNA in whole primate ovaries. In common with
previously studied species such as the human (Duncan
ct al. 1996) and the ruminant (Smith G W ct al. 1994),
the marmoset corpus luteum expresses a large amount of
TIMP-1 message. As TIMP-1 protein synthesis has been
demonstrated in these species (Smith ct al. 1993, Juengel
ct al. 1994, Duncan ct al. 1996), it is likely that TIMP-1 is
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also a major secretory product of the marmoset corpus
luteum.
Induction of luteolysis resulted in a marked fall in the
level ot TIMP-1 expression in the marmoset corpus
luteum. The mechanism and control of this fall and its role
in tissue remodelling is unclear. The fall in TIMP-1
expression may facilitate increased metalloproteinase
digestion ot the luteal matrix during regression. However,
although rat ovaries and human corpora lutea express
metalloproteinases (Endo eta/. 1993, Duncan et al. 1995),
and TIMP-2 is also expressed in the ovine corpora
lutea (Smith et al. 1995), detailed information about the
expression of these factors, their localisation, and relation¬
ship to TIMP-1 during induced luteolysis is not yet
available.
The timing of the fall in TIMP-1 expression in associ¬
ation with the drop in progesterone concentration would
also be consistent with a recently proposed steroidogenic
role for TIMP-1 (Boujrad et al. 1995). There is, however,
no indication from these data as to whether the observed
changes in TIMP-1 expression are a cause or a conse¬
quence of the reduced steroid synthesis. A further consid¬
eration is that significant changes in luteal morphology can
be seen by 24 h after induced luteal regression in the
marmoset (Fraser et al. 1995a). The fall in TIMP-1
expression may therefore be related to the death of viable
luteal cells in the corpus luteum at this time (Fraser et al.
1995c).
These findings are contrary to previous observations of
the effects ot induced luteolysis in the cow (Juengel ct al.
1994). TIMP-1 expression in the bovine corpus luteum
was found to increase up to 24 h after prostaglandin F2a
injection and then return to pretreatment levels within
48 h. This occurs at a time when increasing cell death
is observed in the bovine corpus luteum (Juengel
et al. 1993). We have examined TIMP-1 expression at 12
and 24 h after induced luteolysis and found a marked and
persistent fall in TIMP-1 expression. However, the luteo-
lytic processes of the primate and the ruminant are
different in both nature and time span (Auletta & Flint
1988) and this study provides further evidence of these
differences.
We have shown that TIMP-1 is also expressed by
follicles in the primate ovary and that the localisation
changes relative to the apparent size of the follicle. These
data are limited in that two-dimensional interpretation of
three-dimensional pre-ovulatorv follicles may lead to an
underestimation of the size and nature of some follicles.
Volume changes may also result from processing and
sectioning of the tissue. In spite of these deficiencies, a
consistent pattern was observed in the follicular localisation
ot TIMP-1 mRNA relative to the size of the follicle.
TIMP-1 is first expressed in the thecal cell layer of
pre-antrai follicles which are larger than 200 pm in diam¬
eter. This is the stage when the follicle becomes
gonadotrophin-dependent (Zeleznik & Fairchild Benyo
1994) and LH receptors can first be detected in the theca
(Richards & Midgely 1976). In the rat. LH stimulates the
secretion of TIMP-like protein and increases TIMP-1
mRNA (Mann et al. 1991, Morgan et al. 1994). It is
therefore possible that TIMP-1 expression in the thecal
cells is related to the action of LH. In the testis. TIMP-1
production by the Sertoli cells is induced by FSH (Ulisse
et al. 1994, Boujrad et al. 1995). Although the granulosal
cells express FSH receptors at this stage and respond to
FSH (Zeleznik & Fairchild Benyo 1994), they do not
express TIMP-1 mRNA. It is therefore likely that the
control of TIMP-1 expression by FSH is different in the
ovarian follicle and the testicular tubule.
In contrast, all the large pre-ovulatory follicles
(>T5mm) expressed TIMP-1 in the granulosal cells.
Smith et al. (1994u) showed that the ovulatory gonado-
trophin surge induced granulosal cell TIMP-1 expression
in the sheep. Our results are consistent with a similar
pre-ovulatory induction of TIMP-1 in the granulosa cells
of the primate ovary. As the granulosa cells express the LH
receptor at this stage (Richards & Midgely 1976), the
increased TIMP-l expression may be directly induced by
LH. It is not clear why the thecal cells stop expressing
TIMP-1. but this pattern ofTlMP-1 expression is seen in
the granulosa-derived and the theca-denved cells of the
human corpus luteum throughout its functional lifespan
(Duncan et al. 1996).
The expression of TIMP-1 in the atretic follicles was
very different. This was independent of luteolvtic treat¬
ment or stage of the ovarian cycle. There was a patchy
expression in the thecal and granulosal cell layers but
marked expression around the basal lamina at the cellular
interface. During follicular atresia, the steroidogenic cells
degenerate (Hay et al. 1976) and the basal lamina breaks
down (Bagavandoss ct al. 1983). These data are consistent
with a role for matrix metalloproteinase involvement in
the tissue remodelling associated with follicular atresia.
The expression of TIMP-1 may be induced to control
local metalloproteinases involved in the breakdown of the
basal lamina. However, the expression of metalloprotein¬
ases in the atretic follicle has not yet been described, but
they have been shown to be expressed during the break¬
down of the follicle wall during ovulation (Reich ct al.
1985, Russell ct al. 1995).
The physiological role of TIMP-1 in the steroidogenic
cells of the follicle is not clear. It is likely that it is involved
in the regulation of the matrix remodelling which occurs
during follicular growth and development. TIMP-1 has
been shown to have proliferative effects on cells in
vitro (Hayakawa et al. 1992) but it remains to be estab¬
lished whether it can function as a growth factor in
vivo. In addition, the pattern of TIMP-1 expression is
similar to the localisation ot several steroidogenic enzymes
in different sizes of follicle (Richards ct al. 1995). This
is consistent with a role for TIMP-1 as a steroidogenic
agent.
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TIMP-1 was also found to be expressed in other tissues.
This is not surprising as TIMP-1 is involved in tissue
remodelling throughout the body (Salamonsen 1996). The
luteal phase ovary expressed far higher levels of TIMP-1
mRNA than any of the other tissues investigated. Expression
in the placenta and adrenal has previously been noted in the
ewe (Hampton ct al. 1995). TIMP-1 expression has pre¬
viously been reported in human endometrium (Hampton &
Salamonsen 1994) but we did not detect it in the marmoset
endometrium. This may be because the marmoset monkey
does not have a menstrual cycle and lacks cyclical endo¬
metrial remodelling. Sertoli cell expression of TIMP-1 has
been reported in the rat (Boujrad et al. 1995). As the vast
majority of total testicular RNA is of germ cell origin, we
were best able to confirm its expression in the marmoset
testis by in situ hybridisation.
TIMP-1 was particularly expressed by steroidogenic
tissues such as the ovary, placenta, testis and adrenal. This
expression was generally localised to the steroidogenic cells
of these organs. Although the ovary and placenta undergo
extensive remodelling during their lifespan, the adult
adrenal and testis do not. Whether TIMP-1 has any role
in these tissues other than specific inhibition of metallo-
proteinases has yet to be determined. However, these
data are consistent with an additional role for TIMP-1 as a
facilitator of steroidogenesis in vivo. The ontogeny and the
role of TIMP-1 in endocrine glands requires further in¬
vestigation and functional studies ofTIMP-1 are required.
In conclusion, the fall in TIMP-1 expression in associ¬
ation with primate luteolysis and its changing localisation
during the lifespan of the follicle support a role for
modulation of TIMP-1 in the control of tissue remodel¬
ling. In addition, these data and the predominant expres¬
sion of TIMP-1 in steroidogenic tissues support the
concept that TIMP-1 has an additional role as a facilitator
in steroidogenesis.
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ABSTRACT
Luteolysis is associated with tissue remodeling probably involving
the matrix metalloproteinases (MMPs) and their specific tissue in¬
hibitors (TIMPs). This study investigated the expression and local¬
ization of the major MMPs and TIMPs in the human corpus luteum
throughout the luteal phase and after luteal rescue with hCG. Cor¬
pora lutea (n = 9) were collected at hysterectomy and were dated by
serial urinary LH estimation. In addition, corpora lutea (n = 3) were
collected from women who had received daily doubling doses of hCG
to mimic the hormonal changes of early pregnancy. MMP-1, MMP-2,
MMP-9, TIMP-1, TIMP-2, and TIMP-3 were investigated by zymog-
raphy, reverse zymography, Northern blotting, and in situ hybrid¬
ization. There was no change in the expression of MMP-1, TIMP-1,
and TIMP-2 throughout the luteal phase or after luteal rescue. Little
TIMP-3 could be detected in the corpus luteum. MMP-9 activity
peaked in the early and late luteal phase. The expression and activity
of MMP-2 were maximal in the late luteal phase. Exposure to hCG
during luteal rescue in vivo was associated with a reduction (P < 0.05)
in the expression and activity ofMMP-2. Messenger ribonucleic acids
(mRNAs) for MMP-1, MMP-2, and TIMP-2 were localized to the con¬
nective tissue stroma and the thecal-lutein cells of the corpus luteum.
In contrast, TIMP-1 mRNAwas localized to the granulosa-lutein cells,
and MMP-9 mRNA was expressed in scattered cells within the ste¬
roidogenic and nonsteroidogenic cell layers. In conclusion, during
maternal recognition ofpregnancy, hCG prevents the normal increase
in MMP-2 in the late luteal phase. MMPs can function in an envi¬
ronment containing large amounts ofTIMP-1, as they have a different
cellular localization. (J Clin Endocrinol Metab 83: 2470-2478, 1998)
UNLESS hCG is secreted from the implanting blastocyst,the human corpus luteum will undergo structural and
functional luteolysis (1). The corpus luteum changes from the
most active endocrine gland in the body, with a blood flow
per unit mass much greater than that of the kidney (2), to a
small fibrous remnant in a matter of days. This extensive
tissue remodeling is likely to involve a group of zinc-depen¬
dent proteolytic enzymes known as the matrix metallopro¬
teinases (MMPs) (3-5). These enzymes have been implicated
in a wide variety of biological processes that involve remod¬
eling of the extracellular matrix (ECM), such as ovulation,
menstruation, angiogenesis, and tumor growth and metas¬
tasis (6-8).
The activity of MMPs is controlled at several levels, in¬
cluding synthesis as proenzymes, enzyme activation, and the
production of specific tissue inhibitors (9, 10). Tissue inhib¬
itors of metalloproteinases (TIMPs) are of particular interest,
as TIMP-1 is one of the major products of the corpus luteum.
It is produced in large amounts by the corpus luteum of
many species, including the rat (11), sheep (12), cow (13), pig
(14),monkey (15), and human (16). In addition, it has recently
been reported that TIMP-2 is produced by corpora lutea of
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rats (11), sheep (17), and cows (18), and that TIMP-3 can also
be detected in rat ovaries (11).
TIMPs bind to and inhibit metalloproteinase enzymes
with a one to one stoichiometry (10). As TIMP-1, in partic¬
ular, is produced in large amounts throughout the normal
luteal phase (16), it is not clear how metalloproteinase en¬
zymes function in an environment containing large amounts
of specific inhibitor. This study aimed to investigate the
expression and localization of the common MMPs and their
specific tissue inhibitors in the human corpus luteum
throughout the normal luteal phase and the effect of luteal




All reagents were obtained from Sigma Chemical Co. (Poole, UK),
unless otherwise stated. Prof. M. R. Waterman of Vanderbilt University
(Nashville, TN) provided the antibody to 17a-hydroxylase. The probes
to MMP-2 (gelatinase-A), MMP-9 (gelatinase-B), TIMP-1, and TIMP-2
were provided by British Biotech Pharmaceuticals (Oxford, UK). Probes
for TIMP-3 and MMP-1 (interstitial collagenase) were purchased from
University Technologies International (Calgary, Canada). The reverse
zymography kit was also obtained commercially from University Tech¬
nologies International. All restriction enzymes and ribonucleic acid
(RNA) polymerases were obtained from Promega (Southampton, UK).
Human placental tissue was obtained from the local maternity hospital.
Collection of corpora lutea
Corpora lutea were enucleated at the time of hysterectomy in women
undergoing surgery for benign conditions as described previously (16).
In all women, only one corpus luteum was identified on the surface of
one of the ovaries. In each case this corpus luteum was removed and
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studied as described below. All women were healthy, aged 32-45 yr,
with regular menstrual cycles and had not received any form of hor¬
monal treatment for at least 3 months before taking part in the study. The
date of the LH surge was determined by estimation of LH concentrations
in serial early morning urine samples collected before operation (19). On
this basis, three corpora lutea classified as early luteal (LH+1 to LH+5),
three as midluteal (LH+6 to LH + 10), and three as late luteal (LH + 11
to LH + 14) were investigated. In addition, three women were given im
injections of hCG (Profasi, Serono Laboratories, Welwyn Garden City,
UK) from LH+7 in daily doubling doses, starting at 125 1U, for 6-8 days
until surgery. This regimen has been shown to reproduce the hormonal
changes of early pregnancy (20). An additional corpus luteum was
obtained from a woman who had received hCG for 8 days to achieve
luteal rescue, but the operation was postponed. This corpus luteum was
collected 3 days after the final hCG injection.
At operation, the whole corpus luteum was enucleated from the ovary
by blunt dissection, and the ovary was oversewn. The tissue was im¬
mediately divided into radial blocks to ensure that the whole thickness
of the gland was represented in any piece. Two pieces of tissue were
rapidly snap-frozen in liquid nitrogen and stored at -70 C for subse¬
quent protein and RNA extraction. One piece was frozen in embedding
medium (Tissue-Tek OCT compound, Miles, Elkhart, IN) and stored at
— 70 C. Serial frozen sections (6 p,m) were cut onto ribonuclease-free
slides coated with poly-L-lysine (50 p.g/1) and stored at —70 C until use.
In each case, an endometrial biopsy was fixed in 4% paraformaldehyde
and processed into paraffin wax for luteal phase dating by tissue mor¬
phometry (21). Plasma was taken before surgery, and the progesterone
concentration was measured using a standard RIA (22). This study was
approved by the Reproductive Medicine Branch of the South-East of
Scotland ethics committee, and informed consent was obtained from all
patients before tissue collection.
Gelatin zymography
Protein was extracted from corpora lutea in 0.1% (wt/vol) SDS at 4
C. The protein content of the sample after sonication was measured
using the method of Bradford (23). Seventy-five micrograms of protein
in sample buffer [10% (vol/vol) glycerol, 1% (wt/vol) SDS, and 0.04%
(vol/vol) bromophenol blue] were applied, without heating or reduc¬
tion, to an 11% (wt/vol) polyacrylamide gel containing 1 mg/mL gelatin
and 0.1% (wt/vol) SDS. After electrophoretic separation of proteins, the
gels were incubated in 2.5% Triton X-100 for 30 min to remove the SDS.
The gels were then incubated for 16 h at 37 C in 50 mmol/L Tris-HCl
(pH 7.6) containing 0.2 mol/L NaCl, 5 mmol/L CaCl2, and 0.02% (wt/
vol) Brij 35. The gels were stained in staining solution [30% (vol/vol)
methanol, 10% glacial acetic acid, and 0.5% (wt/vol) Coomassie brilliant
blue G250] and then destained in the same solution in the absence of dye.
Reverse zymography
Reverse zymography using 75 /xg of each protein sample was per¬
formed using a commercial kit. Briefly, 12% (wt/vol) polyacrylamide
gels containing 0.1% (wt/vol) SDS, 1 mg/mL gelatin, and a solution of
secreted metalloproteinases (as supplied) were prepared. After electro¬
phoresis, the gels were washed overnight in a solution of 2.5% Triton
X-100, 50 mmol/L Tris-HCl (pH 7.5), and 5 mmol/L CaCl2. The gels
were rinsed in water and incubated in 50mmol/L Tris-HCl (pH 7.5) and
5 mmol/L CaCl2 with gentle shaking for 24 h at 37 C. Staining and
destaining were carried out as described above, and bands correspond¬
ing to TIMP-1, TIMP-2, and TIMP-3 were identified by reference to the
standards supplied with the kit.
Northern blot analysis
Total cellular RNA was isolated by the method of Chomczynski and
Sacchi (24) using a commercial kit, and its concentrationwas determined
by absorption at 260 nm. Total RNA (20 p-g) was denatured, electro-
phoresed in a 1.5% formaldehyde-agarose gel, and transferred to a nylon
membrane (Amersham International, Aylesbury, UK) by capillary ac¬
tion in 20 X SSC (1 X SSC is 150 mmol/L NaCl and 15 mmol/L sodium
citrate, pH 7). Northern blot analysis was conducted as described pre¬
viously (16) using [3ZP]deoxy-CTP-labeled complementary DNA
probes. The complementary DNA probes were derived from the fol¬
lowing plasmids: a 0.7-kb fragment of human MMP-1 in pBluescript, a
1.6-kb fragment (6-1576 bp) of human MMP-2 in pGEM 4Z, a 1.3-kb
fragment (759-2105 bp) of human MMP-9 in pGEM4Z, full-length hu¬
man TIMP-1 in pGEM4Z, full-length human TIMP-2 in pGEM4Z, and
a 0.2-kb fragment (400-600 bp) of human TIMP-3 in pBluescript. After
washing (16), the blots were laid onto a phosphor screen for 48-72 h and
visualized using a Phosphorlmager computer (Molecular Dynamics,
Maidstone, UK). The blots were then stripped (14) and reprobed with
a 32P end-labeled oligonucleotide that hybridizes to 18S RNA, as de¬
scribed previously (25). The molecular size of fhe bands was calculated
with reference to a standard RNA mol wt marker (Promega) run in an
adjacent lane.
In situ hybridization
Isotopic in situ hybridization was performed on frozen sections using
35S-labeled riboprobes. Antisense and sense riboprobes incorporating
35S-labeled UTP (Amersham International) were synthesized using a
commercial kit (Promega). The riboprobes were generated from the
above plasmids using the following restriction enzymes and RNA poly¬
merases: MMP-1, HmdIII with T7 polymerase (antisense), and Notl with
T3 polymerase (sense); MMP-2, EcoRI with T7 polymerase (antisense),
and HmdIII with SP6 polymerase (sense); MMP-9, EcoRI with T7 poly¬
merase (antisense), and Pstl with SP6 polymerase (sense); TIMP-1, Kpnl
with T7 polymerase (antisense), and HmdIII with SP6 polymerase
(sense); and TIMP-2, HmdIII with SP6 polymerase (antisense), and EcoRI
with T7 polymerase (sense).
In situ hybridization was conducted according to the method de¬
scribed previously (15) at 55 C using 1 X 106 cpm S-labeled antisense
riboprobe. The 35S-labeled sense riboprobe (1 X 106 cpm) was added to
serial sections as a negative control. After washing under increasingly
stringent conditions (15), the slides were dipped in photographic emul¬
sion (Kodak NTB-2, IBI,Cambridge, UK) and incubated at 4C for 21 days
in the dark. After developing (Kodak D19) and fixing (Kodak Unifix) at
15 C in the dark, the sections were washed in water, counterstained with
hematoxylin, dehydrated through graded alcohols, and mounted (Per-
tex, Cellpath, Hemel Hempstead, UK).
Immunohistochemistry
Frozen sections were fixed at 4 C in 15% (vol/vol) aqueous picric acid
containing 2% (wt/vol) paraformaldehyde, pH 7.4, for 10 min and
washed in phosphate-buffered saline for 20 min at 4 C. Nonspecific
binding was blocked using a goat serum solution [normal goat serum
(SAPU, Carluke, UK) diluted 1:5 inTris-buffered salinewith 5% (wt/vol)
BSA]. The primary antibody to 17a-hydroxylase was diluted to a con¬
centration of 1:1500 in Tris-buffered saline and applied to the section for
20 h at 4 C. Antibody binding was visualized with an avidin-biotin-
alkaline phosphatase complex (AB-AP kit, Dako, High Wycombe, UK)
using biotinylated goat antirabbit Igs (Dako) as the secondary antibody.
Coloration was achieved using a substrate that produced a red end
product (Alkaline Phosphatase Substrate Kit I, Vector Laboratories, Pe¬
terborough, UK). Sections were counterstained with hematoxylin, de¬
hydrated, and mounted as described above.
Analysis of results
The intensities of the 92- and 66-kDa bands detected by zymography
were measured by computer-aided densitometric image analysis (NIH
Image 1.55, NIH, Bethesda, MD) after image capture and inversion.
Northern blot band intensity was measured using the Phosphorlmager
computer. To correct for minor differences in loading, the ratio of the
relative band intensity to the 18S band intensity was used for data
analysis. One-way ANOVA was used to investigate differences in ex¬
pression throughout the luteal phase. The rescued corpora lutea were
compared to the late luteal corpora lutea using an unpaired t test. A
commercial software package was used for statistical analysis (StatView
4.0, Abacus Concepts, Berkeley, CA).
Results
Plasma progesterone concentrations
The classification of the corpora lutea by serial urinary LH
measurement agreed with the luteal phase dating of endo-
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metrial biopsies using the method of Li et al. (21). The plasma
progesterone concentrations were 35.3 ± 9.8 nmol/L in the
early luteal samples, 41.0 ± 9.9 nmol/L in the midluteal
samples, and 19.2 ± 12.9 nmol/L in the late luteal samples.
After luteal rescue by exogenous hCG, plasma progesterone
concentrations had increased to 52.6 ± 1.5 nmol/L. The
plasma progesterone concentration in the postrescue sample
was 9.16 nmol/L.
Identification of metalloproteinases and their
tissue inhibitors
Three distinct bands of gelatinase activity at 92, 72, and 66
kDa were detected in the human corpus luteum by gelatin
zymography (Fig. 1). These are consistent with MMP-9 and
the latent and active forms of MMP-2, respectively (4, 26).
Reverse zymography demonstrated a band of inhibition of
gelatinase activity at approximately 28 kDa and a lighter
band at 21 kDa (Fig. 2). These correspond to TIMP-1 and
TIMP-2, respectively (4, 27). An additional band al 24 kDa
was seen in human placental tissue, but was absent from
corpora lutea. This is consistent with TIMP-3 (27), which is
produced by decidual tissue (28). TIMP-1 and TIMP-2 could
be detected in samples taken from different stages of the
luteal phase and after luteal rescuewith exogenous hCG (Fig.
2). The activities of MMP-2 and MMP-9 changed over the
luteal phase (Fig. 3). MMP-9 activity peaked in the early and
late luteal phase and was lowest in the midluteal phase (P <
0.05). In contrast, MMP-2 activity increased throughout the
luteal phase to a maximum in the late luteal phase (P < 0.05).
Luteal rescue with hCG resulted in lower MMP-2 activity
than during the late luteal phase in the absence of hCG (P <
0.05). When the corpus luteum was rescued with hCG, and
trophic support was withdrawn (in the postrescue sample),
large amounts of MMP-2 activity were clearly identified by
zymography (Fig. 1).
Expression ofmetalloproteinases and their tissue inhibitors
A single band of approximately 0.9 kb corresponding to
TIMP-1 (16, 29) was detected in human corpora lutea by
Northern blotting (Fig. 4). This confirms our previously re¬
ported results (16). Northern blotting for TIMP-2 resulted in
a single band of 3.6 kb (Fig. 4). This is consistent with the
Fig. 1. Representative gelatin zymogram of human corpora lutea
extracts from the early (LH+1 to LH+5), mid (LH+6 to LH+10), and
late (LH+11 to LH+14) luteal phase and after luteal rescue by hCG
(hCGx6 to hCGx8). The extractmarked with an asterisk is taken from
a corpus luteum that was rescued with hCG for 8 days and then
collected 3 days after the final exposure to hCG. The bands are bright
against a dark background, and the molecular size of each band in
kilodaltons is indicated on the left.
Fig. 2. Representative reverse zymogram of protein extracts from
human placenta (P) and corpora lutea collected in the early (E; LH+1
to LH+5), mid (M; LH+6 to LH + 10), and late (L; LH+11 to LH+14)
luteal phase and after luteal rescue (R) with exogenous hCG (hCGx6
to hCGx8) in vivo. The bands are seen as dark against a lighter
background, and the molecular size of each band in kilodaltons is
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Fig. 3. Activities ofMMP-2 and MMP-9 in human corpora lutea. The
inverse intensity of the bands for MMP-9 (92-kDa) and the active form
of MMP-2 (66-kDa) on gelatin zymography in the early (LH+1 to
LH + 5), mid (LH+6 to LH + 10), and late (LH+11 to LH+14) luteal
phase and after luteal rescuewith hCG (hCGx6 to hCGx8). Values are
the mean ± sd (n = 3/group). Differences (P < 0.05) in mean activities
are shown (a, by t test; b, by ANOVA).
transcript size for TIMP-2 messenger RNA (mRNA) in the
human (30). SeveralmRNA species corresponding to TIMP-3
(28) were detected in the placenta, but were not seen in the
human corpus luteum (data not shown). As we have previ¬
ously reported (16), there were no significant differences in
the level of TIMP-1 expression throughout the luteal phase
or after luteal rescue with hCG (Fig. 5). Likewise, TIMP-2
expression did not change throughout the luteal phase or
after luteal rescue (Fig. 5).
Specific mRNA transcripts of 3.5 kb were detected in cor¬
pora lutea after Northern blotting for MMP-2. This is con¬
sistent with the reported transcript size of MMP-2 (31). In
addition, Northern blotting for MMP-1 demonstrated tran¬
scripts of 3.6 kb and approximately 1.0 kb in human corpora
lutea (data not shown). Little MMP-9 expression could be
detected by Northern blotting despite clear identification by
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Fig. 4. Representative Northern blot for TIMP-1, TIMP-2, and
MMP-2 in human corpora lutea in the early (LH+l to LH+5), mid
(LH+6 to LH+10), and late (LH +11 to LH+14) luteal phase and after
luteal rescue with hCG (hCGx6 to hCGx8). Specific hybridization
bands are dark against a lighter background. The approximate sizes
in kilobases of the bands are indicated, and the 18S RNA bands are
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Fig. 5. Expression of TIMP-1 and TIMP-2 in the human corpus lu-
teum. The intensities of TIMP-1 and TIMP-2 mRNAs, corrected for
18S intensity, in the early (LH + l to LH+5), mid (LH+6 to LH+10),
and late (LH +11 to LH+14) luteal phase and after luteal rescue with
exogenous hCG (hCGx6 to hCGx8) in vivo are shown. Values are the
mean ± sd (n = 3/group). There were no significant differences in the
level of expression throughout the luteal phase (by ANOVA) or after
luteal rescue (by t test).
0.05) in rescued corpora lutea than that in the late luteal phase
in the absence of hCG (Fig. 6). There were no differences in
MMP-1 expression throughout the luteal phase or after luteal
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Fig. 6. Expression ofMMP-1 and MMP-2 mRNA in the human cor¬
pus luteum. The intensities of the major MMP-1 and MMP-2 mRNA
bands, corrected for 18S intensity, in the early (LH+1 to LH+5), mid
(LH+6 to LH+10), and late (LH+11 to LH + 14) luteal phase and after
luteal rescue with exogenous hCG (hCGx6 to hCGx8) in vivo are
shown. Values are the mean ± sd (n = 3/group). Significant differ¬
ences are shown (a, P < 0.05, by ANOVA).
Localization ofmetalloproteinases and their
tissue inhibitors
mRNA for TIMP-1, TIMP-2, MMP-1, MMP-2, and MMP-9
were localized in human corpora lutea by isotopic in situ
hybridization. Each of these mRNA species had a specific
pattern of localization that persisted throughout the normal
luteal phase and after luteal rescue with exogenous hCG. In
agreement with our previous findings, TIMP-1 was highly
expressed in the granulosa-lutein cells of the corpus luteum
(Fig. 7, a and b) (16). In contrast, TIMP-2 was localized to
different regions of the corpus luteum. TIMP-2 was ex¬
pressed at the periphery of the granulosa-lutein cells (Fig. 7c).
Comparison with serial sections immunostained for 17a-
hydroxylase to identify the thecal-lutein cells showed that
TIMP-2 was expressed by the thecal-lutein cells (Fig. 7d). In
addition, TIMP-2 was expressed in the fibrous connective
tissue surrounding the steroidogenic cells (Fig. 7c).
MMP-1 was heavily expressed by the cells of the stroma
and connective tissue of the corpus luteum (Fig. 8a). Only
very low levels of expression were seen in the area of the
gland containing steroidogenic cells (Fig. 8, a and b). MMP-2
was localized to the thecal-lutein cells and surrounding con¬
nective tissue (Fig. 8c). MMP-2 could also be detected around
the vasculature and occasionally in cells within blood ves¬
sels. Little MMP-2 expression could be detected in the gran¬
ulosa-lutein cell population. The distribution of MMP-9 was
different, as expression was localized to individual cells
within the gland (Fig. 8d). Although these cells were con¬
centrated along the thecal-lutein cell layer and vascular con¬
nective tissue, some cells within the granulosa-lutein com¬
partment were also found to express MMP-9 (Fig. 8d). This
pattern of expression of MMPs and TIMPs was consistent
and was seen in all serial sections examined (Fig. 9).
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Fig. 7. Localization ofTIMP-1 and TIMP-2 mRNA in the human corpus luteum. a, Darkfield image ofTIMP-1 in situ hybridization in the early
luteal corpus luteum, showing expression in the granulosa-lutein cells; b, negative control of a, showing few silver grains with no specific
distribution; c, serial section of a, showing darkfield image of TIMP-2 in situ hybridization; expression of TIMP-2 is in a different cellular
compartment from that ofTIMP-1; d, serial section ofc immunostained for 17a-hydroxylase to localize the thecal-lutein cells. G, Granulosa-lutein
cells; T, thecal-lutein cells; S, connective tissue stroma. Scale bar = 100 /xm.
Discussion
This study demonstrates the expression and localization of
the MMPs and their specific tissue inhibitors in the primate
corpus luteum. TIMP-1 has already been described as amajor
product of the corpus luteum of several species (12-16). We
have now found that TIMP-2 is also expressed by the human
corpus luteum. This agrees with the observation of Smith et
al., who described TIMP-2 expression in ovine (17) and bo¬
vine (18) follicles and corpora lutea. In contrast to TIMP-1
and TIMP-2, TIMP-3 is a not thought to be a secreted mol¬
ecule, but, rather, is a component of the ECM (4, 32). Al¬
though we detected TIMP-3 mRNA in the human placenta,
where it has previously been described (26), we found little
expression in the corpus luteum. Similarly, Uria et al. did not
detect TIMP-3 expression in the human ovary (33). However,
TIMP-3 mRNA has been reported in the ovary of the pseu-
dopregnant rat (11). This may reflect the different time pe¬
riods examined, or it may be a species difference. In the
human, it seems that TIMP-1 and TIMP-2 are themajor luteal
TIMPs.
In the small numbers we analyzed, the expression of
TIMP-2 did not change during the functional luteal phase or
after luteal rescue with exogenous hCG. TIMP-2 expression
was found to change during the luteal phase in ovine corpora
lutea (17). Smith et al. reported that TIMP-2 expression was
maximal in the early luteal phase and significantly lower in
the late luteal phase (17). In the cow, TIMP-2 expression was
reported to increase significantly from the early to the mid-
luteal phase (18), and expression was increased after PG-
induced luteolysis (13). Further evidence of a species differ¬
ence is that the primary TIMP-2 transcript size in the sheep
corpus luteum is 1.0 kb (17), whereas in the human corpus
luteum and other tissues (30) the size is 3.5 kb. In the human
corpus luteum, control of tissue remodeling during the func¬
tional luteal phase does not appear to be related to alterations
in the levels of expression of TIMPs.
Collagenase (MMP-1) and gelatinases A and B (MMP-2
and MMP-9) are expressed in the human corpus luteum.
MMP-2 and MMP-9 have previously been detected by zy-
mography in homogenates of rat ovaries (26), bovine corpus
luteum (34), and luteinized human granulosa cells (35, 36).
MMP-1, MMP-2, and MMP-9 mRNAs have been described
in the pseudopregnant rat ovary (37). Collagen and other
components of the ECM are an integral part of the structure
of the corpus luteum (3, 38). The human corpus luteum
expresses enzymes with the capacity to proteolytically break
down these components of the ECM.
The expression and activity of MMPs in the corpus luteum
changed during the luteal phase. MMP-2 expression and
activity were maximal in the late luteal corpus luteum. This
is consistent with a role in tissue remodeling associated with
luteolysis. In the rat, PRL-induced structural luteolysis was
associated with the activity of metalloproteinase enzymes,
particularly MMP-2 (26). Interestingly, Aston et al. recently
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Fig. 8. Localization of mRNA for the major MMPs in the human corpus luteum. a, Darkfield image of in situ hybridization for MMP-1 in the
midluteal phase corpus luteum, showing expression in the connective tissue stroma with minimal expression in the granulosa-lutein cell layer;
b, serial section of a immunostained for 17a-hydroxylase to localize the thecal-lutein cells; c, darkfield in situ hybridization showing the
localization of MMP-2 mRNA; d, darkfield in situ hybridization showing the localization of MMP-9 mRNA in the same corpus luteum. G,
Granulosa-lutein cells; T, thecal-lutein cells; S, connective tissue stroma. Scale bar = 100 pun.
reported that MMP-2 activity increased with length of time
of culture of luteinized granulosa cells (36). The major MMP
secreted from ovine luteal explants was MMP-2 (39). Ex¬
pression of MMP-2 in the corpus luteum may be associated
with the tissue remodeling at the time of luteolysis.
In contrast, high levels of MMP-9 activity were also de¬
tected in the early luteal phase. It is possible that MMP-9 is
involved in the extensive tissue remodeling that occurs dur¬
ing the formation of the corpus luteum from the ruptured
follicle (3). A role of MMP-9 in the formation of the corpus
luteum is supported by the finding that it is the primary
metalloproteinase detected in follicle explants (39). In addi¬
tion, MMP-9 is the major MMP secreted into the culture
medium of luteinized bovine (38) and human granulosa cells
(35,36). Dispersed luteal cells from 4-day-old bovine corpora
lutea had both MMP-2 and MMP-9 activities, but MMP-9
activity decreased with duration of culture (34), and MMP-9
was seen in the medium of cultured human granulosa cells
only during the first 2 days of culture (35). This provides
preliminary evidence that MMP-9 may have a role in ovu¬
lation and the tissue remodeling associated with the forma¬
tion of the corpus luteum.
Compared to that during the late luteal phase, exposure of
the corpus luteum to hCG during luteal rescue was associ¬
ated with reduced expression and activity ofMMP-2. This is
clearly different from the process of ovulation, when LH/
hCG stimulates an increase in MMP-1 and MMP-2 expres¬
sion (5, 40, 41). Follicular levels ofMMP-2 increase between
the LH surge and ovulation (39). In cultures of luteinized
granulosa cells, hCG also was shown to reduce the expres¬
sion of MMP-2 and MMP-9 (36, 42). Human granulosa cells
cultured on a thin layer of ECM are lost from culture in the
absence of gonadotropin (36). These cells are released from
culture via an active process suppressed by hCG (43). One of
the effects of hCG during maternal recognition of pregnancy
appears to be the inhibition of metalloproteinase expression.
MMP-1 and MMP-2 had similar cellular localizations in
the human corpus luteum. They were expressed in the con¬
nective tissue stroma, the vascular pedicles, and the thecal-
lutein cell layer. Fibroblasts and endothelial cells are sources
of MMPs (44), and they are likely to express MMP-1 and
MMP-2 in the corpus luteum. In the endometrium (7) and in
ovarian cancers (8), cells of the stroma also have been shown
to express these enzymes. Although the expression of
MMP-2 was maximal in the late luteal phase, its localization
in the corpus luteum was not affected. This suggests that the
source of MMP during luteolysis is the periphery of the
gland. In contrast, MMP-9 mRNA was localized to single
cells in steroidogenic and nonsteroidogenic cell layers. The
identity of these cells is uncertain, but they are probably
white blood cells. Polymorphonuclear leukocytes express
MMP-9 (45), and we found that expression was often asso¬
ciated with blood vessels. Cells of the immune system, in¬
cluding macrophages, are also constituents of the human
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17a-Hydroxylase
MMP-9
Fig. 9. Relationship between the localization of the major MMPs and TIMPs in the late luteal corpus luteum. A composition of serial sections
after in situ hybridization for MMP-1, MMP-2, MMP-9, TIMP-1, and TIMP-2 and immunohistochemistry for 17a-hydroxylase arranged around
the lightfield section of the corpus luteum showing the pattern of expression ofMMPs and TIMPs. G, Granulosa-lutein cells; T, thecal-lutein
cells; S, connective tissue stroma. Scale bar = 200 p,m.
corpus luteum (46) and may be a source, or stimulator, of
MMP expression.
It is unclear whether MMPs are expressed by the granu¬
losa-lutein cells of the corpus luteum. Few grains were lo¬
calized to this cell layer, and when present, they were in
isolated individual cells. This finding is contrary to reports
using cultures of luteinized granulosa cells (35, 36). In vitro
MMP-9 expression falls with continuing culture. This has led
some researchers to suggest thatMMP-9 activity is related to
leukocytes that accompany the granulosa cells in the first few
days of culture (35). However, it is thought that bovine and
human granulosa cells and bovine luteal cell dispersates in
culture secreteMMP-2 (34,35,38). Although it is possible that
MMP-2 activity in these cultures results from white cell or
thecal contamination, it is likely that granulosa-lutein cells
have the potential to express MMPs and are induced to do
so in culture. However, it is clear that the main site ofMMP-2
expression in the corpus luteum is not the granulosa-lutein
cells.
TIMP-1 and TIMP-2 have different cellular localizations in
the corpus luteum. TIMP-2 was localized to the thecal-lutein
cells and the surrounding connective tissue stroma. Smith et
al. found TIMP-2 in the theca of the ovine follicle (17). This
is consistent with the primary localization of TIMP-2 in the
follicle being maintained in the mature corpus luteum. The
localization of TIMP-2 was similar to those of MMP-1 and
MMP-2. This suggests that TIMP-2 may have a role in the
local regulation of these enzymes in the corpus luteum. In¬
deed, it has been suggested that TIMP-2 displays a preference
for MMP-2 (47). However, as we have previously reported
(16), the localization of TIMP-1 is different. It is possible that
TIMP-1 has other roles in addition to inhibition of metallo-
proteinases in the corpus luteum (17, 48, 49). However, the
lack of significant ovarian disturbance in mice without a
functional TIMP-1 gene (50) means that the role of high
TIMP-1 expression in granulosa-lutein cells is not clear.
It was not clear how MMPs could function in the corpus
luteum, which expresses large amounts of the specific in-
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hibitor TIMP-1 (13, 16). We have shown that MMPs are
expressed in different areas of the corpus luteum than
TIMP-1. In addition, where MMPs were expressed in the
granulosa-lutein cellular layer, expression was in foci of in¬
dividual cells. The localization of MMPs seems to be a key
factor in their activity in the corpus luteum.
In conclusion, the expression of MMP-2 in the late luteal
phase may indicate a role for this enzyme in the tissue re¬
modeling associated with luteolysis. One function of hCG
during luteal rescue is to prevent this increase in MMP ex¬
pression. As TIMP-1 and TIMP-2 change little, it is likely that
control ofMMP activity in the corpus luteum involves chang¬
ing MMP, rather than TIMP, expression. MMPs are localized
in different areas than TIMP-1, and where they are expressed
in the same area, they are expressed in foci. This may explain
how MMPs can function in the background of large amounts
of TIMP-1.
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It has been shown that immune cells, particularly macro¬
phages, accumulate in the corpus luteum during luteolysis.
This study aimed to investigate the effect of maternal
recognition of pregnancy on the localization and numbers
of macrophages in the human corpus luteum. Corpora
lutea (it = 12) were obtained from normally cycling women
at the time of hysterectomy and were dated on the basis
of serial urinary luteinizing hormone (LH) estimation. In
addition, corpora lutea (n = 4) were collected from women
who had received daily doubling doses of human chorionic
gonadotrophin (HCG) to mimic the hormonal changes of
early pregnancy. Macrophages were localized by immuno-
histochemistry using an anti-CD68 antibody. Steroidogenic
cells, steroidogenic cells of thecal origin and endothelial
cells were identified on serial sections by immunohisto-
chemistry for 3p-hydroxysteroid dehydrogenase, 17a-
hydroxylase and von Willebrand factor, respectively. The
luteal cells capable of responding directly to HCG were
identified by isotopic in-situ hybridization for messenger
RNA encoding LH/HCG receptors. Macrophages were
localized primarily to the vascular connective tissue and
theca-lutein areas of the corpus luteum, although some
were found in the granulosa-lutein cell layer. Macrophage
numbers increased throughout the luteal phase to a max¬
imum in the late-luteal phase (P < 0.05). Luteal 'rescue'
with HCG was associated with a marked reduction in the
numbers of tissue macrophages when compared with those
of the late-luteal phase (P < 0.001). One of the effects of
HCG during maternal recognition of pregnancy is to
prevent the normal influx of macrophages into the corpus
luteum. As LH/HCG receptors localized to the steroidogenic
cells, this implies a fundamental role for steroidogenic cell
products in the control of macrophage influx into the
human corpus luteum.
Key words: corpus luteum/macrophages/human chorionic
gonadotrophin/pregnancy/luteoiysis
Introduction
In a non-conception cycle, the primate corpus luteum undergoes
luteolysis with a loss of functional and structural integrity.
© European Society for Human Reproduction and Embryology
The molecular events involved in luteolysis and how they are
prevented by exposure to human chorionic gonadotrophin
(HCG) during maternal recognition of pregnancy remain
unclear (Behrman et al., 1993). One feature of luteolysis,
however, is the marked accumulation of immune cells in the
corpus luteum. This increase in the number of immune cells
has been reported in a variety of species, including rodents
(Brannstrom et al., 1994a), rabbits (Naftalin et al., 1997),
ruminants (Murdoch, 1987; Lei et al., 1991), and women
(Wang et al., 1992a; Best et al., 1996; Takaya et al., 1997).
As these species use disparate mechanisms to control their
corpora lutea (Auletta and Flint, 1988), this common increase
implies a fundamental role for immune cells, or their cytokine
products (Brannstrom and Norman, 1993), in the luteolytic
process.
The main immune cell to be localized in the human corpus
luteum during luteolysis is the macrophage (Wang et al.,
1992a; Brannstrom et al., 1994b; Best et al., 1996). However,
macrophage products have been shown to have both positive
and negative effects on progesterone secretion. Macrophage
products have been reported to have pro-steroidogenic effects
in cell culture (Kirsch et al., 1981. 1983; Halme et al., 1985).
In addition, in the early stages of luteal function, macrophages
are thought to have primarily luteotrophic effects (Brannstrom
and Norman, 1993). Other macrophage products, however,
such as tumour necrosis factor a (TNFa), prostaglandin F2a
(PGF2a), reactive oxygen species and nitric oxide, have been
shown to have negative effects on steroidogenesis (Benyo and
Pate, 1992; Grusenmeyer and Pate, 1992; Van Voorhis et al.,
1994; Vega et al., 1995; Kato et al., 1997). Whereas macro¬
phages are likely to be involved in the phagocytic clearance
of cell debris (Paavola, 1979; Takaya et al., 1997) after
functional luteolysis, it is still not clear what role tissue
macrophages have in the functional corpus luteum.
We postulated that the primary role of macrophages in the
human corpus luteum was luteolytic, rather than luteotrophic,
and that macrophage numbers would not increase in the
'rescued' corpus luteum of early pregnancy. To test this
hypothesis, we investigated the number of macrophages in the
human corpus luteum throughout the functional luteal phase
by immunohistochemistry. We compared the numbers of
macrophages in corpora lutea in the late-luteal phase, where
progesterone output is falling, with corpora lutea 'rescued'
with exogenous HCG, where progesterone output is increasing.
We also postulated that any increase in macrophages within
the corpus luteum was by de-novo influx, rather than by local
changes in cellular localization. To test this hypothesis, we
identified the structural architecture of the corpus luteum
by immunohistochemistry and compared the localization of
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macrophages throughout the luteal phase and after luteal
'rescue' with exogenous HCG. In the final part of the study,
we investigated the site of action of HCG on macrophages
during luteal 'rescue' by localizing luteinizing hormone (LH)/




All reagents were obtained from Sigma Chemical (Poole, Dorset,
UK), unless otherwise stated. The mouse monoclonal antibodies to
human CD68 (PG-M1) and von Willebrand factor were obtained
commercially (Dako Ltd, High Wycombe, Bucks, UK). The polyclonal
rabbit antibody to human 17ot-hydroxylase was kindly provided by
Prof. M.R. Waterman (Vanderbilt University, Nashville. TN, USA).
The polyclonal rabbit antibody to human placental type I
3p-hydroxysteroid dehydrogenase (3(3-HSD) was kindly provided by
Prof. Van Luu-The (CHUL Research Centre. Quebec, Canada). A
1.5-kb cDNA construct, corresponding to nucleotide 542 to the last
nucleotide of the open reading frame (2124), of the human LH
receptor in pBluescript (Stratagene, Cambridge, Cambs, UK) was
kindly provided by Dr M.Atger of the Faculte de Medecine de
Bicetre, Universite Paris-Sud, Le Kremlin-Bicetre, France.
Collection of tissue
Corpora lutea were enucleated at the time of hysterectomy in 16
women undergoing surgery for benign conditions, typically dysmenor-
rhoea, uterine fibroids or menorrhagia. All women were healthy, aged
from 32^15 years with regular menstrual cycles and had not received
any form of hormonal treatment for at least 3 months prior to taking
part in the study. The corpora lutea were dated on the basis of serial
urinary LH measurements on samples collected daily prior to operation
(Djahanbakhch et al., 1981a). On this basis, four corpora lutea were
classified as early- (LH+1 to LH+5), four as mid- (LH+6 to LH+10)
and four as late- (LH+ 11 to LH+14) luteal. In addition, four women
received daily intramuscular injections of HCG (Profasi: Serono
Laboratories, Welwyn Garden City, UK) from LH+7 in daily doubling
doses, starting at 125 IU, for 5 to 8 days until surgery. This regimen
has been shown to reproduce the hormonal changes of early pregnancy
(Illingworth et al., 1990).
The whole corpus luteum was enucleated from the ovary by blunt
dissection and the ovary oversewn as previously described (Duncan
et al., 1996a,b). The tissue was divided immediately into radial blocks
in order to ensure that the whole thickness of the gland was represented
in any piece. One piece was fixed in 4% paraformaldehyde for 24 h
and embedded in paraffin wax for subsequent immunohistochemistry
and another piece was frozen in embedding medium (Tissue-Tek
OCT compound. Miles Inc.. Elkhart, IN, USA) and stored at -70°C.
Frozen sections (5 pm) were cut from this block on to poly-L-lysine
(50 pg/l)-coated slides and stored at -70°C until use. In each case
an endometrial biopsy was also fixed in paraformaldehyde and
processed into paraffin wax for luteal-phase dating by tissue morpho¬
metry (Li et al., 1988). Plasma was taken before surgery and
progesterone concentration was measured by a standard radioimmuno¬
assay (Djahanbakhch et al., 1981b). This study was approved by the
Reproductive Medicine Subcommittee of the South East Scotland
Research Ethics Committee, and informed consent was obtained from
all patients prior to tissue collection.
Immunohistochemistry
Five-micrometre paraffin wax sections were cut on to poly-L-lysine
(50 pg/l)-coated slides, de-waxed and rehydrated. As preliminary
experiments indicated that antigen retrieval using trypsinization was
necessary for the detection of the CD68 antigen and von Willebrand
factor, these sections were incubated in 0.1% (w/v) trypsin with 0.1%
(w/v) calcium chloride, buffered to pH 7.4 with 0.25 M Tris-HCl,
for 30 min at 37°C. The sections were then washed in 0.05 M Tris-
buffered saline (TBS) pH 8. Endogenous peroxidase activity was
blocked with 2% (v/v) hydrogen peroxide in 60% methanol for 30
min at room temperature. This tissue was then permeabilized with
0.1% Triton-XlOO in TBS and rinsed in TBS prior to blocking with
20% (v/v) normal rabbit serum in TBS with 4% (w/v) bovine serum
albumin for 20 min. Sections were incubated with the primary
antibody, monoclonal mouse anti-human macrophage CD68 antigen
diluted 1:50 in TBS, or the mouse anti-human von Willebrand factor
diluted 1:25, for 1 h at room temperature (Rodger et al., 1997).
Mouse immunoglobulin G (IgG) (Vector Laboratories, Peterborough,
Cambs, UK) at an equivalent antibody concentration was used as a
negative control.
Antibody binding was indicated by an avidin-biotin horseradish
peroxidase (Dako Ltd) reaction with a biotinylated rabbit anti-mouse
(Dako Ltd) secondary antibody at a dilution of 1:100 in TBS. The
reaction was developed with diamino-benzidine to give a stable brown
end-product (Vector Laboratories). Sections were then washed in
water, counter-stained with haematoxylin, dehydrated through graded
alcohols and mounted with Pertex mounting medium (Cellpath, Hemel
Hempstead, Herts, UK).
Steroidogenic cells were identified in serial sections by immuno¬
histochemistry for 3|3-HSD (Riley et al., 1992). Here, polyclonal
rabbit anti-human 3J3-HSD was used in a dilution of 1:1000. Immuno¬
histochemistry was performed as described above, without trypsiniz¬
ation, using normal goat serum (SAPU, Carluke, Lanarkshire, UK)
to block non-specific binding, and specific binding was detected
using biotinylated goat anti-rabbit immunoglobulins (Dako Ltd).
Steroidogenic cells of thecal origin were identified in serial sections by
immunohistochemistry for 17a-hydroxylase as described previously
(Rodger et al., 1995; Duncan et al., 1996a). Briefly, the polyclonal
rabbit anti-human 17a-hydroxylase antibody was used at a 1:750
dilution, normal goat serum was used to block non-specific binding,
and biotinylated goat anti-rabbit immunoglobulins were used as the
secondary antibody. Rabbit serum with an equivalent immunoglobulin
concentration (Dako Ltd) was used as a negative control.
In-situ hybridization
Isotopic in-situ hybridization for LH/HCG receptors was performed
using antisense and sense [35S]-labelled riboprobes as described
previously (Duncan et al., 1996b). Briefly, the antisense probe,
incorporating [35S]-labelled UTP (Amersham International pic, Ayles¬
bury, Bucks, UK), was generated from the plasmid vector linearized
by Hindlll (Promega, Southampton, Hants, UK) using T3 RNA
polymerase (Promega). The [35S]-labelled sense probe was used as a
negative control. This was generated from the plasmid vector linear¬
ized by ECoRl (Promega) using T7 RNA polymerase (Promega).
As preliminary experiments with fixed serial sections gave technic¬
ally poor results, LH/HCG receptor mRNA was localized in frozen
sections from the same corpora lutea. Frozen sections (5 pm) were
fixed in 4% paraformaldehyde, rinsed and then acetylated in 0.25%
(v/v) acetic anhydride (BDH Laboratory Supplies, Poole, Dorset,
UK). After dehydrating through graded alcohols and drying under
vacuum, 100 pi of hybridization buffer (50% deionized formamide,
10% dextran sulphate, 1 XDenhardt's solution, 0.5 mg/ml yeast tRNA,
10 mM dithiothreitol. 0.3 M NaCl, 10 mM Tris, 1 mM EDTA, pH
8) containing IX 106 cpm radiolabeled riboprobe was added to each
section, and the slides were incubated overnight at 55°C in a
moist chamber.
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The following day the slides were treated with RNase A (20 pg/
ml), and washed in increasingly stringent conditions. The sections
were then dehydrated through graded alcohols, allowed to dry and
dipped in Kodak NTB-2 photographic emulsion (IB! Ltd, Cambridge.
Cambs. UK). After incubation in the dark for 21 days, they were
developed (Kodak D-19) and fixed (Kodak Unifix) at 15°C. The
sections were then rinsed, counter-stained with haematoxylin and
mounted. They were viewed under dark-field illumination, and the
localization of the silver grains was determined by reference to the
image viewed under light-field illumination.
Image analysis
The number of macrophages was counted by an observer blinded to
the tissue identity, and this was repeated the following week to
confirm the reproducibility of the results. Macrophage numbers in all
sections during the repeat count were within 5% of the initial count.
Macrophages were identified by intense brown staining on tissue
sections. Only positive cells where the nuclei could be identified
were counted in order to avoid counting tiny fragments of cells
present in the tissue section. Sections were analysed using a stratified
random sampling technique using a graticule lens. The stratified
random sampling technique involved taking random fields from a
grid of 24 fields arranged around a fixed, non-random, point (the
centre of the section). At least five fields of each section were counted
and the running mean was monitored to confirm adequate sampling.
The granulosa-lutein cell layers, the theca-lutein cell layers and the
surrounding stroma were identified by morphology and by comparison
with serial sections immunostained for 3(3-HSD and 17cc-hydroxylase.
In addition to the total number of macrophages, the number of
macrophages in these layers was also recorded.
The number of macrophages at different stages of the luteal phase,
and the number in the different cellular layers, were analysed by one¬
way analysis of variance with a 5% level of significance. Where
significant differences were found to exist, pairwise comparisons
using the Bonferroni/Dunn method were performed using commercial




The classification of the corpora lutea by serial urinary LH
measurement agreed with the luteal-phase dating of endometrial
biopsies using the method of Li et al. (1988). As reported
previously (Duncan et al., 1996b), the plasma progesterone
concentrations were 36.36 ± 9.28 nmol/1 in the early luteal
samples, 40.35 ± 9.88 nmol/1 in the mid-luteal samples and
18.80 ± 12.81 nmol/1 in the late luteal samples. After luteal
'rescue' by exogenous HCG the plasma progesterone concen¬
trations had increased to 52.75 ± 1.09 nmol/1.
Functional anatomy of the corpus luteum
Steroidogenic cells were identified in human corpora lutea by
the immunolocalization of 3p-HSD (Figure la). Luteal cells
of both thecal and granulosal origin express this enzyme. The
theca-lutein cells were specifically identified by immunolocal¬
ization of 17a-hydroxylase (Figure lb). These cells formed
clearly distinct populations, located around the peripheral
margin of the granulosa-lutein cells. Vascular endothelial cells
were localized by immunohistochemistry for von Willebrand
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Figure I. Functional anatomy of the human corpus luteum: (a)
mid-luteal corpus luteum immunostained for 3P-hydroxysteroid
dehydrogenase showing staining of the steroidogenic cells with no
staining of the connective tissue core; (b) the same corpus luteum
as (a) immunostained for 17a-hydroxylase showing staining in the
theca-lutein cells; (c) the same corpus luteum as (a) immunostained
for von Willebrand factor to demonstrate the endothelial cells; (d) a
closer view of the granulosa-lutein cell layer of another mid-luteal
corpus iuteum immunostained for von Willebrand factor, showing
strong endothelial cell immunostaining in the vascular connective
tissue invaginations (arrow); (e) dark-field view of a mid-luteal
corpus luteum after isotopic in-situ hybridization for luteinizing
hormone (LH) receptor mRNA. showing grains distributed over the
steroidogenic cells; and (f) the same corpus luteum as (e) after
immunohistochemistry for macrophages (CD68 positive cells)
showing the distribution of macrophages around the periphery of
the granulosa-lutein cell layer, a different localization from LH
receptor mRNA. (G) Granulosa-lutein cell layer, (T) Theca-lutein
cell layer (arrow) in (a) to (d) connective tissue invaginations.
Scale bar = 100 pm.
supply. Endothelial cells were also scattered throughout the
granulosa-lutein cell layers, particularly in the radial invagina¬
tions from the theca-lutein cell layer (Figure Id). LH receptors
were localized by isotopic mRNA in-situ hybridization
(Figure le). As described previously, they were localized to
the steroidogenic cell population (Duncan et al., 1996b). When
compared with immunostained sections, no hybridization signal
could be detected in endothelial cells, stromal cells or cells
lacking the morphological characteristics of steroidogenic cells.
Localization of tissue macrophages
Macrophages, as described by immunohistochemical localiz¬
ation of the CD68 antigen, could be localized in all corpora lutea
studied (Figure 2a). No staining was present in negative control
sections where the primary antibody was replaced with an
equivalent concentration of IgG (Figure 2b). Many more macro¬
phages could be detected in late-luteal corpora lutea (Figure 2c)
than after luteal 'rescue' with exogenous HCG (Figure 2d). The
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Figure 2. Macrophage localization in the human corpus luteum: (a) mid-luteal corpus luteum with macrophages (CD68 positive cells,
brown) localized to the periphery of the steroidogenic cells in the theca-lutein layer (T) and also to the granulosa-lutein cell layer (G) and
surrounding connective tissue stroma: (b) negative control serial section of (a) showing the theca-lutein (T) and granulosa-lutein (G) cell
layers with no specific staining visible: (c) increased numbers of macrophages in the theca-lutein (T) and granulosa-lutein (G) cell layers in
a late-luteal corpus luteum; and (d) corpus luteum after luteal 'rescue' with human chorionic gonadotrophin showing fewer macrophages in
the theca-lutein (T) and granulosa-lutein (G) cell layers. Scale bar = 100 urn.
numbers of macrophages in the corpora lutea at different stages
of the luteal phase were counted. The macrophage content of the
corpus luteum increased throughout the luteal phase reaching a
maximum in the late-luteal phase (P < 0.05) (Figure 3). Luteal
'rescue' with HCG was associatedwith a reduction in the number
of macrophages (Figure 3), which was significantly lower than
in the late-luteal phase (P < 0.001).
Macrophages were particularly prominent in the theca¬
lutein cell layer at all stages (Figure If, Figure 2a). In the
granulosa-lutein cell layer, they were usually seen in associ¬
ation with the vascular in-foldings, particularly in the late-luteal
phase (Figure 2c). The numbers of macrophages specifically
located within the granulosa cell layer showed the same pattern
as the overall macrophage content throughout the luteal phase
(Figure 4). There were no differences in the percentages of
macrophages specifically located to the granulosa-lutein cell
layer at any stage of the luteal phase. The localization of the
LH receptor (Figure le) in the human corpus luteum was
clearly different from the localization of CD-68 positive tissue
macrophages (Figure If).
Discussion
We have compared the macrophage content in the corpora lutea
of women who received exogenous HCG at concentrations
equivalent to that of early pregnancy with that of corpora lutea
obtained from untreated women at clearly defined stages of
the luteal phase. We found that the macrophage content was
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Figure 3. Macrophage numbers in corpora lutea: numbers of CD68
positive cells in sections of human corpus luteum in the early-
LH+1 to LH+5, mid- (LH+6 to LH+10) and late- (LH+11 to
LH+14) luteal phase and after luteal 'rescue' with human chorionic
gonadotrophin (HCG) (HCGX5 to HCGX8). Values are mean ±
SEM (n = 4 per group). Values were analysed by one-way analysis
of variance and, where significant differences at the 5% level were
observed, pairwise comparisons were conducted using the
Bonferroni/Dunn method (*P < 0.05, **P < 0.001).
untreated women from the same stage of the luteal phase. This
suggests that macrophage accumulation is associated with the
loss of luteal integrity during luteolysis and that one of the
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Figure 4. Macrophage numbers within the granulosa-lutein cell
layer: numbers of CD68 positive cells in sections of human corpus
luteum in the early-LH+1 to LH + 5), mid- (LH+ 6 to LH+10) and
late- (LH+11 to LH+14) luteal phase and after luteal 'rescue' with
human chorionic gonadotrophin (HCG) (HCGX5 to HCGX8).
Values are mean ± SEM (n = 4 per group). Values were analysed
by one-way analysis of variance and. where significant differences
at the 5% level were observed, pairwise comparisons were
conducted using the Bonferroni/Dunn method (*P < 0.05).
effects of HCG during luteal 'rescue' is to prevent the
accumulation of macrophages in the corpus luteum.
In this study we have concentrated on the numbers and
localization of macrophages in the corpus luteum. Various
other immune cells have also been identified in the corpus
luteum. including polymorphonuclear leukocytes (Brannstrom
et al., 1994b) and T-cells (Best et al., 1996). However, it is
clear that macrophages are the predominant immune cell
subpopulation in the human and rabbit corpus luteum
(Bagavandoss et al., 1990; Wang et al., 1992a; Best et al.,
1996). In addition, unlike other immune cells, macrophages
have clearly been shown to vary in number during the lifespan
of the corpus luteum, being particularly abundant in the
regressing corpus luteum (Brannstrom et al., 1994b; Best et al.,
1996). Although other immune cells may be affected during
luteal 'rescue', it is likely that the clearest and most predomin¬
ant effect is that on tissue macrophage content.
Our study confirms that macrophage influx increases during
the functional lifespan of the corpus luteum. Macrophage
accumulation in the corpus luteum is a feature of luteolysis in
a variety of animal species, including rats (Brannstrom et al..
1994a), rabbits (Bagavandoss et al., 1990; Naftalin et al.,
1997), pigs (Hehnke et al., 1994), sheep (Murdoch, 1987) and
women (Brannstrom et al., 1994b; Best et al., 1996; Takaya
et al., 1997). Macrophages are clearly present in large numbers
in the regressing corpus luteum after menstruation in women
(Wang et al., 1992a; Brannstrom et al., 1994b; Takaya et al.,
1997). However, there has been some debate about the accumu¬
lation of macrophages in the late-luteal phase when the corpus
luteum is still producing progesterone. Brannstrom et al.
(1994b) failed to find an increase in luteal macrophages in the
late-luteal phase. In contrast, other studies (Lei et al., 1991;
Best et al., 1996) reported increased macrophages in the
functional corpora lutea in the late-luteal phase. It is likely
that the discrepant findings of Brannstrom et al. (1994b) are
explained by their more extended definition of the late-luteal
phase (from LH+ 8) and the fact that macrophage influx is a
feature of luteal ageing.
The role of macrophage accumulation in the late-luteal
phase is not fully established. It is not clear whether it is a
cause or consequence of falling progesterone synthesis. Clearly
macrophage products can inhibit steroidogenesis in vitro. Nitric
oxide (Van Voorhis et al., 1994), TNFa (Benyo and Pate,
1992; Wang et al., 1992b), PGF2a (Grusenmeyer and Pate,
1992), reactive oxygen species (Vega et al., 1995; Kato et al.,
1997) and interleukins (Sjogren et al., 1991) have all been
shown to inhibit the steroidogenic pathway. In addition, cell
death by apoptosis is a feature of luteolysis in many species
(Dharmarajan et al., 1994; Zheng et al., 1994; Shikone et al.,
1996) and apoptosis can be promoted by macrophage products,
such as free oxygen radicals, TNFa and some interleukins
(Hale et al., 1996; Jacobson, 1996; Spencer et al., 1996).
Macrophages may have a role in structural luteolysis; they can
clear cellular debris by phagocytosis (Paavola, 1979) and
activate the matrix metalloproteinase enzymes (Hurwitz et al.,
1993; Hulboy et al., 1997) which have been implicated in the
remodelling associated with luteolysis (Endo et al., 1993; Luck
and Zhao, 1995). Whether it is a cause or consequence of
falling progesterone synthesis, it is likely that the accumulation
of macrophages in the late-luteal phase has a negative effect
on the structure and function of the corpus luteum.
Macrophages, however, have been shown to have both pro-
steroidogenic and luteotrophic properties under some condi¬
tions. It remains possible that the macrophage accumulation
in the functional luteal phase is a luteotrophic response to
failing progesterone synthesis. Macrophage-derived products
have been shown to enhance progesterone output from luteal
cells in culture (Kirsch et al., 1983; Halme et al., 1985), and
macrophages may secrete factors important for angiogenesis
and tissue reorganization. Brannstrom and Norman (1993)
postulated a luteotrophic effect of macrophages in the early
luteal phase. In addition, as macrophages could enhance
progesterone synthesis (Kirsch et al., 1981, 1983) and promote
proliferation of granulosa cells (Fukumatsu et al., 1992),
Bukovsky et al. (1995) also proposed a luteotrophic role of
macrophages. In the rat corpus luteum, non-steroido-
genic cells, probably white blood cells, have also been shown
to have potent stimulatory effects on luteal cell steroidogenesis
(Nelson et al., 1992). It is not clear, therefore, whether the
accumulation of macrophages in the corpus luteum would
always be associated with a fall in progesterone synthesis.
We have demonstrated that luteal 'rescue' with exogenous
HCG to mimic the early stages of pregnancy is associated
with a reduction in the numbers of macrophages in the
late-luteal corpus luteum. This supports the hypothesis that
macrophages have a primarily luteolytic, rather than luteo¬
trophic, role in the human corpus luteum. Our findings are
different from those of some sub-primate species. Brannstrom
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et al. (1994a) found particularly high concentrations of macro¬
phages in the rat corpus luteum during the early stages of
pregnancy and pseudopregnancy. They found sixfold more
macrophages in the corpus luteum of early pregnancy than
during luteolysis (Brannstrom etal., 1994a). This accumulation
of macrophages is also seen in the corpus luteum of pregnant
rabbits (Bagavandoss et al., 1990). In the rabbit corpus luteum,
oestrogen withdrawal induces macrophage invasion, but sub¬
sequent oestrogen replacement maintained progesterone pro¬
duction and did not necessarily reduce macrophage numbers
(Naftalin et al., 1997). Indeed, in that model system, the
relative numbers of macrophages had no apparent relationship
to progesterone synthesis. They concluded that the presence of
macrophages did not preclude the continuation of progesterone
production (Naftalin et al., 1997). It is not known whether the
human corpus luteum can continue to function in the presence
of increasing numbers ofmacrophages but, clearly, macrophage
influx is not a feature of luteal 'rescue' with HCG.
What promotes the influx of macrophages into the failing
corpus luteum? Several chemoattractant and macrophage-
stimulatory molecules have now been identified, including
cytokines such as interleukin 8 (Norman and Briinnstrom,
1994), granulocyte-macrophage colony stimulating factor
(Nicola, 1989) and monocyte chemoattractant protein 1
(MCP-1) (Leonard and Yoshimura, 1990). These molecules
can be detected in the ovary (Robertson and Seamark, 1990;
Zhao et al., 1995; Arici et al., 1997). Recently, Townson et al.
(1996) reported increased expression of MCP-1 in the corpus
luteum during luteal regression in rats. This increase preceded
the appearance of macrophages in the corpus luteum and they
concluded that MCP-1 may have a prominent role in the
immunological process of luteal regression. Induction of struc¬
tural luteolysis by prolactin in rat corpus luteum (Bowen et al.,
1996), and by oestrogen withdrawal in the -rabbit corpus
luteum (Naftalin et al., 1997), is associated with macrophage
accumulation and expression of MCP-1. MCP-1 can be stimu¬
lated by cytokines (Oppenheim et al., 1991; Arici et al., 1997)
which can be found in the corpus luteum during luteolysis
(Brannstrom and Norman, 1993). However, MCP-1 expression
can also be stimulated by HCG in granulosa-lutein cell
culture (Arici et al., 1997). Data on the expression of these
chemoattractant molecules in the human corpus luteum
throughout the luteal phase are not yet available, but would
clearly be of great interest.
How does exposure to HCG during luteal 'rescue' prevent
the influx of macrophages into the corpus luteum? HCG exerts
its biological actions by binding to, and activating, LH receptors
(Cole et al., 1973). LH receptors are localized to the steroido¬
genic cells of the corpus luteum (Nishimori et al., 1995;
Duncan et al., 1996b), and we have shown the localization of
these receptors is different from the localization of macro¬
phages. Although we were not able to co-localize macrophages
and LH receptors on the same tissue section, it is unlikely that
macrophages themselves express the LH receptor. The effect
of HCG on macrophage accumulation therefore seems to be
mediated through the steroidogenic cells. This effect is likely
to be associated with the production or withdrawal of steroid
or non-steroid molecules from the cells expressing LH/HCG
receptors. Progesterone itself may function as a signal molecule
as progesterone receptors can be localized to the human corpus
luteum (Suzuki et al., 1994). While these receptors appear to
be present on steroidogenic cells (Suzuki et al., 1994; Hild-
Petito and Fazleabas, 1997), they can also be found on other
cells within the connective tissue stroma (Suzuki et al.,
1994). It is not known whether luteal macrophages express
progesterone receptors or whether luteal sex steroids can affect
migration directly.
In our study, macrophages were found to be associated with
the theca-lutein cell layer and the vasculature of the corpus
luteum. An early study reported that macrophages were pre¬
dominant in the granulosa-lutein cell layer of the human
corpus luteum (Gillim et al., 1969). However, later studies
found a predominance in the theca-lutein layer (Wang et al.,
1992a. Brannstrom et al., 1994b). We have used steroidogenic
markers to confirm this observation. Brannstrom et al. (1994b)
reported that macrophages were more abundant in the theca¬
lutein layer and were particularly associated with blood vessels.
The relationship with blood vessels may suggest a recruitment
of monocyte/macrophages from the circulation. In our study
macrophage numbers increased during the late-luteal phase, in
all cellular compartments. This is consistent with recruitment
from the circulation rather than local migration. Interestingly,
MCP-1 is secreted by several cell types including endothelial
cells and fibroblasts (Leonard and Yoshimura, 1990). In the
rat corpus luteum, luteal vascular cells appear to be a source
of MCP-1 (Townson et al., 1996). The endothelial cells and
their communication with the steroidogenic cells of the corpus
luteum may play a major role in the control of macrophage
recruitment.
In conclusion, this study has shown that macrophages
accumulate in the human corpus luteum during the luteal phase
and are maximal in the late-luteal phase. One of the effects
of HCG during luteal 'rescue' is to prevent this influx of
macrophages into the corpus luteum. As macrophages do not
express LH/HCG receptors, this effect is mediated indirectly
through factors produced by the steroidogenic cells. Further
work is needed to study the expression of chemoattractant
molecules in the human corpus luteum throughout the luteal
phase and after luteal 'rescue' with HCG.
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